Current insurance and contractholder liabilities

5,388

5,514

Pharmacy and other service costs payable

28,465

19,815

Accounts payable

9,294

8,553

Accrued expenses and other liabilities

9,387

9,955

Short-term debt

3,035

2,775

Liabilities of businesses held for sale

2,410

2,104

Total current liabilities

57,979

48,716

Non-current insurance and contractholder liabilities

10,254

10,904

Deferred tax liabilities, net

6,975

7,173

Separate account liabilities

3,215

3,441

Long-term debt

28,937

28,155

7,278

7,430

Liabilities of businesses held for sale, non-current

0

591

TOTAL LIABILITIES

114,638

106,410

Contingencies — Note 21

Redeemable noncontrolling interests

0

107

Shareholders' equity

Common stock

^[1]

4

Additional paid-in capital

31,288

30,669

Accumulated other comprehensive loss

(2,341)

(1,864)

Retained earnings

43,519

41,652

Less: Treasury stock, at cost

(31,437)

(24,238)

TOTAL SHAREHOLDERS' EQUITY

41,033

46,223

Other noncontrolling interests

210

21

Total equity

41,243

46,244

Total liabilities and equity

$ 155,881

$ 152,761

[1]	Par value per share, $0.01; shares issued, 403 million as of December 31, 2024 and 400 million as of December 31, 2023; authorized shares, 600 million.

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Common stock, shares issued (in shares)	402,512,000	399,894,000	397,819,000
Common stock, shares authorized (in shares)	600,000,000	600,000,000	600,000,000

Consolidated Statements of Changes in Total Equity - USD ($) $ in Millions	Total	Shareholders' Equity	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive (Loss)	Retained Earnings	Treasury Stock	Other Non- controlling Interests
Balance at Dec. 31, 2021	$ 46,976	$ 46,958	$ 4	$ 29,574	$ (1,068)	$ 32,623	$ (14,175)	$ 18
Changes in Total Equity
Effect of issuing stock for employee benefit plans	583	583		659			(76)
Other comprehensive income (loss)	(590)	(590)			(590)
Net income	6,771	6,704				6,704		67
Common dividends declared	(1,387)	(1,387)				(1,387)
Repurchase of common stock	(7,593)	(7,593)					(7,593)
Other transactions impacting noncontrolling interests	(72)	0		0				(72)
Balance at Dec. 31, 2022	44,688	44,675	4	30,233	(1,658)	37,940	(21,844)	13
Balance at Dec. 31, 2021	54
Change in Redeemable Noncontrolling Interests
Other comprehensive loss	(2)
Net income	11
Other transactions impacting noncontrolling interests	3
Balance at Dec. 31, 2022	66
Changes in Total Equity
Effect of issuing stock for employee benefit plans	365	365		477			(112)
Other comprehensive income (loss)	(206)	(206)			(206)
Net income	5,192	5,164				5,164		28
Common dividends declared	(1,452)	(1,452)				(1,452)
Repurchase of common stock	(2,282)	(2,282)					(2,282)
Other transactions impacting noncontrolling interests	(61)	(41)		(41)				(20)
Balance at Dec. 31, 2023	46,244	46,223	4	30,669	(1,864)	41,652	(24,238)	21
Change in Redeemable Noncontrolling Interests
Other comprehensive loss	0
Net income	180
Other transactions impacting noncontrolling interests	(139)
Balance at Dec. 31, 2023	107
Changes in Total Equity
Effect of issuing stock for employee benefit plans	499	499		619			(120)
Other comprehensive income (loss)	(477)	(477)			(477)
Net income	3,778	3,434				3,434		344
Common dividends declared	(1,567)	(1,567)				(1,567)
Repurchase of common stock	(7,079)	(7,079)		0			(7,079)
Other transactions impacting noncontrolling interests	(155)	0		0				(155)
Balance at Dec. 31, 2024	41,243	$ 41,033	$ 4	$ 31,288	$ (2,341)	$ 43,519	$ (31,437)	$ 210
Change in Redeemable Noncontrolling Interests
Other comprehensive loss	0
Net income	0
Other transactions impacting noncontrolling interests	(107)
Balance at Dec. 31, 2024	$ 0

Consolidated Statements of Changes in Total Equity (Parenthetical) - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement of Stockholders' Equity [Abstract]
Common dividends declared (in dollars per share)	$ 5.60	$ 4.92	$ 4.48

Consolidated Statements of Cash Flows - USD ($)
$ in Millions

12 Months Ended

Dec. 31, 2024

Dec. 31, 2023

Dec. 31, 2022

Cash Flows from Operating Activities

Net income

$ 3,778

$ 5,372

$ 6,782

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

2,775

3,035

2,937

Investment losses, net

2,737

78

487

Deferred income tax benefit

(95)

(1,659)

(472)

Net (gain) loss on sale of businesses

(24)

1,499

(1,662)

Net changes in assets and liabilities, net of non-operating effects:

Accounts receivable, net

(7,369)

(1,663)

(2,237)

Inventories

(1,032)

(868)

(1,055)

Reinsurance recoverable and Other assets

(485)

(539)

393

Insurance liabilities

(591)

584

(336)

Pharmacy and other service costs payable

8,757

2,030

1,760

Accounts payable and Accrued expenses and other liabilities

1,138

3,481

1,734

NET CASH PROVIDED BY OPERATING ACTIVITIES

774

463

325

10,363

11,813

8,656

Proceeds from investments sold:

Debt securities and equity securities

856

1,078

1,744

Investment maturities and repayments:

Debt securities and equity securities

839

972

1,327

Commercial mortgage loans

188

186

98

Other sales, maturities and repayments (primarily short-term and other long-term investments)

752

586

1,039

Investments purchased or originated:

Debt securities and equity securities

(1,386)

(4,334)

(2,756)

Commercial mortgage loans

(54)

(118)

(161)

Other (primarily short-term and other long-term investments)

(1,309)

(1,205)

(1,563)

Property and equipment purchases, net

(1,406)

(1,573)

(1,295)

Acquisitions, net of cash acquired

(131)

(447)

0

Divestitures, net of cash sold

521

13

4,835

Renewable energy tax credit equity investments

(1,030)

(313)

(125)

NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES

58

(19)

(45)

(2,102)

(5,174)

3,098

Deposits and interest credited to contractholder deposit funds

166

167

164

Withdrawals and benefit payments from contractholder deposit funds

(228)

(223)

(220)

Net change in short-term debt

(402)

1,198

(2,059)

Repayment of long-term debt

(3,000)

(2,967)

(500)

Net proceeds on issuance of long-term debt

4,462

1,491

0

Repurchase of common stock

(7,034)

(2,284)

(7,607)

Issuance of common stock

305

187

389

Common stock dividend paid

(1,567)

(1,450)

(1,384)

NET CASH USED IN FINANCING ACTIVITIES

(349)

(413)

(23)

(7,647)

(4,294)

(11,240)

Effect of foreign currency rate changes on cash, cash equivalents and restricted cash

(20)

16

(86)

Net increase in cash, cash equivalents and restricted cash

594

2,361

428

Cash, cash equivalents and restricted cash January 1, including held for sale assets

8,337

^[1]

5,976

^[1]

5,548

Cash, cash equivalents and restricted cash December 31, including held for sale assets

^[1]

8,931

8,337

5,976

Cash and cash equivalents reclassified to assets of businesses held for sale

(1,339)

(467)

0

Cash, cash equivalents and restricted cash and cash equivalents December 31,

^[1]

7,592

7,870

5,976

Supplemental Disclosure of Cash Information:

Income taxes paid, net of refunds

898

1,471

1,850

Interest paid

$ 1,342

$ 1,330

$ 1,229

[1]	Restricted cash and cash equivalents were reported in other long-term investments.

Description of Business	12 Months Ended
Description of Business	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Note 1 – Description of Business The Cigna Group, together with its subsidiaries (either individually or collectively referred to as the "Company," "we," "us" or "our"), is a global health company committed to creating a better future for every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. Powered by our people and our brands, we advance our mission to improve the health and vitality of those we serve. Our subsidiaries offer a differentiated set of pharmacy, medical, behavioral, dental, and related products and services. The majority of these products and services are offered through employers and other entities, such as governmental and nongovernmental organizations, unions and associations. Cigna Healthcare also offers health and dental insurance products to individuals in the United States and select international markets. In addition to these operations, The Cigna Group also has certain run-off operations. A full description of our segments follows: The Evernorth Health Services reportable segment includes the Pharmacy Benefit Services and the Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the health care system to work better and help people live richer, healthier lives. Pharmacy Benefit Services drives high-quality, cost-effective pharmacy care through various services such as drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management and access to our home delivery pharmacy. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, as well as clinical programs to help our clients drive better whole-person health outcomes through care services. The Cigna Healthcare reportable segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. U.S. Healthcare provides medical plans and other benefits and solutions for insured clients, self-insured clients and individual health insurance plans. U.S. Healthcare also includes the Medicare Advantage and related businesses pending divestiture to Health Care Services Corporation ("HCSC") (see Note 5 to the Consolidated Financial Statements for further information). International Health provides health care solutions in our international markets, as well as health care benefits for globally mobile individuals and employees of multinational organizations. Other Operations comprises the remainder of our business operations, which includes certain continuing (corporate-owned life insurance ("COLI")), run-off and other non-strategic businesses. Our run-off businesses include the (i) variable annuity reinsurance business that was effectively exited through reinsurance with Berkshire Hathaway Life Insurance Company of Nebraska ("Berkshire") in 2013, (ii) settlement annuity business and (iii) individual life insurance and annuity and retirement benefits businesses, which were sold through reinsurance agreements. Corporate reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate financing less net investment income on investments not supporting segment and other operations), certain litigation matters, expense associated with our frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments.

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Basis of Presentation The Consolidated Financial Statements include the accounts of The Cigna Group and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Certain amounts in the Consolidated Statements of Cash Flows and Note 20 "Income Taxes" to the Consolidated Financial Statements have been reclassified to conform to current year presentation and did not have a significant impact on our Consolidated Financial Statements. Amounts recorded in the Consolidated Financial Statements necessarily reflect management's estimates and assumptions about medical costs, investment, tax and receivable valuations, interest rates, and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment. Recent Accounting Pronouncements There were no new accounting standards adopted during the year ended December 31, 2024 that had a material impact on our Consolidated Financial Statements. There are no significant accounting pronouncements not yet adopted as of December 31, 2024. Significant Accounting Policies The Company's accounting policies are described either in this Note or in the applicable Notes to the Consolidated Financial Statements as listed in the table of contents on page 62. A.Cash and Cash Equivalents Cash and cash equivalents are carried at cost that approximates fair value. Cash equivalents consist of short-term investments with maturities of three months or less from the time of purchase. The Company reclassifies cash overdraft positions to liabilities when the legal right of offset does not exist. B.Inventories Inventories consist of prescription drugs and medical supplies and are stated at the lower of first-in-first-out cost or net realizable value. C.Translation of Foreign Currencies The Company generally conducts its international business through foreign operating entities that maintain assets and liabilities in local currencies that are their functional currencies. The Company uses exchange rates as of the balance sheet date to translate assets and liabilities into U.S. dollars. Translation gains or losses on functional currencies, net of applicable taxes, are recorded in Accumulated other comprehensive loss. The Company uses average monthly exchange rates during the year to translate revenues and expenses into U.S. dollars. D.Pharmacy Revenues and Costs Pharmacy Revenues. Pharmacy revenues are primarily derived from providing pharmacy benefit management services to clients and customers. Pharmacy revenues are recognized when control of the promised goods or services is transferred to clients and customers in an amount that reflects the consideration the Company expects to receive for those goods or services. The Company provides or makes available various services supporting benefit management and claims administration and is generally obligated to provide prescription drugs to clients' members using multiple distribution methods, including retail networks, home delivery and specialty pharmacies. These goods and services are integrated into a single performance obligation to process claims, dispense prescription drugs and provide other services over the contract period (generally three years). This performance obligation is satisfied as the business stands ready to fulfill its obligation. Revenues for dispensing prescription drugs through retail pharmacies are reported gross and consist of the prescription price (ingredient cost and dispensing fee) contracted with clients, including the customer copayment, and any associated fees for services, because the Company acts as the principal in these arrangements. When a prescription is presented to a retail network pharmacy, the Company is solely responsible for customer eligibility, drug utilization review, drug-to-drug interaction review, any required clinical intervention, plan provision information, payment to the pharmacy and client billing. These revenues are recognized based on the full prescription price when the pharmacy claim is processed and approved for payment. The Company also provides benefit design and formulary consultation services to clients and negotiates separate contractual relationships with clients and network pharmacies. These factors indicate that the Company has control over these transactions until the prescription is processed. Revenues are billed, due and recognized at contract rates either on a periodic basis or as services are provided (such as based on volume of claims processed). This recognition pattern aligns with the benefits from services provided. Home delivery and specialty pharmacy revenues are due and recognized as each prescription is shipped, net of reserves for discounts and contractual allowances estimated based on historical experience. Any differences between estimates and actual collections are reflected in Pharmacy revenues when payments are received. Historically, adjustments to original estimates and returns have not been material. The Company has elected the practical expedient to account for shipping and handling as a fulfillment activity. We may also provide certain financial and performance guarantees, including a minimum level of discounts a client may receive, generic utilization rates and various service levels. Clients may be entitled to receive compensation if we fail to meet the guarantees. Actual performance is compared to the contractual guarantee for each measure throughout the period and the Company defers revenue for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted and paid at the end of the annual guarantee period. Historically, adjustments to original estimates have not been material. The liability for these financial and performance guarantees was $1.9 billion as of December 31, 2024 and $1.6 billion as of December 31, 2023. The Company administers programs through which we may receive rebates and other vendor consideration from pharmaceutical manufacturers. The amounts of such rebates or other vendor consideration shared with pharmacy benefit management services clients vary based on the contractual arrangement with the client and in some cases the type of consideration received from the pharmaceutical manufacturer. Rebates and other vendor consideration payable to pharmacy benefit management services clients are recorded as a reduction of Pharmacy revenues. Estimated amounts payable to clients are based on contractual sharing arrangements between the Company and the client and these amounts are adjusted when amounts are collected from pharmaceutical manufacturers in accordance with the contractual arrangement between the Company and the client. Historically, these adjustments have not been material. Other pharmacy service revenues are earned by distributing specialty pharmaceuticals and medical supplies to providers, clinics and hospitals. These revenues are billed, due and recognized at contracted rates as prescriptions and supplies are shipped and services are provided. Pharmacy Costs. Pharmacy costs include the cost of prescriptions sold, network pharmacy claim costs and copayments. Also included are direct costs of dispensing prescriptions including supplies, shipping and handling, and direct costs associated with clinical programs, such as drug utilization management and medication adherence counseling. Home delivery and specialty pharmacy costs are recognized when the drug is shipped, and retail network costs are recognized when the drug is processed and approved for payment. Rebates and other vendor consideration received when providing pharmacy benefit management services are recorded as a reduction of pharmacy costs. Rebates are recognized as prescriptions are shipped or processed and approved for payment. Historically, the effect of adjustments resulting from the reconciliation of rebates recognized to the amounts billed and collected, net of contractual allowances, has not been material. The Company maintains reimbursement guarantees with certain retail network pharmacies. For each such guarantee, the Company records a pharmacy and other service costs payable or prepaid asset for applicable retail network claims based on our actual performance throughout the period against the contractual reimbursement rate. The Company's contracts with certain retail pharmacies give the Company the right to adjust reimbursement rates during the annual guarantee period. E.Premiums and Related Expenses Premiums for short-duration group health, accident and life insurance and managed care coverages are recognized as revenue on a pro rata basis over the contract period. Benefits and expenses are recognized when incurred and, for our Cigna Healthcare business, are presented net of pharmaceutical manufacturer rebates. For experience-rated contracts, premium revenue includes an adjustment for experience-rated refunds based on contract terms and calculated using the customer's experience (including estimates of incurred but not reported claims). Premiums received for the Company's Medicare Advantage plans, Medicare Part D plans and Individual and Family Plans from the Centers for Medicare and Medicaid Services ("CMS") and customers are recognized as revenue ratably over the contract period. CMS provides risk-adjusted premium payments for Medicare Advantage plans and Medicare Part D plans based on our customer demographics and medical diagnoses, which may change from period to period based on the underlying health factors of our customers. The Company recognizes changes to risk-adjusted premiums as revenue when the amounts are determinable and collection is reasonably assured. Revenue adjustments are generally settled semiannually with CMS. The final revenue adjustment is generally settled with CMS in the year following the contract year. Medicare Part D premiums include payments from CMS for risk-sharing adjustments that are estimated quarterly based on claim experience by comparing actual incurred prescription drug costs to the estimated costs submitted in the original contracts. These adjustments may result in more or less revenue from CMS. Final revenue adjustments generally occur in the year following the contract year. The Patient Protection and Affordable Care Act ("ACA") prescribed a risk adjustment program to mitigate the risk for participating health insurance companies selling individual coverage on the public exchanges. The risk adjustment program reallocates funds from insurers with lower risk populations to insurers with higher risk populations based on the relative risk scores of participants. We estimate our receivable or payable based on the risk of our customers compared to the risk of other customers in the same state and market, considering data obtained from industry studies and the United States Department of Health and Human Services ("HHS"). Receivables or payables are recorded as adjustments to premium revenue based on our year-to-date experience when the amounts are reasonably estimable and collection is reasonably assured. Final revenue adjustments are determined by HHS in the year following the policy year. Premium revenue may also include an adjustment to reflect the estimated effect of rebates due to customers under medical loss ratio provisions of the ACA. These rebate liabilities are settled in the subsequent year. Liabilities related to experience-rated refunds, risk adjustment programs and the minimum medical loss ratio are included in Accrued expenses and other liabilities (current). Premiums for long-duration insurance contracts, including supplemental health, accident and individual life insurance and annuity products, and excluding universal life and investment-related products, are recognized as revenue when due. Cigna Healthcare long-duration premium revenues are associated with contracts that provide coverage greater than one year or are guaranteed to be renewed at the option of the policyholder beyond one year. Benefits and expenses are matched with premiums. Revenue for universal life products is recognized as follows: •Investment income on assets supporting universal life products is recognized in Net investment income as earned. •Charges for mortality, administration and policy surrender are recognized in Premiums as earned. Administrative fees are considered earned when services are provided. Benefits and expenses for universal life products consist of benefit claims in excess of policyholder account balances and income earned by policyholders. Expenses are recognized when claims are incurred and income is credited to policyholders in accordance with contract provisions. The unrecognized portion of premiums received is recorded as unearned premiums included in Insurance and contractholder liabilities (current and non-current) (see Note 9 to the Consolidated Financial Statements for further information). F.Fees and Related Expenses The majority of the Company's service fee revenues are derived from the following programs: •Administrative Services Only ("ASO") arrangements allow plan sponsors to self-fund claims and assume the risk of medical or other benefit costs. In return for fees from these clients, the Company provides access to our participating provider networks and other services supporting benefit management. •Fee-for-service clinical solutions offered to clients, such as drug utilization management and medication adherence counseling help clients to drive better health outcomes at a lower cost by identifying and addressing potentially unsafe or wasteful prescribing, dispensing and utilization of prescription drugs, and communicating with, or supporting communications with, physicians, pharmacies and patients. •Wholesale Marketplace Drug Formulary Management services include either our drug formulary administrative service arrangements or our formulary processing arrangements. Drug formulary administrative services may include formulary consultation, administration of rebate contracts, rebate submission, collection from drug manufacturers and the distribution of rebates to clients. Services may also include facilitating audits of data submissions and reporting of rebates to clients. •Health benefit management solutions are offered primarily to sponsors of health benefit plans to drive cost reductions and improve quality outcomes for clients as well as provide behavioral health services to third-party health plans, employers and administrators. In certain arrangements, the Company assumes the financial obligation for third-party provider costs for medical services provided to the health plan's customers. Arrangements are generally short-term (one year or less) except for certain three-year health benefit management solutions contracts, and each consists of a single performance obligation. Performance obligations are satisfied as services are provided to clients, either on a stand-ready or utilization basis. Fees are billed, due and recognized at contracted rates on a periodic basis, generally monthly or agreed-upon arrangements terms. Fee revenues for services are generally recorded on a gross basis with the associated direct and indirect costs presented in Pharmacy and other service costs, or Selling, general and administrative expenses. Retained rebates reported in Fees and other revenues in our formulary processing arrangements are either recognized gross as services are provided to clients, consistent with the related service fee, or net as rebates are processed. The latter applies in arrangements in which the Company is permitted to retain a portion of rebates collected in exchange for services, but the Company does not obtain control of the retained rebate until rebates are transferred to the client. Fees for services may include variable consideration as a component of the transaction price, which is estimated at contract inception, recognized and adjusted through the contract period through Accrued expenses and other liabilities. Variable consideration includes certain health benefit management contracts requiring the Company to share the results of medical cost experience that differ from specified targets and ASO performance guarantees that compensate clients if certain service standards, clinical outcomes or financial metrics are not met.

Accounts Receivable, Net

12 Months Ended

Dec. 31, 2024

Receivables [Abstract]

Accounts Receivable, Net

Note 3 – Accounts Receivable, Net

Accounting Policy. We bill pharmaceutical manufacturers based on management's interpretation of contractual terms and estimate a contractual allowance based on the best information available at the time a claim is processed. Contractual allowances for certain rebates receivable from pharmaceutical manufacturers are determined by reviewing payment experience and specific known items that

could be adjusted under contract terms. The Company's estimation process for contractual allowances for pharmaceutical manufacturer receivables generally results in an allowance for balances outstanding greater than 90 days.

Contractual allowances for certain receivables from third-party payors are based on their contractual terms and are estimated based on the Company's best information available at the time revenue is recognized.

The allowance for expected credit losses for current accounts receivable is based primarily on past collections experience relative to the length of time receivables are past due; however, when available evidence reasonably supports an assumption that counterparty credit risk over the expected payment period will differ from current and historical payment collections, a forecasting adjustment is reflected in the allowance for expected credit losses.

Discounts and claims adjustments issued to customers in the form of client credits and other non-credit adjustments are based on the current status of each customer's receivable balance, current economic and market conditions and a variety of other factors, including the length of time the receivables are past due, the financial health of customers and our past experience.

Receivables and any associated allowance are written off only when all collection attempts have failed and such amounts are determined unrecoverable. We regularly review the adequacy of these allowances based on a variety of factors, including age of the outstanding receivable and collection history. When circumstances related to specific collection patterns change, estimates of the recoverability of receivables are adjusted.

The Company's accounts receivable include amounts due from clients, third-party payors, customers and pharmaceutical manufacturers, and are presented net of allowances. These balances include the following:

•Noninsurance customer receivables - amounts due from customers for noninsurance services, primarily pharmacy benefit management and ASO contracts.

•Pharmaceutical manufacturers receivables - amounts due from pharmaceutical manufacturers.

•Insurance customer receivables - amounts due from customers under insurance and managed care contracts, primarily premiums receivable and amounts due from CMS.

•Other receivables - all other accounts receivable not included in the categories above.

The following amounts were included within Accounts receivable, net:


(In millions)	December 31, 2024		December 31, 2023
Noninsurance customer receivables	$	11,879	$	8,044
Pharmaceutical manufacturers receivables	10,914		8,169
Insurance customer receivables	3,199		2,359
Other receivables	162		272
Total	$	26,154	$	18,844
Accounts receivable, net classified as assets of businesses held for sale	(1,927)		(1,122)
Total	$	24,227	$	17,722

These receivables are reported net of our allowances of $5.0 billion and $3.7 billion as of December 31, 2024 and 2023, respectively. As of December 31, 2024 and 2023, these allowances were primarily comprised of $4.3 billion and $3.1 billion, respectively, associated with contractual allowances for certain pharmaceutical manufacturers rebate receivables; $388 million and $386 million, respectively, associated with contractual allowances for third-party payor noninsurance customer receivables; and $84 million and $90 million, respectively, associated with allowances for current expected credit losses. The remaining allowances include discounts and claims adjustments issued to customers in the form of client credits and other non-credit adjustments.

Accounts Receivable Factoring Facility

The Company maintains an uncommitted factoring facility (the "Facility") under which certain accounts receivable may be sold on a nonrecourse basis to a financial institution. The Facility began in July 2023 with an initial term of two years, followed by automatic one-year renewal terms unless terminated by either party. The Facility's total capacity at inception was $1.0 billion and was amended to $1.5 billion in May 2024. The transactions under the Facility are accounted for as a sale and recorded as a reduction to accounts receivable in the Consolidated Balance Sheets because control of, and risk related to, the accounts receivable are transferred to the financial institution. Although the sale is made without recourse, we provide collection services related to the transferred assets. Amounts associated with this Facility are reflected within Net cash provided by operating activities in the Consolidated Statements of

Cash Flows. Factoring fees paid under this Facility are reflected in Interest expense and other in the Consolidated Statements of Income.

We sold pharmaceutical manufacturers receivables under the Facility of $5.5 billion and $2.1 billion during the years ended December 31, 2024 and December 31, 2023, respectively. For the years ended December 31, 2024 and December 31, 2023, factoring fees paid were not material. As of December 31, 2024 and December 31, 2023, all sold accounts receivable had been collected from pharmaceutical manufacturers and had been removed from the Company's Consolidated Balance Sheets. As of December 31, 2024 and December 31, 2023, there were $1.0 billion and $515 million, respectively, of collections from pharmaceutical manufacturers that had not been remitted to the financial institution. Such amounts are recorded within Accrued expenses and other liabilities in the Consolidated Balance Sheets.

Supplier Finance Program

12 Months Ended

Dec. 31, 2024

Payables and Accruals [Abstract]

Supplier Finance Program

Note 4 – Supplier Finance Program

The Company facilitates a voluntary supplier finance program (the "Program") that provides suppliers the opportunity to sell their accounts receivable due from us (i.e., our payment obligations to the suppliers) to a financial institution, on a non-recourse basis, in order to be paid earlier than our payment terms require. The Cigna Group is not a party to the Program and agrees to commercial terms with its suppliers independently of their participation in the Program. Amounts due to suppliers that participate in the Program are generally paid within one month following the invoice date. A supplier's participation in the Program has no impact on the Company's payment terms and the Company has no economic interest in a supplier's decision to participate in the Program. The suppliers, at their sole discretion, determine which invoices, if any, to sell to the financial institution. No guarantees or pledged assets are provided by the Company or any of our subsidiaries under the Program.

The obligations confirmed as valid within the Program by the financial institutions were as follows and are reflected in Accounts payable in the Consolidated Balance Sheets:


	For the Years Ended December 31,
(in millions)	2024		2023
Confirmed obligations outstanding at the beginning of the year	$	1,536	$	1,303
Invoices confirmed during the year	39,091		36,224
Less: confirmed invoices paid during the year	38,990		35,991
Confirmed obligations outstanding at the end of the year	$	1,637	$	1,536

The amounts confirmed as valid for both periods are predominately associated with one supplier.

As of December 31, 2024, we have been informed by the financial institution that an immaterial amount of the Company's outstanding payment obligations were voluntarily elected by suppliers to be sold to the financial institution under the Program.

Assets and Liabilities of Businesses Held for Sale

12 Months Ended

Dec. 31, 2024

Discontinued Operations and Disposal Groups [Abstract]

Assets and Liabilities of Business Held for Sale

Note 5 – Assets and Liabilities of Businesses Held for Sale

Accounting Policy. The Company classifies assets and liabilities as held for sale ("disposal group") when management commits to a plan to sell the disposal group, the sale is probable within one year and the disposal group is available for immediate sale in its present condition. The Company considers various factors, particularly whether actions required to complete the plan indicate it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. Assets held for sale are measured at the lower of carrying value or fair value less costs to sell. Any loss resulting from the measurement is recognized in the period the held for sale criteria are met. Conversely, gains are not recognized until the date of the sale. When the disposal group is classified as held for sale, depreciation and amortization for most long-lived assets ceases and the Company tests the assets for impairment. Deferred policy acquisition costs continue to be amortized.

In January 2024, the Company entered into a definitive agreement to sell the Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses (the "Disposal Group") to HCSC subject to applicable regulatory approvals and other customary closing conditions, including purchase price adjustments to align with the final balance sheet of the divested businesses (the "HCSC transaction"). The initial $3.3 billion purchase price is anticipated to increase at closing, reflecting higher statutory surplus for the legal entities that will convey to HCSC. The transaction is expected to close in the first quarter of 2025.

The Company determined that the Disposal Group met the criteria to be classified as held for sale and aggregated and classified the assets and liabilities as held for sale in our Consolidated Balance Sheets as of December 31, 2024 and December 31, 2023.

The Company measured the assets and liabilities of the Disposal Group at estimated fair value less costs to sell based on an estimated $4.7 billion purchase price as of December 31, 2024 and initial $3.3 billion purchase price as of December 31, 2023 and recognized within Net gain (loss) on sale of businesses in the Consolidated Statements of Income an estimated loss of $472 million pre-tax ($363 million after-tax) for the year ended December 31, 2024 and $1.5 billion pre-tax ($1.4 billion after-tax) for the year ended December 31, 2023. The estimated loss on sale for both periods primarily represents goodwill impairments of $302 million pre-tax in 2024 and $1.2 billion pre-tax in 2023.

The assets and liabilities of businesses held for sale were as follows:


(In millions)	December 31, 2024		December 31, 2023
Cash and cash equivalents	$	1,339	$	467
Investments	1,444		1,438
Accounts receivable, net	1,927		1,122
Other assets, including Goodwill (1)	2,294		2,963
Total assets of businesses held for sale	7,004		5,990
Insurance and contractholder liabilities	1,579		1,636
All other liabilities	831		1,059
Total liabilities of businesses held for sale	$	2,410	$	2,695

(1) Includes Goodwill of $94 million as of December 31, 2024 and $396 million as of December 31, 2023.

Integration and Transaction-Related Costs

In 2024 and 2023, the Company incurred transaction-related costs associated with the HCSC transaction. In 2023 and 2022, the Company also incurred net costs mainly related to the sale of our international life, accident and supplemental benefits businesses. Additionally in 2022, the Company incurred costs related to the sale of the Group Disability and Life business as well as the acquisition of MDLIVE, Inc. ("MD Live"). These costs incurred consisted primarily of certain projects to separate or integrate the Company's systems, products and services; fees for legal, advisory and other professional services; and certain employment-related costs. These costs were $275 million pre-tax ($211 million after-tax), $45 million pre-tax ($35 million after-tax) and $135 million pre-tax ($103 million after-tax) for the years ended December 31, 2024, December 31, 2023 and December 31, 2022, respectively.

Earnings Per Share

12 Months Ended

Dec. 31, 2024

Earnings Per Share [Abstract]

Earnings Per Share

Note 6 – Earnings Per Share

Accounting Policy. The Company computes basic earnings per share using the weighted-average number of unrestricted common and deferred shares outstanding. Diluted earnings per share also includes the dilutive effect of outstanding employee stock options and restricted stock using the treasury stock method and the effect of strategic performance shares.

Basic and diluted earnings per share were computed as follows:




	For the Years Ended December 31,
	2024						2023						2022
(Shares in thousands, dollars in millions, except per share amounts)	Basic		Effect of Dilution		Diluted		Basic		Effect of Dilution		Diluted		Basic		Effect of Dilution		Diluted
Shareholders' net income	$	3,434			$	3,434	$	5,164			$	5,164	$	6,704			$	6,704
Shares:
Weighted average	280,294				280,294		293,892				293,892		309,546				309,546
Common stock equivalents			2,924		2,924				2,990		2,990				3,519		3,519
Total shares	280,294		2,924		283,218		293,892		2,990		296,882		309,546		3,519		313,065
Earnings per share	$	12.25	$	(0.13)	$	12.12	$	17.57	$	(0.18)	$	17.39	$	21.66	$	(0.25)	$	21.41

The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was anti-dilutive:



	For the Years Ended December 31,
(In millions)	2024	2023	2022
Anti-dilutive options	1.1	0.9	1.0

Debt

12 Months Ended

Dec. 31, 2024

Debt Disclosure [Abstract]

Debt

Note 7 – Debt

The outstanding amounts of debt (net of issuance costs, discounts or premiums) and finance leases were as follows:


(In millions)	December 31, 2024		December 31, 2023
Short-term debt
Commercial paper	$	880	$	1,237
$500 million, 0.613% Notes due March 2024	—		500
$790 million, 3.500% Notes due June 2024 (1)	—		996
$900 million, 3.250% Notes due April 2025 (2)	897		—
$1,216 million, 4.125% Notes due November 2025 (1)	1,215		—
Other, including finance leases	43		42
Total short-term debt	$	3,035	$	2,775





Long-term debt
$900 million, 3.250% Notes due April 2025 (2)	$	—	$	882
$1,216 million, 4.125% Notes due November 2025 (1)	—		2,197
$1,284 million, 4.500% Notes due February 2026 (1)	1,285		1,502
$550 million, 1.250% Notes due March 2026 (1)	549		798
$700 million, 5.685% Notes due March 2026	699		698
$1,500 million, 3.400% Notes due March 2027	1,466		1,450
$259 million, 7.875% Debentures due May 2027	259		259
$600 million, 3.050% Notes due October 2027	598		597
$3,800 million, 4.375% Notes due October 2028	3,790		3,787
$1,000 million, 5.000% Notes due May 2029	995		—
$1,400 million, 2.400% Notes due March 2030 (1) (2)	1,386		1,493
$1,500 million, 2.375% Notes due March 2031 (2)	1,384		1,397
$750 million, 5.125% Notes due May 2031	745		—
$45 million, 8.080% Step Down Notes due January 2033	45		45
$800 million, 5.400% Notes due March 2033	795		794
$1,250 million, 5.250% Notes due February 2034 (2)	1,226		—
$190 million, 6.150% Notes due November 2036	190		190
$2,200 million, 4.800% Notes due August 2038	2,193		2,193
$750 million, 3.200% Notes due March 2040	744		744
$121 million, 5.875% Notes due March 2041	119		119
$448 million, 6.125% Notes due November 2041	485		487
$317 million, 5.375% Notes due February 2042	315		315
$1,500 million, 4.800% Notes due July 2046	1,469		1,467
$1,000 million, 3.875% Notes due October 2047	990		989
$3,000 million, 4.900% Notes due December 2048	2,971		2,970
$1,250 million, 3.400% Notes due March 2050	1,237		1,237
$1,500 million, 3.400% Notes due March 2051	1,479		1,479
$1,500 million, 5.600% Notes due February 2054	1,482		—

Other, including finance leases	41		66
Total long-term debt	$	28,937	$	28,155

(1)Included in the February 2024 debt tender offers discussed below.

(2)The Company has entered into interest rate swap contracts hedging a portion of these fixed-rate debt instruments as of December 31, 2024. See Note 11 to the Consolidated Financial Statements for further information about the Company's interest rate risk management and these derivative instruments.

Short-Term and Credit Facilities Debt

Revolving Credit Agreements. Our revolving credit agreements provide us with the ability to borrow amounts for general corporate purposes, including providing liquidity support if necessary under our commercial paper program discussed below. As of December 31, 2024, there were no outstanding balances under these revolving credit agreements.

In April 2024, The Cigna Group replaced its previous revolving credit agreements and entered into the following (the "Credit Agreements"):

•A $5.0 billion five-year revolving credit and letter of credit agreement that will mature in April 2029 with an option to extend the maturity date for additional one-year periods, subject to consent of the banks. The Company can borrow up to $5.0 billion under the credit agreement for general corporate purposes, with up to $500 million available for issuance of letters of credit.

•A $1.5 billion 364-day revolving credit agreement that will mature in April 2025. The Company can borrow up to $1.5 billion under the credit agreement for general corporate purposes. This agreement includes the option to "term out" any revolving loans that are outstanding at maturity by converting them into a term loan maturing on the one-year anniversary of conversion.

Each of the Credit Agreements includes an option to increase commitments in an aggregate amount of up to $1.5 billion across both facilities for a maximum total commitment of $8.0 billion. The Credit Agreements allow for borrowings at either a base rate or an adjusted term Secured Overnight Funding Rate ("SOFR") plus, in each case, an applicable margin based on the Company's senior unsecured credit ratings.

Each facility also contains customary covenants and restrictions, including a financial covenant that the Company's leverage ratio, as defined in the Credit Agreements, may not exceed 60% subject to certain exceptions upon the consummation of an acquisition.

Commercial Paper. Under our commercial paper program, we may issue short-term, unsecured commercial paper notes privately placed on a discounted basis through certain broker-dealers at any time not to exceed an aggregate amount of $6.5 billion. Our commercial paper program size was increased from $5.0 billion to $6.5 billion in July 2024. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. The weighted average interest rate of our commercial paper was 4.65% at December 31, 2024.

Long-Term Debt

Debt Issuance and Debt Tender Offers. In February 2024, we issued $4.5 billion of new senior notes, as detailed in the table below. The proceeds from this debt were used to pay the consideration for the cash tender offers as described below. We used the remaining net proceeds to fund the repayment of our senior notes that matured in March 2024 and for general corporate purposes, including repayment of indebtedness and repurchases of shares of our common stock. Interest on this debt is paid semiannually.

Principal

Maturity Date

Interest Rate

Net Proceeds

Redeemable Date(1)

"Make Whole" Premium (2)

$1,000 million

May 15, 2029

5.000%

$995 million

April 15, 2029

15

$750 million

May 15, 2031

5.125%

$746 million

March 15, 2031

15

$1,250 million

February 15, 2034

5.250%

$1,244 million

November 15, 2033

20

$1,500 million

February 15, 2054

5.600%

$1,485 million

August 15, 2053

20

(1) Redeemable at any time prior to this date at a "make whole" premium, defined below. Redeemable at par on or after this date.

(2) "Make whole" premium calculated using the most directly comparable U.S. Treasury rate plus the amount of basis points set forth in this column.

In the first quarter of 2024, the Company completed the repurchase of a total of $1.8 billion in aggregate principal amount of existing senior notes that were tendered to the Company pursuant to cash tender offers.

Debt Maturities. Maturities of outstanding long-term debt as of December 31, 2024 are as follows:


(In millions)	Scheduled Maturities (1)
2025	$	2,116
2026	$	2,534
2027	$	2,359
2028	$	3,800
2029	$	1,000
Maturities after 2029	$	19,522

(1) Long-term debt maturity amounts include current maturities of long-term debt. Finance leases are excluded from this table.

Interest Expense

Interest expense on long-term and short-term debt was $1.5 billion in 2024, $1.4 billion in 2023 and $1.3 billion in 2022.

Debt Covenants

The Company was in compliance with its debt covenants as of December 31, 2024.

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Common and Preferred Stock

12 Months Ended

Dec. 31, 2024

Common and Preferred Stock

Note 8 – Common and Preferred Stock

The Cigna Group has a total of 25 million shares of $1 par value preferred stock authorized for issuance. No shares of preferred stock were outstanding at December 31, 2024, 2023 or 2022.

The following table presents the share activity of The Cigna Group:


	For the Years Ended December 31,
(Shares in thousands)	2024	2023	2022
Common: Par value $0.01; 600,000 shares authorized
Outstanding- January 1,	292,504	298,676	322,948
Net issued for stock option exercises and other benefit plans	2,198	1,619	3,173
Repurchased common stock	(20,913)	(7,791)	(27,445)
Outstanding- December 31,	273,789	292,504	298,676
Treasury stock	128,723	107,390	99,143
Issued- December 31,	402,512	399,894	397,819

Dividends

The following table provides details of the Company's dividend payments:


Record Date	Payment Date	Amount per Share	Total Amount Paid (in millions)
2024
March 6, 2024	March 21, 2024	$1.40	$401
June 4, 2024	June 20, 2024	$1.40	$392
September 4, 2024	September 19, 2024	$1.40	$390
December 4, 2024	December 19, 2024	$1.40	$384
2023
March 8, 2023	March 23, 2023	$1.23	$368
June 7, 2023	June 22, 2023	$1.23	$362
September 6, 2023	September 21, 2023	$1.23	$362
December 6, 2023	December 21, 2023	$1.23	$358
2022
March 9, 2022	March 24, 2022	$1.12	$357
June 8, 2022	June 23, 2022	$1.12	$352
September 7, 2022	September 22, 2022	$1.12	$341
December 6, 2022	December 21, 2022	$1.12	$334

On January 30, 2025, the Board of Directors declared the first quarter cash dividend of $1.51 per share of The Cigna Group common stock to be paid on March 20, 2025 to shareholders of record on March 5, 2025. The Company currently intends to pay regular quarterly dividends, with future declarations subject to approval by its Board of Directors and the Board of Director's determination that the declaration of dividends remains in the best interests of The Cigna Group and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on the Company's financial position, results of operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board may deem relevant.

Accelerated Share Repurchase Agreements

In February 2024, as part of our share repurchase program, we entered into separate accelerated share repurchase agreements with Deutsche Bank AG and Bank of America, N.A. to repurchase $3.2 billion of common stock in aggregate. The total number of shares of our common stock repurchased under the agreements was approximately 9.3 million, at $344.98 per share. The per share amount was calculated based on the daily volume-weighted average share price of our common stock over the term of the agreements, less a discount.

Insurance and Contractholder Liabilities

12 Months Ended

Dec. 31, 2024

Insurance Loss Reserves [Abstract]

Insurance and Contractholder Liabilities

A.Account Balances – Insurance and Contractholder Liabilities

The Company's insurance and contractholder liabilities were comprised of the following:


	December 31, 2024						December 31, 2023
(In millions)	Current		Non-current		Total		Current		Non-current		Total
Unpaid claims and claim expenses
Cigna Healthcare	$	4,932	$	86	$	5,018	$	5,017	$	75	$	5,092
Other Operations	147		144		291		99		154		253
Future policy benefits
Cigna Healthcare	91		507		598		97		518		615
Other Operations	157		3,140		3,297		163		3,375		3,538
Contractholder deposit funds
Cigna Healthcare	9		115		124		12		133		145
Other Operations	366		5,958		6,324		362		6,178		6,540
Market risk benefits	25		760		785		37		966		1,003
Unearned premiums	753		31		784		846		22		868
Total	6,480		10,741		17,221		6,633		11,421		18,054
Insurance and contractholder liabilities classified as liabilities of businesses held for sale (1)	(1,092)		(487)		(1,579)		(1,119)		(517)		(1,636)
Total insurance and contractholder liabilities	$	5,388	$	10,254	$	15,642	$	5,514	$	10,904	$	16,418

(1) Amounts classified as liabilities of businesses held for sale include $983 million of Unpaid claims, $408 million of Future policy benefits, $85 million of Unearned premiums and $103 million of Contractholder deposit funds as of December 31, 2024 and $823 million of Unpaid claims, $429 million of Future policy benefits, $261 million of Unearned premiums and $123 million of Contractholder deposit funds as of December 31, 2023.

Insurance and contractholder liabilities expected to be paid within one year are classified as current.

Accounting Policy - Unearned Premium. The unrecognized portion of premiums received is recorded as unearned premiums included in Insurance and contractholder liabilities (current and non-current).

The Company evaluates certain insurance contracts subject to premium deficiency testing and recognizes a premium deficiency loss and corresponding reserve when expected claims costs, claims adjustment expenses, maintenance costs, and unamortized acquisition costs exceed unearned premium. Anticipated investment income is considered in the calculation of premium deficiency.

Unpaid Claims and Claim Expenses – Cigna Healthcare

This liability reflects estimates of the ultimate cost of claims that have been incurred but not reported, expected development on reported claims, claims that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities.

Accounting Policy. The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.

The Company compares key assumptions used to establish the medical costs payable to actual experience for each reporting period. The unpaid claims liability is adjusted through current period Shareholders' net income when actual experience differs from these assumptions. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trend.

The liability is primarily calculated using "completion factors" developed by comparing the claim incurral date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1) electronic (auto-adjudication) versus manual claim processing; 2) frequency and timeliness of provider claims submissions; 3) number of customers; and 4) the mix of products. The Company uses historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current

estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period.

The Company relies more heavily on medical cost trend analysis that reflects expected claim payment patterns and other relevant operational considerations for more recent months. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of health benefits offered, including inpatient, outpatient and pharmacy; the impact of copays and deductibles; changes in provider practices; and changes in consumer demographics and consumption behavior.

The total of incurred but not reported liabilities plus expected development on reported claims and reported claims in process was $4.6 billion at December 31, 2024 and $4.8 billion at December 31, 2023.

Activity, net of intercompany transactions, in the unpaid claims liability for the Cigna Healthcare segment was as follows:




	For the Years Ended December 31,
(In millions)	2024 (1)		2023 (1)		2022
Beginning balance	$	5,092	$	4,176	$	4,261
Less: Reinsurance and other amounts recoverable	236		221		261
Beginning balance, net	4,856		3,955		4,000

Incurred costs related to:
Current year	38,347		35,953		31,342
Prior years	(456)		(279)		(259)
Total incurred	37,891		35,674		31,083
Paid costs related to:
Current year	33,718		31,322		27,583
Prior years	4,170		3,451		3,545
Total paid	37,888		34,773		31,128

Ending balance, net	4,859		4,856		3,955
Add: Reinsurance and other amounts recoverable	159		236		221
Ending balance	$	5,018	$	5,092	$	4,176

(1) Includes unpaid claims amounts classified as liabilities of businesses held for sale. As of December 31, 2024 and December 31, 2023, includes $983 million and $823 million classified as liabilities of businesses held for sale, respectively.

Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and pending claims of certain business for which the Company administers the plan benefits without any right of offset. See Note 10 to the Consolidated Financial Statements for additional information on reinsurance.

Variances in incurred costs related to prior years' unpaid claims and claim expenses that resulted from the differences between actual experience and the Company's key assumptions were as follows:




	For the Years Ended December 31,
	2024				2023
(Dollars in millions)	$		% (1)		$		% (2)
Actual completion factors and other	$	223	0.6	%	$	70	0.2	%
Medical cost trend	233		0.7		209		0.7

Total favorable variance	$	456	1.3	%	$	279	0.9	%

(1)Percentage of current year incurred costs as reported for the year ended December 31, 2023.

(2)Percentage of current year incurred costs as reported for the year ended December 31, 2022.

Favorable prior year development in both years primarily reflects lower than expected utilization of medical services as compared to our assumptions.

The following table depicts the incurred and paid claims development and unpaid claims liability as of December 31, 2024 (net of reinsurance) reported in the Cigna Healthcare segment. The information about incurred and paid claims development for the year ended December 31, 2023 is presented as supplementary information and is unaudited.


	Incurred Costs
Incurral Year	2023 (Unaudited)		2024		Unpaid Claims and Claim Expenses
(In millions)
2023	$	34,878	$	34,437	213
2024			37,179		4,460
Cumulative incurred costs for the periods presented			$	71,616

	Cumulative Costs Paid
Incurral Year	2023 (Unaudited)		2024
(In millions)
2023	$	30,380	$	34,224
2024			32,719
Cumulative paid costs for the periods presented			$	66,943

Outstanding liabilities for the periods presented, net of reinsurance			$	4,673
Other long-duration liabilities not included in development table above			186
Net unpaid claims and claims expenses - Cigna Healthcare			4,859
Reinsurance and other amounts recoverable			159
Unpaid claims and claim expenses - Cigna Healthcare			$	5,018

Incurred claims do not typically remain outstanding for multiple years; more than 95% of health claims incurred in a year are paid by the end of the following year.

There is no single or common claim frequency metric used in the health care industry. The Company believes a relevant metric for its health insurance business is the number of customers for whom an insured medical claim was paid. Customers for whom no insured medical claim was paid are excluded from the calculation. Claims that did not result in a liability are not included in the frequency metric. The claim frequency for 2024 and 2023 was approximately 5.3 million and 5.5 million, respectively.

Future Policy Benefits

Accounting Policy. Future policy benefits represent the present value of estimated future obligations, estimated using actuarial methods, for long-duration insurance policies and annuity products currently in force, consisting primarily of reserves for annuity contracts, life insurance benefits and certain supplemental health products that are guaranteed renewable beyond one year.

Contracts are grouped at a level no higher than issue year, based on the original contract issue date, and at lower levels of disaggregation within each issue year for certain businesses to reflect factors including product type, plan type and currency. Management estimates these obligations based on assumptions for premiums, interest rates, mortality or morbidity, future claim adjudication expenses and surrenders. Mortality, morbidity and surrender assumptions are based on the Company's own experience and published actuarial tables and are updated at least annually, to the extent changes in circumstances require. Interest rate assumptions are based on market-level yields for low credit risk fixed income instruments ("upper-medium grade fixed income instrument"). For interest accretion purposes, interest rates are fixed at the year of the cohort's inception; however, for purposes of liability measurement, they are updated to the current rate quarterly, with all changes in the interest rate from inception to current period reported through Accumulated other comprehensive loss. For contracts issued domestically, we use observable inputs from a published spot rate curve for terms up to 30 years and extrapolate for longer terms using a constant forward rate approach. For contracts issued by foreign operating entities with functional currencies other than the U.S. dollar, we use observable inputs to approximate a risk free rate and add a credit spread adjustment to align with a low-credit risk fixed income instrument. For terms beyond the last observable risk free rates, which vary by international market, we extrapolate to the ultimate forward rate assuming a constant credit spread.

For the annuity business, the premium paying period is shorter than the benefit coverage period, and a deferred profit liability is reported in future policy benefits representing gross premium received in excess of net premiums. Deferred profit liability is amortized based on expected future benefit payments.

As of December 31, 2024, approximately 34% of the liability for future policy benefits, excluding amounts held for sale, was supported by assets in trust for the benefit of the ceding company under reinsurance agreements.

Cigna Healthcare

Other Operations

The weighted average interest rates applied and duration for future policy benefits in Other Operations, consisting of annuity and life insurance products, were as follows:


	As of
	December 31, 2024		December 31, 2023
Interest accretion rate	5.64	%	5.64	%
Current discount rate	5.42	%	4.87	%
Weighted average duration	10.8 years		11.4 years

Obligations for annuities represent discounted periodic benefits to be paid to an individual or groups of individuals over their remaining lives. Other Operations' traditional insurance contracts, which are in run-off, have no premium remaining to be collected; therefore, future policy benefit reserves represent the present value of expected future policy benefits, discounted using the current discount rate, and the remaining amortizable deferred profit liability.

Future policy benefits for Other Operations includes deferred profit liability of $366 million and $384 million as of December 31, 2024 and December 31, 2023, respectively. As of December 31, 2024, December 31, 2023 and December 31, 2022, future policy benefits excluding deferred profit liability were $2.9 billion, $3.2 billion and $3.2 billion, respectively. The decrease in future policy benefit reserves as of December 31, 2024 was primarily driven by benefit payments and current discount rate increases. Undiscounted expected future policy benefits were $4.3 billion and $4.5 billion as of December 31, 2024 and December 31, 2023, respectively. As of December 31, 2024 and December 31, 2023, $0.9 billion and $1.0 billion, respectively, of the future policy benefit reserve was recoverable through treaties with external reinsurers.

Contractholder Deposit Funds

Accounting Policy. Liabilities for contractholder deposit funds primarily include deposits received from customers for investment-related and universal life products as well as investment earnings on their fund balances in Other Operations. These liabilities are adjusted to reflect administrative charges and, for universal life fund balances, mortality charges. Interest credited on these funds is accrued ratably over the contract period.

Contractholder deposit fund liabilities within Other Operations were $6.3 billion, $6.5 billion and $6.7 billion as of December 31, 2024, December 31, 2023 and December 31, 2022, respectively. Approximately 38% of the balance is reinsured externally as of both December 31, 2024 and December 31, 2023. Activity in these liabilities is presented net of reinsurance in the Consolidated Statements of Cash Flows. The net year-to-date decrease in contractholder deposit fund liabilities generally relates to withdrawals and benefit payments from contractholder deposit funds, partially offset by deposits and interest credited to contractholder deposit funds.

As of December 31, 2024, the weighted average crediting rate, net amount at risk and cash surrender value for contractholder deposit fund liabilities not effectively exited through reinsurance were 3.33%, $2.8 billion and $2.8 billion, respectively. The comparative amounts as of December 31, 2023 were 3.31%, $3.0 billion and $2.8 billion, respectively. More than 99% of the $4.0 billion liability, as of both December 31, 2024 and December 31, 2023, not reinsured externally is for contracts with guaranteed interest rates of 3% - 4%, and approximately $1.2 billion as of both December 31, 2024 and December 31, 2023, represented contracts with policies at the guarantee. As of both December 31, 2024 and December 31, 2023, $1.2 billion was 50-150 basis points ("bps") above the guarantee and the remaining $1.6 billion represented contracts above the guarantee that pay the policyholder based on the greater of a guaranteed minimum cash value or the actual cash value. As of both December 31, 2024 and December 31, 2023, more than 90% of these contracts have actual cash values of at least 110% of the guaranteed cash value.

Market Risk Benefits

Liabilities for market risk benefits ("MRBs") consist of variable annuity reinsurance contracts in Other Operations. These liabilities arise under annuities and riders to annuities written by ceding companies that guarantee the benefit received at death and, for a subset of policies, also provide contractholders the option, within 30 days of a policy anniversary after the appropriate waiting period, to elect minimum income payments. The Company's capital market risk exposure on variable annuity reinsurance contracts arises when the reinsured guaranteed minimum benefit exceeds the contractholder's account value in the related underlying mutual funds at the time

the insurance benefit is payable under the respective contract. The Company receives and pays premium periodically based on the terms of the reinsurance agreements.

Accounting Policy. Variable annuity reinsurance liabilities are measured as MRBs at fair value, net of nonperformance risk, with fluctuations in value gross of reinsurer nonperformance risk reported in benefit expenses, while fluctuations in the Company's own nonperformance risk (own credit risk) are reported in Accumulated other comprehensive loss. Nonperformance risk reflects risk that a party might default and therefore not fulfill its obligations (i.e., nonpayment risk). The nonperformance risk adjustment reflects a market participant's view of nonpayment risk by adding an additional spread to the discount rate in the calculation of both (a) the variable annuity reinsurance liabilities to be paid by the Company and (b) the variable annuity reinsurance assets to be paid by the reinsurers, after considering collateral. The Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy described in Note 12 to the Consolidated Financial Statements because assumptions related to future annuitant behavior are largely unobservable. As discussed further in Note 10 to the Consolidated Financial Statements, due to the reinsurance agreements covering these liabilities, the liabilities do not generally impact net income except for the change in nonperformance risk on the reinsurance recoverable, which is reported in benefit expenses and does not offset the nonperformance risk valuation on the liability. Variable annuity liabilities are established using capital market assumptions and assumptions related to future annuitant behavior (including mortality, lapse and annuity election rates).

Market risk benefits activity was as follows:





	For the Years Ended December 31,
(Dollars in millions)	2024		2023
Balance, beginning of year	$	1,003	$	1,268
Balance, beginning of year, before the effect of nonperformance risk (own credit risk)	1,085		1,379
Changes due to expected run-off	(12)		(19)
Changes due to capital markets versus expected	(233)		(254)
Changes due to policyholder behavior versus expected	(39)		(5)
Assumption changes	37		(16)
Balance, end of period, before the effect of changes in nonperformance risk (own credit risk)	838		1,085
Nonperformance risk (own credit risk), end of period	(53)		(82)
Balance, end of period	$	785	$	1,003
Reinsured market risk benefit, end of period	$	836	$	1,081

The following table presents the account value, net amount at risk, average attained age of contractholders (weighted by exposure) and the number of contractholders for guarantees assumed by the Company. The net amount at risk is the amount that the Company would have to pay to contractholders if all deaths or annuitizations occurred as of the earliest possible date in accordance with the insurance contract. As of December 31, 2024, the account value increased primarily due to favorable equity market performance, which resulted in a decrease to the net amount at risk. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded.


(Dollars in millions, excludes impact of reinsurance ceded)	December 31, 2024		December 31, 2023
Account value	$	7,777	$	7,736
Net amount at risk	$	1,283	$	1,609
Average attained age of contractholders (weighted by exposure)	77.7 years		77.3 years
Number of contractholders (estimated)	130,000		140,000

Reinsurance

12 Months Ended

Dec. 31, 2024

Reinsurance Disclosures [Abstract]

Reinsurance

Note 10 – Reinsurance

The Company's insurance subsidiaries enter into agreements with other insurance companies to limit losses from large exposures and to permit recovery of a portion of incurred losses. Reinsurance is ceded primarily in acquisition and disposition transactions when the underwriting company is not being acquired. Reinsurance does not relieve the originating insurer of liability. Therefore, reinsured liabilities must continue to be reported along with the related reinsurance recoverables. The Company regularly evaluates the financial condition of its reinsurers and monitors concentrations of its credit risk.

Accounting Policy. Reinsurance recoverables represent amounts due from reinsurers for both paid and unpaid claims of the Company's insurance businesses. The Company bears the risk of loss if its reinsurers and retrocessionaires do not meet or are unable to meet their reinsurance obligations to the Company. Most reinsurance recoverables are classified as non-current assets. The current portion of reinsurance recoverables is reported in Other current assets and consists primarily of recoverables on paid claims expected to be settled within one year. Reinsurance recoverables are presented net of allowances, consisting primarily of an allowance for expected credit losses, which is recognized on reinsurance recoverable balances each period and adjusted through Medical costs and other benefit expenses. Estimates of the allowance for expected credit losses are based on internal and external data used to develop expected loss rates over the anticipated duration of the recoverable asset that vary by external credit rating and collateral level.

Collateral levels are defined internally based on the fair value of the collateral relative to the carrying amount of the reinsurance recoverable, the frequency at which collateral is required to be replenished and the potential for volatility in the collateral's fair value.

The Company's reinsurance recoverables as of December 31, 2024 are presented at amount due by range of external credit rating and collateral level in the following table, with reinsurance recoverables that are market risk benefits separately presented at fair value:


(In millions)	Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable		Collateral Provisions Exist That May Mitigate Risk of Credit Loss (1)		No Collateral		Total
Ongoing Operations
A- equivalent and higher current ratings (2)	$	—	$	7	$	233	$	240
BBB- to BBB+ equivalent current credit ratings (2)	—		—		63		63
Not rated	144		1		3		148
Acquisition, disposition or run-off activities
BBB+ equivalent and higher current ratings (2)(3)	476		2,854		136		3,466

Not rated	—		6		3		9
Total reinsurance recoverables before market risk benefits	$	620	$	2,868	$	438	$	3,926
Allowance for uncollectible reinsurance							(30)
Market risk benefits							836
Total reinsurance recoverables (4)							$	4,732

(1)Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level.

(2)Certified by a Nationally Recognized Statistical Ratings Organization ("NRSRO").

(3)Comprised of 21 reinsurers of which 73% is held by two reinsurers, Lincoln National Life Insurance Company and Lincoln Life and Annuity Company of New York.

(4)Includes $159 million of current reinsurance recoverables that are reported in Other current assets and $195 million of reinsurance recoverables classified as assets of businesses held for sale.

The Company entered into an agreement with Berkshire to effectively exit the variable annuity reinsurance business via a reinsurance transaction in 2013. Variable annuity contracts are accounted for as assumed and ceded reinsurance and categorized as market risk benefits as discussed in Note 9 to the Consolidated Financial Statements. Berkshire reinsured 100% of the Company's future cash flows in this business, net of other reinsurance arrangements existing at that time. The reinsurance agreement is subject to an overall limit with approximately $3.0 billion remaining at December 31, 2024. As a result of the reinsurance transaction, amounts payable are offset by a corresponding reinsurance recoverable, provided the increased recoverable remains within the overall Berkshire limit. As of both December 31, 2024 and 2023, market risk benefits (shown in the table net of nonperformance risk as of December 31, 2024) are predominantly reinsured by Berkshire, which is rated AA+ by an NRSRO. Approximately 95% of the Berkshire recoverable is secured by assets in a trust.

Effects of Reinsurance

Total short-duration contract premiums (direct, assumed and ceded) were $43.9 billion, $42.3 billion and $36.9 billion for the years ended December 31, 2024, 2023 and 2022, respectively. Total long-duration contract premiums (direct, assumed and ceded) were $2.0 billion, $1.9 billion and $3.0 billion for the years ended December 31, 2024, 2023 and 2022, respectively. Reinsurance recoveries of $573 million, $456 million and $702 million as of December 31, 2024, 2023 and 2022, respectively, have been netted against Medical costs and other benefit expenses in the Company’s Consolidated Statements of Income.

Both short- and long-duration premiums are primarily direct premiums; the amounts assumed and ceded were not material. Total short-duration contract written premiums were $42.6 billion, $41.1 billion and $35.0 billion for the years ended December 31, 2024, 2023 and 2022, respectively.

Investments

12 Months Ended

Dec. 31, 2024

Investments [Abstract]

Investments

Note 11 – Investments

The following table summarizes the Company's investments by category and current or long-term classification:


	December 31, 2024						December 31, 2023
(In millions)	Current		Long-Term		Total		Current		Long-Term		Total
Debt securities	$	463	$	8,960	$	9,423	$	590	$	9,265	$	9,855
Equity securities	7		554		561		31		3,331		3,362
Commercial mortgage loans	108		1,243		1,351		182		1,351		1,533
Policy loans	—		1,156		1,156		—		1,211		1,211
Other long-term investments	—		4,576		4,576		—		4,181		4,181
Short-term investments	170		—		170		206		—		206
Total	$	748	$	16,489	$	17,237	$	1,009	$	19,339	$	20,348
Investments classified as assets of businesses held for sale (1)	(83)		(1,361)		(1,444)		(84)		(1,354)		(1,438)
Investments per Consolidated Balance Sheets	$	665	$	15,128	$	15,793	$	925	$	17,985	$	18,910

(1) Investments related to the HCSC transaction that were held for sale as of December 31, 2024. These investments were primarily comprised of debt securities.

Accounting Policy. Debt securities, commercial mortgage loans, derivative financial instruments and short-term investments with contractual maturities during the next 12 months are classified on the balance sheet as current investments, unless they are held as statutory deposits or restricted for other purposes and then they are classified as Long-term investments. Equity securities may include funds that are used in our cash management strategy and are classified as current investments. All other investments are classified as Long-term investments. See Note 12 for information about the valuation of the Company's investment portfolio.

Investment Portfolio

Debt Securities

Accounting Policy. Debt securities (including bonds, mortgage and other asset-backed securities, and preferred stocks redeemable by the investor) are classified as available for sale and are carried at fair value with changes in fair value recorded either in Accumulated other comprehensive loss within Shareholders' equity or in credit loss expense based on fluctuations in the allowance for credit losses, as further discussed below. When the Company intends to sell or determines that it is more likely than not to be required to sell an impaired debt security, the excess of amortized cost over fair value is directly written down with a charge to Net investment losses. Certain asset-backed securities are considered variable interest entities. See Note 13 for additional information.

The Company reviews declines in fair value from a debt security's amortized cost basis to determine whether a credit loss exists and, when appropriate, recognizes a credit loss allowance with a corresponding charge to credit loss expense, presented in Net investment losses in the Company's Consolidated Statements of Income. The allowance for credit loss represents the excess of amortized cost over the greater of its fair value or the net present value of the debt security's projected future cash flows (based on qualitative and quantitative factors, including the probability of default and the estimated timing and amount of recovery). Each period, the allowance for credit loss is adjusted as needed through credit loss expense.

The Company does not measure an allowance for credit losses for accrued interest receivables. When interest payments are delinquent based on contractual terms or when certain terms (interest rate or maturity date) of the investment have been restructured, accrued interest, reported in Other current assets, is written off through a charge to Net investment income and interest income is recognized on a cash basis.

The amortized cost and fair value by contractual maturity periods for debt securities were as follows as of December 31, 2024:



(In millions)	Amortized Cost		Fair Value
Due in one year or less	$	622	$	553
Due after one year through five years	3,927		3,759
Due after five years through ten years	3,164		2,960
Due after ten years	2,041		1,813
Mortgage and other asset-backed securities	371		338
Total	$	10,125	$	9,423

Actual maturities of these securities could differ from their contractual maturities used in the table above because issuers may have the right to call or prepay obligations, with or without penalties.

Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below:


(In millions)	Amortized Cost		Allowance for Credit Loss		Unrealized Appreciation		Unrealized Depreciation		Fair Value
December 31, 2024
Federal government and agency	$	276	$	—	$	14	$	(9)	$	281
State and local government	37		—		1		(1)		37
Foreign government	350		—		5		(11)		344
Corporate	9,091		(111)		102		(659)		8,423
Mortgage and other asset-backed	371		—		1		(34)		338
Total	$	10,125	$	(111)	$	123	$	(714)	$	9,423


December 31, 2023
Federal government and agency	$	251	$	—	$	24	$	(8)	$	267
State and local government	37		—		2		(1)		38
Foreign government	355		—		10		(13)		352
Corporate	9,338		(33)		158		(630)		8,833
Mortgage and other asset-backed	398		—		1		(34)		365
Total	$	10,379	$	(33)	$	195	$	(686)	$	9,855

Review of Declines in Fair Value. Management reviews debt securities in an unrealized loss position to determine whether a credit loss allowance is needed based on criteria that include severity of decline; financial health and specific prospects of the issuer; and changes in the regulatory, economic or general market environment of the issuer's industry or geographic region.

The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded (by investment grade and the length of time these securities have been in an unrealized loss position). Unrealized depreciation on these debt securities is primarily due to declines in fair value resulting from increasing interest rates since these securities were purchased.


	December 31, 2024							December 31, 2023
(Dollars in millions)	Fair Value		Amortized Cost		Unrealized Depreciation		Number of Issues	Fair Value		Amortized Cost		Unrealized Depreciation		Number of Issues
One year or less
Investment grade	$	1,203	$	1,227	$	(24)	545	$	330	$	338	$	(8)	142
Below investment grade	245		250		(5)		739	161		170		(9)		135
More than one year
Investment grade	4,687		5,319		(632)		1,297	5,441		6,036		(595)		1,590
Below investment grade	416		469		(53)		123	701		775		(74)		486
Total	$	6,551	$	7,265	$	(714)	2,704	$	6,633	$	7,319	$	(686)	2,353

Equity Securities

Accounting Policy. Equity securities with a readily determinable fair value consist primarily of public equity investments in the health care sector and mutual funds that invest in fixed income debt securities while those without a readily determinable fair value consist of private equity investments. Changes in the fair values of equity securities that have a readily determinable fair value are reported in Net investment losses. Equity securities without a readily determinable fair value are carried at cost minus impairment plus or minus changes resulting from observable price changes.

The following table provides the values of the Company's equity security investments:


	December 31, 2024				December 31, 2023
(In millions)	Cost		Carrying Value		Cost		Carrying Value
Equity securities with readily determinable fair values	$	635	$	37	$	656	$	51
Equity securities with no readily determinable fair value	3,215		524		3,248		3,311
Total	$	3,850	$	561	$	3,904	$	3,362

We are a minority owner in VillageMD, a provider of primary, multi-specialty and urgent care services that is majority-owned by Walgreens Boots Alliance, Inc. These securities are included in equity securities with no readily determinable fair value in the above

table. We determined our investment in VillageMD was fully impaired and recorded a $2.7 billion loss in Net investment losses in the Company's Consolidated Statements of Income during the year ended December 31, 2024.

Commercial Mortgage Loans

Accounting Policy. Commercial mortgage loans are carried at unpaid principal balances, net of an allowance for expected credit losses, and classified as either current or long-term investments based on their contractual maturities. Changes in the allowance for expected credit losses are recognized as credit loss expense and presented in Net investment losses in the Company's Consolidated Statements of Income.

Each period, the Company establishes (or adjusts) its allowance for expected credit losses for commercial mortgage loans. The allowance for expected credit losses is based on a credit risk category that is assigned to each loan at origination using key credit quality indicators, including debt service coverage and loan-to-value ratios. Credit risk categories are updated as key credit quality indicators change. An expected loss rate, assigned based on the credit risk category, is applied to each loan's unpaid principal balance to develop the aggregate allowance for expected credit losses. Commercial mortgage loans are considered impaired and written off against the allowance when it is probable that the Company will not collect all amounts due per the terms of the promissory note. In the event of a foreclosure, the allowance for credit losses is based on the excess of the carrying value of the mortgage loan over the fair value of its underlying collateral.

Mortgage loans held by the Company are made exclusively to commercial borrowers and are diversified by property type, location and borrower. Loans are generally issued at fixed rates of interest and are secured by high-quality, primarily completed and substantially leased operating properties.

Credit Quality. The Company regularly evaluates and monitors credit risk. Mortgage origination professionals employ an internal credit quality rating system designed to evaluate the relative risk of the transaction at origination that is then updated each year as part of the annual portfolio loan review. The Company evaluates and monitors credit quality on a consistent and ongoing basis. The annual portfolio review performed in the second quarter of 2024 confirmed ongoing strong overall credit quality in line with the previous year's results.

Quality ratings are based on our evaluation of a number of key inputs related to the loan. The two most significant contributors to the credit quality rating are the debt service coverage and loan-to-value ratios. The debt service coverage ratio measures the amount of property cash flow available to meet annual interest and principal payments on debt, with a ratio below 1.0 indicating that there is not enough cash flow to cover the required loan payments. The loan-to-value ratio, commonly expressed as a percentage, compares the amount of the loan to the fair value of the underlying property collateralizing the loan.

The following table summarizes the credit risk profile of the Company's commercial mortgage loan portfolio:


(Dollars in millions)	December 31, 2024					December 31, 2023
Loan-to-Value Ratio	Carrying Value		Average Debt Service Coverage Ratio	Average Loan-to-Value Ratio		Carrying Value		Average Debt Service Coverage Ratio	Average Loan-to-Value Ratio
Below 60%	$	547	2.07			$	802	2.13
60% to 79%	595		1.83			574		1.77
80% to 100%	209		0.51			157		0.65



Total	$	1,351	1.70	69	%	$	1,533	1.82	64	%

Policy Loans

Accounting Policy. Policy loans, primarily associated with our corporate-owned life insurance business, are carried at unpaid principal balances plus accumulated interest, the total of which approximates fair value. These loans are collateralized by life insurance policy cash values and therefore have minimal exposure to credit loss. Interest rates are reset annually based on a rolling average of benchmark interest rates.

Other Long-Term Investments

Accounting Policy. Other long-term investments include investments in unconsolidated entities, including certain limited partnerships and limited liability companies holding real estate, securities or loans, and health care-related investments. These investments are carried at cost plus the Company's ownership percentage of reporting income or loss, based on the financial statements of the

underlying investments that are generally reported at fair value. Income or loss from these investments is reported on a one-quarter lag due to the timing of when financial information is received from the general partner or manager of the investments.

Other long-term investments also include investment real estate carried at depreciated cost less any impairment write-downs to fair value when cash flows indicate that the carrying value may not be recoverable. Depreciation is generally recorded using the straight-line method based on the estimated useful life of each asset. Investment real estate as of December 31, 2024 and 2023 is expected to be held longer than one year and may include real estate acquired through the foreclosure of commercial mortgage loans.

Additionally, foreign currency swaps carried at fair value and certain restricted deposits are reported in the table below as "Other." See discussion below for information on the Company's accounting policies for derivative financial instruments.

Other long-term investments and related commitments are diversified by issuer, property type and geographic regions. These investments are primarily unconsolidated variable interest entities (see Note 13 for additional information). The following table provides unfunded commitment and carrying value information for these investments. The Company expects to disburse approximately 31% of the committed amounts in 2025.

Our limited partnership investments are reduced as the Company receives cash distributions for returns on its investment that were previously recognized in Net investment income. The amount of these cash distributions was $344 million in 2024, $253 million in 2023 and $487 million in 2022.



					Unfunded Commitments as of
	Carrying Value as of December 31,
(In millions)	2024		2023		December 31, 2024
Real estate investments	$	1,763	$	1,606	$	850
Securities partnerships	2,587		2,400		1,809
Other	226		175		—
Total	$	4,576	$	4,181	$	2,659

Short-Term Investments

Accounting Policy. Security investments with maturities of greater than three months to one year from time of purchase are classified as short-term, available for sale and carried at fair value that approximates cost.

Concentration of Risk

The Company did not have a concentration of investments in a single issuer or borrower exceeding 10% of shareholders' equity as of December 31, 2024 or 2023.

Derivative Financial Instruments

The Company uses derivative financial instruments to manage the characteristics of investment assets (such as duration, yield, currency and liquidity) to meet the varying demands of the related insurance and contractholder liabilities. The Company also uses derivative financial instruments to hedge the risk of changes in the net assets of certain of its foreign subsidiaries due to changes in foreign currency exchange rates and to hedge the interest rate risk of certain long-term debt.

Accounting Policy. Derivatives are recorded in our Consolidated Balance Sheets at fair value and are classified as current or non-current according to their contractual maturities. Further information on our policies for determining fair value are discussed in Note 12. The Company applies hedge accounting when derivatives are designated, qualified and highly effective as hedges. Under hedge accounting, the changes in fair value of the derivative and the hedged risk are generally recognized together and offset each other when reported in Shareholders' net income. Various qualitative or quantitative methods appropriate for each hedge are used to formally assess and document hedge effectiveness at inception and each period throughout the life of a hedge.

Fair Value Hedges of the Foreign Exchange-Related Changes in Fair Values of Certain Foreign-Denominated Bonds:

This program hedges the foreign exchange-related changes in fair values of certain foreign-denominated bonds. The notional value of these derivatives matches the amortized cost of the hedged bonds. A majority of these instruments are denominated in Euros, with the remaining instruments denominated in British Pounds Sterling and Australian Dollars. Swap fair values are reported in Long-term investments or Other non-current liabilities. Offsetting changes in fair values attributable to the foreign exchange risk of the swap contracts and the hedged bonds are reported in Net investment losses. The portion of the swap contracts' changes in fair value excluded from the assessment of hedge effectiveness is recorded in Other comprehensive loss and recognized in Net investment

income as swap coupon payments are accrued, offsetting the foreign-denominated coupons received on the designated bonds. Net cash flows are reported in Operating activities, while exchanges of notional principal amounts are reported in Investing activities.

Fair Value Hedges of the Interest Rate Exposure on the Company's Long-Term Debt:

This program converts a portion of the interest rate exposure on the Company's long-term debt from fixed to variable rates. This more closely aligns the Company's interest expense with the interest income received on its cash equivalent and short-term investment balances. The variable rates are benchmarked to SOFR. Using fair value hedge accounting, the fair values of the swap contracts are reported in other assets or other liabilities. The critical terms of these swaps match those of the long-term debt being hedged. As a result, the carrying value of the hedged debt is adjusted to reflect changes in its fair value driven by SOFR. The effects of those adjustments on interest expense are offset by the effects of corresponding changes in the swaps' fair value. The net impact from the hedge reported in Interest expense and other reflects interest expense on the hedged debt at the variable interest rate. Cash flows relating to these contracts are reported in Operating activities.

Net Investment Hedges of Certain Foreign Subsidiaries Operating Principally in Currencies Other than the U.S. Dollar:

This program reduces the risk of changes in net assets due to changes in foreign currency spot exchange rates for certain foreign subsidiaries that conduct their business principally in currencies other than the U.S. Dollar. The notional value of hedging instruments matches the hedged amount of subsidiary net assets. Foreign currency swap contracts are denominated in Euros. The fair values of the foreign currency swap and forward contracts are reported in other assets or other liabilities. The changes in fair values of these instruments are reported in Other comprehensive loss, specifically in translation of foreign currencies. The portion of the change in fair values relating to foreign exchange spot rates will be recognized in earnings upon deconsolidation of the hedged foreign subsidiaries. Cash flows relating to these contracts are reported in Investing activities.

The effects of derivative financial instruments used in our individual hedging strategies were not material to the Consolidated Financial Statements as of December 31, 2024 and December 31, 2023. The gross fair values of our derivative financial instruments are presented in Note 12 to the Consolidated Financial Statements. The following table summarizes the types and notional quantity of derivative instruments held by the Company:


	Notional Value as of
(In millions)	December 31, 2024		December 31, 2023
Type of Instrument
Fair value hedge - Foreign currency swap contracts	$	975	$	1,026
Fair value hedge - Interest rate swap contracts	$	2,700	$	1,500
Net investment hedge - Foreign currency swap contracts	$	415	$	415

Net Investment Income

Accounting Policy. When interest and principal payments on investments are current, the Company recognizes interest income when it is earned. The Company recognizes interest income on a cash basis when interest payments are delinquent based on contractual terms or when certain terms (interest rate or maturity date) of the investment have been restructured. For unconsolidated entities that are included in other long-term investments, investment income is generally recognized according to the Company's share of the reported income or loss on the underlying investments. Investment income attributed to the Company's separate accounts is excluded from our earnings because associated gains and losses generally accrue directly to separate account policyholders.

The components of Net investment income were as follows:


	For the Years Ended December 31,
(In millions)	2024		2023		2022
Debt securities	$	492	$	500	$	572
Equity securities (1)	(114)		123		14
Commercial mortgage loans	61		65		59
Policy loans	56		60		59
Other long-term investments	75		123		390
Short-term investments and cash	447		339		115
Total investment income	1,017		1,210		1,209
Less investment expenses	44		44		54
Net investment income	$	973	$	1,166	$	1,155

(1)Includes a $182 million impairment of dividend receivable for the year ended December 31, 2024. See the Equity Securities section of Note 11A to the Consolidated Financial Statements for additional information.

Investment Gains and Losses

Accounting Policy. Investment gains and losses are based on specifically identified assets and result from sales, investment asset write-downs, changes in the fair value of certain derivatives and equity securities and changes in allowances for credit losses on debt securities and commercial mortgage loan investments.

Net investment losses before income taxes were $2,737 million, $78 million and $487 million for the years ended December 31, 2024, 2023 and 2022, respectively. This increase was primarily driven by the impairment of equity securities in 2024. These amounts exclude investment gains and losses attributed to the Company's separate accounts because those gains and losses generally accrue directly to separate account policyholders.

Fair Value Measurements

12 Months Ended

Dec. 31, 2024

Fair Value Disclosures [Abstract]

Fair Value Measurements

Note 12 – Fair Value Measurements

Accounting Policy. The Company carries certain financial instruments at fair value in the financial statements including debt securities, certain equity securities, short-term investments and derivatives. Other financial instruments are measured at fair value only under certain conditions, such as when impaired or when there are observable price changes for equity securities with no readily determinable fair value.

Fair value is defined as the price at which an asset could be exchanged in an orderly transaction between market participants at the balance sheet date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a market participant, not the amount that would be paid to settle the liability with the creditor.

The Company's financial assets and liabilities carried at fair value have been classified based upon a hierarchy defined by GAAP. The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level 3). An asset's or a liability's classification is based on the lowest level of input that is significant to its measurement. For example, a financial asset or liability carried at fair value would be classified in Level 3 if unobservable inputs were significant to the instrument's fair value, even though the measurement may be derived using inputs that are both observable (Levels 1 and 2) and unobservable (Level 3).

The Company estimates fair values using prices from third parties or internal pricing methods. Fair value estimates received from third-party pricing services are based on reported trade activity and quoted market prices when available and other market information that a market participant would use to estimate fair value. The internal pricing methods are performed by the Company's investment professionals and generally involve using discounted cash flow analyses, incorporating current market inputs for similar financial instruments with comparable terms and credit quality as well as other qualitative factors. In instances where there is little or no market activity for the same or similar instruments, fair value is estimated using methods, models and assumptions that the Company believes a hypothetical market participant would use to determine a current transaction price. These valuation techniques involve some level of estimation and judgment that becomes significant with increasingly complex instruments or pricing models.

The Company is responsible for determining fair value and for assigning the appropriate level within the fair value hierarchy based on the significance of unobservable inputs. The Company reviews methodologies, processes and controls of third-party pricing services and compares prices on a test basis to those obtained from other external pricing sources or internal estimates. The Company performs ongoing analyses of both prices received from third-party pricing services and those developed internally to determine that they represent appropriate estimates of fair value. The controls executed by the Company include evaluating changes in prices and monitoring for potentially stale valuations. The Company also performs sample testing of sales values to confirm the accuracy of prior fair value estimates. The minimal exceptions identified during these processes indicate that adjustments to prices are infrequent and do not significantly impact valuations. An annual due diligence review of the most significant pricing service is conducted to review their processes, methodologies and controls. This review includes a walk-through of inputs for a sample of securities held across various asset types to validate the documented pricing process.

Financial Assets and Financial Liabilities Carried at Fair Value

The following table provides information about the Company's financial assets and liabilities carried at fair value. Further information regarding insurance assets and liabilities carried at fair value is provided in Note 9E to the Consolidated Financial Statements. Separate account assets are also recorded at fair value on the Company's Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to contractholders.


(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)				Significant Other Observable Inputs (Level 2)				Significant Unobservable Inputs (Level 3)				Total
	December 31, 2024		December 31, 2023		December 31, 2024		December 31, 2023		December 31, 2024		December 31, 2023		December 31, 2024		December 31, 2023
Financial assets at fair value
Debt securities
Federal government and agency	$	165	$	130	$	116	$	137	$	—	$	—	$	281	$	267
State and local government	—		—		37		38		—		—		37		38
Foreign government	—		—		344		352		—		—		344		352
Corporate	—		—		8,049		8,432		374		401		8,423		8,833
Mortgage and other asset-backed	—		—		295		319		43		46		338		365
Total debt securities	165		130		8,841		9,278		417		447		9,423		9,855
Equity securities (1)	1		4		36		47		—		—		37		51
Short-term investments	—		—		170		206		—		—		170		206
Derivative assets	—		—		168		131		—		1		168		132
Financial liabilities at fair value
Derivative liabilities	$	—	$	—	$	1	$	4	$	—	$	—	$	1	$	4

(1)Excludes certain equity securities that have no readily determinable fair value.

Level 1 Financial Assets

Inputs for instruments classified in Level 1 include unadjusted quoted prices for identical assets in active markets accessible at the measurement date. Active markets provide pricing data for trades occurring at least weekly and include exchanges and dealer markets.

Assets in Level 1 include actively traded U.S. government bonds and exchange-listed equity securities. A relatively small portion of the Company's investment assets are classified in this category given the narrow definition of Level 1 and the Company's investment asset strategy to maximize investment returns.

Level 2 Financial Assets and Financial Liabilities

Inputs for instruments classified in Level 2 include quoted prices for similar assets or liabilities in active markets, quoted prices from those willing to trade in markets that are not active, or other inputs that are market-observable or can be corroborated by market data for the term of the instrument. Such other inputs include market interest rates and volatilities, spreads, and yield curves. An instrument is classified in Level 2 if the Company determines that unobservable inputs are insignificant.

Debt and Equity Securities. Third-party pricing services and internal methods often use recent trades of securities with similar features and characteristics because many debt securities do not trade daily. Pricing models are used to determine these prices when recent trades are not available. These models calculate fair values by discounting future cash flows at estimated market interest rates. Such market rates are derived by calculating the appropriate spreads over comparable U.S. Treasury securities based on the credit quality, industry and structure of the asset. Typical inputs and assumptions to pricing models include, but are not limited to, a combination of benchmark yields, reported trades, issuer spreads, liquidity, benchmark securities, bids, offers, reference data, and industry and economic events. For mortgage-backed securities, inputs and assumptions may also include characteristics of the issuer, collateral attributes, prepayment speeds and credit rating. Nearly all of these instruments are valued using recent trades or pricing models.

Short-term Investments are carried at fair value that approximates cost. The Company compares market prices for these securities to recorded amounts on a regular basis to validate that current carrying amounts approximate exit prices. The short-term nature of the investments and corroboration of the reported amounts over the holding period support their classification in Level 2.

Derivative Assets and Liabilities classified in Level 2 represent over-the-counter instruments, such as foreign currency forward and swap contracts. Fair values for these instruments are determined using market-observable inputs, including forward currency and interest rate curves and widely published market-observable indices. Credit risk related to the counterparty and the Company is considered when estimating the fair values of these derivatives. The nature and use of these derivative financial instruments are described in Note 11.

Level 3 Financial Assets and Financial Liabilities

Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Additionally, as discussed in Note 9E to the Consolidated Financial Statements, the Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy.

The Company classifies certain newly issued, privately placed, complex or illiquid securities in Level 3. Approximately 5% of debt securities are priced using significant unobservable inputs and classified in this category.

Fair values of mortgage and other asset-backed securities, as well as corporate and government debt securities, are primarily determined using pricing models that incorporate the specific characteristics of each asset and related assumptions, including the investment type and structure, credit quality, industry and maturity date in comparison to current market indices, spreads, and liquidity of assets with similar characteristics. Inputs and assumptions for pricing may also include characteristics of the issuer, collateral attributes, and prepayment speeds for mortgage and other asset-backed securities. Recent trades in the subject security or similar securities are assessed when available, and the Company may also review published research in its evaluation, as well as the issuer's financial statements.

Quantitative Information about Unobservable Inputs

The significant unobservable input used to value our corporate and government debt securities and mortgage and other asset-backed securities is an adjustment for liquidity. This adjustment is needed to reflect current market conditions and issuer circumstances when there is limited trading activity for the security.

The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities. The range and weighted average basis point amounts for liquidity reflect the Company's best estimates of the unobservable adjustments a market participant would make to calculate these fair values. An increase in liquidity spread adjustments would result in a lower fair value measurement, while a decrease would result in a higher fair value measurement.


	Fair Value as of					Unobservable Adjustment Range (Weighted Average by Quantity) as of
(Fair value in millions)	December 31, 2024		December 31, 2023		Unobservable Input December 31, 2024	December 31, 2024		December 31, 2023
Debt securities
Corporate	$	373	$	401	Liquidity	60 - 1520 (370)	bps	70 - 1235 (310)	bps
Mortgage and other asset-backed securities	43		46		Liquidity	100 - 550 (280)	bps	95 - 640 (310)	bps
Other debt securities	1		—
Total Level 3 debt securities	$	417	$	447

Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value

The following table summarizes the changes in financial assets and financial liabilities classified in Level 3. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs.



	Years Ended December 31,
(In millions)		2024		2023
Debt Securities
Beginning balance		$	447	$	447
Losses included in Shareholders' net income		(69)		(2)
(Losses) gains included in Other comprehensive loss		(9)		8

Purchases, sales and settlements
Purchases		17		10
Sales		(2)		—
Settlements		(21)		(52)
Total purchases, sales and settlements		(6)		(42)
Transfers into / (out of) Level 3
Transfers into Level 3		72		95
Transfers out of Level 3		(18)		(59)
Total transfers into / (out of) Level 3		54		36
Ending balance		$	417	$	447
Total losses included in Shareholders' net income attributable to instruments held at the reporting date		$	(69)	$	(2)
Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period		$	(9)	$	3

Total gains and losses included in Shareholders' net income in the tables above are reflected in the Consolidated Statements of Income as Net investment losses and Net investment income. Gains and losses included in Other comprehensive loss, net of tax in the tables above are reflected in Net unrealized appreciation (depreciation) on securities and derivatives in the Consolidated Statements of Comprehensive Income.

Transfers into or out of the Level 3 category occur when unobservable inputs, such as the Company's best estimate of what a market participant would use to determine a current transaction price, become more or less significant to the fair value measurement. Market activity typically decreases during periods of economic uncertainty, and this decrease in activity reduces the availability of market observable data. As a result, the level of unobservable judgment that must be applied to the pricing of certain instruments increases and is typically observed through the widening of liquidity spreads. Transfers between Level 2 and Level 3 during 2024 and 2023 primarily reflected changes in liquidity estimates for certain private placement issuers across several sectors. See discussion under Quantitative Information about Unobservable Inputs above for more information.

Separate Accounts

Accounting Policy. Separate account assets and liabilities are contractholder funds maintained in accounts with specific investment objectives. Our subsidiaries or external advisors manage invested assets of separate accounts on behalf of contractholders, including The Cigna Group Pension Plan, variable universal life products sold through our corporate-owned life insurance products and the run-off businesses. The assets of these accounts are legally segregated and are not subject to claims that arise out of any of the Company's other businesses. These separate account assets are carried at fair value with equal amounts recorded for related separate account liabilities. The investment income and fair value gains and losses of separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company's Consolidated Statements of Income and Cash Flows. Fees and charges earned for mortality risks, asset management or administrative services are reported in either Premiums or Fees and other revenues. Investments that are measured using the practical expedient of net asset value ("NAV") are excluded from the fair value hierarchy. The separate account activity for the year ended December 31, 2024 and 2023 was primarily driven by changes in the market values of the underlying separate account investments.

Fair values of Separate account assets were as follows:


	Quoted Prices in Active Markets for Identical Assets (Level 1)				Significant Other Observable Inputs (Level 2)				Significant Unobservable Inputs (Level 3)				Total
(In millions)	December 31, 2024		December 31, 2023		December 31, 2024		December 31, 2023		December 31, 2024		December 31, 2023		December 31, 2024		December 31, 2023
Guaranteed separate accounts (See Note 21)	$	231	$	226	$	345	$	352	$	—	$	—	$	576	$	578
Non-guaranteed separate accounts (1)	267		158		5,575		5,797		228		217		6,070		6,172
Subtotal	$	498	$	384	$	5,920	$	6,149	$	228	$	217	6,646		6,750
Non-guaranteed separate accounts priced at NAV as a practical expedient (1)													632		680
Total													$	7,278	$	7,430

Non-guaranteed separate accounts include $3.8 billion as of December 31, 2024 and $4.0 billion as of December 31, 2023 in assets supporting the Company's pension plans, including $0.2 billion classified in Level 3 both as of December 31, 2024 and December 31, 2023. Non-guaranteed separate accounts are primarily comprised of securities partnerships, real estate and real estate funds.

Separate account assets classified as Level 1 primarily include exchange-listed equity securities. Level 2 assets primarily include corporate and structured bonds valued using recent trades of similar securities or pricing models that discount future cash flows at estimated market interest rates as described above, and actively traded institutional and retail mutual fund investments.

Separate account assets classified in Level 3 primarily support the Company's pension plans and include certain newly issued, privately placed, complex or illiquid securities that are priced using methods discussed above, as well as commercial mortgage loans. Activity, including transfers into and out of Level 3, was not material for the years ended December 31, 2024 or 2023.

Assets and Liabilities Measured at Fair Value under Certain Conditions

Some financial assets and liabilities are not carried at fair value, such as commercial mortgage loans that are carried at unpaid principal, investment real estate that is carried at depreciated cost and equity securities with no readily determinable fair value when there are no observable market transactions. However, these financial assets and liabilities may be measured using fair value under certain conditions, such as when investments become impaired and are written down to their fair value, or when there are observable price changes from orderly market transactions of equity securities that otherwise had no readily determinable fair value.

During 2024, we determined our investment in VillageMD was fully impaired and recorded a $2.7 billion loss in Net investment losses in the Company's Consolidated Statements of Income. For the year ended December 31, 2023, impairments recognized requiring the assets and liabilities described above to be measured at fair value were not material. Observable price changes for equity securities with no readily determinable fair value were not material for the year ended December 31, 2024 and December 31, 2023.

Fair Value Disclosures for Financial Instruments Not Carried at Fair Value

The following table includes the Company's financial instruments not recorded at fair value but for which fair value disclosure is required. In addition to universal life products and finance leases, financial instruments that are carried in the Company's Consolidated Balance Sheets at amounts that approximate fair value are excluded from the following table.


	Classification in Fair Value Hierarchy	December 31, 2024				December 31, 2023
(In millions)		Fair Value		Carrying Value		Fair Value		Carrying Value
Commercial mortgage loans	Level 3	$	1,256	$	1,351	$	1,430	$	1,533
Long-term debt, including current maturities, excluding finance leases	Level 2	$	28,392	$	31,008	$	28,033	$	29,585

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

Equity Method Investments and Joint Ventures [Abstract]

Variable Interest Entities	12 Months Ended
Variable Interest Entities	Dec. 31, 2024
Variable Interest Entities [Abstract]
Variable Interest Entities	Note 13 – Variable Interest Entities When the Company becomes involved with a variable interest entity and when there is a change in the Company's involvement with an entity, the Company must determine if it is the primary beneficiary and must consolidate the entity. The Company is considered the primary beneficiary if it has the power to direct the entity's most significant economic activities and has the right to receive benefits or obligation to absorb losses that could be significant to the entity. The Company evaluates the following criteria: the structure and purpose of the entity; the risks and rewards created by and shared through the entity; and the Company's ability to direct its activities, receive its benefits and absorb its losses relative to the other parties involved with the entity, including its sponsors, equity holders, guarantors, creditors and servicers. The Company determined it was not a primary beneficiary in any material variable interest entity as of December 31, 2024 or 2023. The Company's involvement in variable interest entities for which it is not the primary beneficiary is described below. Securities Limited Partnerships and Real Estate Limited Partnerships. The Company owns interests in securities limited partnerships and real estate limited partnerships that are defined as unconsolidated variable interest entities. These partnerships invest in the equity or mezzanine debt of privately held companies and real estate properties. General partners unaffiliated with the Company control decisions that most significantly impact the partnership's operations, and the limited partners do not have substantive kick-out or participating rights. The Company has invested in approximately 195 limited partnerships that have a carrying value of $3.2 billion as of December 31, 2024 reported in other long-term investments. As of December 31, 2024, we have commitments to contribute an additional $2.4 billion to these entities, and the Company's maximum exposure to loss from these investments is $5.6 billion, calculated as the sum of our carrying value and the additional funding commitments. Our noncontrolling interest in each of these limited partnerships is generally less than 10% of the partnership ownership interests. See Note 11 for further information on the Company's accounting policy for other long-term investments. The Company has guaranteed debt payments to mortgage lenders for certain real estate limited partnerships should potential environmental obligations arise. No liability has been incurred related to these guarantees, and the Company's maximum exposure to these guarantees was approximately $272 million as of December 31, 2024. Other Variable Interest Entities. The Company is involved in other types of variable interest entities, including certain asset-backed and corporate securities, real estate joint ventures that develop properties for residential and commercial use, independent physician associations that provide care management services, and international health care joint ventures. As of December 31, 2024, the Company's maximum exposure to loss is $0.4 billion from certain asset-backed and corporate securities and $0.9 billion from real estate joint ventures, which represents the sum of our carrying value and the additional funding commitments for these entities. The carrying values and maximum exposures for the remaining unconsolidated variable interest entities were not material as of December 31, 2024. The Company has not provided, and does not intend to provide, financial support to any of the variable interest entities in excess of its maximum exposure. We perform ongoing qualitative analyses of our involvement with these variable interest entities to determine if consolidation is required.

Collectively Significant Operating Unconsolidated Subsidiaries

12 Months Ended

Dec. 31, 2024

Collectively Significant Operating Unconsolidated Subsidiaries

Note 14 – Collectively Significant Operating Unconsolidated Subsidiaries

In addition to equity method investments in certain limited partnerships and limited liability companies holding real estate, securities or loans (as disclosed in Note 11), we maintain a portfolio of operating joint ventures accounted for as equity method investments. Operating joint ventures had a carrying value of $656 million as of December 31, 2024 and $911 million as of December 31, 2023, of which $43 million as of December 31, 2024 and $214 million as of December 31, 2023 related to our joint venture in China. Total Accumulated Other Comprehensive Income (Loss) ("AOCI") includes losses of $979 million as of December 31, 2024 and $510 million as of December 31, 2023 related to the Company's share of operating joint ventures primarily driven by the requirement to update discount rate assumptions for certain long-duration liabilities.

For the years ended December 31, 2024, 2023 and 2022, none of our equity method investments were individually significant.

In the fourth quarter of 2024, we sold a portion of an operating joint venture, reducing our ownership. As a result, we recognized $496 million within Net gain (loss) on sale of businesses in our Consolidated Statements of Income.

Accounting Policy. We record in our Consolidated Statements of Income our proportionate share of net income or loss generated by operating joint ventures within Fees and other revenues. In certain instances, income or loss is reported on a one-month lag due to the timing of when financial information is received.

The below summarized results of operations and financial position of the operating joint ventures reflects the latest available financial information and does not represent the Company's proportionate share of the assets, liabilities or earnings of such entities.


	For the Years Ended December 31,
(In millions)	2024		2023		2022
Revenues	$	7,309	$	5,962	$	4,665
Net income (loss)	$	607	$	98	$	(12)


(In millions)	December 31, 2024		December 31, 2023
Total assets	$	34,395	$	26,681
Total liabilities	$	33,892	$	25,534

Accumulated Other Comprehensive Income (Loss)

12 Months Ended

Dec. 31, 2024

Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]

Accumulated Other Comprehensive Income (Loss)

Note 15 – Accumulated Other Comprehensive Income (Loss)

Accumulated Other Comprehensive Income (Loss) includes net unrealized appreciation (depreciation) on securities and derivatives, change in discount rate and instrument-specific credit risk for certain long-duration insurance contractholder liabilities (Note 9 to the Consolidated Financial Statements), foreign currency translation, and the net postretirement benefits liability adjustment. AOCI includes the Company's share from unconsolidated entities reported on the equity method. Generally, tax effects in AOCI are established at the currently enacted tax rate and reclassified to Shareholders' net income in the same period that the related pre-tax AOCI reclassifications are recognized.

Shareholders' other comprehensive loss, net of tax, for the years ended 2024, 2023 and 2022 is primarily attributable to the change in discount rates for certain long-duration liabilities and unrealized changes in the market values of securities and derivatives, including the impacts from unconsolidated entities reported on the equity method.

Changes in the components of AOCI were as follows:


	For the Years Ended December 31,

(In millions)	2024		2023		2022
Securities and Derivatives


Beginning balance	$	171	$	(332)	$	1,266

Unrealized appreciation (depreciation) on securities and derivatives, before reclassification, net of tax (expense) benefit of $(207), $(146) and $467, respectively	601		474		(1,807)

Amounts reclassified to Shareholders' net income, net of tax (benefit) of $(16), $(8) and $(48), respectively	60		29		209
Other comprehensive income (loss), net of tax	661		503		(1,598)
Ending balance	$	832	$	171	$	(332)
Net long-duration insurance and contractholder liabilities measurement adjustments


Beginning balance	$	(971)	$	(256)	$	(765)

Net current period change in discount rate for certain long-duration liabilities, net of tax benefit (expense) of $357, $222 and $(122), respectively	(1,044)		(691)		520

Net current period change in instrument-specific credit risk for market risk benefits, net of tax benefit of $6, $5 and $3, respectively	(23)		(24)		(11)
Other comprehensive (loss) income, net of tax	(1,067)		(715)		509
Ending balance	$	(2,038)	$	(971)	$	(256)
Translation of foreign currencies


Beginning balance	$	(149)	$	(154)	$	(233)

Net translation of foreign currencies, before reclassification, net of tax benefit (expense) of $2, $5 and $(33), respectively	(60)		5		(310)

Amounts reclassified to Shareholders' net income, net of tax expense of $—, $— and $29, respectively	11		—		387
Other comprehensive (loss) income, net of tax	(49)		5		77


Less: Net translation (loss) on foreign currencies attributable to noncontrolling interests	—		—		(2)
Shareholders' other comprehensive (loss) income, net of tax	(49)		5		79
Ending balance	$	(198)	$	(149)	$	(154)
Postretirement benefits liability
Beginning balance	$	(915)	$	(916)	$	(1,336)

Amounts reclassified to Shareholders' net income, net of tax (benefit) of $(7), $(11) and $(16), respectively	22		35		48

Net change due to valuation update, before reclassification, net of tax benefit (expense) of $14, $12 and $(115), respectively	(44)		(34)		372
Other comprehensive (loss) income, net of tax	(22)		1		420
Ending balance	$	(937)	$	(915)	$	(916)
Total Accumulated other comprehensive loss


Beginning balance	$	(1,864)	$	(1,658)	$	(1,068)

Shareholders' other comprehensive (loss), net of tax benefit of $149, $79 and $165, respectively	(477)		(206)		(590)
Ending balance	$	(2,341)	$	(1,864)	$	(1,658)

Pension

12 Months Ended

Dec. 31, 2024

Retirement Benefits [Abstract]

Pension

Note 16 – Pension

A.About Our Plans

The Company sponsors U.S. and non-U.S. defined benefit pension plans; future benefit accruals for the domestic plans are frozen.

Accounting Policy. The Company measures the assets and liabilities of its domestic pension plans as of December 31. Benefit obligations are measured at the present value of estimated future payments based on actuarial assumptions. The Company uses the corridor method to account for changes in the benefit obligation when actual results differ from those assumed or when assumptions change. These changes are called net unrecognized actuarial gains (losses). Under the corridor method, net unrecognized actuarial gains (losses) are initially recorded in Accumulated other comprehensive loss. When the unrecognized gain (loss) exceeds 10% of the benefit obligation, that excess is amortized to expense over the expected remaining lives of plan participants. The net plan expense is reported in Interest expense and other in the Consolidated Statements of Income.

We measure plan assets at fair value for balance sheet purposes and to measure pension benefit costs. When the actual return differs from the expected return, those differences are reflected in the net unrealized actuarial gain (loss) discussed above.

B.Funded Status and Amounts Included in Accumulated Other Comprehensive Loss

The following table summarizes the projected benefit obligations and assets related to our U.S. and non-U.S. pension plans:


	For the Years Ended December 31,
(In millions)	2024		2023
Change in benefit obligation
Benefit obligation, January 1	$	3,934	$	3,948
Service cost	1		1
Interest cost	194		204

Actuarial (gains) losses, net (1)	(146)		93
Benefits paid from plan assets	(328)		(294)

Other	(12)		(18)
Benefit obligation, December 31	3,643		3,934
Change in plan assets
Fair value of plan assets, January 1	4,138		4,186
Actual return on plan assets	40		246
Benefits paid	(328)		(294)

Contributions	4		—
Fair value of plan assets, December 31	3,854		4,138
Funded status	$	211	$	204
Amounts presented in Consolidated Balance Sheets
Other assets	$	211	$	204

(1) 2024 gains reflect an increase in the discount rate, while 2023 losses reflect a decrease in the discount rate.

We fund our qualified pension plans at least at the minimum amount required by the Employee Retirement Income Security Act of 1974 and the Pension Protection Act of 2006. The Company made immaterial contributions to the qualified pension plans in 2024. For 2025, contributions to the qualified pension plans are expected to be immaterial. Future years' contributions will ultimately be based on a wide range of factors, including but not limited to asset returns, discount rates and funding targets. Nonqualified pension plans are generally funded on a pay-as-you-go basis as there are no plan assets for these plans.

Benefit Payments. The following benefit payments are expected to be paid in:


(In millions)
2025	$	315
2026	$	314
2027	$	311
2028	$	309
2029	$	306
2030 - 2034	$	1,443

Amounts reflected in the pension assets (liabilities) shown above that have not yet been reported in Net income and, therefore, have been included in Accumulated other comprehensive loss consisted of the following:


(In millions)	December 31, 2024		December 31, 2023
Unrecognized net (losses)	$	(1,228)	$	(1,207)
Unrecognized prior service cost	(4)		(4)
Postretirement benefits liability adjustment	$	(1,232)	$	(1,211)

C.Cost of Our Plans

Net pension cost was as follows:


	For the Years Ended December 31,
(In millions)	2024		2023		2022
Service cost	$	1	$	1	$	2
Interest cost	194		204		140
Expected long-term return on plan assets	(247)		(204)		(272)
Amortization of:
Prior actuarial losses, net	39		52		89


Curtailment loss	1		—		—
Net (benefit) cost	$	(12)	$	53	$	(41)

D.Assumptions Used for Pension


	For the Years Ended December 31,
	2024	2023
Discount rate:
Pension benefit obligation	5.57%	5.10%
Pension benefit cost	5.10%	5.43%
Expected long-term return on plan assets:
Pension benefit cost	6.50%	6.50%
Mortality table for pension obligations	White Collar mortality table with MP 2021 projection scale	White Collar mortality table with MP 2021 projection scale

The Company develops discount rates by applying actual annualized yields for high-quality bonds by duration to the expected pension plan liability cash flows. The bond yields represent a diverse mix of actively traded high-quality fixed income securities that have an above-average return at each duration as management believes this approach is representative of the yield achieved through plan asset investment strategy. The expected long-term return on plan assets was developed considering historical long-term actual returns, expected long-term market conditions, plan asset mix and management's plan asset investment strategy.

E.Pension Plan Assets

As of December 31, 2024, pension assets included $3.8 billion invested in the separate accounts of Connecticut General Life Insurance Company, a subsidiary of the Company, and an additional $0.1 billion invested in funds of unaffiliated investment managers.

The fair values of pension assets by category are as follows:


(In millions)	December 31, 2024		December 31, 2023
Debt securities:
Federal government and agency	$	99	$	12
Corporate	2,673		2,780
Asset-backed	138		121
Fund investments	76		278
Total debt securities	2,986		3,191
Equity securities:
Domestic	21		27
International, including funds and pooled separate accounts (1)	6		6
Total equity securities	27		33
Securities partnerships, including pooled separate accounts (1)	402		419
Real estate and real estate funds, including pooled separate accounts (1)	228		270
Commercial mortgage loans	27		46

Guaranteed deposit account contract	47		48
Cash equivalents and other current assets, net	137		131
Total pension assets at fair value	$	3,854	$	4,138

(1) A pooled separate account has several participating benefit plans and each owns a share of the total pool of investments.

The Company's current target investment allocation percentages are 90% fixed income and 10% in other investments, including private equity (securities partnerships), public equity securities, and real estate, and are developed by management as guidelines, although the fair values of each asset category are expected to vary as a result of changes in market conditions. The Company will evaluate further allocation changes to equity securities, other investments and fixed income securities as funding levels change.

See Note 12 for further details regarding how fair value is determined, including the level within the fair value hierarchy and the procedures we use to validate fair value measurements. The Company classifies substantially all debt securities in Level 2 for pension plan assets. These assets are valued using recent trades of similar securities or are fund investments priced using their daily net asset value that is the exit price. All domestic equity securities and international equity funds within pension assets are classified as Level 3.

Securities partnerships, real estate and hedge funds are valued using net asset value as a practical expedient and are excluded from the fair value hierarchy. See Note 12 for additional disclosures related to these assets invested in the separate accounts of the Company's subsidiary. Certain securities as described in Note 12, as well as commercial mortgage loans and guaranteed deposit account contracts, are classified in Level 3 because unobservable inputs used in their valuation are significant.

F.401(k) Plan

The Company sponsors a 401(k) plan. All employees are immediately eligible for the plan at hire. The Company matches a portion of employees' contributions to the plan and may increase its matching contributions if the Company's annual performance meets certain targets. Plan participants may invest in various funds that invest in the Company's common stock, several diversified stock funds, a bond fund or stable value funds. The Company common stock fund under the plan constitutes an "employee stock ownership plan" as defined in the Internal Revenue Code. Dividends from the Company common stock fund are reinvested in a participant's stock fund account unless the participant elects to receive the dividends in cash. The Company's annual expense for the plan was $301 million, $296 million and $274 million for the years ended December 31, 2024, 2023 and 2022, respectively.

The entire disclosure for retirement benefits.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 70
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480794/715-70-50-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480482/715-20-55-17

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (q)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/715/tableOfContent

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (o)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (p)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 60
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480266/715-60-50-3

Share-Based Payment Arrangement [Abstract]

Employee Incentive Plans

12 Months Ended

Dec. 31, 2024

Employee Incentive Plans

Note 17 – Employee Incentive Plans

A.About Our Plans

The People Resources Committee (the "Committee") of the Board of Directors awards stock options, restricted stock grants, restricted stock units, deferred stock and strategic performance shares to certain employees. The Company issues original issue shares for these awards.

The Company records compensation expense for stock and option awards over their vesting periods primarily based on the estimated fair value at the grant date. Fair value is determined differently for each type of award as discussed below.

Shares of common stock available for award were as follows:

(In millions)

December 31, 2024

December 31, 2023

December 31, 2022

Common shares available for award

12.4

14.4

16.6

B.Stock Options

Accounting Policy. The Company awards options to purchase The Cigna Group common stock at the market price of the stock on the grant date. Options vest over periods ranging from one year to three years and expire no later than 10 years from grant date. Fair value is estimated using the Black-Scholes option pricing model by applying the assumptions presented below. That fair value is reduced by options expected to be forfeited during the vesting period. The Company estimates forfeitures at the grant date based on our experience and adjusts the expense to reflect actual forfeitures over the vesting period. The fair value of options, net of forfeitures, is recognized in Selling, general and administrative expenses on a straight-line basis over the vesting period.

Black-Scholes option pricing model assumptions and the resulting fair value of options are presented in the following table:


	2024			2023			2022
Dividend yield	1.74		%	1.58		%	1.98		%
Expected volatility	30.0		%	30.0		%	30.0		%
Risk free interest rate	4.0		%	3.6		%	1.6		%
Expected option life	4.8 years			4.7 years			4.5 years
Weighted average fair value of options	$	92.36		$	79.66		$	50.61

The dividend yield reflects expected future dividends. The Company intends to continue to pay dividends for the foreseeable future. The expected volatility reflects the past daily stock price volatility of The Cigna Group stock. The Company does not consider volatility implied in the market prices of traded options to be a good indicator of future volatility because remaining traded options will expire within one year. The risk free interest rate is derived using the four-year U.S. Treasury bond yield rate as of the award date for the primary annual grant. Expected option life reflects the Company's historical experience.

The following table shows the status of, and changes in, common stock options:


	For the Years Ended December 31,
	2024			2023			2022
(Options in thousands)	Options	Weighted Average Exercise Price		Options	Weighted Average Exercise Price		Options	Weighted Average Exercise Price
Outstanding - January 1	6,696	$	202.02	6,992	$	186.54	8,490	$	169.47
Granted	781	$	336.48	915	$	294.37	1,375	$	226.95
Exercised	(1,727)	$	178.82	(1,080)	$	174.66	(2,617)	$	149.97
Expired or canceled	(95)	$	278.78	(131)	$	246.95	(256)	$	211.22
Outstanding - December 31	5,655	$	226.38	6,696	$	202.02	6,992	$	186.54
Options exercisable at year-end	3,941	$	196.01	4,616	$	179.28	4,410	$	168.97

Compensation expense of $69 million related to unvested stock options at December 31, 2024 will be recognized over the next two years (weighted average period).

The table below summarizes information for stock options exercised:


	For the Years Ended December 31,
(In millions)	2024		2023		2022
Intrinsic value of options exercised	$	275	$	126	$	313
Cash received for options exercised	$	305	$	187	$	389
Tax benefit from options exercised	$	34	$	17	$	47

The following table summarizes information for outstanding common stock options:


	December 31, 2024
	Options Outstanding		Options Exercisable
Number (in thousands)	5,655		3,941
Total intrinsic value (in millions)	$	341	$	320
Weighted average exercise price	$	226.38	$	196.01
Weighted average remaining contractual life	5.8 years		4.7 years

C.Restricted Stock

The Company awards restricted stock (grants and units) to the Company's employees that vest over periods ranging from one year to three years. Recipients of restricted stock awards accumulate dividends during the vesting period, but generally forfeit their awards and accumulated dividends if their employment terminates before the vesting date.

Accounting Policy. Fair value of restricted stock awards is equal to the market price of The Cigna Group common stock on the date of grant. This fair value is reduced by awards that are expected to forfeit. At the grant date, the Company estimates forfeitures based on experience and adjusts the expense to reflect actual forfeitures over the vesting period. This fair value, net of forfeitures, is recognized in Selling, general and administrative expenses over the vesting period on a straight-line basis.

The following table shows the status of, and changes in, restricted stock awards:


	For the Years Ended December 31,
	2024			2023			2022
(Awards in thousands)	Grants/Units	Weighted Average Fair Value at Award Date		Grants/Units	Weighted Average Fair Value at Award Date		Grants/Units	Weighted Average Fair Value at Award Date
Outstanding - January 1	1,404	$	257.38	1,535	$	219.25	1,524	$	202.85
Awarded	624	$	319.39	700	$	294.60	876	$	229.60
Vested	(713)	$	245.35	(759)	$	214.70	(714)	$	197.83
Forfeited	(65)	$	283.62	(72)	$	256.24	(151)	$	215.02
Outstanding - December 31	1,250	$	302.42	1,404	$	257.38	1,535	$	219.25

The fair value of vested restricted stock at the vesting date was as follows:


	For the Years Ended December 31,
(In millions)	2024		2023		2022
Fair value of vested restricted stock	$	238	$	220	$	167

Approximately 8,900 employees held 1.3 million restricted stock awards at the end of 2024 with $203 million of related compensation expense to be recognized over the next two years (weighted average period).

D.Strategic Performance Shares ("SPSs")

The Company awards SPSs to executives and certain other key employees generally with a performance period of three years. Half of these shares are subject to a market condition (total shareholder return relative to industry peer companies), and half are subject to a performance condition (cumulative adjusted net income). These targets are set by the Committee at the beginning of the performance period. Holders of these awards receive shares of The Cigna Group common stock at the end of the performance period ranging anywhere from 0% to 200% of the original awards.

Accounting Policy. Compensation expense for SPSs is recorded over the performance period. Fair value is determined at the grant date for "market condition" SPSs using a Monte Carlo simulation model and not subsequently adjusted regardless of the final outcome. Expense is initially accrued for "performance condition" SPSs based on the most likely outcome, but evaluated for adjustment each period for updates in the expected outcome. Expense is adjusted to the actual outcome (number of shares awarded multiplied by the share price at the grant date) at the end of the performance period.

The following table shows the status of, and changes in, SPSs:


	For the Years Ended December 31,
	2024			2023			2022
(Awards in thousands)	Shares	Weighted Average Fair Value at Award Date		Shares	Weighted Average Fair Value at Award Date		Shares	Weighted Average Fair Value at Award Date
Outstanding - January 1	686	$	243.90	780	$	212.68	860	$	197.07
Awarded	195	$	336.81	219	$	293.85	294	$	230.69
Vested	(242)	$	214.93	(250)	$	191.78	(261)	$	183.60
Forfeited	(38)	$	289.35	(63)	$	237.50	(113)	$	207.75
Outstanding - December 31	601	$	282.83	686	$	243.90	780	$	212.68

The weighted average fair value per share of SPSs for expense purposes, including the Monte Carlo factor, at the award date for the years ended December 31, 2024, 2023 and 2022 was $377.23, $329.11 and $258.37, respectively.

The fair value of vested SPSs at the vesting date was as follows:


	For the Years Ended December 31,
	2024			2023			2022
(Shares in thousands; $ in millions)	Shares	Fair Value		Shares	Fair Value		Shares	Fair Value
Shares of The Cigna Group common stock distributed upon SPS vesting	257	$	86	257	$	76	137	$	31

Approximately 600 employees held 601,000 SPSs at the end of 2024, and $64 million of related compensation expense is expected to be recognized over the next two years. The amount of expense for "performance condition" SPSs will vary based on actual performance in 2025 and 2026.

E.Compensation Cost and Tax Effects of Share-Based Compensation

The Company records tax benefits in Shareholders' net income during the vesting period based on the amount of expense being recognized. The difference between tax benefits based on the expense and the actual tax benefit realized are also recorded in income tax expense when stock options are exercised, or when restricted stock and SPSs vest.


	For the Years Ended December 31,
(In millions)	2024		2023		2022
Total compensation cost for shared-based awards	$	308	$	286	$	264
Tax benefits recognized	$	94	$	92	$	80

Goodwill, Other Intangibles and Property and Equipment

12 Months Ended

Dec. 31, 2024

Goodwill Other Intangibles And Property And Equipment [Abstract]

Goodwill, Other Intangibles, and Property and Equipment

Note 18 – Goodwill, Other Intangibles, and Property and Equipment

A.Goodwill

Accounting Policy. Goodwill represents the excess of the cost of businesses acquired over the fair value of their net assets. The resulting goodwill is assigned to those reporting units expected to realize cash flows from the acquisition, based on those reporting units' relative fair values. The Company's reporting units are aligned with its operating segments as described in Note 1.

The Company conducts its annual quantitative evaluation for goodwill impairment during the third quarter at the reporting unit level and writes it down through Shareholders' net income if impaired. On a quarterly basis, the Company performs a qualitative impairment assessment to determine if events or changes in circumstances indicate that it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. The fair value of a reporting unit is generally estimated based on discounted cash flow analysis and market approach models using assumptions that the Company believes a hypothetical market participant would use to determine a current transaction price. Following a change in reporting units or held for sale determination, goodwill is allocated using relative fair value. The significant assumptions and estimates used in determining fair value primarily include the discount rate and future cash flows. A discount rate is selected to correspond with each reporting unit's weighted average cost of capital, consistent with that used for investment decisions considering the specific and detailed operating plans and strategies within each reporting unit. Projections of future cash flows differ by reporting unit and are consistent with our ongoing strategic projections. Future cash flows for Evernorth Health Services reporting units are primarily driven by the forecasted gross margins of the business, as well as operating expenses and long-term growth rates. Future cash flows for our other reporting units are primarily driven by forecasted revenues, benefit expenses, operating expenses and long-term growth rates.

Goodwill Activity. Goodwill activity was as follows:


(In millions)	Evernorth Health Services		Cigna Healthcare		Total
Balance at January 1, 2023	$	35,130	$	10,681	$	45,811

Goodwill transferred to assets of businesses held for sale(1)	—		(1,553)		(1,553)
Impact of foreign currency translation and other adjustments	—		1		1
Goodwill at December 31, 2023	35,130		9,129		44,259
Goodwill acquired	114		—		114

Impact of foreign currency translation and other adjustments	190		(193)		(3)
Goodwill at December 31, 2024	$	35,434	$	8,936	$	44,370

(1) See Note 5 to the Consolidated Financial Statements for further discussion of 2024 and 2023 goodwill impairments.

B.Other Intangible Assets

Accounting Policy. The Company's Other intangible assets primarily include purchased customer and producer relationships, trademarks, and provider networks. The fair value of purchased customer relationships and the amortization method were determined as of the dates of purchase using an income approach that relies on projected future net cash flows, including key assumptions for customer attrition and discount rates. The Company's definite-lived intangible assets are amortized on an accelerated or straight-line basis, reflecting their pattern of economic benefits, over periods from 6 to 30 years. Management revises amortization periods if it believes there has been a change in the length of time that an intangible asset will continue to have value. Costs incurred to renew or extend the terms of these intangible assets are generally expensed as incurred.

The Company's amortized intangible assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If the total of the expected future undiscounted cash flows generated by the underlying asset group is less than the carrying amount of the asset group, the Company recognizes an impairment charge equal to the difference between the carrying value of the asset group and its estimated fair value. The Company's indefinite-lived intangible assets are reviewed for impairment at least annually by comparing their fair value with their carrying value. If the carrying value exceeds fair value, that excess is recognized as an impairment loss.

Components of Other Assets, Including Other Intangibles. Other intangible assets were comprised of the following:


(In millions)	Cost		Accumulated Amortization		Net Carrying Value
December 31, 2024
Customer relationships	$	29,971	$	9,119	$	20,852
Trade name - Express Scripts	8,400				8,400
Other	316		131		185
Other intangible assets (1)	38,687		9,250		29,437
Value of business acquired ("VOBA" reported in Other assets) (2)	211		142		69
Total	$	38,898	$	9,392	$	29,506
December 31, 2023
Customer relationships	$	29,978	$	7,645	$	22,333
Trade name - Express Scripts	8,400				8,400
Other	317		110		207
Other intangible assets (1)	38,695		7,755		30,940
Value of business acquired (reported in Other assets) (2)	211		142		69
Total	$	38,906	$	7,897	$	31,009

(1) Includes $20 million and $77 million of Other intangible assets classified as assets of businesses held for sale as of December 31, 2024 and December 31, 2023, respectively.

(2) Includes $69 million of VOBA classified as assets of businesses held for sale as of both December 31, 2024 and December 31, 2023.

The Company has indefinite-lived intangible assets totaling $8.5 billion at both December 31, 2024 and December 31, 2023, largely consisting of the Express Scripts trade name.

C.Property and Equipment

Accounting Policy. Property and equipment is carried at cost less accumulated depreciation. Cost includes interest, real estate taxes and other costs incurred during construction when applicable. Internal-use software that is acquired, developed or modified solely to meet the Company's internal needs, with no plan to market externally, is also included in this category. Costs directly related to acquiring, developing or modifying internal-use software are capitalized.

The Company calculates depreciation and amortization principally using the straight-line method generally based on the estimated useful life of each asset as follows: buildings and improvements, 10 to 40 years; purchased and internally developed software, 3 to 5 years; and furniture and equipment (including computer equipment), 3 to 10 years. Improvements to leased facilities are depreciated over the lesser of the remaining lease term or the estimated life of the improvement. The Company considers events and circumstances that would indicate the carrying value of property, equipment or capitalized software might not be recoverable. An impairment charge is recorded if the Company determines the carrying value of any of these assets is not recoverable. The Company also reviews and shortens the estimated useful lives of these assets, if necessary.

Components of Property and Equipment. Property and equipment was comprised of the following:


(In millions)	Cost		Accumulated Amortization		Net Carrying Value
December 31, 2024
Internal-use software	$	11,295	$	8,167	$	3,128
Other property and equipment	2,115		1,287		828
Total property and equipment (1)	13,410		9,454		3,956


December 31, 2023
Internal-use software	$	10,155	$	7,161	$	2,994
Other property and equipment	2,282		1,405		877
Total property and equipment (1)	12,437		8,566		3,871

(1)Includes $302 million and $176 million of Property and equipment net carrying value classified as assets of businesses held for sale as of December 31, 2024 and December 31, 2023, respectively.

Components of Depreciation and Amortization. Depreciation and amortization expense was comprised of the following:


	For the Years Ended December 31,
(In millions)	2024		2023		2022
Internal-use software	$	1,021	$	1,216	$	1,068
Other property and equipment	248		260		251
Value of business acquired (reported in Other assets)	—		7		12
Other intangibles	1,506		1,552		1,606
Total depreciation and amortization	$	2,775	$	3,035	$	2,937

The Company estimates annual pre-tax amortization for intangible assets, including internal-use software, over the next five calendar years to be as follows:


(In millions)	Pre-tax Amortization
2025	$	2,339
2026	$	2,050
2027	$	2,015
2028	$	1,943
2029	$	1,557

Discloses the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain or loss on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss. This element may be used as a single block of text to include the entire intangible asset disclosure including data and tables. Disclosure of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, building and production equipment. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures. This element may be used as a single block of text to include the entire PPE disclosure, including data and tables.

Shareholders Equity and Dividend Restrictions

12 Months Ended

Dec. 31, 2024

Shareholders' Equity And Dividend Restrictions

Note 19 – Shareholders' Equity and Dividend Restrictions

State insurance departments and foreign jurisdictions that regulate certain of the Company's subsidiaries prescribe accounting practices (differing in some respects from GAAP) to determine statutory net income and surplus. The Company's life, accident, and health insurance and Health Maintenance Organization ("HMO") subsidiaries are regulated by such statutory requirements. The statutory net income of the Company's life, accident, and health insurance and HMO subsidiaries for the years ended, and their statutory surplus as of, December 31 were as follows:


(In billions)	2024		2023		2022
Net income	$	3.9	$	5.3	$	5.7
Surplus	$	16.0	$	14.9	$	16.4

The Company's HMO and life, accident and health insurance subsidiaries are also subject to minimum statutory surplus requirements and may be required to maintain investments on deposit with state departments of insurance or other regulatory bodies. Additionally, these subsidiaries may be subject to regulatory restrictions on the amount of annual dividends or other distributions (such as loans or cash advances) that insurance companies may extend to their parent companies without prior approval. These amounts, including restricted GAAP net assets of the Company's subsidiaries, were as follows:


(In billions)	December 31, 2024
Minimum statutory surplus required by regulators (1)	$	5.2
Investments on deposit with regulatory bodies	$	0.4
Maximum dividend distributions permitted in 2025 without regulatory approval	$	3.9
Maximum loans to the parent company permitted without regulatory approval	$	1.4
Restricted GAAP net assets of subsidiaries of The Cigna Group	$	11.3

(1) Excludes amounts associated with foreign operated equity method joint ventures.

Permitted practices used by the Company's insurance subsidiaries in 2024 that differed from prescribed regulatory accounting had an immaterial impact on statutory surplus.

Undistributed earnings for equity method investments are $1.2 billion as of December 31, 2024

Income Taxes

12 Months Ended

Dec. 31, 2024

Income Tax Disclosure [Abstract]

Income Taxes

Note 20 – Income Taxes

Accounting Policy. Deferred income taxes are reflected in the Consolidated Balance Sheets for differences between the financial and income tax reporting bases of the Company's underlying assets and liabilities, and are established based upon enacted tax rates and laws. Deferred income tax assets are recognized when available evidence indicates that realization is more likely than not, and a valuation allowance is established to the extent this standard is not met. The deferred income tax provision generally represents the net change in deferred income tax assets and liabilities during the reporting period excluding adjustments to Accumulated other comprehensive income (loss) or amounts recorded in connection with a business combination. The current income tax provision generally represents estimated amounts due on income tax returns for the year reported to various jurisdictions plus the effect of any uncertain tax positions. The Company uses the deferral method of accounting on investments that generate tax credits. Under this method, the investment tax credits are recognized as a reduction to the related asset, which are generally reported in Other assets in the Consolidated Balance Sheets. The Company recognizes a liability for uncertain tax positions if management believes the probability that the positions will be sustained is 50% or less. For uncertain positions that management believes are more likely than not to be sustained, the Company recognizes a liability based upon management's estimate of the most likely settlement outcome with the taxing authority. The liabilities for uncertain tax positions are classified as current when the position is expected to be settled within 12 months or the statute of limitation expires within 12 months.

Income taxes attributable to the Company's foreign operations are generally provided using the respective foreign jurisdictions' tax rate.

Income Tax Expense

The components of income taxes were as follows:


	For the Years Ended December 31,
(In millions)	2024		2023		2022
Current taxes
U.S. income taxes	$	1,167	$	1,459	$	1,679
Foreign income taxes	248		161		219
State income taxes	171		180		189
Total current taxes	1,586		1,800		2,087
Deferred taxes (tax benefits)
U.S. income tax benefits	(142)		(533)		(275)
Foreign income taxes (tax benefits)	64		(1,046)		(28)
State income tax benefits	(17)		(80)		(169)
Total deferred tax benefits	(95)		(1,659)		(472)
Total income taxes	$	1,491	$	141	$	1,615

Total income taxes were different from the amount computed using the nominal federal income tax rate for the following reasons:


	For the Years Ended December 31,
	2024				2023				2022
(In millions)	$		%		$		%		$		%
Tax expense at nominal rate	$	1,107	21.0	%	$	1,158	21.0	%	$	1,763	21.0	%
Change in valuation allowance	767		14.6		1,290		23.4		—		—
State income tax (benefit), net of federal income tax benefit	62		1.2		(39)		(0.7)		16		0.2
Investment tax credits	(111)		(2.1)		(48)		(0.8)		(14)		(0.2)
Impact of businesses held for sale	(129)		(2.4)		(213)		(3.9)		—		—
Effect of foreign earnings	(252)		(4.9)		(173)		(3.1)		(96)		(1.2)
Other foreign tax attributes	—		—		(153)		(2.8)		—		—
Swiss tax attributes	—		—		(1,674)		(30.4)		—		—

Impact of sale of businesses	—		—		—		—		(37)		(0.4)
Other	47		0.9		(7)		(0.1)		(17)		(0.2)
Total income taxes	$	1,491	28.3	%	$	141	2.6	%	$	1,615	19.2	%

Consolidated pre-tax income from the Company's foreign operations was approximately 62% of the Company's pre-tax income in 2024, 48% in 2023 and 46% in 2022. The increase over 2023 is primarily attributable to a reduction in domestic earnings driven by the current-year impairment of equity securities (discussed below).

Investment Tax Credits. Company investments in renewable energy projects provided $1,057 million, $453 million and $129 million of investment tax credits for the years ended December 31, 2024, 2023 and 2022, respectively. The Company accounted for the tax credits using the deferral method and accordingly reduced the associated carrying value of the related assets by these amounts.

Impairment of Equity Securities. In 2024, the Company recorded a deferred tax benefit of $636 million and an equal amount of valuation allowance in connection with the impairment of equity securities. The valuation allowance had the effect of increasing the Company's effective tax rate.

Deferred Income Taxes

Deferred income tax assets and liabilities were as follows:


(In millions)	December 31, 2024		December 31, 2023
Deferred tax assets
Foreign tax attributes	$	1,752	$	1,827
Deferred loss - sale of business	773		584
Investments	561		—
Other insurance and contractholder liabilities	300		353
Loss carryforwards	270		200
Other accrued liabilities	207		244
Employee and retiree benefit plans	177		217
Unrealized depreciation on investments and foreign currency translation	93		81
Policy acquisition expenses	—		39
Other	256		242
Deferred tax assets before valuation allowance	4,389		3,787
Valuation allowance for deferred tax assets	(2,332)		(1,498)
Deferred tax assets, net of valuation allowance	2,057		2,289
Deferred tax liabilities
Acquisition-related basis differences	7,822		8,105
Depreciation and amortization	243		371
Policy acquisition expenses	74		—




Total deferred tax liabilities	8,139		8,476
Net deferred income tax liabilities (1)	$	(6,082)	$	(6,187)

(1)Deferred tax liabilities, net in the Consolidated Balance Sheets as of December 31, 2024, excludes $954 million reported in Other assets and $61 million reported in liabilities of businesses held for sale. Deferred tax liabilities, net in the Consolidated Balance Sheets as of December 31, 2023, excludes $1,055 million reported in Other assets and $69 million reported in liabilities of businesses held for sale.

Management believes that future results will be sufficient to realize the Company's gross deferred tax assets ("DTAs") that remain after valuation allowance. Valuation allowances have been established against certain federal, state and foreign tax attributes. There are multiple expiration dates associated with these tax attributes.

As of December 31, 2024, the Company had approximately $880 million in DTAs associated with the impairment of equity securities and other unrealized investment losses (See Note 11). As discussed above, a valuation allowance of $636 million has been established against the DTAs related to the impairment of equity securities. We have determined that a valuation allowance against the remaining DTAs is not currently required based on the Company's loss carryback capacity and ability and intent to hold certain investment securities until recovery.

Foreign Jurisdiction Tax Attributes. As of both December 31, 2024 and 2023, the Company had DTAs of approximately $1.8 billion associated with foreign tax law changes and agreements in certain tax jurisdictions and a related $772 million valuation allowance against these deferred tax assets based on projections of future earnings and requirements to utilize the assets within certain time periods. It is possible in future periods that the Company may revalue these net deferred tax assets due to modifications in certain assumptions, such as forecasted future earnings.

Sale of Medicare Advantage and Related Businesses. As of December 31, 2024 and 2023, the Company has recorded $773 million and $584 million, respectively, of deferred tax benefits and a valuation allowance of $715 million and $584 million, respectively, in connection with the HCSC transaction. The valuation allowance has been recorded due to the uncertainty relative to the recovery of the deferred tax benefits as the Company does not anticipate having capital gain capacity to offset these capital losses.

Uncertain Tax Positions

Reconciliations of unrecognized tax benefits were as follows:


	For the Years Ended December 31,
(In millions)	2024		2023		2022
Balance at January 1,	$	1,399	$	1,343	$	1,230
(Decrease) increase due to prior year positions	(7)		(26)		8

Increase due to current year positions	165		107		137
Reduction related to settlements with taxing authorities	(22)		(13)		(4)
Reduction related to lapse of applicable statute of limitations	(58)		(12)		(28)
Balance at December 31,	$	1,477	$	1,399	$	1,343

Substantially all unrecognized tax benefits would increase Shareholders' net income if recognized.

The Company classifies net interest expense on uncertain tax positions as a component of income tax expense and in Other non-current liabilities in the Consolidated Balance Sheets. In addition to the amounts in the table above, the liability for net interest expense on uncertain tax positions was approximately $228 million, $220 million and $176 million as of December 31, 2024, December 31, 2023 and December 31, 2022, respectively.

Other Tax Matters

The statutes of limitations for the Company's consolidated federal income tax returns through 2016 have closed. The statute of limitations for the Company's 2020 tax return has also closed. However, The Cigna Group filed amended returns for both the 2015 and 2016 tax years, which are under review by the Internal Revenue Service ("IRS"). Additionally, the IRS is examining the Company's returns for 2017 and 2018. The IRS has examined Express Scripts' tax returns for 2010 through 2018, for which there remains significant disputed matters. In addition, the Company has pending refund claims for various years. The Company has established adequate reserves for these matters.

The Company conducts business in a number of state and foreign jurisdictions and may be engaged in multiple audit proceedings at any given time. Generally, no further state or foreign audit activity is expected for tax years prior to 2013 for Express Scripts entities and 2014 for all other entities of The Cigna Group.

Pillar Two. On December 15, 2022, the European Union ("EU") Member States formally adopted the EU's Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development ("OECD") Pillar Two Framework that was supported by over 130 countries worldwide. The EU effective dates are January 1, 2024 and January 1, 2025, for different aspects of the directive. A significant number of other countries are also implementing similar legislation, and the OECD continues to release additional guidance on these rules. The Company is within the scope of the OECD Pillar Two model rules and continues to evaluate the potential impact on future periods of the Pillar Two Framework.

The entire disclosure for income tax.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

Contingencies and Other Matters	12 Months Ended
Contingencies and Other Matters	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Contingencies and Other Matters	Note 21 – Contingencies and Other Matters The Company, through its subsidiaries, is contingently liable for various guarantees provided in the ordinary course of business. A.Financial Guarantees: Retiree and Life Insurance Benefits The Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets to provide for benefit payments. As of December 31, 2024, employers maintained assets that generally exceeded the benefit obligations under these arrangements of approximately $410 million. An additional liability is established if management believes that the Company will be required to make payments under the guarantees; there were no additional liabilities required for these guarantees, net of reinsurance, as of December 31, 2024. Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy. The Company does not expect that these financial guarantees will have a material effect on the Company's consolidated results of operations, liquidity or financial condition. B.Certain Other Guarantees The Company had indemnification obligations as of December 31, 2024 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with laws or regulations, or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a stated dollar amount or a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation. There were no recorded liabilities for these indemnification obligations as of December 31, 2024. C.Guaranty Fund Assessments The Company operates in a regulatory environment that may require its participation in assessments under state insurance guaranty association laws. The Company's exposure to assessments for certain obligations of insolvent insurance companies to policyholders and claimants is based on its share of business written in the relevant jurisdictions. There were no material charges or credits resulting from existing or new guaranty fund assessments for the year ended December 31, 2024. Legal and Regulatory Matters The Company is routinely involved in numerous claims, lawsuits, regulatory inquiries and audits, government investigations, including under the federal False Claims Act and state false claims acts initiated by a government investigating body or by a qui tam relator's filing of a complaint under court seal, and other legal matters arising, for the most part, in the ordinary course of managing a global health company. Additionally, the Company has received and is cooperating with subpoenas or similar processes from various governmental agencies requesting information, all arising in the normal course of its business. Disputed tax matters arising from audits by the IRS or other state and foreign jurisdictions, including those resulting in litigation, are accounted for under GAAP guidance for uncertain tax positions, as described in Note 20. Accounting Policy. The Company accrues for legal and regulatory matters when a loss contingency is both probable and estimable. The estimated loss is generally recorded in Selling, general and administrative expenses and represents the Company's best estimate of the loss contingency. If the loss estimate is a range, the Company accrues the minimum amount in the range if no amount is better than any other estimated amount in the range. Legal costs to defend the Company's litigation and arbitration matters are expensed as incurred in cases that the Company cannot reasonably estimate the ultimate cost to defend. If the Company can reasonably estimate the cost to defend, a liability for these costs is accrued when the claim is reported. Pending litigation and legal or regulatory matters that the Company has identified with a reasonably possible material loss and certain other material litigation matters are described below. For those matters that the Company has identified with a reasonably possible material loss, the Company provides disclosure in the aggregate of accruals and range of loss, or a statement that such information cannot be estimated. The Company's accrual for the matter discussed below under "Litigation Matters" is not material. Due to numerous uncertain factors presented in this case, it is not possible to estimate an aggregate range of loss (if any) for this matter at this time. In light of the uncertainties involved in this matter, there is no assurance that its ultimate resolution will not exceed the amount currently accrued by the Company. An adverse outcome in this matter could be material to the Company's results of operations, financial condition or liquidity for any particular period. The outcomes of lawsuits are inherently unpredictable and we may be unsuccessful in this ongoing litigation matter or any future claims or litigation. Litigation Matters Express Scripts Litigation with Elevance. In March 2016, Elevance Health, Inc. ("Elevance") filed a lawsuit in the United States District Court for the Southern District of New York alleging various breach of contract claims against Express Scripts relating to the parties' rights and obligations under the periodic pricing review section of the pharmacy benefit management agreement between the parties, including allegations that Express Scripts failed to negotiate new pricing concessions in good faith, as well as various alleged service issues. Elevance also requested that the court enter declaratory judgment that Express Scripts is required to provide Elevance competitive benchmark pricing, that Elevance can terminate the agreement, and that Express Scripts is required to provide Elevance with post-termination services at competitive benchmark pricing for one year following any termination by Elevance. Elevance claimed it is entitled to $13 billion in additional pricing concessions over the remaining term of the agreement, as well as $1.8 billion for one year following any contract termination by Elevance and $150 million damages for service issues ("Elevance's Allegations"). On April 19, 2016, in response to Elevance's complaint, Express Scripts filed its answer denying Elevance's Allegations in their entirety and asserting affirmative defenses and counterclaims against Elevance. The court subsequently granted Elevance's motion to dismiss two of six counts of Express Scripts' amended counterclaims. Express Scripts filed its Motion for Summary Judgment on August 27, 2021. Elevance completed filing of its Response to Express Scripts' Motion for Summary Judgment on October 16, 2021. Express Scripts filed its Reply in Support of its Motion for Summary Judgment on November 19, 2021. On March 31, 2022, the court granted summary judgment in favor of Express Scripts on all of Elevance's pricing claims for damages totaling $14.8 billion and on most of Elevance's claims relating to service issues. Elevance's only remaining service claims relate to the review or processing of prior authorizations, with alleged damages over $100 million. On November 1, 2023, the parties signed a settlement agreement pursuant to which Express Scripts agreed to resolve the service-related claims. The settlement agreement is not an admission of liability or fault by Express Scripts, the Company or its subsidiaries. Following the settlement, Elevance retained the right to appeal the pricing-related claims that were previously dismissed by the court, and Express Scripts retained the ability to reassert its own pricing-related claims in the event any appeal by Elevance is successful. Elevance filed its Notice of Appeal of its pricing-related claims on December 12, 2023. Elevance filed its opening appellate brief on April 24, 2024. Express Scripts filed its answering appellate brief on July 24, 2024. The Second Circuit held oral arguments on Elevance's appeal on October 22, 2024. On October 31, 2024, the Second Circuit released a unanimous opinion summarily affirming the district court's entry of summary judgment in favor of Express Scripts. Elevance filed a petition for rehearing en banc on November 14, 2024; the petition was denied on December 19, 2024.

Segment Information

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Segment Information

Note 22 – Segment Information

See Note 1 to the Consolidated Financial Statements for a description of our segments. A description of our basis for reporting segment operating results is outlined below. Intersegment revenues primarily reflect pharmacy and care services transactions between the Evernorth Health Services and Cigna Healthcare segments. The Chairman and Chief Executive Officer is the chief operating decision maker ("CODM") responsible for making decisions about resources to be allocated to the segment and assessing its performance.

The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management, including the CODM, believes these metrics reflect the underlying results of business operations and facilitate analysis of trends in underlying revenue, expenses and profitability to enable resource allocation decisions. We define pre-tax adjusted income (loss) from operations as income (loss) before income taxes excluding pre-tax income (loss) attributable to noncontrolling interests, net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management, including the CODM, believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results.

The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management, including the CODM, believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management, including the CODM, believes they are not indicative of past or future underlying performance of the business.

The Company does not report total assets by segment because this is not a metric used by the CODM to allocate resources or evaluate segment performance.

The following table presents the special items charges (benefits) recorded by the Company, as well as the respective financial statement line items impacted:


	For the Years Ended December 31,
		2024	2023				2022
(In millions)			Pre-tax		After-tax		Pre-tax		After-tax		Pre-tax		After-tax
Integration and transaction-related costs (Selling, general and administrative expenses)			$	275	$	211	$	45	$	35	$	135	$	103
Impairment of dividend receivable (Net investment income)			182		138		—		—		—		—
Deferred tax expenses (benefits), net (Income taxes, less amount attributable to noncontrolling interests)			—		84		—		(1,071)		—		—
Net (gain) loss on sale of businesses			(24)		(2)		1,499		1,429		(1,662)		(1,332)
Charge for organizational efficiency plan (Selling, general and administrative expenses)			—		—		252		193		22		17
Charges (benefits) associated with litigation matters (Selling, general and administrative expenses)			—		—		201		171		(28)		(20)


Total impact from special items			$	433	$	431	$	1,997	$	757	$	(1,533)	$	(1,232)

Summarized segment financial information was as follows:


(In millions)	Evernorth Health Services		Cigna Healthcare		Other Operations		Corporate and Eliminations		Total
2024
Revenues from external customers	$	198,177	$	47,528	$	440	$	3	$	246,148
Intersegment revenues	3,775		4,972		79		(8,826)
Net investment income	21		618		309		25		973
Total revenues	201,973		53,118		828		(8,798)		247,121
Net investment results from certain equity method investments	—		(204)		—		—		(204)

Special item related to impairment of dividend receivable	182		—		—		—		182
Adjusted revenues	$	202,155	$	52,914	$	828	$	(8,798)	$	247,099
Pharmacy and other service costs	190,968		—
Medical costs	—		37,887
Selling, general and administrative expenses	3,779		10,805
Other segment items (1)
Interest (expense) and other	(2)		7
Less income attributable to noncontrolling interests	405		—
Pre-tax adjusted income (loss) from operations	7,001		4,229		(9)		(1,688)		9,533

Income (loss) before income taxes	$	3,929	$	3,315	$	(12)	$	(1,963)	$	5,269
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(405)		—		—		—		(405)
Net investment losses (2)	2,129		401		3		—		2,533
Amortization of acquired intangible assets	1,662		41		—		—		1,703
Special items
Integration and transaction-related costs	—		—		—		275		275
Impairment of dividend receivable	182		—		—		—		182

(Gain) loss on sale of businesses	(496)		472		—		—		(24)




Pre-tax adjusted income (loss) from operations	$	7,001	$	4,229	$	(9)	$	(1,688)	$	9,533

Other Segment Information
Depreciation and amortization	$	2,319	$	417	$	9	$	30	$	2,775

(1)Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.

(2)Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.


(In millions)	Evernorth Health Services		Cigna Healthcare		Other Operations		Corporate and Eliminations		Total
2023
Revenues from external customers	$	147,588	$	46,219	$	291	$	1	$	194,099
Intersegment revenues	5,670		4,332		—		(10,002)
Net investment income	241		597		305		23		1,166
Total revenues	153,499		51,148		596		(9,978)		195,265
Net investment results from certain equity method investments	—		57		—		—		57

Adjusted revenues	$	153,499	$	51,205	$	596	$	(9,978)	$	195,322
Pharmacy and other service costs	143,571		—
Medical costs	—		35,678
Selling, general and administrative expenses	3,340		11,055
Other segment items (1)
Interest (expense) and other	(2)		8
Less income attributable to noncontrolling interests	144		2
Pre-tax adjusted income (loss) from operations	6,442		4,478		96		(1,698)		9,318

Income (loss) before income taxes	$	4,768	$	2,664	$	76	$	(1,995)	$	5,513
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(144)		(2)		—		—		(146)
Net investment losses (2)	—		133		2		—		135
Amortization of acquired intangible assets	1,774		45		—		—		1,819
Special items
Integration and transaction-related costs	—		—		—		45		45


Loss on sale of businesses	—		1,481		18		—		1,499
Charge for organizational efficiency plan	—		—		—		252		252
Charges associated with litigation matters	44		157		—		—		201


Pre-tax adjusted income (loss) from operations	$	6,442	$	4,478	$	96	$	(1,698)	$	9,318

Other Segment Information
Depreciation and amortization	$	2,438	$	569	$	3	$	25	$	3,035

(1)Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.

(2)Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.


(In millions)	Evernorth Health Services		Cigna Healthcare		Other Operations		Corporate and Eliminations		Total
2022
Revenues from external customers	$	135,786	$	41,738	$	1,839	$	—	$	179,363
Intersegment revenues	4,463		2,535		—		(6,998)
Net investment income	86		638		424		7		1,155
Total revenues	140,335		44,911		2,263		(6,991)		180,518
Net investment results from certain equity method investments	—		126		—		—		126

Adjusted revenues	$	140,335	$	45,037	$	2,263	$	(6,991)	$	180,644
Pharmacy and other service costs	131,284		—
Medical costs	—		31,119
Selling, general and administrative expenses	2,856		9,827
Other segment items (1)
Interest (expense) and other	(2)		12
Less income attributable to noncontrolling interests	66		4
Pre-tax adjusted income (loss) from operations	6,127		4,099		509		(1,466)		9,269

Income (loss) before income taxes	$	4,421	$	3,470	$	2,101	$	(1,595)	$	8,397
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(66)		(4)		(14)		—		(84)
Net investment losses (2)	—		530		83		—		613
Amortization of acquired intangible assets	1,772		103		1		—		1,876
Special items
Integration and transaction-related costs	—		—		—		135		135


(Gain) on sale of businesses	—		—		(1,662)		—		(1,662)
Charge for organizational efficiency plan	—		—		—		22		22
(Benefits) associated with litigation matters	—		—		—		(28)		(28)


Pre-tax adjusted income (loss) from operations	$	6,127	$	4,099	$	509	$	(1,466)	$	9,269

Other Financial Information
Depreciation and amortization	$	2,283	$	638	$	6	$	10	$	2,937

(1)Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.

(2)Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.

Revenue from external customers includes Pharmacy revenues, Premiums and Fees and other revenues. The following table presents these revenues by product, premium and service type:


	For the Years Ended December 31,
(In millions)		2024		2023		2022
Products (Pharmacy revenues) (ASC 606)
Network revenues		$	105,340	$	67,514	$	64,946
Home delivery and specialty revenues		72,476		65,732		61,283
Other revenues		11,545		9,047		6,753
Total Evernorth Health Services		189,361		142,293		132,982
Other Operations		60		—		—
Corporate and eliminations		(4,059)		(5,050)		(4,416)
Total Pharmacy revenues		185,362		137,243		128,566
Insurance premiums (ASC 944)
Cigna Healthcare
U.S. Healthcare
Employer insured		17,576		16,490		15,199
Medicare Advantage		8,679		8,771		7,896
Stop loss		6,744		6,143		5,461
Individual and Family Plans		3,951		5,088		2,636
Other		4,938		4,095		3,996
U.S. Healthcare		41,888		40,587		35,188
International Health		3,624		3,295		2,906
Total Cigna Healthcare		45,512		43,882		38,094
Divested International businesses		—		—		1,596
Other Operations excluding Divested International businesses		380		281		225
Corporate and eliminations		104		74		1
Total Premiums		45,996		44,237		39,916
Services (Fees) (ASC 606) and Other revenues (1)
Evernorth Health Services		12,591		10,965		7,267
Cigna Healthcare		6,988		6,669		6,179
Other Operations		79		10		18
Corporate and eliminations		(4,868)		(5,025)		(2,583)
Total Fees and other revenues (1)		14,790		12,619		10,881
Total revenues from external customers		$	246,148	$	194,099	$	179,363

(1)Other revenues for the years ended December 31, 2024, 2023 and 2022 were $584 million, $210 million and $168 million, respectively.

Major Customers. Revenues from a single pharmacy benefit client were approximately 16% of consolidated revenues for the year ended December 31, 2024. These amounts were reported in the Evernorth Health Services segment.

Additionally, revenues from U.S. Federal Government agencies, under a number of contracts, were approximately 11%, 15% and 14% of consolidated revenues for the years ended December 31, 2024, 2023 and 2022, respectively. These amounts were reported in the Evernorth Health Services and Cigna Healthcare segments.

U.S. and Foreign Revenues. U.S. and foreign revenues from external customers are shown below. The Company's foreign revenues are generated by its foreign operating entities. In the periods shown, no single foreign country contributed more than 2% of consolidated revenues from external customers.


	For the Years Ended December 31,
(In millions)	2024		2023		2022
United States	$	241,563	$	189,840	$	174,540
Foreign countries (1)	4,585		4,259		4,823
Total revenues from external customers	$	246,148	$	194,099	$	179,363

(1) In 2022, included revenues from the divested International businesses of $1.6 billion.

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Condensed Financial Information Disclosure [Abstract]

Schedule I - Condensed Financial Information of The Cigna Group

12 Months Ended

Dec. 31, 2024

Schedule I - Condensed Financial Information of The Cigna Group

THE CIGNA GROUP AND SUBSIDIARIES

SCHEDULE I

CONDENSED FINANCIAL INFORMATION OF THE CIGNA GROUP

(REGISTRANT)

STATEMENTS OF INCOME


	For the Years Ended December 31,

(In millions)	2024		2023		2022
Revenues
Net investment income and other revenue	$	26	$	22	$	5
Intercompany interest income	469		516		478
Total revenues	495		538		483
Operating expenses
Selling, general and administrative expenses	14		2		2
Total operating expenses	14		2		2
Income from operations	481		536		481
Interest expense and other	(1,388)		(1,332)		(1,215)
Intercompany interest expense	(2)		(118)		(147)


Loss before income taxes	(909)		(914)		(881)
Income tax benefits	(189)		(192)		(183)
Loss of parent company	(720)		(722)		(698)
Equity in income of subsidiaries	4,154		5,886		7,402
Shareholders' net income	3,434		5,164		6,704
Shareholders' other comprehensive income (loss), net of tax
Net unrealized appreciation (depreciation) on securities and derivatives	661		503		(1,598)
Net long-duration insurance and contractholder liabilities measurement adjustments	(1,067)		(715)		509
Net translation (losses) gains of foreign currencies	(49)		5		79
Postretirement benefits liability adjustment	(22)		1		420
Shareholders' other comprehensive loss, net of tax	(477)		(206)		(590)
Shareholders' comprehensive income	$	2,957	$	4,958	$	6,114

See Notes to Financial Statements on the following pages.

THE CIGNA GROUP AND SUBSIDIARIES

SCHEDULE I

CONDENSED FINANCIAL INFORMATION OF THE CIGNA GROUP

(REGISTRANT)

BALANCE SHEETS


	As of December 31,
(In millions)	2024		2023
Assets
Cash and cash equivalents	$	164	$	303

Other current assets	103		6
Total current assets	267		309
Investments in subsidiaries	62,887		69,703
Intercompany receivable	10,546		11,475
Other non-current assets	71		77
TOTAL ASSETS	$	73,771	$	81,564
Liabilities
Short-term debt	$	2,848	$	2,448
Other current liabilities	1,528		1,854
Total current liabilities	4,376		4,302
Long-term debt	28,134		27,151
Intercompany payable	195		3,874
Other non-current liabilities	33		14
TOTAL LIABILITIES	32,738		35,341
Shareholders' equity
Common stock (shares issued, 403 and 400; authorized, 600)	4		4
Additional paid-in capital	31,288		30,669
Accumulated other comprehensive loss	(2,341)		(1,864)
Retained earnings	43,519		41,652
Less treasury stock, at cost	(31,437)		(24,238)
TOTAL SHAREHOLDERS' EQUITY	41,033		46,223
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$	73,771	$	81,564

See Notes to Financial Statements on the following pages.

THE CIGNA GROUP AND SUBSIDIARIES

SCHEDULE I

CONDENSED FINANCIAL INFORMATION OF THE CIGNA GROUP

(REGISTRANT)

STATEMENTS OF CASH FLOWS


	For the Years Ended December 31,

(In millions)	2024		2023		2022
Cash Flows from Operating Activities
Shareholders' net income	$	3,434	$	5,164	$	6,704
Adjustments to reconcile shareholders' net income
to net cash provided by operating activities
Equity in income of subsidiaries	(4,154)		(5,886)		(7,402)

Dividends received from subsidiaries	2,916		1,381		2,056
Other liabilities	(306)		540		5
Other, net	243		640		298
NET CASH PROVIDED BY OPERATING ACTIVITIES	2,133		1,839		1,661
Cash Flows from Investing Activities
Net change in amounts due from affiliates	—		622		(901)
Net proceeds from short-term investments sold	—		—		99

NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	—		622		(802)
Cash Flows from Financing Activities
Net change in amounts due to affiliates	4,761		1,473		10,392
Net change in commercial paper	(357)		1,237		(2,027)

Repayment of long-term debt	(2,731)		(2,822)		(430)
Net proceeds on issuance of long-term debt	4,462		1,491		—
Issuance of common stock	305		187		389
Common dividends paid	(1,567)		(1,450)		(1,384)
Repurchase of common stock	(7,034)		(2,284)		(7,607)
Tax withholding on stock compensation and other	(117)		(110)		(73)

NET CASH USED IN FINANCING ACTIVITIES	(2,278)		(2,278)		(740)
Net (decrease) increase in cash, cash equivalents and restricted cash	(145)		183		119
Cash, cash equivalents and restricted cash, beginning of year	335		152		33
Cash, cash equivalents and restricted cash, end of year (1)	$	190	$	335	$	152
Noncash Investing and Financing Activities:
Net amounts due from affiliates settled through capital transactions	(7,565)		(5,221)		(5,037)

(1) Includes restricted cash reported in Other non-current assets.

See Notes to Financial Statements on the following pages.

THE CIGNA GROUP AND SUBSIDIARIES

SCHEDULE I

CONDENSED FINANCIAL INFORMATION OF THE CIGNA GROUP

(REGISTRANT)

NOTES TO CONDENSED FINANCIAL STATEMENTS

The accompanying condensed financial statements should be read in conjunction with the Consolidated Financial Statements and the accompanying notes thereto contained in this Annual Report on Form 10-K ("Form 10-K").

Note 1 - For purposes of these condensed financial statements, wholly owned and majority-owned subsidiaries of The Cigna Group (the "Company") are recorded using the equity method of accounting. The Cigna Group, through its predecessor companies, was incorporated in Delaware in 1981. Cigna Corporation was renamed The Cigna Group in February 2023.

Note 2 - See Note 7 – Debt included in Part II, Item 8 of this Form 10-K for a description of the short-term and long-term debt obligations of The Cigna Group and its subsidiaries.

Short-term and Credit Facilities Debt

Revolving Credit Agreements. Our revolving credit agreements provide us with the ability to borrow amounts for general corporate purposes, including for the purpose of providing liquidity support if necessary under our commercial paper program discussed below. As of December 31, 2024, there were no outstanding balances under these revolving credit agreements.

In April 2024, The Cigna Group replaced its previous revolving credit agreements and entered into the following revolving credit agreements (the "Credit Agreements"):

•A $5.0 billion five-year revolving credit and letter of credit agreement that will mature in April 2029 with an option to extend the maturity date for additional one-year periods, subject to consent of the banks. The Company can borrow up to $5.0 billion under the credit agreement for general corporate purposes, with up to $500 million available for issuance of letters of credit.

•A $1.5 billion 364-day revolving credit agreement that will mature in April 2025. The Company can borrow up to $1.5 billion under the credit agreement for general corporate purposes. This agreement includes the option to "term out" any revolving loans that are outstanding at maturity by converting them into a term loan maturing on the one-year anniversary of conversion.

Each of the Credit Agreements includes an option to increase commitments in an aggregate amount of up to $1.5 billion across both facilities for a maximum total commitment of $8.0 billion. The Credit Agreements allow for borrowings at either a base rate or an adjusted term Secured Overnight Funding Rate ("SOFR") plus, in each case, an applicable margin based on the Company's senior unsecured credit ratings.

Each facility also contains customary covenants and restrictions, including a financial covenant that the Company's leverage ratio, as defined in the Credit Agreements, may not exceed 60%, subject to certain exceptions upon the consummation of an acquisition.

Commercial Paper. Under our commercial paper program, we may issue short-term, unsecured commercial paper notes privately placed on a discounted basis through certain broker-dealers at any time not to exceed an aggregate amount of $6.5 billion. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. The commercial paper program had approximately $0.9 billion outstanding as of December 31, 2024 and an average interest rate of 4.65%.

Long-Term Debt

Debt Issuance and Debt Tender Offers. In February 2024, we issued $4.5 billion of new senior notes. The proceeds from this debt were used to pay the consideration for the cash tender offers as described below. We used the remaining net proceeds to fund the

repayment of our senior notes that matured in March 2024 and for general corporate purposes, including repayment of indebtedness and repurchases of shares of our common stock. Interest on this debt is paid semiannually.

Principal

Maturity Date

Interest Rate

Net Proceeds

Redeemable Date(1)

"Make Whole" Premium (2)

$1,000 million

May 15, 2029

5.000%

$995 million

April 15, 2029

15

$750 million

May 15, 2031

5.125%

$746 million

March 15, 2031

15

$1,250 million

February 15, 2034

5.250%

$1,244 million

November 15, 2033

20

$1,500 million

February 15, 2054

5.600%

$1,485 million

August 15, 2053

20

(1) Redeemable at any time prior to this date at a "make whole" premium, defined below. Redeemable at par on or after this date.

(2) "Make whole" premium calculated using the most directly comparable U.S. Treasury rate plus the amount of basis points set forth in this column.

In the first quarter of 2024, the Company completed the repurchase of $1.7 billion in aggregate principal amount of existing senior notes that were tendered to the Company pursuant to cash tender offers.

Debt Maturities. Maturities of the Company's long-term debt are as follows:


(In millions)
2025	$	1,973
2026	$	2,301
2027	$	2,056
2028	$	3,800
2029	$	1,000
Maturities after 2029	$	19,292

Debt Covenants. The Company was in compliance with its debt covenants as of December 31, 2024.

Note 3 - The Company's intercompany receivables consist primarily of net intercompany loan amounts due from Evernorth Health, Inc. of $8.5 billion as of December 31, 2024 and 2023. Interest income on the loan receivable was accrued at an average rate of 5.50% in 2024.

The Company's intercompany payables primarily reflect intercompany balances due to affiliates as of December 31, 2024. During the year ended December 31, 2024, the Company settled the majority of outstanding intercompany payables via non-cash capital transactions.

Note 4 - The Company guaranteed approximately $9.4 billion primarily related to intercompany indebtedness and financial obligations of certain direct and indirect wholly-owned subsidiaries. There were immaterial liabilities required for these guarantees as of December 31, 2024.

Note 5 - In February 2024, as part of our existing share repurchase program, we entered into separate accelerated share repurchase agreements with Deutsche Bank AG and Bank of America, N.A. to repurchase $3.2 billion of common stock in aggregate. The total number of shares of our common stock repurchased under the agreements was approximately 9.3 million.

Schedule II - Valuation and Qualifying Accounts and Reserves

12 Months Ended

Dec. 31, 2024

SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]

Schedule II - Valuation and Qualifying Accounts and Reserves

THE CIGNA GROUP AND SUBSIDIARIES

SCHEDULE II

VALUATION AND QUALIFYING ACCOUNTS AND RESERVES


(In millions)	Balance at Beginning of Year		Charged (Credited) to Costs and Expenses		Charged (Credited) to Other Accounts		Other Deductions		Balance at End of Year
Description
2024
Investment asset valuation reserves
Available-for-sale debt securities	$	33	$	87	$	—	$	(9)	$	111
Commercial mortgage loans	$	31	$	(1)	$	—	$	—	$	30
Accounts receivable, net	$	163	$	176	$	(1)	$	(152)	$	186
Deferred tax asset valuation allowance	$	1,498	$	866	$	(32)	$	—	$	2,332
Reinsurance recoverables	$	35	$	(5)	$	—	$	—	$	30
2023
Investment asset valuation reserves
Available-for-sale debt securities	$	44	$	11	$	—	$	(22)	$	33
Commercial mortgage loans	$	21	$	10	$	—	$	—	$	31
Accounts receivable, net	$	160	$	90	$	1	$	(88)	$	163
Deferred tax asset valuation allowance	$	208	$	1,286	$	4	$	—	$	1,498
Reinsurance recoverables	$	35	$	—	$	—	$	—	$	35
2022
Investment asset valuation reserves
Available-for-sale debt securities	$	23	$	43	$	—	$	(22)	$	44
Commercial mortgage loans	$	6	$	15	$	—	$	—	$	21
Accounts receivable, net	$	126	$	99	$	—	$	(65)	$	160
Deferred tax asset valuation allowance	$	246	$	(13)	$	(25)	$	—	$	208
Reinsurance recoverables	$	28	$	7	$	—	$	—	$	35

Insider Trading Arrangements	3 Months Ended	12 Months Ended
Insider Trading Arrangements	Dec. 31, 2024 shares	Dec. 31, 2024 shares
Trading Arrangements, by Individual
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Elder Granger [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On December 11, 2024, Retired Maj. Gen. Elder Granger, M.D., Director of The Cigna Group, adopted a 10b5-1 plan. General Granger's plan provides for the exercise of vested stock options and the associated sale of up to 2,376 shares of The Cigna Group common stock through December 19, 2025.
Name	Retired Maj. Gen. Elder Granger, M.D.
Title	Director of The Cigna Group
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	December 11, 2024
Arrangement Duration	373 days
Trading Arrangement, Stock Options [Member] \| Elder Granger [Member]
Trading Arrangements, by Individual
Aggregate Available	2,376	2,376

Insider Trading Policies and Procedures	12 Months Ended
Insider Trading Policies and Procedures	Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
Cybersecurity Risk Management and Strategy Disclosure	Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	Cybersecurity Strategy and Risk Management Our comprehensive cybersecurity program is supported by policies and procedures designed to protect our systems and operations as well as the sensitive personal information and data of our clients and customers from foreseeable cybersecurity threats. This program is an integral component of our enterprise risk management program. Core to our security model is our defense-in-depth framework, comprising multiple layers of processes and technologies that help prevent, detect and respond to threats. Our approach to safeguarding against external threats incorporates a suite of preventive technologies, including malicious email blocking, defenses against automated attacks and multifactor authentication. Event monitoring technologies run continuously, detecting suspected intrusion attempts and alerting our Cybersecurity Incident Response Team. We undertake a number of critical security processes to mitigate and protect against cybersecurity risks, which include but are not limited to (i) identity and access management; (ii) security awareness and training; (iii) security operations and monitoring; (iv) change management; (v) disaster recovery/business continuity; (vi) intelligence feeds; (vii) physical security; (viii) third-party vendor security reviews; (ix) vulnerability management/patching; and (x) cybersecurity incident reporting. We routinely manage cybersecurity risks through a defined framework that includes activities aimed at the identification, assessment, treatment and monitoring of risks. Cybersecurity risk assessment results are used by senior management to make informed decisions about where to allocate resources to reduce cybersecurity risks and improve overall security posture. We examine our entire program annually with third parties and measure the program against generally accepted industry standards and frameworks, such as an internationally recognized security control framework established by the NIST and used by companies to assess and improve their ability to prevent, detect and respond to cyberattacks. Our cybersecurity policies and standards are reviewed annually and are mainly guided by the NIST 800-53 Cybersecurity Framework. In addition to the NIST framework, we leverage the International Organization for Standardization 27001 and 27002 standards. Our information protection policies and standards are informed by NIST 800-53b, moderate-level security control baseline requirements. To enhance our preparedness and practice our collective cybersecurity response capabilities, we conduct tabletop exercises with leaders, stakeholders, subject matter experts and certain executives that are developed in partnership with external security experts. These events are designed to exercise and engage some of the most critical areas of cybersecurity incident response and preparedness through an interactive/evolving, simulated scenario. In addition to these internal measures, the effectiveness of components of our overall cybersecurity program is frequently evaluated by external third parties, which includes work performed over various levels of control assessments for specific business lines and core processes. These include Health Information Trust Alliance for health care data security, PCI DSS for payment security and System Organization Controls 2 for information security and related controls for specific business lines and core processes. We also perform an annual maturity assessment and benchmark our security controls to identify opportunities to strengthen our cybersecurity program. As part of our Global Threat Management Program, a dedicated Incident Handling Team, comprising both technical and management personnel, determines the severity of a validated cybersecurity event across the enterprise and is responsible for the development and ongoing maintenance of our comprehensive Global Incident Response Plan ("GIRP"). The GIRP is reviewed quarterly at a minimum but may be updated as needed based on lessons learned, changes in key teams or processes or other circumstances as warranted, and the procedures therein are tested annually. The GIRP's incident handling procedures dictate our actions during each phase of an incident, including the assembly of a broad, cross-functional Computer Security Incident Response Team, the formulation of a response, and post-incident reviews and corrective actions. Our information protection department maintains a risk register that is used to manage cybersecurity risks associated with its business activities, technology assets and its interaction with business, information technology and security parties, internal and external. Cybersecurity risks are also periodically reviewed by Enterprise Risk Management to ensure appropriate oversight of cybersecurity risk management activities. Suppliers that have access to, host or transmit our data are contractually required to comply with our Security Policies and Standards. Additionally, suppliers may be subject to periodic security audits or risk assessments, which include security questionnaires, security capabilities and maturity assessments, controls evidence reviews, application vulnerability assessments, public internet presence monitoring, and alignment reviews with service-specific industry standards. Follow-up activities are performed as needed. Contracts with suppliers also include critical security requirements, such as right to audit, technology requirements and hiring practices, including background checks for those who have access to our network. To further ensure supplier resilience and continuity, we regularly evaluate and assess our critical supplier relationships and business continuity plans, enabling us to quickly adapt and maintain operations in the event of prolonged disruption. As of the date of this report, we do not believe that any risks from any cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations or financial condition. That said, as discussed more fully under Part I, Item 1A "Risk Factors – Strategic and Operational Risks – As a large global health company, we and our vendors are subject to cyberattacks or other privacy or data security incidents. If we are unable to prevent or contain the effects of any such attacks, or fail to ensure vendors do the same, we may suffer exposure to substantial liability, reputational harm, loss of revenue or other damages," the sophistication of cybersecurity threats continues to increase, and the preventive actions we take to reduce the risk of cybersecurity incidents and protect our systems and information may become insufficient. Accordingly, no matter how well designed or implemented our controls are, we will not be able to anticipate all attacks of these types, and we may not be able to implement effective preventive measures against such security breaches in a timely manner.
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	Our comprehensive cybersecurity program is supported by policies and procedures designed to protect our systems and operations as well as the sensitive personal information and data of our clients and customers from foreseeable cybersecurity threats. This program is an integral component of our enterprise risk management program.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Board of Directors Oversight [Text Block]	Cybersecurity Governance Our Board has ultimate oversight over our privacy and cybersecurity programs and strategy and is responsible for ensuring that we have risk management policies and processes in place to meet and mitigate evolving risks and threats. Certain members of the Board have cybersecurity certifications. The Board executes this oversight directly and through both the Audit Committee, for cybersecurity purposes, and the Compliance Committee, for privacy purposes. In these capacities, these committees are regularly briefed by the Global Chief Information Security Officer ("GCISO") and Chief Privacy Officer on cybersecurity and privacy matters. These briefings are designed to provide visibility about the identification, assessment and management of critical risks, audit findings, and management's risk mitigation strategies. Additionally, these briefings include information about current trends in the environment, incident preparedness, artificial intelligence and various components of our cybersecurity and privacy programs. On an annual basis, the Board reviews our cybersecurity program, including the threat landscape and related controls, and periodically conducts cybersecurity tabletop exercises. Our dedicated cybersecurity team is led by our GCISO. Our current GCISO joined the Company in October 2023 and works closely with senior management to develop and innovate the cybersecurity strategy and risk management. Prior to joining the team, our GCISO held senior information security roles at other global organizations where this individual defined information security strategies, built global information security programs, implemented cybersecurity capabilities that protect consumers, wholesale partners and brands, and oversaw the security of a global payment network, a corporate network and digital assets.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	Our Board has ultimate oversight over our privacy and cybersecurity programs and strategy and is responsible for ensuring that we have risk management policies and processes in place to meet and mitigate evolving risks and threats. Certain members of the Board have cybersecurity certifications. The Board executes this oversight directly and through both the Audit Committee, for cybersecurity purposes, and the Compliance Committee, for privacy purposes.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	The Board executes this oversight directly and through both the Audit Committee, for cybersecurity purposes, and the Compliance Committee, for privacy purposes. In these capacities, these committees are regularly briefed by the Global Chief Information Security Officer ("GCISO") and Chief Privacy Officer on cybersecurity and privacy matters. These briefings are designed to provide visibility about the identification, assessment and management of critical risks, audit findings, and management's risk mitigation strategies. Additionally, these briefings include information about current trends in the environment, incident preparedness, artificial intelligence and various components of our cybersecurity and privacy programs. On an annual basis, the Board reviews our cybersecurity program, including the threat landscape and related controls, and periodically conducts cybersecurity tabletop exercises.
Cybersecurity Risk Role of Management [Text Block]	Our dedicated cybersecurity team is led by our GCISO. Our current GCISO joined the Company in October 2023 and works closely with senior management to develop and innovate the cybersecurity strategy and risk management. Prior to joining the team, our GCISO held senior information security roles at other global organizations where this individual defined information security strategies, built global information security programs, implemented cybersecurity capabilities that protect consumers, wholesale partners and brands, and oversaw the security of a global payment network, a corporate network and digital assets.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	Our Board has ultimate oversight over our privacy and cybersecurity programs and strategy and is responsible for ensuring that we have risk management policies and processes in place to meet and mitigate evolving risks and threats. Certain members of the Board have cybersecurity certifications. The Board executes this oversight directly and through both the Audit Committee, for cybersecurity purposes, and the Compliance Committee, for privacy purposes. In these capacities, these committees are regularly briefed by the Global Chief Information Security Officer ("GCISO") and Chief Privacy Officer on cybersecurity and privacy matters
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	Prior to joining the team, our GCISO held senior information security roles at other global organizations where this individual defined information security strategies, built global information security programs, implemented cybersecurity capabilities that protect consumers, wholesale partners and brands, and oversaw the security of a global payment network, a corporate network and digital assets.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	The Board executes this oversight directly and through both the Audit Committee, for cybersecurity purposes, and the Compliance Committee, for privacy purposes. In these capacities, these committees are regularly briefed by the Global Chief Information Security Officer ("GCISO") and Chief Privacy Officer on cybersecurity and privacy matters. These briefings are designed to provide visibility about the identification, assessment and management of critical risks, audit findings, and management's risk mitigation strategies. Additionally, these briefings include information about current trends in the environment, incident preparedness, artificial intelligence and various components of our cybersecurity and privacy programs. On an annual basis, the Board reviews our cybersecurity program, including the threat landscape and related controls, and periodically conducts cybersecurity tabletop exercises. Our dedicated cybersecurity team is led by our GCISO. Our current GCISO joined the Company in October 2023 and works closely with senior management to develop and innovate the cybersecurity strategy and risk management. Prior to joining the team, our GCISO held senior information security roles at other global organizations where this individual defined information security strategies, built global information security programs, implemented cybersecurity capabilities that protect consumers, wholesale partners and brands, and oversaw the security of a global payment network, a corporate network and digital assets.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Consolidated Financial Statements include the accounts of The Cigna Group and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Certain amounts in the Consolidated Statements of Cash Flows and Note 20 "Income Taxes" to the Consolidated Financial Statements have been reclassified to conform to current year presentation and did not have a significant impact on our Consolidated Financial Statements. Amounts recorded in the Consolidated Financial Statements necessarily reflect management's estimates and assumptions about medical costs, investment, tax and receivable valuations, interest rates, and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment.
Recent Accounting Pronouncements, Recently Adopted Accounting Guidance and Accounting Guidance Not Yet Adopted	Recent Accounting Pronouncements There were no new accounting standards adopted during the year ended December 31, 2024 that had a material impact on our Consolidated Financial Statements. There are no significant accounting pronouncements not yet adopted as of December 31, 2024.
Cash and Cash Equivalents	Cash and cash equivalents are carried at cost that approximates fair value. Cash equivalents consist of short-term investments with maturities of three months or less from the time of purchase. The Company reclassifies cash overdraft positions to liabilities when the legal right of offset does not exist.
Inventories	Inventories consist of prescription drugs and medical supplies and are stated at the lower of first-in-first-out cost or net realizable value.
Translation of Foreign Currencies	The Company generally conducts its international business through foreign operating entities that maintain assets and liabilities in local currencies that are their functional currencies. The Company uses exchange rates as of the balance sheet date to translate assets and liabilities into U.S. dollars. Translation gains or losses on functional currencies, net of applicable taxes, are recorded in Accumulated other comprehensive loss. The Company uses average monthly exchange rates during the year to translate revenues and expenses into U.S. dollars.
Revenue Recognition	. Pharmacy revenues are primarily derived from providing pharmacy benefit management services to clients and customers. Pharmacy revenues are recognized when control of the promised goods or services is transferred to clients and customers in an amount that reflects the consideration the Company expects to receive for those goods or services. The Company provides or makes available various services supporting benefit management and claims administration and is generally obligated to provide prescription drugs to clients' members using multiple distribution methods, including retail networks, home delivery and specialty pharmacies. These goods and services are integrated into a single performance obligation to process claims, dispense prescription drugs and provide other services over the contract period (generally three years). This performance obligation is satisfied as the business stands ready to fulfill its obligation. Revenues for dispensing prescription drugs through retail pharmacies are reported gross and consist of the prescription price (ingredient cost and dispensing fee) contracted with clients, including the customer copayment, and any associated fees for services, because the Company acts as the principal in these arrangements. When a prescription is presented to a retail network pharmacy, the Company is solely responsible for customer eligibility, drug utilization review, drug-to-drug interaction review, any required clinical intervention, plan provision information, payment to the pharmacy and client billing. These revenues are recognized based on the full prescription price when the pharmacy claim is processed and approved for payment. The Company also provides benefit design and formulary consultation services to clients and negotiates separate contractual relationships with clients and network pharmacies. These factors indicate that the Company has control over these transactions until the prescription is processed. Revenues are billed, due and recognized at contract rates either on a periodic basis or as services are provided (such as based on volume of claims processed). This recognition pattern aligns with the benefits from services provided. Home delivery and specialty pharmacy revenues are due and recognized as each prescription is shipped, net of reserves for discounts and contractual allowances estimated based on historical experience. Any differences between estimates and actual collections are reflected in Pharmacy revenues when payments are received. Historically, adjustments to original estimates and returns have not been material. The Company has elected the practical expedient to account for shipping and handling as a fulfillment activity. We may also provide certain financial and performance guarantees, including a minimum level of discounts a client may receive, generic utilization rates and various service levels. Clients may be entitled to receive compensation if we fail to meet the guarantees. Actual performance is compared to the contractual guarantee for each measure throughout the period and the Company defers revenue for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted and paid at the end of the annual guarantee period. Historically, adjustments to original estimates have not been material. The liability for these financial and performance guarantees was $1.9 billion as of December 31, 2024 and $1.6 billion as of December 31, 2023. The Company administers programs through which we may receive rebates and other vendor consideration from pharmaceutical manufacturers. The amounts of such rebates or other vendor consideration shared with pharmacy benefit management services clients vary based on the contractual arrangement with the client and in some cases the type of consideration received from the pharmaceutical manufacturer. Rebates and other vendor consideration payable to pharmacy benefit management services clients are recorded as a reduction of Pharmacy revenues. Estimated amounts payable to clients are based on contractual sharing arrangements between the Company and the client and these amounts are adjusted when amounts are collected from pharmaceutical manufacturers in accordance with the contractual arrangement between the Company and the client. Historically, these adjustments have not been material. Other pharmacy service revenues are earned by distributing specialty pharmaceuticals and medical supplies to providers, clinics and hospitals. These revenues are billed, due and recognized at contracted rates as prescriptions and supplies are shipped and services are provided. Pharmacy Costs. Pharmacy costs include the cost of prescriptions sold, network pharmacy claim costs and copayments. Also included are direct costs of dispensing prescriptions including supplies, shipping and handling, and direct costs associated with clinical programs, such as drug utilization management and medication adherence counseling. Home delivery and specialty pharmacy costs are recognized when the drug is shipped, and retail network costs are recognized when the drug is processed and approved for payment. Rebates and other vendor consideration received when providing pharmacy benefit management services are recorded as a reduction of pharmacy costs. Rebates are recognized as prescriptions are shipped or processed and approved for payment. Historically, the effect of adjustments resulting from the reconciliation of rebates recognized to the amounts billed and collected, net of contractual allowances, has not been material. The Company maintains reimbursement guarantees with certain retail network pharmacies. For each such guarantee, the Company records a pharmacy and other service costs payable or prepaid asset for applicable retail network claims based on our actual performance throughout the period against the contractual reimbursement rate. The Company's contracts with certain retail pharmacies give the Company the right to adjust reimbursement rates during the annual guarantee period. E.Premiums and Related Expenses Premiums for short-duration group health, accident and life insurance and managed care coverages are recognized as revenue on a pro rata basis over the contract period. Benefits and expenses are recognized when incurred and, for our Cigna Healthcare business, are presented net of pharmaceutical manufacturer rebates. For experience-rated contracts, premium revenue includes an adjustment for experience-rated refunds based on contract terms and calculated using the customer's experience (including estimates of incurred but not reported claims). Premiums received for the Company's Medicare Advantage plans, Medicare Part D plans and Individual and Family Plans from the Centers for Medicare and Medicaid Services ("CMS") and customers are recognized as revenue ratably over the contract period. CMS provides risk-adjusted premium payments for Medicare Advantage plans and Medicare Part D plans based on our customer demographics and medical diagnoses, which may change from period to period based on the underlying health factors of our customers. The Company recognizes changes to risk-adjusted premiums as revenue when the amounts are determinable and collection is reasonably assured. Revenue adjustments are generally settled semiannually with CMS. The final revenue adjustment is generally settled with CMS in the year following the contract year. Medicare Part D premiums include payments from CMS for risk-sharing adjustments that are estimated quarterly based on claim experience by comparing actual incurred prescription drug costs to the estimated costs submitted in the original contracts. These adjustments may result in more or less revenue from CMS. Final revenue adjustments generally occur in the year following the contract year. The Patient Protection and Affordable Care Act ("ACA") prescribed a risk adjustment program to mitigate the risk for participating health insurance companies selling individual coverage on the public exchanges. The risk adjustment program reallocates funds from insurers with lower risk populations to insurers with higher risk populations based on the relative risk scores of participants. We estimate our receivable or payable based on the risk of our customers compared to the risk of other customers in the same state and market, considering data obtained from industry studies and the United States Department of Health and Human Services ("HHS"). Receivables or payables are recorded as adjustments to premium revenue based on our year-to-date experience when the amounts are reasonably estimable and collection is reasonably assured. Final revenue adjustments are determined by HHS in the year following the policy year. Premium revenue may also include an adjustment to reflect the estimated effect of rebates due to customers under medical loss ratio provisions of the ACA. These rebate liabilities are settled in the subsequent year. Liabilities related to experience-rated refunds, risk adjustment programs and the minimum medical loss ratio are included in Accrued expenses and other liabilities (current). Premiums for long-duration insurance contracts, including supplemental health, accident and individual life insurance and annuity products, and excluding universal life and investment-related products, are recognized as revenue when due. Cigna Healthcare long-duration premium revenues are associated with contracts that provide coverage greater than one year or are guaranteed to be renewed at the option of the policyholder beyond one year. Benefits and expenses are matched with premiums. Revenue for universal life products is recognized as follows: •Investment income on assets supporting universal life products is recognized in Net investment income as earned. •Charges for mortality, administration and policy surrender are recognized in Premiums as earned. Administrative fees are considered earned when services are provided. Benefits and expenses for universal life products consist of benefit claims in excess of policyholder account balances and income earned by policyholders. Expenses are recognized when claims are incurred and income is credited to policyholders in accordance with contract provisions. The unrecognized portion of premiums received is recorded as unearned premiums included in Insurance and contractholder liabilities (current and non-current) (see Note 9 to the Consolidated Financial Statements for further information). F.Fees and Related Expenses The majority of the Company's service fee revenues are derived from the following programs: •Administrative Services Only ("ASO") arrangements allow plan sponsors to self-fund claims and assume the risk of medical or other benefit costs. In return for fees from these clients, the Company provides access to our participating provider networks and other services supporting benefit management. •Fee-for-service clinical solutions offered to clients, such as drug utilization management and medication adherence counseling help clients to drive better health outcomes at a lower cost by identifying and addressing potentially unsafe or wasteful prescribing, dispensing and utilization of prescription drugs, and communicating with, or supporting communications with, physicians, pharmacies and patients. •Wholesale Marketplace Drug Formulary Management services include either our drug formulary administrative service arrangements or our formulary processing arrangements. Drug formulary administrative services may include formulary consultation, administration of rebate contracts, rebate submission, collection from drug manufacturers and the distribution of rebates to clients. Services may also include facilitating audits of data submissions and reporting of rebates to clients. •Health benefit management solutions are offered primarily to sponsors of health benefit plans to drive cost reductions and improve quality outcomes for clients as well as provide behavioral health services to third-party health plans, employers and administrators. In certain arrangements, the Company assumes the financial obligation for third-party provider costs for medical services provided to the health plan's customers. Arrangements are generally short-term (one year or less) except for certain three-year health benefit management solutions contracts, and each consists of a single performance obligation. Performance obligations are satisfied as services are provided to clients, either on a stand-ready or utilization basis. Fees are billed, due and recognized at contracted rates on a periodic basis, generally monthly or agreed-upon arrangements terms. Fee revenues for services are generally recorded on a gross basis with the associated direct and indirect costs presented in Pharmacy and other service costs, or Selling, general and administrative expenses. Retained rebates reported in Fees and other revenues in our formulary processing arrangements are either recognized gross as services are provided to clients, consistent with the related service fee, or net as rebates are processed. The latter applies in arrangements in which the Company is permitted to retain a portion of rebates collected in exchange for services, but the Company does not obtain control of the retained rebate until rebates are transferred to the client. Fees for services may include variable consideration as a component of the transaction price, which is estimated at contract inception, recognized and adjusted through the contract period through Accrued expenses and other liabilities. Variable consideration includes certain health benefit management contracts requiring the Company to share the results of medical cost experience that differ from specified targets and ASO performance guarantees that compensate clients if certain service standards, clinical outcomes or financial metrics are not met.
Cost of Goods and Service	. Pharmacy revenues are primarily derived from providing pharmacy benefit management services to clients and customers. Pharmacy revenues are recognized when control of the promised goods or services is transferred to clients and customers in an amount that reflects the consideration the Company expects to receive for those goods or services. The Company provides or makes available various services supporting benefit management and claims administration and is generally obligated to provide prescription drugs to clients' members using multiple distribution methods, including retail networks, home delivery and specialty pharmacies. These goods and services are integrated into a single performance obligation to process claims, dispense prescription drugs and provide other services over the contract period (generally three years). This performance obligation is satisfied as the business stands ready to fulfill its obligation. Revenues for dispensing prescription drugs through retail pharmacies are reported gross and consist of the prescription price (ingredient cost and dispensing fee) contracted with clients, including the customer copayment, and any associated fees for services, because the Company acts as the principal in these arrangements. When a prescription is presented to a retail network pharmacy, the Company is solely responsible for customer eligibility, drug utilization review, drug-to-drug interaction review, any required clinical intervention, plan provision information, payment to the pharmacy and client billing. These revenues are recognized based on the full prescription price when the pharmacy claim is processed and approved for payment. The Company also provides benefit design and formulary consultation services to clients and negotiates separate contractual relationships with clients and network pharmacies. These factors indicate that the Company has control over these transactions until the prescription is processed. Revenues are billed, due and recognized at contract rates either on a periodic basis or as services are provided (such as based on volume of claims processed). This recognition pattern aligns with the benefits from services provided. Home delivery and specialty pharmacy revenues are due and recognized as each prescription is shipped, net of reserves for discounts and contractual allowances estimated based on historical experience. Any differences between estimates and actual collections are reflected in Pharmacy revenues when payments are received. Historically, adjustments to original estimates and returns have not been material. The Company has elected the practical expedient to account for shipping and handling as a fulfillment activity. We may also provide certain financial and performance guarantees, including a minimum level of discounts a client may receive, generic utilization rates and various service levels. Clients may be entitled to receive compensation if we fail to meet the guarantees. Actual performance is compared to the contractual guarantee for each measure throughout the period and the Company defers revenue for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted and paid at the end of the annual guarantee period. Historically, adjustments to original estimates have not been material. The liability for these financial and performance guarantees was $1.9 billion as of December 31, 2024 and $1.6 billion as of December 31, 2023. The Company administers programs through which we may receive rebates and other vendor consideration from pharmaceutical manufacturers. The amounts of such rebates or other vendor consideration shared with pharmacy benefit management services clients vary based on the contractual arrangement with the client and in some cases the type of consideration received from the pharmaceutical manufacturer. Rebates and other vendor consideration payable to pharmacy benefit management services clients are recorded as a reduction of Pharmacy revenues. Estimated amounts payable to clients are based on contractual sharing arrangements between the Company and the client and these amounts are adjusted when amounts are collected from pharmaceutical manufacturers in accordance with the contractual arrangement between the Company and the client. Historically, these adjustments have not been material. Other pharmacy service revenues are earned by distributing specialty pharmaceuticals and medical supplies to providers, clinics and hospitals. These revenues are billed, due and recognized at contracted rates as prescriptions and supplies are shipped and services are provided. Pharmacy Costs. Pharmacy costs include the cost of prescriptions sold, network pharmacy claim costs and copayments. Also included are direct costs of dispensing prescriptions including supplies, shipping and handling, and direct costs associated with clinical programs, such as drug utilization management and medication adherence counseling. Home delivery and specialty pharmacy costs are recognized when the drug is shipped, and retail network costs are recognized when the drug is processed and approved for payment. Rebates and other vendor consideration received when providing pharmacy benefit management services are recorded as a reduction of pharmacy costs. Rebates are recognized as prescriptions are shipped or processed and approved for payment. Historically, the effect of adjustments resulting from the reconciliation of rebates recognized to the amounts billed and collected, net of contractual allowances, has not been material. The Company maintains reimbursement guarantees with certain retail network pharmacies. For each such guarantee, the Company records a pharmacy and other service costs payable or prepaid asset for applicable retail network claims based on our actual performance throughout the period against the contractual reimbursement rate. The Company's contracts with certain retail pharmacies give the Company the right to adjust reimbursement rates during the annual guarantee period. E.Premiums and Related Expenses Premiums for short-duration group health, accident and life insurance and managed care coverages are recognized as revenue on a pro rata basis over the contract period. Benefits and expenses are recognized when incurred and, for our Cigna Healthcare business, are presented net of pharmaceutical manufacturer rebates. For experience-rated contracts, premium revenue includes an adjustment for experience-rated refunds based on contract terms and calculated using the customer's experience (including estimates of incurred but not reported claims). Premiums received for the Company's Medicare Advantage plans, Medicare Part D plans and Individual and Family Plans from the Centers for Medicare and Medicaid Services ("CMS") and customers are recognized as revenue ratably over the contract period. CMS provides risk-adjusted premium payments for Medicare Advantage plans and Medicare Part D plans based on our customer demographics and medical diagnoses, which may change from period to period based on the underlying health factors of our customers. The Company recognizes changes to risk-adjusted premiums as revenue when the amounts are determinable and collection is reasonably assured. Revenue adjustments are generally settled semiannually with CMS. The final revenue adjustment is generally settled with CMS in the year following the contract year. Medicare Part D premiums include payments from CMS for risk-sharing adjustments that are estimated quarterly based on claim experience by comparing actual incurred prescription drug costs to the estimated costs submitted in the original contracts. These adjustments may result in more or less revenue from CMS. Final revenue adjustments generally occur in the year following the contract year. The Patient Protection and Affordable Care Act ("ACA") prescribed a risk adjustment program to mitigate the risk for participating health insurance companies selling individual coverage on the public exchanges. The risk adjustment program reallocates funds from insurers with lower risk populations to insurers with higher risk populations based on the relative risk scores of participants. We estimate our receivable or payable based on the risk of our customers compared to the risk of other customers in the same state and market, considering data obtained from industry studies and the United States Department of Health and Human Services ("HHS"). Receivables or payables are recorded as adjustments to premium revenue based on our year-to-date experience when the amounts are reasonably estimable and collection is reasonably assured. Final revenue adjustments are determined by HHS in the year following the policy year. Premium revenue may also include an adjustment to reflect the estimated effect of rebates due to customers under medical loss ratio provisions of the ACA. These rebate liabilities are settled in the subsequent year. Liabilities related to experience-rated refunds, risk adjustment programs and the minimum medical loss ratio are included in Accrued expenses and other liabilities (current). Premiums for long-duration insurance contracts, including supplemental health, accident and individual life insurance and annuity products, and excluding universal life and investment-related products, are recognized as revenue when due. Cigna Healthcare long-duration premium revenues are associated with contracts that provide coverage greater than one year or are guaranteed to be renewed at the option of the policyholder beyond one year. Benefits and expenses are matched with premiums. Revenue for universal life products is recognized as follows: •Investment income on assets supporting universal life products is recognized in Net investment income as earned. •Charges for mortality, administration and policy surrender are recognized in Premiums as earned. Administrative fees are considered earned when services are provided. Benefits and expenses for universal life products consist of benefit claims in excess of policyholder account balances and income earned by policyholders. Expenses are recognized when claims are incurred and income is credited to policyholders in accordance with contract provisions. The unrecognized portion of premiums received is recorded as unearned premiums included in Insurance and contractholder liabilities (current and non-current) (see Note 9 to the Consolidated Financial Statements for further information). F.Fees and Related Expenses The majority of the Company's service fee revenues are derived from the following programs: •Administrative Services Only ("ASO") arrangements allow plan sponsors to self-fund claims and assume the risk of medical or other benefit costs. In return for fees from these clients, the Company provides access to our participating provider networks and other services supporting benefit management. •Fee-for-service clinical solutions offered to clients, such as drug utilization management and medication adherence counseling help clients to drive better health outcomes at a lower cost by identifying and addressing potentially unsafe or wasteful prescribing, dispensing and utilization of prescription drugs, and communicating with, or supporting communications with, physicians, pharmacies and patients. •Wholesale Marketplace Drug Formulary Management services include either our drug formulary administrative service arrangements or our formulary processing arrangements. Drug formulary administrative services may include formulary consultation, administration of rebate contracts, rebate submission, collection from drug manufacturers and the distribution of rebates to clients. Services may also include facilitating audits of data submissions and reporting of rebates to clients. •Health benefit management solutions are offered primarily to sponsors of health benefit plans to drive cost reductions and improve quality outcomes for clients as well as provide behavioral health services to third-party health plans, employers and administrators. In certain arrangements, the Company assumes the financial obligation for third-party provider costs for medical services provided to the health plan's customers. Arrangements are generally short-term (one year or less) except for certain three-year health benefit management solutions contracts, and each consists of a single performance obligation. Performance obligations are satisfied as services are provided to clients, either on a stand-ready or utilization basis. Fees are billed, due and recognized at contracted rates on a periodic basis, generally monthly or agreed-upon arrangements terms. Fee revenues for services are generally recorded on a gross basis with the associated direct and indirect costs presented in Pharmacy and other service costs, or Selling, general and administrative expenses. Retained rebates reported in Fees and other revenues in our formulary processing arrangements are either recognized gross as services are provided to clients, consistent with the related service fee, or net as rebates are processed. The latter applies in arrangements in which the Company is permitted to retain a portion of rebates collected in exchange for services, but the Company does not obtain control of the retained rebate until rebates are transferred to the client. Fees for services may include variable consideration as a component of the transaction price, which is estimated at contract inception, recognized and adjusted through the contract period through Accrued expenses and other liabilities. Variable consideration includes certain health benefit management contracts requiring the Company to share the results of medical cost experience that differ from specified targets and ASO performance guarantees that compensate clients if certain service standards, clinical outcomes or financial metrics are not met.

Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.

Accounts Receivable, Net (Policies)	12 Months Ended
Accounts Receivable, Net (Policies)	Dec. 31, 2024
Receivables [Abstract]
Accounts Receivable	Accounting Policy. We bill pharmaceutical manufacturers based on management's interpretation of contractual terms and estimate a contractual allowance based on the best information available at the time a claim is processed. Contractual allowances for certain rebates receivable from pharmaceutical manufacturers are determined by reviewing payment experience and specific known items that could be adjusted under contract terms. The Company's estimation process for contractual allowances for pharmaceutical manufacturer receivables generally results in an allowance for balances outstanding greater than 90 days. Contractual allowances for certain receivables from third-party payors are based on their contractual terms and are estimated based on the Company's best information available at the time revenue is recognized. The allowance for expected credit losses for current accounts receivable is based primarily on past collections experience relative to the length of time receivables are past due; however, when available evidence reasonably supports an assumption that counterparty credit risk over the expected payment period will differ from current and historical payment collections, a forecasting adjustment is reflected in the allowance for expected credit losses. Discounts and claims adjustments issued to customers in the form of client credits and other non-credit adjustments are based on the current status of each customer's receivable balance, current economic and market conditions and a variety of other factors, including the length of time the receivables are past due, the financial health of customers and our past experience. Receivables and any associated allowance are written off only when all collection attempts have failed and such amounts are determined unrecoverable. We regularly review the adequacy of these allowances based on a variety of factors, including age of the outstanding receivable and collection history. When circumstances related to specific collection patterns change, estimates of the recoverability of receivables are adjusted. The Company's accounts receivable include amounts due from clients, third-party payors, customers and pharmaceutical manufacturers, and are presented net of allowances. These balances include the following: •Noninsurance customer receivables - amounts due from customers for noninsurance services, primarily pharmacy benefit management and ASO contracts. •Pharmaceutical manufacturers receivables - amounts due from pharmaceutical manufacturers. •Insurance customer receivables - amounts due from customers under insurance and managed care contracts, primarily premiums receivable and amounts due from CMS. •Other receivables - all other accounts receivable not included in the categories above. The transactions under the Facility are accounted for as a sale and recorded as a reduction to accounts receivable in the Consolidated Balance Sheets because control of, and risk related to, the accounts receivable are transferred to the financial institution. Although the sale is made without recourse, we provide collection services related to the transferred assets. Amounts associated with this Facility are reflected within Net cash provided by operating activities in the Consolidated Statements of Cash Flows. Factoring fees paid under this Facility are reflected in Interest expense and other in the Consolidated Statements of Income. As of December 31, 2024 and December 31, 2023, all sold accounts receivable had been collected from pharmaceutical manufacturers and had been removed from the Company's Consolidated Balance Sheets. As of December 31, 2024 and December 31, 2023, there were $1.0 billion and $515 million, respectively, of collections from pharmaceutical manufacturers that had not been remitted to the financial institution. Such amounts are recorded within Accrued expenses and other liabilities in the Consolidated Balance Sheets.

Assests and Liabilities of Businesses Held for Sale (Policies)	12 Months Ended
	Dec. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]
Assets and Liabilities of Businesses Held for Sale	Accounting Policy. The Company classifies assets and liabilities as held for sale ("disposal group") when management commits to a plan to sell the disposal group, the sale is probable within one year and the disposal group is available for immediate sale in its present condition. The Company considers various factors, particularly whether actions required to complete the plan indicate it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. Assets held for sale are measured at the lower of carrying value or fair value less costs to sell. Any loss resulting from the measurement is recognized in the period the held for sale criteria are met. Conversely, gains are not recognized until the date of the sale. When the disposal group is classified as held for sale, depreciation and amortization for most long-lived assets ceases and the Company tests the assets for impairment. Deferred policy acquisition costs continue to be amortized.

Earnings Per Share (Policies)	12 Months Ended
Earnings Per Share (Policies)	Dec. 31, 2024
Earnings Per Share [Abstract]
Earnings Per Share	Accounting Policy. The Company computes basic earnings per share using the weighted-average number of unrestricted common and deferred shares outstanding. Diluted earnings per share also includes the dilutive effect of outstanding employee stock options and restricted stock using the treasury stock method and the effect of strategic performance shares.

Insurance and Contractholder Liabilities (Policies)	12 Months Ended
Insurance and Contractholder Liabilities (Policies)	Dec. 31, 2024
Insurance Loss Reserves [Abstract]
Unearned Premium	Accounting Policy - Unearned Premium. The unrecognized portion of premiums received is recorded as unearned premiums included in Insurance and contractholder liabilities (current and non-current). The Company evaluates certain insurance contracts subject to premium deficiency testing and recognizes a premium deficiency loss and corresponding reserve when expected claims costs, claims adjustment expenses, maintenance costs, and unamortized acquisition costs exceed unearned premium. Anticipated investment income is considered in the calculation of premium deficiency.
Unpaid Claims and Claims Expenses	This liability reflects estimates of the ultimate cost of claims that have been incurred but not reported, expected development on reported claims, claims that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities. Accounting Policy. The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. The Company compares key assumptions used to establish the medical costs payable to actual experience for each reporting period. The unpaid claims liability is adjusted through current period Shareholders' net income when actual experience differs from these assumptions. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trend. The liability is primarily calculated using "completion factors" developed by comparing the claim incurral date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1) electronic (auto-adjudication) versus manual claim processing; 2) frequency and timeliness of provider claims submissions; 3) number of customers; and 4) the mix of products. The Company uses historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. The Company relies more heavily on medical cost trend analysis that reflects expected claim payment patterns and other relevant operational considerations for more recent months. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of health benefits offered, including inpatient, outpatient and pharmacy; the impact of copays and deductibles; changes in provider practices; and changes in consumer demographics and consumption behavior. There is no single or common claim frequency metric used in the health care industry. The Company believes a relevant metric for its health insurance business is the number of customers for whom an insured medical claim was paid. Customers for whom no insured medical claim was paid are excluded from the calculation. Claims that did not result in a liability are not included in the frequency metric.
Future Policy Benefits	Accounting Policy. Future policy benefits represent the present value of estimated future obligations, estimated using actuarial methods, for long-duration insurance policies and annuity products currently in force, consisting primarily of reserves for annuity contracts, life insurance benefits and certain supplemental health products that are guaranteed renewable beyond one year. Contracts are grouped at a level no higher than issue year, based on the original contract issue date, and at lower levels of disaggregation within each issue year for certain businesses to reflect factors including product type, plan type and currency. Management estimates these obligations based on assumptions for premiums, interest rates, mortality or morbidity, future claim adjudication expenses and surrenders. Mortality, morbidity and surrender assumptions are based on the Company's own experience and published actuarial tables and are updated at least annually, to the extent changes in circumstances require. Interest rate assumptions are based on market-level yields for low credit risk fixed income instruments ("upper-medium grade fixed income instrument"). For interest accretion purposes, interest rates are fixed at the year of the cohort's inception; however, for purposes of liability measurement, they are updated to the current rate quarterly, with all changes in the interest rate from inception to current period reported through Accumulated other comprehensive loss. For contracts issued domestically, we use observable inputs from a published spot rate curve for terms up to 30 years and extrapolate for longer terms using a constant forward rate approach. For contracts issued by foreign operating entities with functional currencies other than the U.S. dollar, we use observable inputs to approximate a risk free rate and add a credit spread adjustment to align with a low-credit risk fixed income instrument. For terms beyond the last observable risk free rates, which vary by international market, we extrapolate to the ultimate forward rate assuming a constant credit spread. For the annuity business, the premium paying period is shorter than the benefit coverage period, and a deferred profit liability is reported in future policy benefits representing gross premium received in excess of net premiums. Deferred profit liability is amortized based on expected future benefit payments. The net liability for future policy benefits for the segment's supplemental health products represents the present value of benefits expected to be paid to policyholders, net of the present value of expected net premiums, which is the portion of expected future gross premium expected to be collected from policyholders that is required to provide for all expected future benefits and expenses. Obligations for annuities represent discounted periodic benefits to be paid to an individual or groups of individuals over their remaining lives. Other Operations' traditional insurance contracts, which are in run-off, have no premium remaining to be collected; therefore, future policy benefit reserves represent the present value of expected future policy benefits, discounted using the current discount rate, and the remaining amortizable deferred profit liability.
Contractholder Deposit Funds	Accounting Policy. Liabilities for contractholder deposit funds primarily include deposits received from customers for investment-related and universal life products as well as investment earnings on their fund balances in Other Operations. These liabilities are adjusted to reflect administrative charges and, for universal life fund balances, mortality charges. Interest credited on these funds is accrued ratably over the contract period.
Market Risk Benefits	Accounting Policy. Variable annuity reinsurance liabilities are measured as MRBs at fair value, net of nonperformance risk, with fluctuations in value gross of reinsurer nonperformance risk reported in benefit expenses, while fluctuations in the Company's own nonperformance risk (own credit risk) are reported in Accumulated other comprehensive loss. Nonperformance risk reflects risk that a party might default and therefore not fulfill its obligations (i.e., nonpayment risk). The nonperformance risk adjustment reflects a market participant's view of nonpayment risk by adding an additional spread to the discount rate in the calculation of both (a) the variable annuity reinsurance liabilities to be paid by the Company and (b) the variable annuity reinsurance assets to be paid by the reinsurers, after considering collateral. The Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy described in Note 12 to the Consolidated Financial Statements because assumptions related to future annuitant behavior are largely unobservable. As discussed further in Note 10 to the Consolidated Financial Statements, due to the reinsurance agreements covering these liabilities, the liabilities do not generally impact net income except for the change in nonperformance risk on the reinsurance recoverable, which is reported in benefit expenses and does not offset the nonperformance risk valuation on the liability. Variable annuity liabilities are established using capital market assumptions and assumptions related to future annuitant behavior (including mortality, lapse and annuity election rates).

Reinsurance (Policies)	12 Months Ended
Reinsurance (Policies)	Dec. 31, 2024
Reinsurance Disclosures [Abstract]
Reinsurance	Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and pending claims of certain business for which the Company administers the plan benefits without any right of offset. See Note 10 to the Consolidated Financial Statements for additional information on reinsurance. The Company's insurance subsidiaries enter into agreements with other insurance companies to limit losses from large exposures and to permit recovery of a portion of incurred losses. Reinsurance is ceded primarily in acquisition and disposition transactions when the underwriting company is not being acquired. Reinsurance does not relieve the originating insurer of liability. Therefore, reinsured liabilities must continue to be reported along with the related reinsurance recoverables. The Company regularly evaluates the financial condition of its reinsurers and monitors concentrations of its credit risk. Accounting Policy. Reinsurance recoverables represent amounts due from reinsurers for both paid and unpaid claims of the Company's insurance businesses. The Company bears the risk of loss if its reinsurers and retrocessionaires do not meet or are unable to meet their reinsurance obligations to the Company. Most reinsurance recoverables are classified as non-current assets. The current portion of reinsurance recoverables is reported in Other current assets and consists primarily of recoverables on paid claims expected to be settled within one year. Reinsurance recoverables are presented net of allowances, consisting primarily of an allowance for expected credit losses, which is recognized on reinsurance recoverable balances each period and adjusted through Medical costs and other benefit expenses. Estimates of the allowance for expected credit losses are based on internal and external data used to develop expected loss rates over the anticipated duration of the recoverable asset that vary by external credit rating and collateral level. Collateral levels are defined internally based on the fair value of the collateral relative to the carrying amount of the reinsurance recoverable, the frequency at which collateral is required to be replenished and the potential for volatility in the collateral's fair value. Variable annuity contracts are accounted for as assumed and ceded reinsurance and categorized as market risk benefits as discussed in Note 9 to the Consolidated Financial Statements.

Investments (Policies)	12 Months Ended
Investments (Policies)	Dec. 31, 2024
Investments [Abstract]
Investments	Accounting Policy. Debt securities, commercial mortgage loans, derivative financial instruments and short-term investments with contractual maturities during the next 12 months are classified on the balance sheet as current investments, unless they are held as statutory deposits or restricted for other purposes and then they are classified as Long-term investments. Equity securities may include funds that are used in our cash management strategy and are classified as current investments. All other investments are classified as Long-term investments. See Note 12 for information about the valuation of the Company's investment portfolio. Accounting Policy. Debt securities (including bonds, mortgage and other asset-backed securities, and preferred stocks redeemable by the investor) are classified as available for sale and are carried at fair value with changes in fair value recorded either in Accumulated other comprehensive loss within Shareholders' equity or in credit loss expense based on fluctuations in the allowance for credit losses, as further discussed below. When the Company intends to sell or determines that it is more likely than not to be required to sell an impaired debt security, the excess of amortized cost over fair value is directly written down with a charge to Net investment losses. Certain asset-backed securities are considered variable interest entities. See Note 13 for additional information. The Company reviews declines in fair value from a debt security's amortized cost basis to determine whether a credit loss exists and, when appropriate, recognizes a credit loss allowance with a corresponding charge to credit loss expense, presented in Net investment losses in the Company's Consolidated Statements of Income. The allowance for credit loss represents the excess of amortized cost over the greater of its fair value or the net present value of the debt security's projected future cash flows (based on qualitative and quantitative factors, including the probability of default and the estimated timing and amount of recovery). Each period, the allowance for credit loss is adjusted as needed through credit loss expense. The Company does not measure an allowance for credit losses for accrued interest receivables. When interest payments are delinquent based on contractual terms or when certain terms (interest rate or maturity date) of the investment have been restructured, accrued interest, reported in Other current assets, is written off through a charge to Net investment income and interest income is recognized on a cash basis. Review of Declines in Fair Value. Management reviews debt securities in an unrealized loss position to determine whether a credit loss allowance is needed based on criteria that include severity of decline; financial health and specific prospects of the issuer; and changes in the regulatory, economic or general market environment of the issuer's industry or geographic region. Accounting Policy. Equity securities with a readily determinable fair value consist primarily of public equity investments in the health care sector and mutual funds that invest in fixed income debt securities while those without a readily determinable fair value consist of private equity investments. Changes in the fair values of equity securities that have a readily determinable fair value are reported in Net investment losses. Equity securities without a readily determinable fair value are carried at cost minus impairment plus or minus changes resulting from observable price changes. Accounting Policy. Commercial mortgage loans are carried at unpaid principal balances, net of an allowance for expected credit losses, and classified as either current or long-term investments based on their contractual maturities. Changes in the allowance for expected credit losses are recognized as credit loss expense and presented in Net investment losses in the Company's Consolidated Statements of Income. Each period, the Company establishes (or adjusts) its allowance for expected credit losses for commercial mortgage loans. The allowance for expected credit losses is based on a credit risk category that is assigned to each loan at origination using key credit quality indicators, including debt service coverage and loan-to-value ratios. Credit risk categories are updated as key credit quality indicators change. An expected loss rate, assigned based on the credit risk category, is applied to each loan's unpaid principal balance to develop the aggregate allowance for expected credit losses. Commercial mortgage loans are considered impaired and written off against the allowance when it is probable that the Company will not collect all amounts due per the terms of the promissory note. In the event of a foreclosure, the allowance for credit losses is based on the excess of the carrying value of the mortgage loan over the fair value of its underlying collateral. Credit Quality. The Company regularly evaluates and monitors credit risk. Mortgage origination professionals employ an internal credit quality rating system designed to evaluate the relative risk of the transaction at origination that is then updated each year as part of the annual portfolio loan review. The Company evaluates and monitors credit quality on a consistent and ongoing basis. The annual portfolio review performed in the second quarter of 2024 confirmed ongoing strong overall credit quality in line with the previous year's results. Quality ratings are based on our evaluation of a number of key inputs related to the loan. The two most significant contributors to the credit quality rating are the debt service coverage and loan-to-value ratios. The debt service coverage ratio measures the amount of property cash flow available to meet annual interest and principal payments on debt, with a ratio below 1.0 indicating that there is not enough cash flow to cover the required loan payments. The loan-to-value ratio, commonly expressed as a percentage, compares the amount of the loan to the fair value of the underlying property collateralizing the loan. Accounting Policy. Policy loans, primarily associated with our corporate-owned life insurance business, are carried at unpaid principal balances plus accumulated interest, the total of which approximates fair value. These loans are collateralized by life insurance policy cash values and therefore have minimal exposure to credit loss. Interest rates are reset annually based on a rolling average of benchmark interest rates. Accounting Policy. Other long-term investments include investments in unconsolidated entities, including certain limited partnerships and limited liability companies holding real estate, securities or loans, and health care-related investments. These investments are carried at cost plus the Company's ownership percentage of reporting income or loss, based on the financial statements of the underlying investments that are generally reported at fair value. Income or loss from these investments is reported on a one-quarter lag due to the timing of when financial information is received from the general partner or manager of the investments. Other long-term investments also include investment real estate carried at depreciated cost less any impairment write-downs to fair value when cash flows indicate that the carrying value may not be recoverable. Depreciation is generally recorded using the straight-line method based on the estimated useful life of each asset. Investment real estate as of December 31, 2024 and 2023 is expected to be held longer than one year and may include real estate acquired through the foreclosure of commercial mortgage loans. Additionally, foreign currency swaps carried at fair value and certain restricted deposits are reported in the table below as "Other." See discussion below for information on the Company's accounting policies for derivative financial instruments. Other long-term investments and related commitments are diversified by issuer, property type and geographic regions. These investments are primarily unconsolidated variable interest entities (see Note 13 for additional information).Our limited partnership investments are reduced as the Company receives cash distributions for returns on its investment that were previously recognized in Net investment income. Accounting Policy. Security investments with maturities of greater than three months to one year from time of purchase are classified as short-term, available for sale and carried at fair value that approximates cost. Accounting Policy. When interest and principal payments on investments are current, the Company recognizes interest income when it is earned. The Company recognizes interest income on a cash basis when interest payments are delinquent based on contractual terms or when certain terms (interest rate or maturity date) of the investment have been restructured. For unconsolidated entities that are included in other long-term investments, investment income is generally recognized according to the Company's share of the reported income or loss on the underlying investments. Investment income attributed to the Company's separate accounts is excluded from our earnings because associated gains and losses generally accrue directly to separate account policyholders. Accounting Policy. Investment gains and losses are based on specifically identified assets and result from sales, investment asset write-downs, changes in the fair value of certain derivatives and equity securities and changes in allowances for credit losses on debt securities and commercial mortgage loan investments.
Derivative Financial Instruments	Accounting Policy. Derivatives are recorded in our Consolidated Balance Sheets at fair value and are classified as current or non-current according to their contractual maturities. Further information on our policies for determining fair value are discussed in Note 12. The Company applies hedge accounting when derivatives are designated, qualified and highly effective as hedges. Under hedge accounting, the changes in fair value of the derivative and the hedged risk are generally recognized together and offset each other when reported in Shareholders' net income. Various qualitative or quantitative methods appropriate for each hedge are used to formally assess and document hedge effectiveness at inception and each period throughout the life of a hedge. Fair Value Hedges of the Foreign Exchange-Related Changes in Fair Values of Certain Foreign-Denominated Bonds: This program hedges the foreign exchange-related changes in fair values of certain foreign-denominated bonds. The notional value of these derivatives matches the amortized cost of the hedged bonds. A majority of these instruments are denominated in Euros, with the remaining instruments denominated in British Pounds Sterling and Australian Dollars. Swap fair values are reported in Long-term investments or Other non-current liabilities. Offsetting changes in fair values attributable to the foreign exchange risk of the swap contracts and the hedged bonds are reported in Net investment losses. The portion of the swap contracts' changes in fair value excluded from the assessment of hedge effectiveness is recorded in Other comprehensive loss and recognized in Net investment income as swap coupon payments are accrued, offsetting the foreign-denominated coupons received on the designated bonds. Net cash flows are reported in Operating activities, while exchanges of notional principal amounts are reported in Investing activities. Fair Value Hedges of the Interest Rate Exposure on the Company's Long-Term Debt: This program converts a portion of the interest rate exposure on the Company's long-term debt from fixed to variable rates. This more closely aligns the Company's interest expense with the interest income received on its cash equivalent and short-term investment balances. The variable rates are benchmarked to SOFR. Using fair value hedge accounting, the fair values of the swap contracts are reported in other assets or other liabilities. The critical terms of these swaps match those of the long-term debt being hedged. As a result, the carrying value of the hedged debt is adjusted to reflect changes in its fair value driven by SOFR. The effects of those adjustments on interest expense are offset by the effects of corresponding changes in the swaps' fair value. The net impact from the hedge reported in Interest expense and other reflects interest expense on the hedged debt at the variable interest rate. Cash flows relating to these contracts are reported in Operating activities. Net Investment Hedges of Certain Foreign Subsidiaries Operating Principally in Currencies Other than the U.S. Dollar: This program reduces the risk of changes in net assets due to changes in foreign currency spot exchange rates for certain foreign subsidiaries that conduct their business principally in currencies other than the U.S. Dollar. The notional value of hedging instruments matches the hedged amount of subsidiary net assets. Foreign currency swap contracts are denominated in Euros. The fair values of the foreign currency swap and forward contracts are reported in other assets or other liabilities. The changes in fair values of these instruments are reported in Other comprehensive loss, specifically in translation of foreign currencies. The portion of the change in fair values relating to foreign exchange spot rates will be recognized in earnings upon deconsolidation of the hedged foreign subsidiaries. Cash flows relating to these contracts are reported in Investing activities.

Disclosure of accounting policy for investment in financial asset.

Fair Value Measures and Disclosures (Policies)	12 Months Ended
Fair Value Measures and Disclosures (Policies)	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Accounting Policy. The Company carries certain financial instruments at fair value in the financial statements including debt securities, certain equity securities, short-term investments and derivatives. Other financial instruments are measured at fair value only under certain conditions, such as when impaired or when there are observable price changes for equity securities with no readily determinable fair value. Fair value is defined as the price at which an asset could be exchanged in an orderly transaction between market participants at the balance sheet date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a market participant, not the amount that would be paid to settle the liability with the creditor. The Company's financial assets and liabilities carried at fair value have been classified based upon a hierarchy defined by GAAP. The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level 3). An asset's or a liability's classification is based on the lowest level of input that is significant to its measurement. For example, a financial asset or liability carried at fair value would be classified in Level 3 if unobservable inputs were significant to the instrument's fair value, even though the measurement may be derived using inputs that are both observable (Levels 1 and 2) and unobservable (Level 3). The Company estimates fair values using prices from third parties or internal pricing methods. Fair value estimates received from third-party pricing services are based on reported trade activity and quoted market prices when available and other market information that a market participant would use to estimate fair value. The internal pricing methods are performed by the Company's investment professionals and generally involve using discounted cash flow analyses, incorporating current market inputs for similar financial instruments with comparable terms and credit quality as well as other qualitative factors. In instances where there is little or no market activity for the same or similar instruments, fair value is estimated using methods, models and assumptions that the Company believes a hypothetical market participant would use to determine a current transaction price. These valuation techniques involve some level of estimation and judgment that becomes significant with increasingly complex instruments or pricing models. The Company is responsible for determining fair value and for assigning the appropriate level within the fair value hierarchy based on the significance of unobservable inputs. The Company reviews methodologies, processes and controls of third-party pricing services and compares prices on a test basis to those obtained from other external pricing sources or internal estimates. The Company performs ongoing analyses of both prices received from third-party pricing services and those developed internally to determine that they represent appropriate estimates of fair value. The controls executed by the Company include evaluating changes in prices and monitoring for potentially stale valuations. The Company also performs sample testing of sales values to confirm the accuracy of prior fair value estimates. The minimal exceptions identified during these processes indicate that adjustments to prices are infrequent and do not significantly impact valuations. An annual due diligence review of the most significant pricing service is conducted to review their processes, methodologies and controls. This review includes a walk-through of inputs for a sample of securities held across various asset types to validate the documented pricing process. Level 1 Financial Assets Inputs for instruments classified in Level 1 include unadjusted quoted prices for identical assets in active markets accessible at the measurement date. Active markets provide pricing data for trades occurring at least weekly and include exchanges and dealer markets. Assets in Level 1 include actively traded U.S. government bonds and exchange-listed equity securities. A relatively small portion of the Company's investment assets are classified in this category given the narrow definition of Level 1 and the Company's investment asset strategy to maximize investment returns. Level 2 Financial Assets and Financial Liabilities Inputs for instruments classified in Level 2 include quoted prices for similar assets or liabilities in active markets, quoted prices from those willing to trade in markets that are not active, or other inputs that are market-observable or can be corroborated by market data for the term of the instrument. Such other inputs include market interest rates and volatilities, spreads, and yield curves. An instrument is classified in Level 2 if the Company determines that unobservable inputs are insignificant. Debt and Equity Securities. Third-party pricing services and internal methods often use recent trades of securities with similar features and characteristics because many debt securities do not trade daily. Pricing models are used to determine these prices when recent trades are not available. These models calculate fair values by discounting future cash flows at estimated market interest rates. Such market rates are derived by calculating the appropriate spreads over comparable U.S. Treasury securities based on the credit quality, industry and structure of the asset. Typical inputs and assumptions to pricing models include, but are not limited to, a combination of benchmark yields, reported trades, issuer spreads, liquidity, benchmark securities, bids, offers, reference data, and industry and economic events. For mortgage-backed securities, inputs and assumptions may also include characteristics of the issuer, collateral attributes, prepayment speeds and credit rating. Nearly all of these instruments are valued using recent trades or pricing models. Short-term Investments are carried at fair value that approximates cost. The Company compares market prices for these securities to recorded amounts on a regular basis to validate that current carrying amounts approximate exit prices. The short-term nature of the investments and corroboration of the reported amounts over the holding period support their classification in Level 2. Derivative Assets and Liabilities classified in Level 2 represent over-the-counter instruments, such as foreign currency forward and swap contracts. Fair values for these instruments are determined using market-observable inputs, including forward currency and interest rate curves and widely published market-observable indices. Credit risk related to the counterparty and the Company is considered when estimating the fair values of these derivatives. The nature and use of these derivative financial instruments are described in Note 11. Level 3 Financial Assets and Financial Liabilities Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Additionally, as discussed in Note 9E to the Consolidated Financial Statements, the Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy. The Company classifies certain newly issued, privately placed, complex or illiquid securities in Level 3. Approximately 5% of debt securities are priced using significant unobservable inputs and classified in this category. Fair values of mortgage and other asset-backed securities, as well as corporate and government debt securities, are primarily determined using pricing models that incorporate the specific characteristics of each asset and related assumptions, including the investment type and structure, credit quality, industry and maturity date in comparison to current market indices, spreads, and liquidity of assets with similar characteristics. Inputs and assumptions for pricing may also include characteristics of the issuer, collateral attributes, and prepayment speeds for mortgage and other asset-backed securities. Recent trades in the subject security or similar securities are assessed when available, and the Company may also review published research in its evaluation, as well as the issuer's financial statements. Quantitative Information about Unobservable Inputs The significant unobservable input used to value our corporate and government debt securities and mortgage and other asset-backed securities is an adjustment for liquidity. This adjustment is needed to reflect current market conditions and issuer circumstances when there is limited trading activity for the security. Total gains and losses included in Shareholders' net income in the tables above are reflected in the Consolidated Statements of Income as Net investment losses and Net investment income. Gains and losses included in Other comprehensive loss, net of tax in the tables above are reflected in Net unrealized appreciation (depreciation) on securities and derivatives in the Consolidated Statements of Comprehensive Income. Transfers into or out of the Level 3 category occur when unobservable inputs, such as the Company's best estimate of what a market participant would use to determine a current transaction price, become more or less significant to the fair value measurement. Market activity typically decreases during periods of economic uncertainty, and this decrease in activity reduces the availability of market observable data. As a result, the level of unobservable judgment that must be applied to the pricing of certain instruments increases and is typically observed through the widening of liquidity spreads.Assets and Liabilities Measured at Fair Value under Certain Conditions Some financial assets and liabilities are not carried at fair value, such as commercial mortgage loans that are carried at unpaid principal, investment real estate that is carried at depreciated cost and equity securities with no readily determinable fair value when there are no observable market transactions. However, these financial assets and liabilities may be measured using fair value under certain conditions, such as when investments become impaired and are written down to their fair value, or when there are observable price changes from orderly market transactions of equity securities that otherwise had no readily determinable fair value.
Separate Accounts	Accounting Policy. Separate account assets and liabilities are contractholder funds maintained in accounts with specific investment objectives. Our subsidiaries or external advisors manage invested assets of separate accounts on behalf of contractholders, including The Cigna Group Pension Plan, variable universal life products sold through our corporate-owned life insurance products and the run-off businesses. The assets of these accounts are legally segregated and are not subject to claims that arise out of any of the Company's other businesses. These separate account assets are carried at fair value with equal amounts recorded for related separate account liabilities. The investment income and fair value gains and losses of separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company's Consolidated Statements of Income and Cash Flows. Fees and charges earned for mortality risks, asset management or administrative services are reported in either Premiums or Fees and other revenues. Investments that are measured using the practical expedient of net asset value ("NAV") are excluded from the fair value hierarchy. The separate account activity for the year ended December 31, 2024 and 2023 was primarily driven by changes in the market values of the underlying separate account investments. Separate account assets classified as Level 1 primarily include exchange-listed equity securities. Level 2 assets primarily include corporate and structured bonds valued using recent trades of similar securities or pricing models that discount future cash flows at estimated market interest rates as described above, and actively traded institutional and retail mutual fund investments. Separate account assets classified in Level 3 primarily support the Company's pension plans and include certain newly issued, privately placed, complex or illiquid securities that are priced using methods discussed above, as well as commercial mortgage loans.

Variable Interest Entities (Policies)	12 Months Ended
Variable Interest Entities (Policies)	Dec. 31, 2024
Variable Interest Entities [Abstract]
Variable Interest Entities	When the Company becomes involved with a variable interest entity and when there is a change in the Company's involvement with an entity, the Company must determine if it is the primary beneficiary and must consolidate the entity. The Company is considered the primary beneficiary if it has the power to direct the entity's most significant economic activities and has the right to receive benefits or obligation to absorb losses that could be significant to the entity. The Company evaluates the following criteria: the structure and purpose of the entity; the risks and rewards created by and shared through the entity; and the Company's ability to direct its activities, receive its benefits and absorb its losses relative to the other parties involved with the entity, including its sponsors, equity holders, guarantors, creditors and servicers. Securities Limited Partnerships and Real Estate Limited Partnerships. The Company owns interests in securities limited partnerships and real estate limited partnerships that are defined as unconsolidated variable interest entities. These partnerships invest in the equity or mezzanine debt of privately held companies and real estate properties. General partners unaffiliated with the Company control decisions that most significantly impact the partnership's operations, and the limited partners do not have substantive kick-out or participating rights. The Company has invested in approximately 195 limited partnerships that have a carrying value of $3.2 billion as of December 31, 2024 reported in other long-term investments. We perform ongoing qualitative analyses of our involvement with these variable interest entities to determine if consolidation is required.

Collectively Significant Operating Unconsolidated Subsidiaries (Policies)	12 Months Ended
	Dec. 31, 2024
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Operating Joint Ventures	We record in our Consolidated Statements of Income our proportionate share of net income or loss generated by operating joint ventures within Fees and other revenues. In certain instances, income or loss is reported on a one-month lag due to the timing of when financial information is received.

Accumulated Other Comprehensive Income (Loss) (Policies)	12 Months Ended
	Dec. 31, 2024
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
AOCI	Generally, tax effects in AOCI are established at the currently enacted tax rate and reclassified to Shareholders' net income in the same period that the related pre-tax AOCI reclassifications are recognized.

Pension (Policies)	12 Months Ended
Pension (Policies)	Dec. 31, 2024
Retirement Benefits [Abstract]
Pension Plans	Accounting Policy. The Company measures the assets and liabilities of its domestic pension plans as of December 31. Benefit obligations are measured at the present value of estimated future payments based on actuarial assumptions. The Company uses the corridor method to account for changes in the benefit obligation when actual results differ from those assumed or when assumptions change. These changes are called net unrecognized actuarial gains (losses). Under the corridor method, net unrecognized actuarial gains (losses) are initially recorded in Accumulated other comprehensive loss. When the unrecognized gain (loss) exceeds 10% of the benefit obligation, that excess is amortized to expense over the expected remaining lives of plan participants. The net plan expense is reported in Interest expense and other in the Consolidated Statements of Income. We measure plan assets at fair value for balance sheet purposes and to measure pension benefit costs. When the actual return differs from the expected return, those differences are reflected in the net unrealized actuarial gain (loss) discussed above. The Company develops discount rates by applying actual annualized yields for high-quality bonds by duration to the expected pension plan liability cash flows. The bond yields represent a diverse mix of actively traded high-quality fixed income securities that have an above-average return at each duration as management believes this approach is representative of the yield achieved through plan asset investment strategy. The expected long-term return on plan assets was developed considering historical long-term actual returns, expected long-term market conditions, plan asset mix and management's plan asset investment strategy. See Note 12 for further details regarding how fair value is determined, including the level within the fair value hierarchy and the procedures we use to validate fair value measurements. The Company classifies substantially all debt securities in Level 2 for pension plan assets. These assets are valued using recent trades of similar securities or are fund investments priced using their daily net asset value that is the exit price. All domestic equity securities and international equity funds within pension assets are classified as Level 3. Securities partnerships, real estate and hedge funds are valued using net asset value as a practical expedient and are excluded from the fair value hierarchy. See Note 12 for additional disclosures related to these assets invested in the separate accounts of the Company's subsidiary. Certain securities as described in Note 12, as well as commercial mortgage loans and guaranteed deposit account contracts, are classified in Level 3 because unobservable inputs used in their valuation are significant.

Employee Incentive Plans (Policies)	12 Months Ended
Employee Incentive Plans (Policies)	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Employee Incentive Plans	The Company records compensation expense for stock and option awards over their vesting periods primarily based on the estimated fair value at the grant date. Fair value is determined differently for each type of award as discussed below. Accounting Policy. The Company awards options to purchase The Cigna Group common stock at the market price of the stock on the grant date. Options vest over periods ranging from one year to three years and expire no later than 10 years from grant date. Fair value is estimated using the Black-Scholes option pricing model by applying the assumptions presented below. That fair value is reduced by options expected to be forfeited during the vesting period. The Company estimates forfeitures at the grant date based on our experience and adjusts the expense to reflect actual forfeitures over the vesting period. The fair value of options, net of forfeitures, is recognized in Selling, general and administrative expenses on a straight-line basis over the vesting period. Accounting Policy. Fair value of restricted stock awards is equal to the market price of The Cigna Group common stock on the date of grant. This fair value is reduced by awards that are expected to forfeit. At the grant date, the Company estimates forfeitures based on experience and adjusts the expense to reflect actual forfeitures over the vesting period. This fair value, net of forfeitures, is recognized in Selling, general and administrative expenses over the vesting period on a straight-line basis. Accounting Policy. Compensation expense for SPSs is recorded over the performance period. Fair value is determined at the grant date for "market condition" SPSs using a Monte Carlo simulation model and not subsequently adjusted regardless of the final outcome. Expense is initially accrued for "performance condition" SPSs based on the most likely outcome, but evaluated for adjustment each period for updates in the expected outcome. Expense is adjusted to the actual outcome (number of shares awarded multiplied by the share price at the grant date) at the end of the performance period.

Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.C.Q3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.1.Q5)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.3.Q2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2.Q6)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/718/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Goodwill, Other Intangibles and Property and Equipment (Policies)	12 Months Ended
	Dec. 31, 2024
Goodwill Other Intangibles And Property And Equipment [Abstract]
Goodwill	Accounting Policy. Goodwill represents the excess of the cost of businesses acquired over the fair value of their net assets. The resulting goodwill is assigned to those reporting units expected to realize cash flows from the acquisition, based on those reporting units' relative fair values. The Company's reporting units are aligned with its operating segments as described in Note 1. The Company conducts its annual quantitative evaluation for goodwill impairment during the third quarter at the reporting unit level and writes it down through Shareholders' net income if impaired. On a quarterly basis, the Company performs a qualitative impairment assessment to determine if events or changes in circumstances indicate that it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. The fair value of a reporting unit is generally estimated based on discounted cash flow analysis and market approach models using assumptions that the Company believes a hypothetical market participant would use to determine a current transaction price. Following a change in reporting units or held for sale determination, goodwill is allocated using relative fair value. The significant assumptions and estimates used in determining fair value primarily include the discount rate and future cash flows. A discount rate is selected to correspond with each reporting unit's weighted average cost of capital, consistent with that used for investment decisions considering the specific and detailed operating plans and strategies within each reporting unit. Projections of future cash flows differ by reporting unit and are consistent with our ongoing strategic projections. Future cash flows for Evernorth Health Services reporting units are primarily driven by the forecasted gross margins of the business, as well as operating expenses and long-term growth rates. Future cash flows for our other reporting units are primarily driven by forecasted revenues, benefit expenses, operating expenses and long-term growth rates.
Other Intangible Assets	Accounting Policy. The Company's Other intangible assets primarily include purchased customer and producer relationships, trademarks, and provider networks. The fair value of purchased customer relationships and the amortization method were determined as of the dates of purchase using an income approach that relies on projected future net cash flows, including key assumptions for customer attrition and discount rates. The Company's definite-lived intangible assets are amortized on an accelerated or straight-line basis, reflecting their pattern of economic benefits, over periods from 6 to 30 years. Management revises amortization periods if it believes there has been a change in the length of time that an intangible asset will continue to have value. Costs incurred to renew or extend the terms of these intangible assets are generally expensed as incurred. The Company's amortized intangible assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If the total of the expected future undiscounted cash flows generated by the underlying asset group is less than the carrying amount of the asset group, the Company recognizes an impairment charge equal to the difference between the carrying value of the asset group and its estimated fair value. The Company's indefinite-lived intangible assets are reviewed for impairment at least annually by comparing their fair value with their carrying value. If the carrying value exceeds fair value, that excess is recognized as an impairment loss.
Property and Equipment	Accounting Policy. Property and equipment is carried at cost less accumulated depreciation. Cost includes interest, real estate taxes and other costs incurred during construction when applicable. Internal-use software that is acquired, developed or modified solely to meet the Company's internal needs, with no plan to market externally, is also included in this category. Costs directly related to acquiring, developing or modifying internal-use software are capitalized. The Company calculates depreciation and amortization principally using the straight-line method generally based on the estimated useful life of each asset as follows: buildings and improvements, 10 to 40 years; purchased and internally developed software, 3 to 5 years; and furniture and equipment (including computer equipment), 3 to 10 years. Improvements to leased facilities are depreciated over the lesser of the remaining lease term or the estimated life of the improvement. The Company considers events and circumstances that would indicate the carrying value of property, equipment or capitalized software might not be recoverable. An impairment charge is recorded if the Company determines the carrying value of any of these assets is not recoverable. The Company also reviews and shortens the estimated useful lives of these assets, if necessary.

Income Taxes (Policies)	12 Months Ended
Income Taxes (Policies)	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Accounting Policy. Deferred income taxes are reflected in the Consolidated Balance Sheets for differences between the financial and income tax reporting bases of the Company's underlying assets and liabilities, and are established based upon enacted tax rates and laws. Deferred income tax assets are recognized when available evidence indicates that realization is more likely than not, and a valuation allowance is established to the extent this standard is not met. The deferred income tax provision generally represents the net change in deferred income tax assets and liabilities during the reporting period excluding adjustments to Accumulated other comprehensive income (loss) or amounts recorded in connection with a business combination. The current income tax provision generally represents estimated amounts due on income tax returns for the year reported to various jurisdictions plus the effect of any uncertain tax positions. The Company uses the deferral method of accounting on investments that generate tax credits. Under this method, the investment tax credits are recognized as a reduction to the related asset, which are generally reported in Other assets in the Consolidated Balance Sheets. The Company recognizes a liability for uncertain tax positions if management believes the probability that the positions will be sustained is 50% or less. For uncertain positions that management believes are more likely than not to be sustained, the Company recognizes a liability based upon management's estimate of the most likely settlement outcome with the taxing authority. The liabilities for uncertain tax positions are classified as current when the position is expected to be settled within 12 months or the statute of limitation expires within 12 months. Income taxes attributable to the Company's foreign operations are generally provided using the respective foreign jurisdictions' tax rate. The Company classifies net interest expense on uncertain tax positions as a component of income tax expense and in Other non-current liabilities in the Consolidated Balance Sheets.

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

Commitment and Contingencies (Policies)	12 Months Ended
Commitment and Contingencies (Policies)	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Guarantees	Financial Guarantees: Retiree and Life Insurance BenefitsThe Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets to provide for benefit payments.An additional liability is established if management believes that the Company will be required to make payments under the guarantees;Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy.Certain Other GuaranteesThe Company had indemnification obligations as of December 31, 2024 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with laws or regulations, or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a stated dollar amount or a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation.
Commitment and Contingencies	Accounting Policy. The Company accrues for legal and regulatory matters when a loss contingency is both probable and estimable. The estimated loss is generally recorded in Selling, general and administrative expenses and represents the Company's best estimate of the loss contingency. If the loss estimate is a range, the Company accrues the minimum amount in the range if no amount is better than any other estimated amount in the range. Legal costs to defend the Company's litigation and arbitration matters are expensed as incurred in cases that the Company cannot reasonably estimate the ultimate cost to defend. If the Company can reasonably estimate the cost to defend, a liability for these costs is accrued when the claim is reported.

Segment Reporting (Policies)	12 Months Ended
Segment Reporting (Policies)	Dec. 31, 2024
Segment Reporting [Abstract]
Segment Information	Intersegment revenues primarily reflect pharmacy and care services transactions between the Evernorth Health Services and Cigna Healthcare segments. The Chairman and Chief Executive Officer is the chief operating decision maker ("CODM") responsible for making decisions about resources to be allocated to the segment and assessing its performance. The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management, including the CODM, believes these metrics reflect the underlying results of business operations and facilitate analysis of trends in underlying revenue, expenses and profitability to enable resource allocation decisions. We define pre-tax adjusted income (loss) from operations as income (loss) before income taxes excluding pre-tax income (loss) attributable to noncontrolling interests, net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management, including the CODM, believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management, including the CODM, believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management, including the CODM, believes they are not indicative of past or future underlying performance of the business.

Disclosure of accounting policy for segment reporting.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 36
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-36

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Discontinued Operations and Disposal Groups [Abstract]

Accounts Receivable, Net (Tables)

12 Months Ended

Dec. 31, 2024

Receivables [Abstract]

Accounts Receivable, Net

The following amounts were included within Accounts receivable, net:


(In millions)	December 31, 2024		December 31, 2023
Noninsurance customer receivables	$	11,879	$	8,044
Pharmaceutical manufacturers receivables	10,914		8,169
Insurance customer receivables	3,199		2,359
Other receivables	162		272
Total	$	26,154	$	18,844
Accounts receivable, net classified as assets of businesses held for sale	(1,927)		(1,122)
Total	$	24,227	$	17,722

Supplier Finance Program (Tables)

12 Months Ended

Dec. 31, 2024

Payables and Accruals [Abstract]

Supplier Finance Program

The obligations confirmed as valid within the Program by the financial institutions were as follows and are reflected in Accounts payable in the Consolidated Balance Sheets:


	For the Years Ended December 31,
(in millions)	2024		2023
Confirmed obligations outstanding at the beginning of the year	$	1,536	$	1,303
Invoices confirmed during the year	39,091		36,224
Less: confirmed invoices paid during the year	38,990		35,991
Confirmed obligations outstanding at the end of the year	$	1,637	$	1,536

Assets and Liabilities of Businesses Held for Sale (Tables)

12 Months Ended

Dec. 31, 2024

Assets and Liabilities of Business Held for Sale

The assets and liabilities of businesses held for sale were as follows:


(In millions)	December 31, 2024		December 31, 2023
Cash and cash equivalents	$	1,339	$	467
Investments	1,444		1,438
Accounts receivable, net	1,927		1,122
Other assets, including Goodwill (1)	2,294		2,963
Total assets of businesses held for sale	7,004		5,990
Insurance and contractholder liabilities	1,579		1,636
All other liabilities	831		1,059
Total liabilities of businesses held for sale	$	2,410	$	2,695

(1) Includes Goodwill of $94 million as of December 31, 2024 and $396 million as of December 31, 2023.

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-SubTopic 10
-Topic 360
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483475/205-20-45-11

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-3A

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-4A

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5D

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-SubTopic 20
-Topic 205
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-3

Computation of Basic and Diluted Earnings Per Share

Earnings Per Share (Tables)

12 Months Ended

Dec. 31, 2024

Earnings Per Share [Abstract]

Basic and diluted earnings per share were computed as follows:




	For the Years Ended December 31,
	2024						2023						2022
(Shares in thousands, dollars in millions, except per share amounts)	Basic		Effect of Dilution		Diluted		Basic		Effect of Dilution		Diluted		Basic		Effect of Dilution		Diluted
Shareholders' net income	$	3,434			$	3,434	$	5,164			$	5,164	$	6,704			$	6,704
Shares:
Weighted average	280,294				280,294		293,892				293,892		309,546				309,546
Common stock equivalents			2,924		2,924				2,990		2,990				3,519		3,519
Total shares	280,294		2,924		283,218		293,892		2,990		296,882		309,546		3,519		313,065
Earnings per share	$	12.25	$	(0.13)	$	12.12	$	17.57	$	(0.18)	$	17.39	$	21.66	$	(0.25)	$	21.41

Outstanding Employee Stock Options Not Included in the Computation of Diluted Earnings Per Share

The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was anti-dilutive:



	For the Years Ended December 31,
(In millions)	2024	2023	2022
Anti-dilutive options	1.1	0.9	1.0

Debt (Tables)

12 Months Ended

Dec. 31, 2024

Debt Disclosure [Abstract]

Outstanding amounts of debt and finance leases

The outstanding amounts of debt (net of issuance costs, discounts or premiums) and finance leases were as follows:


(In millions)	December 31, 2024		December 31, 2023
Short-term debt
Commercial paper	$	880	$	1,237
$500 million, 0.613% Notes due March 2024	—		500
$790 million, 3.500% Notes due June 2024 (1)	—		996
$900 million, 3.250% Notes due April 2025 (2)	897		—
$1,216 million, 4.125% Notes due November 2025 (1)	1,215		—
Other, including finance leases	43		42
Total short-term debt	$	3,035	$	2,775





Long-term debt
$900 million, 3.250% Notes due April 2025 (2)	$	—	$	882
$1,216 million, 4.125% Notes due November 2025 (1)	—		2,197
$1,284 million, 4.500% Notes due February 2026 (1)	1,285		1,502
$550 million, 1.250% Notes due March 2026 (1)	549		798
$700 million, 5.685% Notes due March 2026	699		698
$1,500 million, 3.400% Notes due March 2027	1,466		1,450
$259 million, 7.875% Debentures due May 2027	259		259
$600 million, 3.050% Notes due October 2027	598		597
$3,800 million, 4.375% Notes due October 2028	3,790		3,787
$1,000 million, 5.000% Notes due May 2029	995		—
$1,400 million, 2.400% Notes due March 2030 (1) (2)	1,386		1,493
$1,500 million, 2.375% Notes due March 2031 (2)	1,384		1,397
$750 million, 5.125% Notes due May 2031	745		—
$45 million, 8.080% Step Down Notes due January 2033	45		45
$800 million, 5.400% Notes due March 2033	795		794
$1,250 million, 5.250% Notes due February 2034 (2)	1,226		—
$190 million, 6.150% Notes due November 2036	190		190
$2,200 million, 4.800% Notes due August 2038	2,193		2,193
$750 million, 3.200% Notes due March 2040	744		744
$121 million, 5.875% Notes due March 2041	119		119
$448 million, 6.125% Notes due November 2041	485		487
$317 million, 5.375% Notes due February 2042	315		315
$1,500 million, 4.800% Notes due July 2046	1,469		1,467
$1,000 million, 3.875% Notes due October 2047	990		989
$3,000 million, 4.900% Notes due December 2048	2,971		2,970
$1,250 million, 3.400% Notes due March 2050	1,237		1,237
$1,500 million, 3.400% Notes due March 2051	1,479		1,479
$1,500 million, 5.600% Notes due February 2054	1,482		—

Other, including finance leases	41		66
Total long-term debt	$	28,937	$	28,155

(1)Included in the February 2024 debt tender offers discussed below.

(2)The Company has entered into interest rate swap contracts hedging a portion of these fixed-rate debt instruments as of December 31, 2024. See Note 11 to the Consolidated Financial Statements for further information about the Company's interest rate risk management and these derivative instruments.

Debt Issuance and Debt Tender Offers. In February 2024, we issued $4.5 billion of new senior notes, as detailed in the table below. The proceeds from this debt were used to pay the consideration for the cash tender offers as described below. We used the remaining net proceeds to fund the repayment of our senior notes that matured in March 2024 and for general corporate purposes, including repayment of indebtedness and repurchases of shares of our common stock. Interest on this debt is paid semiannually.

Principal

Maturity Date

Interest Rate

Net Proceeds

Redeemable Date(1)

"Make Whole" Premium (2)

$1,000 million

May 15, 2029

5.000%

$995 million

April 15, 2029

15

$750 million

May 15, 2031

5.125%

$746 million

March 15, 2031

15

$1,250 million

February 15, 2034

5.250%

$1,244 million

November 15, 2033

20

$1,500 million

February 15, 2054

5.600%

$1,485 million

August 15, 2053

20

(1) Redeemable at any time prior to this date at a "make whole" premium, defined below. Redeemable at par on or after this date.

(2) "Make whole" premium calculated using the most directly comparable U.S. Treasury rate plus the amount of basis points set forth in this column.

Maturities of Outstanding Long-Term Debt

Maturities of outstanding long-term debt as of December 31, 2024 are as follows:


(In millions)	Scheduled Maturities (1)
2025	$	2,116
2026	$	2,534
2027	$	2,359
2028	$	3,800
2029	$	1,000
Maturities after 2029	$	19,522

(1) Long-term debt maturity amounts include current maturities of long-term debt. Finance leases are excluded from this table.

Common and Preferred Stock (Tables)

12 Months Ended

Dec. 31, 2024

Share Activity

The following table presents the share activity of The Cigna Group:


	For the Years Ended December 31,
(Shares in thousands)	2024	2023	2022
Common: Par value $0.01; 600,000 shares authorized
Outstanding- January 1,	292,504	298,676	322,948
Net issued for stock option exercises and other benefit plans	2,198	1,619	3,173
Repurchased common stock	(20,913)	(7,791)	(27,445)
Outstanding- December 31,	273,789	292,504	298,676
Treasury stock	128,723	107,390	99,143
Issued- December 31,	402,512	399,894	397,819

Dividend Payments

The following table provides details of the Company's dividend payments:


Record Date	Payment Date	Amount per Share	Total Amount Paid (in millions)
2024
March 6, 2024	March 21, 2024	$1.40	$401
June 4, 2024	June 20, 2024	$1.40	$392
September 4, 2024	September 19, 2024	$1.40	$390
December 4, 2024	December 19, 2024	$1.40	$384
2023
March 8, 2023	March 23, 2023	$1.23	$368
June 7, 2023	June 22, 2023	$1.23	$362
September 6, 2023	September 21, 2023	$1.23	$362
December 6, 2023	December 21, 2023	$1.23	$358
2022
March 9, 2022	March 24, 2022	$1.12	$357
June 8, 2022	June 23, 2022	$1.12	$352
September 7, 2022	September 22, 2022	$1.12	$341
December 6, 2022	December 21, 2022	$1.12	$334

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-SubTopic 10
-Topic 210
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-4

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-5

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481142/505-10-45-2

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-10

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-8

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-6

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-7

Insurance and Contractholder Liabilities

Insurance and Contractholder Liabilities (Tables)

12 Months Ended

Dec. 31, 2024

Insurance Loss Reserves [Abstract]

The Company's insurance and contractholder liabilities were comprised of the following:


	December 31, 2024						December 31, 2023
(In millions)	Current		Non-current		Total		Current		Non-current		Total
Unpaid claims and claim expenses
Cigna Healthcare	$	4,932	$	86	$	5,018	$	5,017	$	75	$	5,092
Other Operations	147		144		291		99		154		253
Future policy benefits
Cigna Healthcare	91		507		598		97		518		615
Other Operations	157		3,140		3,297		163		3,375		3,538
Contractholder deposit funds
Cigna Healthcare	9		115		124		12		133		145
Other Operations	366		5,958		6,324		362		6,178		6,540
Market risk benefits	25		760		785		37		966		1,003
Unearned premiums	753		31		784		846		22		868
Total	6,480		10,741		17,221		6,633		11,421		18,054
Insurance and contractholder liabilities classified as liabilities of businesses held for sale (1)	(1,092)		(487)		(1,579)		(1,119)		(517)		(1,636)
Total insurance and contractholder liabilities	$	5,388	$	10,254	$	15,642	$	5,514	$	10,904	$	16,418

(1) Amounts classified as liabilities of businesses held for sale include $983 million of Unpaid claims, $408 million of Future policy benefits, $85 million of Unearned premiums and $103 million of Contractholder deposit funds as of December 31, 2024 and $823 million of Unpaid claims, $429 million of Future policy benefits, $261 million of Unearned premiums and $123 million of Contractholder deposit funds as of December 31, 2023.

Activity, net of intercompany transactions, in the unpaid claims liability for the Cigna Healthcare segment was as follows:




	For the Years Ended December 31,
(In millions)	2024 (1)		2023 (1)		2022
Beginning balance	$	5,092	$	4,176	$	4,261
Less: Reinsurance and other amounts recoverable	236		221		261
Beginning balance, net	4,856		3,955		4,000

Incurred costs related to:
Current year	38,347		35,953		31,342
Prior years	(456)		(279)		(259)
Total incurred	37,891		35,674		31,083
Paid costs related to:
Current year	33,718		31,322		27,583
Prior years	4,170		3,451		3,545
Total paid	37,888		34,773		31,128

Ending balance, net	4,859		4,856		3,955
Add: Reinsurance and other amounts recoverable	159		236		221
Ending balance	$	5,018	$	5,092	$	4,176

(1) Includes unpaid claims amounts classified as liabilities of businesses held for sale. As of December 31, 2024 and December 31, 2023, includes $983 million and $823 million classified as liabilities of businesses held for sale, respectively.

Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses

Variances in incurred costs related to prior years' unpaid claims and claim expenses that resulted from the differences between actual experience and the Company's key assumptions were as follows:




	For the Years Ended December 31,
	2024				2023
(Dollars in millions)	$		% (1)		$		% (2)
Actual completion factors and other	$	223	0.6	%	$	70	0.2	%
Medical cost trend	233		0.7		209		0.7

Total favorable variance	$	456	1.3	%	$	279	0.9	%

(1)Percentage of current year incurred costs as reported for the year ended December 31, 2023.

(2)Percentage of current year incurred costs as reported for the year ended December 31, 2022.

Incurred and Paid Claims Development

The following table depicts the incurred and paid claims development and unpaid claims liability as of December 31, 2024 (net of reinsurance) reported in the Cigna Healthcare segment. The information about incurred and paid claims development for the year ended December 31, 2023 is presented as supplementary information and is unaudited.


	Incurred Costs
Incurral Year	2023 (Unaudited)		2024		Unpaid Claims and Claim Expenses
(In millions)
2023	$	34,878	$	34,437	213
2024			37,179		4,460
Cumulative incurred costs for the periods presented			$	71,616

	Cumulative Costs Paid
Incurral Year	2023 (Unaudited)		2024
(In millions)
2023	$	30,380	$	34,224
2024			32,719
Cumulative paid costs for the periods presented			$	66,943

Outstanding liabilities for the periods presented, net of reinsurance			$	4,673
Other long-duration liabilities not included in development table above			186
Net unpaid claims and claims expenses - Cigna Healthcare			4,859
Reinsurance and other amounts recoverable			159
Unpaid claims and claim expenses - Cigna Healthcare			$	5,018

Future Policy Benefit Activity

The weighted average interest rates applied and duration for future policy benefits in the Cigna Healthcare segment, consisting primarily of supplemental health products including individual Medicare supplement, limited benefit health products and individual private medical insurance, were as follows:


	As of
	December 31, 2024		December 31, 2023
Interest accretion rate	2.85	%	2.54	%
Current discount rate	5.10	%	4.92	%
Weighted average duration	8.7 years		7.9 years

The present values of expected net premiums and expected future policy benefits for the Cigna Healthcare segment were as follows:




	For the Years Ended December 31,
(In millions)	2024 (1)		2023
Present value of expected net premiums
Beginning balance	$	9,233	$	8,557
Reversal of effect of beginning of period discount rate assumptions	1,154		1,537
Effect of assumption changes and actual variances from expected experience (2)	5		314
Issuances and lapses	1,982		1,255
Net premiums collected	(1,441)		(1,370)
Interest and other (3)	752		94
Ending balance at original discount rate	11,685		10,387
Effect of end of period discount rate assumptions	(1,232)		(1,154)
Ending balance (4)	$	10,453	$	9,233

Present value of expected policy benefits
Beginning balance	$	9,633	$	8,945
Reversal of effect of discount rate assumptions	1,220		1,611
Effect of assumption changes and actual variances from expected experience (2)	204		112
Issuances and lapses	1,893		1,309
Benefit payments	(1,473)		(1,374)
Interest and other (3)	668		250
Ending balance at original discount rate	12,145		10,853
Effect of discount rate assumptions	(1,309)		(1,220)
Ending balance (5)	$	10,836	$	9,633

Liability for future policy benefits	$	383	$	400
Other (6)	215		215
Total liability for future policy benefits (1)(7)	$	598	$	615

(1)Includes $408 million and $429 million of future policy benefits classified as liabilities of businesses held for sale in the Consolidated Balance Sheets as of December 31, 2024 and December 31, 2023, respectively.

(2)Includes the effect of actual variances from expectations, which decreased the total liability for future policy benefits by $(44) million and $(12) million for the years ended December 31, 2024 and December 31, 2023, respectively.

(3)Includes the foreign exchange rate impact of translating from transactional and functional currency to United States dollar and the impact of flooring the liability at zero. The flooring impact is calculated at the cohort level after discounting the reserves at the current discount rate.

(4)As of December 31, 2024 and December 31, 2023, undiscounted expected future gross premiums were $21.4 billion and $18.7 billion, respectively. As of December 31, 2024 and December 31, 2023, discounted expected future gross premiums were $14.3 billion and $13.5 billion, respectively.

(5)As of December 31, 2024 and December 31, 2023, undiscounted expected future policy benefits were $16.1 billion and $13.3 billion, respectively.

(6)The liability for future policyholder benefits includes immaterial businesses shown as reconciling items above, most of which are in run-off.

(7)$85 million and $72 million reported in Reinsurance recoverables in the Consolidated Balance Sheets as of December 31, 2024 and December 31, 2023, respectively, relate to the liability for future policy benefits. Additionally, $80 million and $79 million of reinsurance recoverables are reported in assets of businesses held for sale in the Consolidated Balance Sheets as of December 31, 2024, and December 31, 2023, respectively.

The weighted average interest rates applied and duration for future policy benefits in Other Operations, consisting of annuity and life insurance products, were as follows:


	As of
	December 31, 2024		December 31, 2023
Interest accretion rate	5.64	%	5.64	%
Current discount rate	5.42	%	4.87	%
Weighted average duration	10.8 years		11.4 years

Summary of Market Risk Benefit

Market risk benefits activity was as follows:





	For the Years Ended December 31,
(Dollars in millions)	2024		2023
Balance, beginning of year	$	1,003	$	1,268
Balance, beginning of year, before the effect of nonperformance risk (own credit risk)	1,085		1,379
Changes due to expected run-off	(12)		(19)
Changes due to capital markets versus expected	(233)		(254)
Changes due to policyholder behavior versus expected	(39)		(5)
Assumption changes	37		(16)
Balance, end of period, before the effect of changes in nonperformance risk (own credit risk)	838		1,085
Nonperformance risk (own credit risk), end of period	(53)		(82)
Balance, end of period	$	785	$	1,003
Reinsured market risk benefit, end of period	$	836	$	1,081

Account Value, Net Amount at Risk and the Number of Contractholders for Guarantees Assumed in the Event of Death

The following table presents the account value, net amount at risk, average attained age of contractholders (weighted by exposure) and the number of contractholders for guarantees assumed by the Company. The net amount at risk is the amount that the Company would have to pay to contractholders if all deaths or annuitizations occurred as of the earliest possible date in accordance with the insurance contract. As of December 31, 2024, the account value increased primarily due to favorable equity market performance, which resulted in a decrease to the net amount at risk. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded.


(Dollars in millions, excludes impact of reinsurance ceded)	December 31, 2024		December 31, 2023
Account value	$	7,777	$	7,736
Net amount at risk	$	1,283	$	1,609
Average attained age of contractholders (weighted by exposure)	77.7 years		77.3 years
Number of contractholders (estimated)	130,000		140,000

Reinsurance (Tables)

12 Months Ended

Dec. 31, 2024

Reinsurance Disclosures [Abstract]

Reinsurance Recoverables

The Company's reinsurance recoverables as of December 31, 2024 are presented at amount due by range of external credit rating and collateral level in the following table, with reinsurance recoverables that are market risk benefits separately presented at fair value:


(In millions)	Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable		Collateral Provisions Exist That May Mitigate Risk of Credit Loss (1)		No Collateral		Total
Ongoing Operations
A- equivalent and higher current ratings (2)	$	—	$	7	$	233	$	240
BBB- to BBB+ equivalent current credit ratings (2)	—		—		63		63
Not rated	144		1		3		148
Acquisition, disposition or run-off activities
BBB+ equivalent and higher current ratings (2)(3)	476		2,854		136		3,466

Not rated	—		6		3		9
Total reinsurance recoverables before market risk benefits	$	620	$	2,868	$	438	$	3,926
Allowance for uncollectible reinsurance							(30)
Market risk benefits							836
Total reinsurance recoverables (4)							$	4,732

(1)Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level.

(2)Certified by a Nationally Recognized Statistical Ratings Organization ("NRSRO").

(3)Comprised of 21 reinsurers of which 73% is held by two reinsurers, Lincoln National Life Insurance Company and Lincoln Life and Annuity Company of New York.

(4)Includes $159 million of current reinsurance recoverables that are reported in Other current assets and $195 million of reinsurance recoverables classified as assets of businesses held for sale.

Investments (Tables)

12 Months Ended

Dec. 31, 2024

Investments [Abstract]

Investments by category and current or long-term classification

The following table summarizes the Company's investments by category and current or long-term classification:


	December 31, 2024						December 31, 2023
(In millions)	Current		Long-Term		Total		Current		Long-Term		Total
Debt securities	$	463	$	8,960	$	9,423	$	590	$	9,265	$	9,855
Equity securities	7		554		561		31		3,331		3,362
Commercial mortgage loans	108		1,243		1,351		182		1,351		1,533
Policy loans	—		1,156		1,156		—		1,211		1,211
Other long-term investments	—		4,576		4,576		—		4,181		4,181
Short-term investments	170		—		170		206		—		206
Total	$	748	$	16,489	$	17,237	$	1,009	$	19,339	$	20,348
Investments classified as assets of businesses held for sale (1)	(83)		(1,361)		(1,444)		(84)		(1,354)		(1,438)
Investments per Consolidated Balance Sheets	$	665	$	15,128	$	15,793	$	925	$	17,985	$	18,910

(1) Investments related to the HCSC transaction that were held for sale as of December 31, 2024. These investments were primarily comprised of debt securities.

Debt Securities by Contractual Maturity

The amortized cost and fair value by contractual maturity periods for debt securities were as follows as of December 31, 2024:



(In millions)	Amortized Cost		Fair Value
Due in one year or less	$	622	$	553
Due after one year through five years	3,927		3,759
Due after five years through ten years	3,164		2,960
Due after ten years	2,041		1,813
Mortgage and other asset-backed securities	371		338
Total	$	10,125	$	9,423

Gross Unrealized Appreciation (Depreciation) on Debt Securities

Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below:


(In millions)	Amortized Cost		Allowance for Credit Loss		Unrealized Appreciation		Unrealized Depreciation		Fair Value
December 31, 2024
Federal government and agency	$	276	$	—	$	14	$	(9)	$	281
State and local government	37		—		1		(1)		37
Foreign government	350		—		5		(11)		344
Corporate	9,091		(111)		102		(659)		8,423
Mortgage and other asset-backed	371		—		1		(34)		338
Total	$	10,125	$	(111)	$	123	$	(714)	$	9,423


December 31, 2023
Federal government and agency	$	251	$	—	$	24	$	(8)	$	267
State and local government	37		—		2		(1)		38
Foreign government	355		—		10		(13)		352
Corporate	9,338		(33)		158		(630)		8,833
Mortgage and other asset-backed	398		—		1		(34)		365
Total	$	10,379	$	(33)	$	195	$	(686)	$	9,855

Summary of Debt Securities with a Decline in Fair Value

The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded (by investment grade and the length of time these securities have been in an unrealized loss position). Unrealized depreciation on these debt securities is primarily due to declines in fair value resulting from increasing interest rates since these securities were purchased.


	December 31, 2024							December 31, 2023
(Dollars in millions)	Fair Value		Amortized Cost		Unrealized Depreciation		Number of Issues	Fair Value		Amortized Cost		Unrealized Depreciation		Number of Issues
One year or less
Investment grade	$	1,203	$	1,227	$	(24)	545	$	330	$	338	$	(8)	142
Below investment grade	245		250		(5)		739	161		170		(9)		135
More than one year
Investment grade	4,687		5,319		(632)		1,297	5,441		6,036		(595)		1,590
Below investment grade	416		469		(53)		123	701		775		(74)		486
Total	$	6,551	$	7,265	$	(714)	2,704	$	6,633	$	7,319	$	(686)	2,353

Equity Security Investments

The following table provides the values of the Company's equity security investments:


	December 31, 2024				December 31, 2023
(In millions)	Cost		Carrying Value		Cost		Carrying Value
Equity securities with readily determinable fair values	$	635	$	37	$	656	$	51
Equity securities with no readily determinable fair value	3,215		524		3,248		3,311
Total	$	3,850	$	561	$	3,904	$	3,362

Summary of the Credit Risk Profile of the Commercial Mortgage Loan Portfolio

The following table summarizes the credit risk profile of the Company's commercial mortgage loan portfolio:


(Dollars in millions)	December 31, 2024					December 31, 2023
Loan-to-Value Ratio	Carrying Value		Average Debt Service Coverage Ratio	Average Loan-to-Value Ratio		Carrying Value		Average Debt Service Coverage Ratio	Average Loan-to-Value Ratio
Below 60%	$	547	2.07			$	802	2.13
60% to 79%	595		1.83			574		1.77
80% to 100%	209		0.51			157		0.65



Total	$	1,351	1.70	69	%	$	1,533	1.82	64	%

Carrying Value Information for Other Long-Term Investments

The following table provides unfunded commitment and carrying value information for these investments. The Company expects to disburse approximately 31% of the committed amounts in 2025.

Our limited partnership investments are reduced as the Company receives cash distributions for returns on its investment that were previously recognized in Net investment income. The amount of these cash distributions was $344 million in 2024, $253 million in 2023 and $487 million in 2022.



					Unfunded Commitments as of
	Carrying Value as of December 31,
(In millions)	2024		2023		December 31, 2024
Real estate investments	$	1,763	$	1,606	$	850
Securities partnerships	2,587		2,400		1,809
Other	226		175		—
Total	$	4,576	$	4,181	$	2,659

Summary of Derivative Instruments Held

The following table summarizes the types and notional quantity of derivative instruments held by the Company:


	Notional Value as of
(In millions)	December 31, 2024		December 31, 2023
Type of Instrument
Fair value hedge - Foreign currency swap contracts	$	975	$	1,026
Fair value hedge - Interest rate swap contracts	$	2,700	$	1,500
Net investment hedge - Foreign currency swap contracts	$	415	$	415

Components of Net Investment Income

The components of Net investment income were as follows:


	For the Years Ended December 31,
(In millions)	2024		2023		2022
Debt securities	$	492	$	500	$	572
Equity securities (1)	(114)		123		14
Commercial mortgage loans	61		65		59
Policy loans	56		60		59
Other long-term investments	75		123		390
Short-term investments and cash	447		339		115
Total investment income	1,017		1,210		1,209
Less investment expenses	44		44		54
Net investment income	$	973	$	1,166	$	1,155

(1)Includes a $182 million impairment of dividend receivable for the year ended December 31, 2024. See the Equity Securities section of Note 11A to the Consolidated Financial Statements for additional information.

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2024

Fair Value Disclosures [Abstract]

Financial Assets and Financial Liabilities Carried at Fair Value

The following table provides information about the Company's financial assets and liabilities carried at fair value. Further information regarding insurance assets and liabilities carried at fair value is provided in Note 9E to the Consolidated Financial Statements. Separate account assets are also recorded at fair value on the Company's Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to contractholders.


(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)				Significant Other Observable Inputs (Level 2)				Significant Unobservable Inputs (Level 3)				Total
	December 31, 2024		December 31, 2023		December 31, 2024		December 31, 2023		December 31, 2024		December 31, 2023		December 31, 2024		December 31, 2023
Financial assets at fair value
Debt securities
Federal government and agency	$	165	$	130	$	116	$	137	$	—	$	—	$	281	$	267
State and local government	—		—		37		38		—		—		37		38
Foreign government	—		—		344		352		—		—		344		352
Corporate	—		—		8,049		8,432		374		401		8,423		8,833
Mortgage and other asset-backed	—		—		295		319		43		46		338		365
Total debt securities	165		130		8,841		9,278		417		447		9,423		9,855
Equity securities (1)	1		4		36		47		—		—		37		51
Short-term investments	—		—		170		206		—		—		170		206
Derivative assets	—		—		168		131		—		1		168		132
Financial liabilities at fair value
Derivative liabilities	$	—	$	—	$	1	$	4	$	—	$	—	$	1	$	4

(1)Excludes certain equity securities that have no readily determinable fair value.

Fair Value and Significant Unobservable Inputs Used in Pricing Debt Securities

The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities. The range and weighted average basis point amounts for liquidity reflect the Company's best estimates of the unobservable adjustments a market participant would make to calculate these fair values. An increase in liquidity spread adjustments would result in a lower fair value measurement, while a decrease would result in a higher fair value measurement.


	Fair Value as of					Unobservable Adjustment Range (Weighted Average by Quantity) as of
(Fair value in millions)	December 31, 2024		December 31, 2023		Unobservable Input December 31, 2024	December 31, 2024		December 31, 2023
Debt securities
Corporate	$	373	$	401	Liquidity	60 - 1520 (370)	bps	70 - 1235 (310)	bps
Mortgage and other asset-backed securities	43		46		Liquidity	100 - 550 (280)	bps	95 - 640 (310)	bps
Other debt securities	1		—
Total Level 3 debt securities	$	417	$	447

Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value

The following table summarizes the changes in financial assets and financial liabilities classified in Level 3. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs.



	Years Ended December 31,
(In millions)		2024		2023
Debt Securities
Beginning balance		$	447	$	447
Losses included in Shareholders' net income		(69)		(2)
(Losses) gains included in Other comprehensive loss		(9)		8

Purchases, sales and settlements
Purchases		17		10
Sales		(2)		—
Settlements		(21)		(52)
Total purchases, sales and settlements		(6)		(42)
Transfers into / (out of) Level 3
Transfers into Level 3		72		95
Transfers out of Level 3		(18)		(59)
Total transfers into / (out of) Level 3		54		36
Ending balance		$	417	$	447
Total losses included in Shareholders' net income attributable to instruments held at the reporting date		$	(69)	$	(2)
Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period		$	(9)	$	3

Fair Values of Separate Account Assets

Fair values of Separate account assets were as follows:


	Quoted Prices in Active Markets for Identical Assets (Level 1)				Significant Other Observable Inputs (Level 2)				Significant Unobservable Inputs (Level 3)				Total
(In millions)	December 31, 2024		December 31, 2023		December 31, 2024		December 31, 2023		December 31, 2024		December 31, 2023		December 31, 2024		December 31, 2023
Guaranteed separate accounts (See Note 21)	$	231	$	226	$	345	$	352	$	—	$	—	$	576	$	578
Non-guaranteed separate accounts (1)	267		158		5,575		5,797		228		217		6,070		6,172
Subtotal	$	498	$	384	$	5,920	$	6,149	$	228	$	217	6,646		6,750
Non-guaranteed separate accounts priced at NAV as a practical expedient (1)													632		680
Total													$	7,278	$	7,430

Non-guaranteed separate accounts include $3.8 billion as of December 31, 2024 and $4.0 billion as of December 31, 2023 in assets supporting the Company's pension plans, including $0.2 billion classified in Level 3 both as of December 31, 2024 and December 31, 2023. Non-guaranteed separate accounts are primarily comprised of securities partnerships, real estate and real estate funds.

Fair Value Disclosures for Financial Instruments Not Carried at Fair Value

The following table includes the Company's financial instruments not recorded at fair value but for which fair value disclosure is required. In addition to universal life products and finance leases, financial instruments that are carried in the Company's Consolidated Balance Sheets at amounts that approximate fair value are excluded from the following table.


	Classification in Fair Value Hierarchy	December 31, 2024				December 31, 2023
(In millions)		Fair Value		Carrying Value		Fair Value		Carrying Value
Commercial mortgage loans	Level 3	$	1,256	$	1,351	$	1,430	$	1,533
Long-term debt, including current maturities, excluding finance leases	Level 2	$	28,392	$	31,008	$	28,033	$	29,585

Collectively Significant Operating Unconsolidated Subsidiaries (Tables)

12 Months Ended

Dec. 31, 2024

Equity Method Investments and Joint Ventures [Abstract]

Operating Joint Venture Investments

The below summarized results of operations and financial position of the operating joint ventures reflects the latest available financial information and does not represent the Company's proportionate share of the assets, liabilities or earnings of such entities.


	For the Years Ended December 31,
(In millions)	2024		2023		2022
Revenues	$	7,309	$	5,962	$	4,665
Net income (loss)	$	607	$	98	$	(12)


(In millions)	December 31, 2024		December 31, 2023
Total assets	$	34,395	$	26,681
Total liabilities	$	33,892	$	25,534

Accumulated Other Comprehensive Income (Loss) (Tables)

12 Months Ended

Dec. 31, 2024

Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]

Changes in the Components of AOCI

Changes in the components of AOCI were as follows:


	For the Years Ended December 31,

(In millions)	2024		2023		2022
Securities and Derivatives


Beginning balance	$	171	$	(332)	$	1,266

Unrealized appreciation (depreciation) on securities and derivatives, before reclassification, net of tax (expense) benefit of $(207), $(146) and $467, respectively	601		474		(1,807)

Amounts reclassified to Shareholders' net income, net of tax (benefit) of $(16), $(8) and $(48), respectively	60		29		209
Other comprehensive income (loss), net of tax	661		503		(1,598)
Ending balance	$	832	$	171	$	(332)
Net long-duration insurance and contractholder liabilities measurement adjustments


Beginning balance	$	(971)	$	(256)	$	(765)

Net current period change in discount rate for certain long-duration liabilities, net of tax benefit (expense) of $357, $222 and $(122), respectively	(1,044)		(691)		520

Net current period change in instrument-specific credit risk for market risk benefits, net of tax benefit of $6, $5 and $3, respectively	(23)		(24)		(11)
Other comprehensive (loss) income, net of tax	(1,067)		(715)		509
Ending balance	$	(2,038)	$	(971)	$	(256)
Translation of foreign currencies


Beginning balance	$	(149)	$	(154)	$	(233)

Net translation of foreign currencies, before reclassification, net of tax benefit (expense) of $2, $5 and $(33), respectively	(60)		5		(310)

Amounts reclassified to Shareholders' net income, net of tax expense of $—, $— and $29, respectively	11		—		387
Other comprehensive (loss) income, net of tax	(49)		5		77


Less: Net translation (loss) on foreign currencies attributable to noncontrolling interests	—		—		(2)
Shareholders' other comprehensive (loss) income, net of tax	(49)		5		79
Ending balance	$	(198)	$	(149)	$	(154)
Postretirement benefits liability
Beginning balance	$	(915)	$	(916)	$	(1,336)

Amounts reclassified to Shareholders' net income, net of tax (benefit) of $(7), $(11) and $(16), respectively	22		35		48

Net change due to valuation update, before reclassification, net of tax benefit (expense) of $14, $12 and $(115), respectively	(44)		(34)		372
Other comprehensive (loss) income, net of tax	(22)		1		420
Ending balance	$	(937)	$	(915)	$	(916)
Total Accumulated other comprehensive loss


Beginning balance	$	(1,864)	$	(1,658)	$	(1,068)

Shareholders' other comprehensive (loss), net of tax benefit of $149, $79 and $165, respectively	(477)		(206)		(590)
Ending balance	$	(2,341)	$	(1,864)	$	(1,658)

Pension (Tables)

12 Months Ended

Dec. 31, 2024

Retirement Benefits [Abstract]

Summary of the Projected Benefit Obligations and Assets Related to Pension Plans

The following table summarizes the projected benefit obligations and assets related to our U.S. and non-U.S. pension plans:


	For the Years Ended December 31,
(In millions)	2024		2023
Change in benefit obligation
Benefit obligation, January 1	$	3,934	$	3,948
Service cost	1		1
Interest cost	194		204

Actuarial (gains) losses, net (1)	(146)		93
Benefits paid from plan assets	(328)		(294)

Other	(12)		(18)
Benefit obligation, December 31	3,643		3,934
Change in plan assets
Fair value of plan assets, January 1	4,138		4,186
Actual return on plan assets	40		246
Benefits paid	(328)		(294)

Contributions	4		—
Fair value of plan assets, December 31	3,854		4,138
Funded status	$	211	$	204
Amounts presented in Consolidated Balance Sheets
Other assets	$	211	$	204

(1) 2024 gains reflect an increase in the discount rate, while 2023 losses reflect a decrease in the discount rate.

Benefit Payments

The following benefit payments are expected to be paid in:


(In millions)
2025	$	315
2026	$	314
2027	$	311
2028	$	309
2029	$	306
2030 - 2034	$	1,443

Postretirement Benefits Liability Adjustment Included in AOCI

Amounts reflected in the pension assets (liabilities) shown above that have not yet been reported in Net income and, therefore, have been included in Accumulated other comprehensive loss consisted of the following:


(In millions)	December 31, 2024		December 31, 2023
Unrecognized net (losses)	$	(1,228)	$	(1,207)
Unrecognized prior service cost	(4)		(4)
Postretirement benefits liability adjustment	$	(1,232)	$	(1,211)

Components of Net Pension Cost

Net pension cost was as follows:


	For the Years Ended December 31,
(In millions)	2024		2023		2022
Service cost	$	1	$	1	$	2
Interest cost	194		204		140
Expected long-term return on plan assets	(247)		(204)		(272)
Amortization of:
Prior actuarial losses, net	39		52		89


Curtailment loss	1		—		—
Net (benefit) cost	$	(12)	$	53	$	(41)

Assumptions Used for Pension


	For the Years Ended December 31,
	2024	2023
Discount rate:
Pension benefit obligation	5.57%	5.10%
Pension benefit cost	5.10%	5.43%
Expected long-term return on plan assets:
Pension benefit cost	6.50%	6.50%
Mortality table for pension obligations	White Collar mortality table with MP 2021 projection scale	White Collar mortality table with MP 2021 projection scale

Fair Value of Pension Assets by Category

The fair values of pension assets by category are as follows:


(In millions)	December 31, 2024		December 31, 2023
Debt securities:
Federal government and agency	$	99	$	12
Corporate	2,673		2,780
Asset-backed	138		121
Fund investments	76		278
Total debt securities	2,986		3,191
Equity securities:
Domestic	21		27
International, including funds and pooled separate accounts (1)	6		6
Total equity securities	27		33
Securities partnerships, including pooled separate accounts (1)	402		419
Real estate and real estate funds, including pooled separate accounts (1)	228		270
Commercial mortgage loans	27		46

Guaranteed deposit account contract	47		48
Cash equivalents and other current assets, net	137		131
Total pension assets at fair value	$	3,854	$	4,138

(1) A pooled separate account has several participating benefit plans and each owns a share of the total pool of investments.

Employee Incentive Plans (Tables)

12 Months Ended

Dec. 31, 2024

Share-Based Payment Arrangement [Abstract]

Shares of Common Stock Available for Award

Shares of common stock available for award were as follows:

(In millions)

December 31, 2024

December 31, 2023

December 31, 2022

Common shares available for award

12.4

14.4

16.6

Black-Sholes Option-Pricing Model Assumptions

Black-Scholes option pricing model assumptions and the resulting fair value of options are presented in the following table:


	2024			2023			2022
Dividend yield	1.74		%	1.58		%	1.98		%
Expected volatility	30.0		%	30.0		%	30.0		%
Risk free interest rate	4.0		%	3.6		%	1.6		%
Expected option life	4.8 years			4.7 years			4.5 years
Weighted average fair value of options	$	92.36		$	79.66		$	50.61

Status of and Changes in Common Stock Options

The following table shows the status of, and changes in, common stock options:


	For the Years Ended December 31,
	2024			2023			2022
(Options in thousands)	Options	Weighted Average Exercise Price		Options	Weighted Average Exercise Price		Options	Weighted Average Exercise Price
Outstanding - January 1	6,696	$	202.02	6,992	$	186.54	8,490	$	169.47
Granted	781	$	336.48	915	$	294.37	1,375	$	226.95
Exercised	(1,727)	$	178.82	(1,080)	$	174.66	(2,617)	$	149.97
Expired or canceled	(95)	$	278.78	(131)	$	246.95	(256)	$	211.22
Outstanding - December 31	5,655	$	226.38	6,696	$	202.02	6,992	$	186.54
Options exercisable at year-end	3,941	$	196.01	4,616	$	179.28	4,410	$	168.97

Summary of Information for Stock Options Exercised and Outstanding

The table below summarizes information for stock options exercised:


	For the Years Ended December 31,
(In millions)	2024		2023		2022
Intrinsic value of options exercised	$	275	$	126	$	313
Cash received for options exercised	$	305	$	187	$	389
Tax benefit from options exercised	$	34	$	17	$	47

The following table summarizes information for outstanding common stock options:


	December 31, 2024
	Options Outstanding		Options Exercisable
Number (in thousands)	5,655		3,941
Total intrinsic value (in millions)	$	341	$	320
Weighted average exercise price	$	226.38	$	196.01
Weighted average remaining contractual life	5.8 years		4.7 years

Status of and Changes in Restricted Stock Awards and the Fair Value of Vested Restricted Stock

The following table shows the status of, and changes in, restricted stock awards:


	For the Years Ended December 31,
	2024			2023			2022
(Awards in thousands)	Grants/Units	Weighted Average Fair Value at Award Date		Grants/Units	Weighted Average Fair Value at Award Date		Grants/Units	Weighted Average Fair Value at Award Date
Outstanding - January 1	1,404	$	257.38	1,535	$	219.25	1,524	$	202.85
Awarded	624	$	319.39	700	$	294.60	876	$	229.60
Vested	(713)	$	245.35	(759)	$	214.70	(714)	$	197.83
Forfeited	(65)	$	283.62	(72)	$	256.24	(151)	$	215.02
Outstanding - December 31	1,250	$	302.42	1,404	$	257.38	1,535	$	219.25

The fair value of vested restricted stock at the vesting date was as follows:


	For the Years Ended December 31,
(In millions)	2024		2023		2022
Fair value of vested restricted stock	$	238	$	220	$	167

Status of and Changes in SPSs

The following table shows the status of, and changes in, SPSs:


	For the Years Ended December 31,
	2024			2023			2022
(Awards in thousands)	Shares	Weighted Average Fair Value at Award Date		Shares	Weighted Average Fair Value at Award Date		Shares	Weighted Average Fair Value at Award Date
Outstanding - January 1	686	$	243.90	780	$	212.68	860	$	197.07
Awarded	195	$	336.81	219	$	293.85	294	$	230.69
Vested	(242)	$	214.93	(250)	$	191.78	(261)	$	183.60
Forfeited	(38)	$	289.35	(63)	$	237.50	(113)	$	207.75
Outstanding - December 31	601	$	282.83	686	$	243.90	780	$	212.68

The fair value of vested SPSs at the vesting date was as follows:


	For the Years Ended December 31,
	2024			2023			2022
(Shares in thousands; $ in millions)	Shares	Fair Value		Shares	Fair Value		Shares	Fair Value
Shares of The Cigna Group common stock distributed upon SPS vesting	257	$	86	257	$	76	137	$	31

Compensation Cost and Tax Effects of Share-based Compensation

Compensation Cost and Tax Effects of Share-Based Compensation

The Company records tax benefits in Shareholders' net income during the vesting period based on the amount of expense being recognized. The difference between tax benefits based on the expense and the actual tax benefit realized are also recorded in income tax expense when stock options are exercised, or when restricted stock and SPSs vest.


	For the Years Ended December 31,
(In millions)	2024		2023		2022
Total compensation cost for shared-based awards	$	308	$	286	$	264
Tax benefits recognized	$	94	$	92	$	80

Goodwill, Other Intangibles and Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2024

Goodwill Other Intangibles And Property And Equipment [Abstract]

Goodwill Activity

Goodwill Activity. Goodwill activity was as follows:


(In millions)	Evernorth Health Services		Cigna Healthcare		Total
Balance at January 1, 2023	$	35,130	$	10,681	$	45,811

Goodwill transferred to assets of businesses held for sale(1)	—		(1,553)		(1,553)
Impact of foreign currency translation and other adjustments	—		1		1
Goodwill at December 31, 2023	35,130		9,129		44,259
Goodwill acquired	114		—		114

Impact of foreign currency translation and other adjustments	190		(193)		(3)
Goodwill at December 31, 2024	$	35,434	$	8,936	$	44,370

(1) See Note 5 to the Consolidated Financial Statements for further discussion of 2024 and 2023 goodwill impairments.

Other Indefinite-Lived Intangible Assets

Other intangible assets were comprised of the following:


(In millions)	Cost		Accumulated Amortization		Net Carrying Value
December 31, 2024
Customer relationships	$	29,971	$	9,119	$	20,852
Trade name - Express Scripts	8,400				8,400
Other	316		131		185
Other intangible assets (1)	38,687		9,250		29,437
Value of business acquired ("VOBA" reported in Other assets) (2)	211		142		69
Total	$	38,898	$	9,392	$	29,506
December 31, 2023
Customer relationships	$	29,978	$	7,645	$	22,333
Trade name - Express Scripts	8,400				8,400
Other	317		110		207
Other intangible assets (1)	38,695		7,755		30,940
Value of business acquired (reported in Other assets) (2)	211		142		69
Total	$	38,906	$	7,897	$	31,009

(1) Includes $20 million and $77 million of Other intangible assets classified as assets of businesses held for sale as of December 31, 2024 and December 31, 2023, respectively.

(2) Includes $69 million of VOBA classified as assets of businesses held for sale as of both December 31, 2024 and December 31, 2023.

Other Finite-Lived Intangible Assets

Other intangible assets were comprised of the following:


(In millions)	Cost		Accumulated Amortization		Net Carrying Value
December 31, 2024
Customer relationships	$	29,971	$	9,119	$	20,852
Trade name - Express Scripts	8,400				8,400
Other	316		131		185
Other intangible assets (1)	38,687		9,250		29,437
Value of business acquired ("VOBA" reported in Other assets) (2)	211		142		69
Total	$	38,898	$	9,392	$	29,506
December 31, 2023
Customer relationships	$	29,978	$	7,645	$	22,333
Trade name - Express Scripts	8,400				8,400
Other	317		110		207
Other intangible assets (1)	38,695		7,755		30,940
Value of business acquired (reported in Other assets) (2)	211		142		69
Total	$	38,906	$	7,897	$	31,009

(1) Includes $20 million and $77 million of Other intangible assets classified as assets of businesses held for sale as of December 31, 2024 and December 31, 2023, respectively.

(2) Includes $69 million of VOBA classified as assets of businesses held for sale as of both December 31, 2024 and December 31, 2023.

Property and Equipment

Property and equipment was comprised of the following:


(In millions)	Cost		Accumulated Amortization		Net Carrying Value
December 31, 2024
Internal-use software	$	11,295	$	8,167	$	3,128
Other property and equipment	2,115		1,287		828
Total property and equipment (1)	13,410		9,454		3,956


December 31, 2023
Internal-use software	$	10,155	$	7,161	$	2,994
Other property and equipment	2,282		1,405		877
Total property and equipment (1)	12,437		8,566		3,871

(1)Includes $302 million and $176 million of Property and equipment net carrying value classified as assets of businesses held for sale as of December 31, 2024 and December 31, 2023, respectively.

Components of Depreciation and Amortization Expense

Depreciation and amortization expense was comprised of the following:


	For the Years Ended December 31,
(In millions)	2024		2023		2022
Internal-use software	$	1,021	$	1,216	$	1,068
Other property and equipment	248		260		251
Value of business acquired (reported in Other assets)	—		7		12
Other intangibles	1,506		1,552		1,606
Total depreciation and amortization	$	2,775	$	3,035	$	2,937

Estimated Annual Pre-Tax Amortization for Intangible Assets

The Company estimates annual pre-tax amortization for intangible assets, including internal-use software, over the next five calendar years to be as follows:


(In millions)	Pre-tax Amortization
2025	$	2,339
2026	$	2,050
2027	$	2,015
2028	$	1,943
2029	$	1,557

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

Shareholders Equity and Dividend Restrictions (Tables)

12 Months Ended

Dec. 31, 2024

Statutory Net Income and Net Assets of the Company's Subsidiaries

The statutory net income of the Company's life, accident, and health insurance and HMO subsidiaries for the years ended, and their statutory surplus as of, December 31 were as follows:


(In billions)	2024		2023		2022
Net income	$	3.9	$	5.3	$	5.7
Surplus	$	16.0	$	14.9	$	16.4

The Company's HMO and life, accident and health insurance subsidiaries are also subject to minimum statutory surplus requirements and may be required to maintain investments on deposit with state departments of insurance or other regulatory bodies. Additionally, these subsidiaries may be subject to regulatory restrictions on the amount of annual dividends or other distributions (such as loans or cash advances) that insurance companies may extend to their parent companies without prior approval. These amounts, including restricted GAAP net assets of the Company's subsidiaries, were as follows:


(In billions)	December 31, 2024
Minimum statutory surplus required by regulators (1)	$	5.2
Investments on deposit with regulatory bodies	$	0.4
Maximum dividend distributions permitted in 2025 without regulatory approval	$	3.9
Maximum loans to the parent company permitted without regulatory approval	$	1.4
Restricted GAAP net assets of subsidiaries of The Cigna Group	$	11.3

(1) Excludes amounts associated with foreign operated equity method joint ventures.

Tabular disclosure of how the entity's reporting under GAAP as of the balance sheet date differs from the results based on prescribed and permitted accounting practices of the state or country of domicile in which a relevant statutory filing is made, or differences in results based on the National Association of Insurance Commissioners (NAIC) prescribed practices, or a combination thereof. Describes the accounting practices used and the related monetary effect on statutory surplus, net income, and risk-based capital. If an insurance enterprise's risk-based capital would have triggered a regulatory event had it not used a permitted practice, that fact is disclosed in the financial statements. Permitted statutory accounting practices include practices not prescribed but allowed by the domiciliary state insurance department regulatory authority.

Components of Income Tax Expense

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2024

Income Tax Disclosure [Abstract]

The components of income taxes were as follows:


	For the Years Ended December 31,
(In millions)	2024		2023		2022
Current taxes
U.S. income taxes	$	1,167	$	1,459	$	1,679
Foreign income taxes	248		161		219
State income taxes	171		180		189
Total current taxes	1,586		1,800		2,087
Deferred taxes (tax benefits)
U.S. income tax benefits	(142)		(533)		(275)
Foreign income taxes (tax benefits)	64		(1,046)		(28)
State income tax benefits	(17)		(80)		(169)
Total deferred tax benefits	(95)		(1,659)		(472)
Total income taxes	$	1,491	$	141	$	1,615

Reconciliation of Total Income Taxes to the Amount Computed Using the Nominal Federal Income Tax Rate

Total income taxes were different from the amount computed using the nominal federal income tax rate for the following reasons:


	For the Years Ended December 31,
	2024				2023				2022
(In millions)	$		%		$		%		$		%
Tax expense at nominal rate	$	1,107	21.0	%	$	1,158	21.0	%	$	1,763	21.0	%
Change in valuation allowance	767		14.6		1,290		23.4		—		—
State income tax (benefit), net of federal income tax benefit	62		1.2		(39)		(0.7)		16		0.2
Investment tax credits	(111)		(2.1)		(48)		(0.8)		(14)		(0.2)
Impact of businesses held for sale	(129)		(2.4)		(213)		(3.9)		—		—
Effect of foreign earnings	(252)		(4.9)		(173)		(3.1)		(96)		(1.2)
Other foreign tax attributes	—		—		(153)		(2.8)		—		—
Swiss tax attributes	—		—		(1,674)		(30.4)		—		—

Impact of sale of businesses	—		—		—		—		(37)		(0.4)
Other	47		0.9		(7)		(0.1)		(17)		(0.2)
Total income taxes	$	1,491	28.3	%	$	141	2.6	%	$	1,615	19.2	%

Deferred Income Tax Assets and Liabilities

Deferred income tax assets and liabilities were as follows:


(In millions)	December 31, 2024		December 31, 2023
Deferred tax assets
Foreign tax attributes	$	1,752	$	1,827
Deferred loss - sale of business	773		584
Investments	561		—
Other insurance and contractholder liabilities	300		353
Loss carryforwards	270		200
Other accrued liabilities	207		244
Employee and retiree benefit plans	177		217
Unrealized depreciation on investments and foreign currency translation	93		81
Policy acquisition expenses	—		39
Other	256		242
Deferred tax assets before valuation allowance	4,389		3,787
Valuation allowance for deferred tax assets	(2,332)		(1,498)
Deferred tax assets, net of valuation allowance	2,057		2,289
Deferred tax liabilities
Acquisition-related basis differences	7,822		8,105
Depreciation and amortization	243		371
Policy acquisition expenses	74		—




Total deferred tax liabilities	8,139		8,476
Net deferred income tax liabilities (1)	$	(6,082)	$	(6,187)

(1)Deferred tax liabilities, net in the Consolidated Balance Sheets as of December 31, 2024, excludes $954 million reported in Other assets and $61 million reported in liabilities of businesses held for sale. Deferred tax liabilities, net in the Consolidated Balance Sheets as of December 31, 2023, excludes $1,055 million reported in Other assets and $69 million reported in liabilities of businesses held for sale.

Reconciliations of Unrecognized Tax Benefits

Reconciliations of unrecognized tax benefits were as follows:


	For the Years Ended December 31,
(In millions)	2024		2023		2022
Balance at January 1,	$	1,399	$	1,343	$	1,230
(Decrease) increase due to prior year positions	(7)		(26)		8

Increase due to current year positions	165		107		137
Reduction related to settlements with taxing authorities	(22)		(13)		(4)
Reduction related to lapse of applicable statute of limitations	(58)		(12)		(28)
Balance at December 31,	$	1,477	$	1,399	$	1,343

Segment Information (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Summary of Special Items

The following table presents the special items charges (benefits) recorded by the Company, as well as the respective financial statement line items impacted:


	For the Years Ended December 31,
		2024	2023				2022
(In millions)			Pre-tax		After-tax		Pre-tax		After-tax		Pre-tax		After-tax
Integration and transaction-related costs (Selling, general and administrative expenses)			$	275	$	211	$	45	$	35	$	135	$	103
Impairment of dividend receivable (Net investment income)			182		138		—		—		—		—
Deferred tax expenses (benefits), net (Income taxes, less amount attributable to noncontrolling interests)			—		84		—		(1,071)		—		—
Net (gain) loss on sale of businesses			(24)		(2)		1,499		1,429		(1,662)		(1,332)
Charge for organizational efficiency plan (Selling, general and administrative expenses)			—		—		252		193		22		17
Charges (benefits) associated with litigation matters (Selling, general and administrative expenses)			—		—		201		171		(28)		(20)


Total impact from special items			$	433	$	431	$	1,997	$	757	$	(1,533)	$	(1,232)

Summarized Segment Financial Information

Summarized segment financial information was as follows:


(In millions)	Evernorth Health Services		Cigna Healthcare		Other Operations		Corporate and Eliminations		Total
2024
Revenues from external customers	$	198,177	$	47,528	$	440	$	3	$	246,148
Intersegment revenues	3,775		4,972		79		(8,826)
Net investment income	21		618		309		25		973
Total revenues	201,973		53,118		828		(8,798)		247,121
Net investment results from certain equity method investments	—		(204)		—		—		(204)

Special item related to impairment of dividend receivable	182		—		—		—		182
Adjusted revenues	$	202,155	$	52,914	$	828	$	(8,798)	$	247,099
Pharmacy and other service costs	190,968		—
Medical costs	—		37,887
Selling, general and administrative expenses	3,779		10,805
Other segment items (1)
Interest (expense) and other	(2)		7
Less income attributable to noncontrolling interests	405		—
Pre-tax adjusted income (loss) from operations	7,001		4,229		(9)		(1,688)		9,533

Income (loss) before income taxes	$	3,929	$	3,315	$	(12)	$	(1,963)	$	5,269
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(405)		—		—		—		(405)
Net investment losses (2)	2,129		401		3		—		2,533
Amortization of acquired intangible assets	1,662		41		—		—		1,703
Special items
Integration and transaction-related costs	—		—		—		275		275
Impairment of dividend receivable	182		—		—		—		182

(Gain) loss on sale of businesses	(496)		472		—		—		(24)




Pre-tax adjusted income (loss) from operations	$	7,001	$	4,229	$	(9)	$	(1,688)	$	9,533

Other Segment Information
Depreciation and amortization	$	2,319	$	417	$	9	$	30	$	2,775

(1)Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.

(2)Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.


(In millions)	Evernorth Health Services		Cigna Healthcare		Other Operations		Corporate and Eliminations		Total
2023
Revenues from external customers	$	147,588	$	46,219	$	291	$	1	$	194,099
Intersegment revenues	5,670		4,332		—		(10,002)
Net investment income	241		597		305		23		1,166
Total revenues	153,499		51,148		596		(9,978)		195,265
Net investment results from certain equity method investments	—		57		—		—		57

Adjusted revenues	$	153,499	$	51,205	$	596	$	(9,978)	$	195,322
Pharmacy and other service costs	143,571		—
Medical costs	—		35,678
Selling, general and administrative expenses	3,340		11,055
Other segment items (1)
Interest (expense) and other	(2)		8
Less income attributable to noncontrolling interests	144		2
Pre-tax adjusted income (loss) from operations	6,442		4,478		96		(1,698)		9,318

Income (loss) before income taxes	$	4,768	$	2,664	$	76	$	(1,995)	$	5,513
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(144)		(2)		—		—		(146)
Net investment losses (2)	—		133		2		—		135
Amortization of acquired intangible assets	1,774		45		—		—		1,819
Special items
Integration and transaction-related costs	—		—		—		45		45


Loss on sale of businesses	—		1,481		18		—		1,499
Charge for organizational efficiency plan	—		—		—		252		252
Charges associated with litigation matters	44		157		—		—		201


Pre-tax adjusted income (loss) from operations	$	6,442	$	4,478	$	96	$	(1,698)	$	9,318

Other Segment Information
Depreciation and amortization	$	2,438	$	569	$	3	$	25	$	3,035

(1)Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.

(2)Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.


(In millions)	Evernorth Health Services		Cigna Healthcare		Other Operations		Corporate and Eliminations		Total
2022
Revenues from external customers	$	135,786	$	41,738	$	1,839	$	—	$	179,363
Intersegment revenues	4,463		2,535		—		(6,998)
Net investment income	86		638		424		7		1,155
Total revenues	140,335		44,911		2,263		(6,991)		180,518
Net investment results from certain equity method investments	—		126		—		—		126

Adjusted revenues	$	140,335	$	45,037	$	2,263	$	(6,991)	$	180,644
Pharmacy and other service costs	131,284		—
Medical costs	—		31,119
Selling, general and administrative expenses	2,856		9,827
Other segment items (1)
Interest (expense) and other	(2)		12
Less income attributable to noncontrolling interests	66		4
Pre-tax adjusted income (loss) from operations	6,127		4,099		509		(1,466)		9,269

Income (loss) before income taxes	$	4,421	$	3,470	$	2,101	$	(1,595)	$	8,397
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(66)		(4)		(14)		—		(84)
Net investment losses (2)	—		530		83		—		613
Amortization of acquired intangible assets	1,772		103		1		—		1,876
Special items
Integration and transaction-related costs	—		—		—		135		135


(Gain) on sale of businesses	—		—		(1,662)		—		(1,662)
Charge for organizational efficiency plan	—		—		—		22		22
(Benefits) associated with litigation matters	—		—		—		(28)		(28)


Pre-tax adjusted income (loss) from operations	$	6,127	$	4,099	$	509	$	(1,466)	$	9,269

Other Financial Information
Depreciation and amortization	$	2,283	$	638	$	6	$	10	$	2,937

(1)Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.

(2)Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.

Revenue from External Customers

Revenue from external customers includes Pharmacy revenues, Premiums and Fees and other revenues. The following table presents these revenues by product, premium and service type:


	For the Years Ended December 31,
(In millions)		2024		2023		2022
Products (Pharmacy revenues) (ASC 606)
Network revenues		$	105,340	$	67,514	$	64,946
Home delivery and specialty revenues		72,476		65,732		61,283
Other revenues		11,545		9,047		6,753
Total Evernorth Health Services		189,361		142,293		132,982
Other Operations		60		—		—
Corporate and eliminations		(4,059)		(5,050)		(4,416)
Total Pharmacy revenues		185,362		137,243		128,566
Insurance premiums (ASC 944)
Cigna Healthcare
U.S. Healthcare
Employer insured		17,576		16,490		15,199
Medicare Advantage		8,679		8,771		7,896
Stop loss		6,744		6,143		5,461
Individual and Family Plans		3,951		5,088		2,636
Other		4,938		4,095		3,996
U.S. Healthcare		41,888		40,587		35,188
International Health		3,624		3,295		2,906
Total Cigna Healthcare		45,512		43,882		38,094
Divested International businesses		—		—		1,596
Other Operations excluding Divested International businesses		380		281		225
Corporate and eliminations		104		74		1
Total Premiums		45,996		44,237		39,916
Services (Fees) (ASC 606) and Other revenues (1)
Evernorth Health Services		12,591		10,965		7,267
Cigna Healthcare		6,988		6,669		6,179
Other Operations		79		10		18
Corporate and eliminations		(4,868)		(5,025)		(2,583)
Total Fees and other revenues (1)		14,790		12,619		10,881
Total revenues from external customers		$	246,148	$	194,099	$	179,363

(1)Other revenues for the years ended December 31, 2024, 2023 and 2022 were $584 million, $210 million and $168 million, respectively.

Foreign and U.S. Revenues from External Customers

U.S. and Foreign Revenues. U.S. and foreign revenues from external customers are shown below. The Company's foreign revenues are generated by its foreign operating entities. In the periods shown, no single foreign country contributed more than 2% of consolidated revenues from external customers.


	For the Years Ended December 31,
(In millions)	2024		2023		2022
United States	$	241,563	$	189,840	$	174,540
Foreign countries (1)	4,585		4,259		4,823
Total revenues from external customers	$	246,148	$	194,099	$	179,363

(1) In 2022, included revenues from the divested International businesses of $1.6 billion.

Schedule I - Condensed Financial Information of The Cigna Group (Tables)

12 Months Ended

Dec. 31, 2024

Condensed Financial Statements, Captions [Line Items]

Outstanding amounts of debt and finance leases

The outstanding amounts of debt (net of issuance costs, discounts or premiums) and finance leases were as follows:


(In millions)	December 31, 2024		December 31, 2023
Short-term debt
Commercial paper	$	880	$	1,237
$500 million, 0.613% Notes due March 2024	—		500
$790 million, 3.500% Notes due June 2024 (1)	—		996
$900 million, 3.250% Notes due April 2025 (2)	897		—
$1,216 million, 4.125% Notes due November 2025 (1)	1,215		—
Other, including finance leases	43		42
Total short-term debt	$	3,035	$	2,775





Long-term debt
$900 million, 3.250% Notes due April 2025 (2)	$	—	$	882
$1,216 million, 4.125% Notes due November 2025 (1)	—		2,197
$1,284 million, 4.500% Notes due February 2026 (1)	1,285		1,502
$550 million, 1.250% Notes due March 2026 (1)	549		798
$700 million, 5.685% Notes due March 2026	699		698
$1,500 million, 3.400% Notes due March 2027	1,466		1,450
$259 million, 7.875% Debentures due May 2027	259		259
$600 million, 3.050% Notes due October 2027	598		597
$3,800 million, 4.375% Notes due October 2028	3,790		3,787
$1,000 million, 5.000% Notes due May 2029	995		—
$1,400 million, 2.400% Notes due March 2030 (1) (2)	1,386		1,493
$1,500 million, 2.375% Notes due March 2031 (2)	1,384		1,397
$750 million, 5.125% Notes due May 2031	745		—
$45 million, 8.080% Step Down Notes due January 2033	45		45
$800 million, 5.400% Notes due March 2033	795		794
$1,250 million, 5.250% Notes due February 2034 (2)	1,226		—
$190 million, 6.150% Notes due November 2036	190		190
$2,200 million, 4.800% Notes due August 2038	2,193		2,193
$750 million, 3.200% Notes due March 2040	744		744
$121 million, 5.875% Notes due March 2041	119		119
$448 million, 6.125% Notes due November 2041	485		487
$317 million, 5.375% Notes due February 2042	315		315
$1,500 million, 4.800% Notes due July 2046	1,469		1,467
$1,000 million, 3.875% Notes due October 2047	990		989
$3,000 million, 4.900% Notes due December 2048	2,971		2,970
$1,250 million, 3.400% Notes due March 2050	1,237		1,237
$1,500 million, 3.400% Notes due March 2051	1,479		1,479
$1,500 million, 5.600% Notes due February 2054	1,482		—

Other, including finance leases	41		66
Total long-term debt	$	28,937	$	28,155

(1)Included in the February 2024 debt tender offers discussed below.

(2)The Company has entered into interest rate swap contracts hedging a portion of these fixed-rate debt instruments as of December 31, 2024. See Note 11 to the Consolidated Financial Statements for further information about the Company's interest rate risk management and these derivative instruments.

Debt Issuance and Debt Tender Offers. In February 2024, we issued $4.5 billion of new senior notes, as detailed in the table below. The proceeds from this debt were used to pay the consideration for the cash tender offers as described below. We used the remaining net proceeds to fund the repayment of our senior notes that matured in March 2024 and for general corporate purposes, including repayment of indebtedness and repurchases of shares of our common stock. Interest on this debt is paid semiannually.

Principal

Maturity Date

Interest Rate

Net Proceeds

Redeemable Date(1)

"Make Whole" Premium (2)

$1,000 million

May 15, 2029

5.000%

$995 million

April 15, 2029

15

$750 million

May 15, 2031

5.125%

$746 million

March 15, 2031

15

$1,250 million

February 15, 2034

5.250%

$1,244 million

November 15, 2033

20

$1,500 million

February 15, 2054

5.600%

$1,485 million

August 15, 2053

20

(1) Redeemable at any time prior to this date at a "make whole" premium, defined below. Redeemable at par on or after this date.

(2) "Make whole" premium calculated using the most directly comparable U.S. Treasury rate plus the amount of basis points set forth in this column.

Maturities of Outstanding Long-Term Debt

Maturities of outstanding long-term debt as of December 31, 2024 are as follows:


(In millions)	Scheduled Maturities (1)
2025	$	2,116
2026	$	2,534
2027	$	2,359
2028	$	3,800
2029	$	1,000
Maturities after 2029	$	19,522

(1) Long-term debt maturity amounts include current maturities of long-term debt. Finance leases are excluded from this table.

The Cigna Group

Condensed Financial Statements, Captions [Line Items]

Outstanding amounts of debt and finance leases

Debt Issuance and Debt Tender Offers. In February 2024, we issued $4.5 billion of new senior notes. The proceeds from this debt were used to pay the consideration for the cash tender offers as described below. We used the remaining net proceeds to fund the

repayment of our senior notes that matured in March 2024 and for general corporate purposes, including repayment of indebtedness and repurchases of shares of our common stock. Interest on this debt is paid semiannually.

Principal

Maturity Date

Interest Rate

Net Proceeds

Redeemable Date(1)

"Make Whole" Premium (2)

$1,000 million

May 15, 2029

5.000%

$995 million

April 15, 2029

15

$750 million

May 15, 2031

5.125%

$746 million

March 15, 2031

15

$1,250 million

February 15, 2034

5.250%

$1,244 million

November 15, 2033

20

$1,500 million

February 15, 2054

5.600%

$1,485 million

August 15, 2053

20

(1) Redeemable at any time prior to this date at a "make whole" premium, defined below. Redeemable at par on or after this date.

(2) "Make whole" premium calculated using the most directly comparable U.S. Treasury rate plus the amount of basis points set forth in this column.

Maturities of Outstanding Long-Term Debt

Maturities of the Company's long-term debt are as follows:


(In millions)
2025	$	1,973
2026	$	2,301
2027	$	2,056
2028	$	3,800
2029	$	1,000
Maturities after 2029	$	19,292

Summary of Significant Accounting Policies (Details) - USD ($) $ in Billions	Dec. 31, 2024	Dec. 31, 2023
Financial and performance guarantees \| Evernorth Health Services
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Guarantee liability	$ 1.9	$ 1.6

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476173/280-10-65-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476173/280-10-65-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482615/740-10-65-9

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482615/740-10-65-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482615/740-10-65-9

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (a)(3)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (a)(3)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-1

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479832/842-10-65-8

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479832/842-10-65-8

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 50
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477123/405-50-65-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 13
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482477/820-10-65-13

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482477/820-10-65-13

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-5

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-5

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-5

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-5

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (h)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (h)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 45: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (h)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (h)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (i)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (i)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 49: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479845/805-20-65-3

Reference 50: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479845/805-20-65-3

Reference 51: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479845/805-20-65-3

Reference 52: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479832/842-10-65-5

Reference 53: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-6

Reference 54: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-6

Reference 55: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-6

Reference 56: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-6

Reference 57: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-6

Reference 58: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 59: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 60: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 61: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 62: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 63: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 64: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 65: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 66: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 67: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 68: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 69: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5

Reference 70: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-4

Reference 71: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-4

Reference 72: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-4

Reference 73: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482615/740-10-65-8

Reference 74: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (d)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482615/740-10-65-8

Reference 75: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-4

Reference 76: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-4

Reference 77: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-4

Reference 78: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483194/926-20-65-2

Reference 79: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483194/926-20-65-2

Reference 80: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483194/926-20-65-2

Reference 81: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 82: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 83: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 84: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 85: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 86: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483421/250-10-45-6

Reference 87: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 88: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 89: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 90: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 91: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 92: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 93: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 94: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 95: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 96: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 97: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 98: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480424/946-10-50-3

Reference 99: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476166/350-60-65-1

Reference 100: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476166/350-60-65-1

Accounts Receivable, Net - Amounts Included in Accounts Receivable, Net (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Accounts, Notes, Loans and Financing Receivable [Line Items]
Noninsurance customer receivables, including held for sale assets	$ 11,879	$ 8,044
Pharmaceutical manufacturers receivable, including held for sale assets	10,914	8,169
Insurance customer receivables, including held for sale assets	3,199	2,359
Other receivables, including held for sale assets	162	272
Total	26,154	18,844
Accounts receivable, net	24,227	17,722
Held-for-Sale \| Medicare Advantage and related Cigna Healthcare businesses
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, net classified as assets of businesses held for sale	$ (1,927)	$ (1,122)

Accounts Receivable, Net - Allowances and Factoring Facility (Details) - USD ($)	1 Months Ended	12 Months Ended
	Jul. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	May 31, 2024
Receivables [Abstract]
Allowance for receivables, current		$ 5,000,000,000.0	$ 3,700,000,000
Pharmaceutical manufacturers receivables allowance		4,300,000,000	3,100,000,000
Noninsurance customer receivables allowance		388,000,000	386,000,000
Allowance for current expected credit losses on accounts receivable		$ 84,000,000	90,000,000
Initial term, uncommitted factoring facility (in years)	2 years
Automatic renewal term, uncommitted factoring facility (in years)		1 year
Total capacity, uncommitted factoring facility	$ 1,000,000,000.0	$ 1,500,000,000		$ 1,500,000,000
Accounts receivable sold, uncommitted factoring facility		5,500,000,000	2,100,000,000
Accounts receivable sold that remain outstanding, uncommitted factoring facility		0	0
Accounts receivable received but not remitted, uncommitted factoring facility		$ 1,000,000,000.0	$ 515,000,000

Supplier Finance Program (Details) - USD ($) $ in Millions	12 Months Ended
Supplier Finance Program (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Payment term (in months)	1 month
Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration]	Accounts payable	Accounts payable
Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]	Accounts payable	Accounts payable
Outstanding payment obligations, current	$ 1,637	$ 1,536	$ 1,303
Supplier Finance Program, Obligation [Roll Forward]
Confirmed obligations outstanding at the beginning of the year	1,536	1,303
Invoices confirmed during the year	39,091	36,224
Supplier Finance Program, Obligation, Settlement	38,990	35,991
Confirmed obligations outstanding at the end of the year	1,637	$ 1,536
Outstanding payment obligations, current, voluntarily elected by suppliers to be sold to the financial institution

Assets and Liabilities of Businesses Held for Sale (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Jan. 31, 2024
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax [Abstract]
Loss on sale of businesses, location, Consolidated Statements of Income	Net gain (loss) on sale of businesses
Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]
Integration and transaction-related costs	$ 275	$ 45	$ 135
Integration and transaction-related costs, after-tax	211	35	$ 103
Held-for-Sale \| Medicare Advantage and related Cigna Healthcare businesses
Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]
Cash and cash equivalents	1,339	467
Investments	1,444	1,438
Accounts receivable, net	1,927	1,122
Other assets, including Goodwill	2,294	2,963
Goodwill classified as Assets of businesses held for sale	94	396
Total assets of businesses held for sale	7,004	5,990
Insurance and contractholder liabilities	1,579	1,636
All other liabilities	831	1,059
Total liabilities of businesses held for sale	2,410	2,695
Held-for-Sale \| Medicare Advantage and related Cigna Healthcare businesses \| Health Care Service Corporation (HCSC)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sale price	4,700			$ 3,300
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax [Abstract]
Estimated loss on sale, pre-tax	472	1,500
Estimated loss on sale, after-tax	363	1,400
Goodwill impairments	$ (302)	$ (1,200)

Earnings Per Share - Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Earnings Per Share [Abstract]
Shareholders' net income	$ 3,434	$ 5,164	$ 6,704
Shares:
Weighted average	280,294	293,892	309,546
Common stock equivalents	2,924	2,990	3,519
Total shares	283,218	296,882	313,065
Earnings per share, basic	$ 12.25	$ 17.57	$ 21.66
Earnings per share, effect of dilution	(0.13)	(0.18)	(0.25)
Earnings per share, diluted	$ 12.12	$ 17.39	$ 21.41

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 6.B)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-11

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Earnings Per Share - Anti-dilutive Options (Details) - shares shares in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Employee Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive options	1.1	0.9	1.0

Debt - Outstanding Amounts of Debt and Finance Leases (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Short-term debt
Commercial paper	$ 880	$ 1,237
Other, including finance leases	43	42
Total short-term debt	3,035	2,775
Long-term debt
Other, including finance leases	41	66
Total long-term debt	28,937	28,155
$500 million, 0.613% Notes due March 2024
Short-term debt
Current maturities	0	500
Long-term debt
Gross value	$ 500
Interest Rate	0.613%
$790 million, 3.500% Notes due June 2024 (1)
Short-term debt
Current maturities	$ 0	996
Long-term debt
Gross value	$ 790
Interest Rate	3.50%
$900 million, 3.250% Notes due April 2025 (2)
Short-term debt
Current maturities	$ 897	0
Long-term debt
Long-term debt	0	882
Gross value	$ 900
Interest Rate	3.25%
$1,216 million, 4.125% Notes due November 2025
Short-term debt
Current maturities	$ 1,215	0
Long-term debt
Long-term debt	0	2,197
Gross value	$ 1,216
Interest Rate	4.125%
$1,284 million, 4.500% Notes due February 2026
Long-term debt
Long-term debt	$ 1,285	1,502
Gross value	$ 1,284
Interest Rate	4.50%
$550 million, 1.250% Notes due March 2026
Long-term debt
Long-term debt	$ 549	798
Gross value	$ 550
Interest Rate	1.25%
$700 million, 5.685% Notes due March 2026
Long-term debt
Long-term debt	$ 699	698
Gross value	$ 700
Interest Rate	5.685%
$1,500 million, 3.400% Notes due March 2027
Long-term debt
Long-term debt	$ 1,466	1,450
Gross value	$ 1,500
Interest Rate	3.40%
$259 million, 7.875% Debentures due May 2027
Long-term debt
Long-term debt	$ 259	259
Gross value	$ 259
Interest Rate	7.875%
$600 million, 3.050% Notes due October 2027
Long-term debt
Long-term debt	$ 598	597
Gross value	$ 600
Interest Rate	3.05%
$3,800 million, 4.375% Notes due October 2028
Long-term debt
Long-term debt	$ 3,790	3,787
Gross value	$ 3,800
Interest Rate	4.375%
$1,000 million, 5.000% Notes due May 2029
Long-term debt
Long-term debt	$ 995	0
Gross value	$ 1,000
Interest Rate	5.00%
$1,400 million, 2.400% Notes due March 2030
Long-term debt
Long-term debt	$ 1,386	1,493
Gross value	$ 1,400
Interest Rate	2.40%
$1,500 million, 2.375% Notes due March 2031
Long-term debt
Long-term debt	$ 1,384	1,397
Gross value	$ 1,500
Interest Rate	2.375%
$750 million, 5.125% Notes due May 2031
Long-term debt
Long-term debt	$ 745	0
Gross value	$ 750
Interest Rate	5.125%
$45 million, 8.080% Step Down Notes due January 2033
Long-term debt
Long-term debt	$ 45	45
Gross value	$ 45
Interest Rate	8.08%
$800 million, 5.400% Notes due March 2033
Long-term debt
Long-term debt	$ 795	794
Gross value	$ 800
Interest Rate	5.40%
$1,250 million, 5.250% Notes due February 2034
Long-term debt
Long-term debt	$ 1,226	0
Gross value	$ 1,250
Interest Rate	5.25%
$190 million, 6.150% Notes due November 2036
Long-term debt
Long-term debt	$ 190	190
Gross value	$ 190
Interest Rate	6.15%
$2,200 million, 4.800% Notes due August 2038
Long-term debt
Long-term debt	$ 2,193	2,193
Gross value	$ 2,200
Interest Rate	4.80%
$750 million, 3.200% Notes due March 2040
Long-term debt
Long-term debt	$ 744	744
Gross value	$ 750
Interest Rate	3.20%
$121 million, 5.875% Notes due March 2041
Long-term debt
Long-term debt	$ 119	119
Gross value	$ 121
Interest Rate	5.875%
$448 million, 6.125% Notes due November 2041
Long-term debt
Long-term debt	$ 485	487
Gross value	$ 448
Interest Rate	6.125%
$317 million, 5.375% Notes due February 2042
Long-term debt
Long-term debt	$ 315	315
Gross value	$ 317
Interest Rate	5.375%
$1,500 million, 4.800% Notes due July 2046
Long-term debt
Long-term debt	$ 1,469	1,467
Gross value	$ 1,500
Interest Rate	4.80%
$1,000 million, 3.875% Notes due October 2047
Long-term debt
Long-term debt	$ 990	989
Gross value	$ 1,000
Interest Rate	3.875%
$3,000 million, 4.900% Notes due December 2048
Long-term debt
Long-term debt	$ 2,971	2,970
Gross value	$ 3,000
Interest Rate	4.90%
$1,250 million, 3.400% Notes due March 2050
Long-term debt
Long-term debt	$ 1,237	1,237
Gross value	$ 1,250
Interest Rate	3.40%
$1,500 million, 3.400% Notes due March 2051
Long-term debt
Long-term debt	$ 1,479	1,479
Gross value	$ 1,500
Interest Rate	3.40%
$1,500 million, 5.600% Notes due February 2054
Long-term debt
Long-term debt	$ 1,482	$ 0
Gross value	$ 1,500
Interest Rate	5.60%

Debt - Short-term and Credit Facilities Debt (Details) - USD ($)	1 Months Ended	12 Months Ended
	Apr. 30, 2024	Dec. 31, 2024	Jul. 31, 2024	Jun. 30, 2024
Debt Instrument [Line Items]
Commercial paper average interest rate		4.65%
Commercial Paper
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 6,500,000,000	$ 6,500,000,000	$ 5,000,000,000.0
Revolving Credit Agreements, April 2024
Debt Instrument [Line Items]
Outstanding balances		$ 0
Aggregate amount of options to increase commitments	$ 1,500,000,000
Maximum total commitment	$ 8,000,000,000.0
Leverage ratio covenant	60.00%
Five-year Revolving Credit Agreement, Maturing April 2029
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 5,000,000,000.0
Credit agreement term	5 years
Credit agreement extension term	1 year
Five-year Revolving Credit Agreement, Maturing April 2029 \| Letter of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 500,000,000
364-day Revolving Credit Agreement, Maturing April 2025
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 1,500,000,000
Credit agreement term	364 days
Credit facility, conversion to term loan, term	1 year

Debt - Debt Issuance and Debt Tender Offers (Details)	1 Months Ended	12 Months Ended
Debt - Debt Issuance and Debt Tender Offers (Details)	Feb. 29, 2024 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Mar. 31, 2024 USD ($)
Debt Instrument [Line Items]
Aggregate principal amount of outstanding debt securities redeemed					$ 1,800,000,000
Repayment of long-term debt		$ 3,000,000,000	$ 2,967,000,000	$ 500,000,000
Senior Notes
Debt Instrument [Line Items]
Principal	$ 4,500,000,000
$1,000 million, 5.000% Notes due May 2029
Debt Instrument [Line Items]
Interest rate		5.00%
Gross value		$ 1,000,000,000
$1,000 million, 5.000% Notes due May 2029 \| Senior Notes
Debt Instrument [Line Items]
Principal	$ 1,000,000,000
Interest rate	5.00%
Net proceeds	$ 995,000,000
Redemption price discount, spread on variable rate	0.0015
$750 million, 5.125% Notes due May 2031
Debt Instrument [Line Items]
Interest rate		5.125%
Gross value		$ 750,000,000
$750 million, 5.125% Notes due May 2031 \| Senior Notes
Debt Instrument [Line Items]
Principal	$ 750,000,000
Interest rate	5.125%
Net proceeds	$ 746,000,000
Redemption price discount, spread on variable rate	0.0015
$1,250 million, 5.250% Notes due February 2034
Debt Instrument [Line Items]
Interest rate		5.25%
Gross value		$ 1,250,000,000
$1,250 million, 5.250% Notes due February 2034 \| Senior Notes
Debt Instrument [Line Items]
Principal	$ 1,250,000,000
Interest rate	5.25%
Net proceeds	$ 1,244,000,000
Redemption price discount, spread on variable rate	0.0020
$1,500 million, 5.600% Notes due February 2054
Debt Instrument [Line Items]
Interest rate		5.60%
Gross value		$ 1,500,000,000
$1,500 million, 5.600% Notes due February 2054 \| Senior Notes
Debt Instrument [Line Items]
Principal	$ 1,500,000,000
Interest rate	5.60%
Net proceeds	$ 1,485,000,000
Redemption price discount, spread on variable rate	0.0020

Debt - Debt Maturities (Details) $ in Millions	Dec. 31, 2024 USD ($)
Long-term Debt
2025	$ 2,116
2026	2,534
2027	2,359
2028	3,800
2029	1,000
Maturities after 2029	$ 19,522

Debt - Interest Expense (Details) - USD ($) $ in Billions	12 Months Ended
Debt - Interest Expense (Details) - USD ($) $ in Billions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Interest expense on long-term and short-term debt	$ 1.5	$ 1.4	$ 1.3

Common and Preferred Stock - Share Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Equity [Abstract]
Preferred stock authorized for issuance (in shares)	25,000,000
Par value of preferred stock (in dollars per share)	$ 1
Shares of preferred stock outstanding (in shares)	0	0	0
Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	600,000,000	600,000,000	600,000,000
Changes in Total Equity
Outstanding - beginning balance (in shares)	292,504,000	298,676,000	322,948,000
Issued for stock option exercises and other benefit plans (in shares)	2,198,000	1,619,000	3,173,000
Repurchased common stock (in shares)	(20,913,000)	(7,791,000)	(27,445,000)
Outstanding - ending balance (in shares)	273,789,000	292,504,000	298,676,000
Treasury stock (in shares)	128,723,000	107,390,000	99,143,000
Common stock, shares issued (in shares)	402,512,000	399,894,000	397,819,000

Common and Preferred Stock - Dividends (Details) - USD ($) $ / shares in Units, $ in Millions														12 Months Ended
	Jan. 30, 2025	Dec. 19, 2024	Sep. 19, 2024	Jun. 20, 2024	Mar. 21, 2024	Dec. 21, 2023	Sep. 21, 2023	Jun. 22, 2023	Mar. 23, 2023	Dec. 21, 2022	Sep. 22, 2022	Jun. 23, 2022	Mar. 24, 2022	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Equity [Abstract]
Amount per share (in dollars per share)		$ 1.40	$ 1.40	$ 1.40	$ 1.40	$ 1.23	$ 1.23	$ 1.23	$ 1.23	$ 1.12	$ 1.12	$ 1.12	$ 1.12
Total amount paid		$ 384	$ 390	$ 392	$ 401	$ 358	$ 362	$ 362	$ 368	$ 334	$ 341	$ 352	$ 357	$ 1,567	$ 1,450	$ 1,384
Subsequent Event [Line Items]
Common dividends declared (in dollars per share)														$ 5.60	$ 4.92	$ 4.48
Subsequent Event
Subsequent Event [Line Items]
Common dividends declared (in dollars per share)	$ 1.51

Common and Preferred Stock - Accelerated Share Repurchase Agreements (Details) - Accelerated Share Repurchase Agreement, February 2024 - USD ($) $ / shares in Units, shares in Millions	8 Months Ended
	Sep. 30, 2024	Feb. 15, 2024
Accelerated Share Repurchases [Line Items]
Accelerated stock repurchase, amount authorized		$ 3,200,000,000
Shares repurchased	9.3
Shares repurchased, cost per share	$ 344.98

Insurance and Contractholder Liabilities - Account Balances (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Current
Market risk benefits, current	$ 25	$ 37
Unearned premiums, current, including held for sale liabilities	753	846
Total, current	6,480	6,633
Current insurance and contractholder liabilities	5,388	5,514
Non-current
Market risk benefits, non-current	760	966
Unearned premiums, non-current, including held for sale liabilities	31	22
Total, non-current	10,741	11,421
Non-current insurance and contractholder liabilities	10,254	10,904
Total
Market risk benefits	785	1,003
Unearned premiums, including held for sale liabilities	784	868
Total	17,221	18,054
Total insurance and contractholder liabilities	15,642	16,418
Held-for-Sale \| Medicare Advantage and related Cigna Healthcare businesses
Current
Insurance and contractholder liabilities current, classified as held for sale	(1,092)	(1,119)
Non-current
Insurance and contractholder liabilities, non-current, classified as held for sale	(487)	(517)
Total
Insurance and contractholder liabilities classified as held for sale	(1,579)	(1,636)
Unpaid claims classified as liabilities of business held for sale	983	823
Unearned premiums classified as liabilities of business held for sale	85	261
Contractholder deposit funds classified as liabilities held for sale	103	123
Cigna Healthcare
Current
Unpaid claims and claim expenses, current, including held for sale liabilities	4,932	5,017
Future policy benefits, current, including held for sale liabilities	91	97
Contractholder deposit funds, current, including held for sale liabilities	9	12
Non-current
Unpaid claims and claim expenses, non-current, including held for sale liabilities	86	75
Future policy benefits, non-current, including held for sale liabilities	507	518
Contractholder deposit funds, non-current, including liabilities held for sale	115	133
Total
Unpaid claims and claim expenses			$ 4,176	$ 4,261
Unpaid claims and claim expenses, including held for sale liabilities	5,018	5,092
Future policy benefits, including held for sale liabilities	598	615
Contractholder deposit funds, including liabilities held for sale	124	145
Cigna Healthcare \| Held-for-Sale \| Medicare Advantage and related Cigna Healthcare businesses
Total
Future policy benefits classified as liabilities of business held for sale	408	429
Other Operations
Current
Unpaid claims and claim expenses, current	147	99
Future policy benefits, current	157	163
Contractholder deposit funds, current	366	362
Non-current
Unpaid claims and claim expenses, non-current	144	154
Future policy benefits, non-current	3,140	3,375
Contractholder deposit funds, non-current	5,958	6,178
Total
Unpaid claims and claim expenses	291	253
Total liability for future policy benefits	3,297	3,538
Contractholder deposit funds	$ 6,324	$ 6,540	$ 6,700

Insurance and Contractholder Liabilities - Unpaid Claims and Claim Expenses - Cigna Healthcare - Activity (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Held-for-Sale \| Medicare Advantage and related Cigna Healthcare businesses
Paid costs related to:
Unpaid claims classified as liabilities of business held for sale	$ 983	$ 823
Cigna Healthcare
Liability for Claims and Claims Adjustment Expense [Line Items]
Total of incurred but not reported liabilities plus expected claim development on reported claims and reported claims in process	4,600	4,800
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Beginning balance		4,176	$ 4,261
Less: Reinsurance and other amounts recoverable		221	261
Beginning balance, net		3,955	4,000
Beginning balance, including held for sale liabilities	5,092
Less: Reinsurance, including held for sale liabilities	236
Beginning balance, net, including held for sale liabilities	4,856
Incurred costs related to:
Current year	38,347	35,953	31,342
Prior years	(456)	(279)	(259)
Total incurred	37,891	35,674	31,083
Paid costs related to:
Current year	33,718	31,322	27,583
Prior years	4,170	3,451	3,545
Total paid	37,888	34,773	31,128
Ending balance, net			3,955
Add: Reinsurance and other amounts recoverable			221
Ending balance			$ 4,176
Ending balance, net, including held for sale liabilities	4,859	4,856
Add: Reinsurance, including held for sale liabilities	159	236
Ending balance, including held for sale liabilities	$ 5,018	$ 5,092

Insurance and Contractholder Liabilities - Unpaid Claims and Claims Expenses - Cigna Healthcare - Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses (Details) - Cigna Healthcare - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]
Favorable (unfavorable) variance, amount	$ 456	$ 279	$ 259
Favorable (unfavorable) variance, percentage	1.30%	0.90%
Actual completion factors and other
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]
Favorable (unfavorable) variance, amount	$ 223	$ 70
Favorable (unfavorable) variance, percentage	0.60%	0.20%
Medical cost trend
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]
Favorable (unfavorable) variance, amount	$ 233	$ 209
Favorable (unfavorable) variance, percentage	0.70%	0.70%

Insurance and Contractholder Liabilities - Unpaid Claims and Claims Expenses - Cigna Healthcare - Incurred and Paid Claims Development and Unpaid Claims Liability (Details) - Cigna Healthcare claim in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($) claim	Dec. 31, 2023 USD ($) claim
Claims Development [Line Items]
Incurred Costs, including assets held for sale	$ 71,616
Cumulative Costs Paid, including assets held for sale	66,943
Outstanding liabilities for the periods presented, net of reinsurance, including assets held for sale	4,673
Other long-duration liabilities not included in development table above, including assets held for sale	186
Net unpaid claims and claims expenses - Cigna Healthcare	4,859	$ 4,856
Reinsurance and other amounts recoverable, including assets held for sale	159	236
Unpaid claims and claim expenses, including held for sale liabilities	$ 5,018	$ 5,092
Percent of health claims paid within one year	95.00%
Claim frequency \| claim	5.3	5.5
Incurral Year - 2023
Claims Development [Line Items]
Incurred Costs, including assets held for sale	$ 34,437	$ 34,878
Cumulative Costs Paid, including assets held for sale	34,224	$ 30,380
Outstanding liabilities for the periods presented, net of reinsurance, including assets held for sale	213
Incurral Year - 2024
Claims Development [Line Items]
Incurred Costs, including assets held for sale	37,179
Cumulative Costs Paid, including assets held for sale	32,719
Outstanding liabilities for the periods presented, net of reinsurance, including assets held for sale	$ 4,460

Insurance and Contractholder Liabilities - Future Policy Benefits - Accounting Policy (Details)	12 Months Ended
	Dec. 31, 2024
Insurance [Abstract]
Observable inputs from published spot rate curve term (in years)	30 years
Percent of the liability for future policy benefits supported by assets held in trust	34.00%

Insurance and Contractholder Liabilities - Future Policy Benefits - Interest Rates and Duration (Details)	Dec. 31, 2024	Dec. 31, 2023
Cigna Healthcare
Insurance and Contractholder Liabilities [Line Items]
Interest accretion rate	2.85%	2.54%
Current discount rate	5.10%	4.92%
Weighted average duration	8 years 8 months 12 days	7 years 10 months 24 days
Other Operations
Insurance and Contractholder Liabilities [Line Items]
Interest accretion rate	5.64%	5.64%
Current discount rate	5.42%	4.87%
Weighted average duration	10 years 9 months 18 days	11 years 4 months 24 days

Insurance and Contractholder Liabilities - Future Policy Benefits - Present Values of Expected Premiums and Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cigna Healthcare
Liability for Future Policy Benefit, Expected Net Premium [Roll Forward]
Beginning balance	$ 9,233	$ 8,557
Reversal of effect of beginning of period discount rate assumptions	1,154	1,537
Effect of assumption changes and actual variances from expected experience		5	$ 314
Issuances and lapses	1,982	1,255
Net premiums collected	(1,441)	(1,370)
Interest and other	752	94
Ending balance at original discount rate	11,685	10,387
Effect of end of period discount rate assumptions	(1,232)	(1,154)
Ending balance	10,453	9,233	8,557
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]
Beginning balance	9,633	8,945
Reversal of effect of discount rate assumptions	1,220	1,611
Effect of assumption changes and actual variances from expected experience (2)		204	112
Issuances and lapses	1,893	1,309
Benefit payments	(1,473)	(1,374)
Interest and other	668	250
Ending balance at original discount rate	12,145	10,853
Effect of discount rate assumptions	(1,309)	(1,220)
Ending balance	10,836	9,633	8,945
Liability for future policy benefits	383	400
Other	215	215
Total liability for future policy benefits, including assets held for sale	598	615
Effect of actual variances from expectations	(44)	(12)
Undiscounted expected future gross premiums	21,400	18,700
Discounted expected future gross premiums	14,300	13,500
Undiscounted expected future policy benefits	16,100	13,300
Cigna Healthcare \| Reinsurance recoverables
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]
Future policy benefits reserve, reinsurance recoverables	85	72
Cigna Healthcare \| Held-for-Sale \| Medicare Advantage and related Cigna Healthcare businesses
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]
Future policy benefits classified as liabilities of business held for sale	408	429
Cigna Healthcare \| Held-for-Sale \| Medicare Advantage and related Cigna Healthcare businesses \| Assets of businesses held for sale
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]
Future policy benefits reserve, reinsurance recoverables	80	79
Other Operations
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]
Total liability for future policy benefits	3,297	3,538
Undiscounted expected future policy benefits	4,300	4,500
Future policy benefits reserve, reinsurance recoverables	900	1,000
Deferred profit liability included in future policy benefits	366	384
Future policy benefit, excluding deferred profit liability	$ 2,900	$ 3,200	$ 3,200

Insurance and Contractholder Liabilities - Contractholder Deposit Funds (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Insurance and Contractholder Liabilities [Line Items]
Contractholder deposit fund liabilities, approximate percent reinsured externally	38.00%	38.00%
Other Operations
Insurance and Contractholder Liabilities [Line Items]
Contractholder deposit funds	$ 6,324	$ 6,540	$ 6,700
Weighted average crediting rate	3.33%	3.31%
Net amount at risk	$ 2,800	$ 3,000
Cash surrender value	$ 2,800	$ 2,800
Other Operations \| Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400
Insurance and Contractholder Liabilities [Line Items]
Contractholder deposit funds not reinsured externally, percent with guaranteed interest rates of 0300 to 0400	99.00%	99.00%
Contractholder deposit funds not reinsured externally	$ 4,000	$ 4,000
Other Operations \| Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400 \| Policyholder Account Balance, at Guaranteed Minimum Crediting Rate
Insurance and Contractholder Liabilities [Line Items]
Contractholder deposit funds not reinsured externally	1,200	1,200
Other Operations \| Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400 \| Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0051 to 0150
Insurance and Contractholder Liabilities [Line Items]
Contractholder deposit funds not reinsured externally	1,200	1,200
Other Operations \| Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400 \| Policyholder Account Balance, Above Guaranteed Minimum Crediting Rate, Based On Greater Of Guaranteed Minimum Cash Value Or Actual Cash Value
Insurance and Contractholder Liabilities [Line Items]
Contractholder deposit funds not reinsured externally	$ 1,600	$ 1,600
Percentage with cash values at more than 110% of guaranteed cash value	90.00%	90.00%
Other Operations \| Minimum \| Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0051 to 0150
Insurance and Contractholder Liabilities [Line Items]
Basis points above guaranteed minimum crediting rate	0.0050	0.0050
Other Operations \| Minimum \| Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400
Insurance and Contractholder Liabilities [Line Items]
Guaranteed minimum credit rating	3.00%	3.00%
Other Operations \| Maximum \| Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0051 to 0150
Insurance and Contractholder Liabilities [Line Items]
Basis points above guaranteed minimum crediting rate	0.0150	0.0150
Other Operations \| Maximum \| Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400
Insurance and Contractholder Liabilities [Line Items]
Guaranteed minimum credit rating	4.00%	4.00%

Insurance and Contractholder Liabilities - Market Risk Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Insurance Loss Reserves [Abstract]
Annuitization election period	30 days
Market Risk Benefit [Roll Forward]
Balance, beginning of year	$ 1,003	$ 1,268
Balance, beginning of year, before the effect of nonperformance risk (own credit risk)	1,085	1,379
Changes due to expected run-off	(12)	(19)
Changes due to capital markets versus expected	(233)	(254)
Changes due to policyholder behavior versus expected	(39)	(5)
Assumption changes	37	(16)
Balance, end of period, before the effect of changes in nonperformance risk (own credit risk)	838	1,085
Nonperformance risk (own credit risk), end of period	(53)	(82)
Balance, end of period	785	1,003
Reinsured market risk benefit, end of period	$ 836	$ 1,081

Insurance and Contractholder Liabilities - Net Amount of Risk and Average Age of Contractholders (Details) - Variable Annuity position in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($) position	Dec. 31, 2023 USD ($) position
Net Amount at Risk by Product and Guarantee [Line Items]
Account value	$ 7,777	$ 7,736
Net amount at risk	$ 1,283	$ 1,609
Average attained age of contractholders (weighted by exposure)	77 years 8 months 12 days	77 years 3 months 18 days
Guaranteed Minimum Death Benefits Total Contractholders \| position	130	140

Reinsurance - Reinsurance Recoverables (Details) $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($) reinsurer	Dec. 31, 2013	Dec. 31, 2023 USD ($)
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits, including assets held for sale	$ 3,926
Allowance for uncollectible reinsurance, including assets held for sale	(30)
Market risk benefits	836		$ 1,081
Total reinsurance recoverables, including assets held for sale	4,732
Held-for-Sale \| Medicare Advantage and related Cigna Healthcare businesses
Ceded Credit Risk [Line Items]
Reinsurance recoverable classified as assets of businesses held for sale	195
Other Current Assets
Ceded Credit Risk [Line Items]
Reinsurance recoverables	159
Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits, including assets held for sale	620
Collateral provisions exist that may mitigate risk of credit loss
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits, including assets held for sale	2,868
No Collateral
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits, including assets held for sale	438
Ongoing Operations \| A- equivalent and higher current ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits, including assets held for sale	240
Ongoing Operations \| BBB- to BBB+ equivalent current credit ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits, including assets held for sale	63
Ongoing Operations \| Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits, including assets held for sale	148
Ongoing Operations \| Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable \| A- equivalent and higher current ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits, including assets held for sale	0
Ongoing Operations \| Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable \| BBB- to BBB+ equivalent current credit ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits, including assets held for sale	0
Ongoing Operations \| Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable \| Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits, including assets held for sale	144
Ongoing Operations \| Collateral provisions exist that may mitigate risk of credit loss \| A- equivalent and higher current ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits, including assets held for sale	7
Ongoing Operations \| Collateral provisions exist that may mitigate risk of credit loss \| BBB- to BBB+ equivalent current credit ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits, including assets held for sale	0
Ongoing Operations \| Collateral provisions exist that may mitigate risk of credit loss \| Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits, including assets held for sale	1
Ongoing Operations \| No Collateral \| A- equivalent and higher current ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits, including assets held for sale	233
Ongoing Operations \| No Collateral \| BBB- to BBB+ equivalent current credit ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits, including assets held for sale	63
Ongoing Operations \| No Collateral \| Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits, including assets held for sale	3
Acquisition, disposition or run-off activities \| BBB+ equivalent and higher current ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits, including assets held for sale	$ 3,466
Number of reinsurers \| reinsurer	21
Acquisition, disposition or run-off activities \| BBB+ equivalent and higher current ratings \| The Lincoln National Life Insurance Company And Lincoln Life And Annuity Of New York \| Reinsurer Concentration Risk \| Reinsurance Recoverables, Gross, Before Reclassification To Disposal Group Assets Held For Sale, Acquisition Disposition Runoff, Nationally Recognized Statistical Rating Organizations, BBB+ Or Higher
Ceded Credit Risk [Line Items]
Concentration percentage	73.00%
Acquisition, disposition or run-off activities \| Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits, including assets held for sale	$ 9
Acquisition, disposition or run-off activities \| Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable \| BBB+ equivalent and higher current ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits, including assets held for sale	476
Acquisition, disposition or run-off activities \| Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable \| Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits, including assets held for sale	0
Acquisition, disposition or run-off activities \| Collateral provisions exist that may mitigate risk of credit loss \| BBB+ equivalent and higher current ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits, including assets held for sale	2,854
Acquisition, disposition or run-off activities \| Collateral provisions exist that may mitigate risk of credit loss \| Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits, including assets held for sale	6
Acquisition, disposition or run-off activities \| No Collateral \| BBB+ equivalent and higher current ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits, including assets held for sale	136
Acquisition, disposition or run-off activities \| No Collateral \| Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits, including assets held for sale	3
Variable Annuity \| Berkshire
Ceded Credit Risk [Line Items]
Reinsurance, Reinsured Risk, Percentage		100.00%
Remaining overall limit under reinsurance agreement	$ 3,000
Variable Annuity \| Secured \| Berkshire \| Collateralization risk \| Market risk benefits reinsurance recoverable, including IBNR and outstanding claims, less premiums due
Ceded Credit Risk [Line Items]
Concentration percentage	95.00%

Reinsurance - Effects of Reinsurance (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Effects of Reinsurance [Line Items]
Premiums	$ 45,996	$ 44,237	$ 39,916
Reinsurance recoveries	573	456	702
Short-duration contracts
Effects of Reinsurance [Line Items]
Premiums	43,900	42,300	36,900
Assumed
Ceded
Written premiums	42,600	41,100	35,000
Long-duration contracts
Effects of Reinsurance [Line Items]
Premiums	2,000	1,900	3,000
Assumed
Ceded

Investments - Investments by Category (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Current
Investments including held for sale assets	$ 748	$ 1,009
Current investments	665	925
Long-term
Investments including held for sale assets	16,489	19,339
Investments per Consolidated Balance Sheets	15,128	17,985
Total
Investments including held for sale assets	17,237	20,348
Total investments	15,793	18,910
Held-for-Sale \| Medicare Advantage and related Cigna Healthcare businesses
Current
Investments classified as assets of business held for sale	(83)	(84)
Long-term
Investments classified as assets of business held for sale	(1,361)	(1,354)
Total
Investments classified as assets of business held for sale	(1,444)	(1,438)
Debt securities
Current
Investments including held for sale assets	463	590
Long-term
Investments including held for sale assets	8,960	9,265
Total
Investments including held for sale assets	9,423	9,855
Equity securities
Current
Investments including held for sale assets	7	31
Long-term
Investments including held for sale assets	554	3,331
Total
Investments including held for sale assets	561	3,362
Commercial mortgage loans
Current
Investments including held for sale assets	108	182
Long-term
Investments including held for sale assets	1,243	1,351
Total
Investments including held for sale assets	1,351	1,533
Policy loans
Current
Investments including held for sale assets	0	0
Long-term
Investments including held for sale assets	1,156	1,211
Total
Investments including held for sale assets	1,156	1,211
Other long-term investments
Current
Investments including held for sale assets	0	0
Long-term
Investments including held for sale assets	4,576	4,181
Total
Investments including held for sale assets	4,576	4,181
Short-term investments
Current
Investments including held for sale assets	170	206
Long-term
Investments including held for sale assets	0	0
Total
Investments including held for sale assets	$ 170	$ 206

Investments - Debt Securities by Contractual Maturity Periods (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Amortized Cost
Due in one year or less, including assets held for sale	$ 622
Due after one year through five years, including assets held for sale	3,927
Due after five years through ten years, including assets held for sale	3,164
Due after ten years, including assets held for sale	2,041
Mortgage and other asset-backed securities, including assets held for sale	371
Total, including assets held for sale	10,125	$ 10,379
Fair Value
Due in one year or less, including assets held for sale	553
Due after one year through five years, including assets held for sale	3,759
Due after five years through ten years, including assets held for sale	2,960
Due after ten years, including assets held for sale	1,813
Mortgage and other asset-backed securities, including assets held for sale	338
Total, including assets held for sale	$ 9,423	$ 9,855

Investments - Gross Unrealized Appreciation (Depreciation) on Debt Securities by Type of Issuer (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Debt Securities, Available-for-sale [Line Items]
Amortized cost, including held for sale assets	$ 10,125	$ 10,379
Allowance for Credit Loss, including held for sale assets	(111)	(33)
Unrealized Appreciation, including held for sale assets	123	195
Unrealized Depreciation, including held for sale assets	(714)	(686)
Fair Value, including held for sale assets	9,423	9,855
Federal government and agency
Debt Securities, Available-for-sale [Line Items]
Amortized cost, including held for sale assets	276	251
Allowance for Credit Loss, including held for sale assets	0	0
Unrealized Appreciation, including held for sale assets	14	24
Unrealized Depreciation, including held for sale assets	(9)	(8)
Fair Value, including held for sale assets	281	267
State and local government
Debt Securities, Available-for-sale [Line Items]
Amortized cost, including held for sale assets	37	37
Allowance for Credit Loss, including held for sale assets	0	0
Unrealized Appreciation, including held for sale assets	1	2
Unrealized Depreciation, including held for sale assets	(1)	(1)
Fair Value, including held for sale assets	37	38
Foreign government
Debt Securities, Available-for-sale [Line Items]
Amortized cost, including held for sale assets	350	355
Allowance for Credit Loss, including held for sale assets	0	0
Unrealized Appreciation, including held for sale assets	5	10
Unrealized Depreciation, including held for sale assets	(11)	(13)
Fair Value, including held for sale assets	344	352
Corporate
Debt Securities, Available-for-sale [Line Items]
Amortized cost, including held for sale assets	9,091	9,338
Allowance for Credit Loss, including held for sale assets	(111)	(33)
Unrealized Appreciation, including held for sale assets	102	158
Unrealized Depreciation, including held for sale assets	(659)	(630)
Fair Value, including held for sale assets	8,423	8,833
Mortgage and other asset-backed
Debt Securities, Available-for-sale [Line Items]
Amortized cost, including held for sale assets	371	398
Allowance for Credit Loss, including held for sale assets	0	0
Unrealized Appreciation, including held for sale assets	1	1
Unrealized Depreciation, including held for sale assets	(34)	(34)
Fair Value, including held for sale assets	$ 338	$ 365

Investments - Debt Securities with a Decline in Fair Value from Amortized Cost (Details) $ in Millions	Dec. 31, 2024 USD ($) position	Dec. 31, 2023 USD ($) position
Total
Total Fair Value, including held for sale assets	$ 6,551	$ 6,633
Total Amortized Cost, including held for sale assets	7,265	7,319
Total Unrealized Depreciation, including held for sale assets	$ (714)	$ (686)
Total Number of Issues, including held for sale assets \| position	2,704	2,353
Investment grade \| Debt securities
One year or less
Fair Value, including held for sale assets	$ 1,203	$ 330
Amortized Cost, including held for sale assets	1,227	338
Unrealized Depreciation, including held for sale assets	$ (24)	$ (8)
Number of Issues, including held for sale assets \| position	545	142
More than one year
Fair Value, including held for sale assets	$ 4,687	$ 5,441
Amortized Cost, including held for sale assets	5,319	6,036
Unrealized Depreciation, including held for sale assets	$ (632)	$ (595)
Number of Issues, including held for sale assets \| position	1,297	1,590
Below investment grade \| Debt securities
One year or less
Fair Value, including held for sale assets	$ 245	$ 161
Amortized Cost, including held for sale assets	250	170
Unrealized Depreciation, including held for sale assets	$ (5)	$ (9)
Number of Issues, including held for sale assets \| position	739	135
More than one year
Fair Value, including held for sale assets	$ 416	$ 701
Amortized Cost, including held for sale assets	469	775
Unrealized Depreciation, including held for sale assets	$ (53)	$ (74)
Number of Issues, including held for sale assets \| position	123	486

Investments - Equity Securities (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Cost
Equity securities with readily determinable fair values	$ 635	$ 656
Equity securities with no readily determinable fair value	3,215	3,248
Total	3,850	3,904
Carrying Value
Equity securities with readily determinable fair values	37	51
Equity securities with no readily determinable fair value	524	3,311
Total	561	$ 3,362
VillageMD
Carrying Value
Amount of impairments or value changes resulting from observable price changes on equity securities with no readily available fair value still held	$ 2,700

Investments - Commercial Mortgage Loans (Details) - Real Estate Loan - Commercial Portfolio Segment $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Schedule of Investments [Line Items]
Carrying value, after allowance for credit loss	$ 1,351
Carrying value, after allowance for credit loss, including assets held for sale		$ 1,533
Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	1.70
Average Loan-to-Value Ratio	69.00%
Average Debt Service Coverage Ratio, including assets held for sale		1.82
Average Loan-to-Value Ratio, including assets held for sale		0.64
Below 60%
Schedule of Investments [Line Items]
Carrying value, after allowance for credit loss	$ 547
Carrying value, after allowance for credit loss, including assets held for sale		$ 802
Below 60% \| Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	2.07
Average Debt Service Coverage Ratio, including assets held for sale		2.13
60% to 79%
Schedule of Investments [Line Items]
Carrying value, after allowance for credit loss	$ 595
Carrying value, after allowance for credit loss, including assets held for sale		$ 574
60% to 79% \| Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	1.83
Average Debt Service Coverage Ratio, including assets held for sale		1.77
80% to 100%
Schedule of Investments [Line Items]
Carrying value, after allowance for credit loss	$ 209
Carrying value, after allowance for credit loss, including assets held for sale		$ 157
80% to 100% \| Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	0.51
Average Debt Service Coverage Ratio, including assets held for sale		0.65

Investments - Other Long-Term Investments (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Investments [Line Items]
Unfunded commitments, percentage expected to fund in next fiscal year	31.00%
Income distributions	$ 344	$ 253	$ 487
Other long term investments, including held for sale assets	4,576	4,181
Unfunded commitments	2,659
Real estate investments
Schedule of Investments [Line Items]
Other long-term investments	1,763	1,606
Unfunded commitments	850
Securities partnerships
Schedule of Investments [Line Items]
Other long-term investments	2,587	2,400
Unfunded commitments	1,809
Other
Schedule of Investments [Line Items]
Other long term investments, including held for sale assets	226	$ 175
Unfunded commitments	$ 0

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column A)(Footnote 2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column A)(Footnote 1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column A)(Footnote 4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column B)(Footnote 7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 8))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column D))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column B)(Footnote 10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 45: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 12))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 13))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 49: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 50: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 51: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 52: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 53: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 54: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 55: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 56: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 57: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 58: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 59: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F)(Footnote 4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 60: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 61: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F)(Footnote 7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 62: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F)(Footnote 8))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 63: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F)(Footnote 9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 64: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 19
-Subparagraph (1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19

Reference 65: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 19
-Subparagraph (3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19

Investments - Derivative Financial Instruments (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Derivative [Line Items]
Derivative gain (loss) reclassified from other comprehensive income into shareholders' net income
Derivative gain (loss) recognized in other comprehensive income
Derivative gain (loss) recognized in the income statement
Designated as Hedging Instrument \| Fair Value Hedging \| Fair value hedge - Foreign currency swap contracts
Derivative [Line Items]
Notional Value	975	1,026
Designated as Hedging Instrument \| Fair Value Hedging \| Fair value hedge - Interest rate swap contracts
Derivative [Line Items]
Notional Value	2,700	1,500
Designated as Hedging Instrument \| Net Investment Hedging \| Fair value hedge - Foreign currency swap contracts
Derivative [Line Items]
Notional Value	$ 415	$ 415

Investments - Components of Net Investment Income (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Net Investment Income [Line Items]
Investment income	$ 1,017	$ 1,210	$ 1,209
Less investment expenses	44	44	54
Net investment income	973	1,166	1,155
Impairment of dividend receivable	182
Debt securities
Net Investment Income [Line Items]
Investment income	492	500	572
Equity securities
Net Investment Income [Line Items]
Investment income	(114)	123	14
Commercial mortgage loans
Net Investment Income [Line Items]
Investment income	61	65	59
Policy loans
Net Investment Income [Line Items]
Investment income	56	60	59
Other long-term investments
Net Investment Income [Line Items]
Investment income	75	123	390
Short-term investments and cash
Net Investment Income [Line Items]
Investment income	$ 447	$ 339	$ 115

Investments - Realized Investment Gains and Losses (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Investments [Abstract]
Net investment (losses), before income taxes	$ (2,737)	$ (78)	$ (487)

Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Financial assets at fair value:
Equity securities	$ 37	$ 51
Liabilities, Fair Value Disclosure [Abstract]
Percent of debt and equity securities classified in Level 3, including assets held for sale	5.00%
Recurring
Financial assets at fair value:
Equity securities	$ 37	51
Short-term investments	170	206
Debt Securities, including held for sale assets	9,423	9,855
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Financial assets at fair value:
Equity securities	1	4
Short-term investments	0	0
Debt Securities, including held for sale assets	165	130
Significant Other Observable Inputs (Level 2) \| Recurring
Financial assets at fair value:
Equity securities	36	47
Short-term investments	170	206
Debt Securities, including held for sale assets	8,841	9,278
Significant Unobservable Inputs (Level 3) \| Recurring
Financial assets at fair value:
Equity securities	0	0
Short-term investments	0	0
Debt Securities, including held for sale assets	417	447
Federal government and agency \| Recurring
Financial assets at fair value:
Debt Securities, including held for sale assets	281	267
Federal government and agency \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Financial assets at fair value:
Debt Securities, including held for sale assets	165	130
Federal government and agency \| Significant Other Observable Inputs (Level 2) \| Recurring
Financial assets at fair value:
Debt Securities, including held for sale assets	116	137
Federal government and agency \| Significant Unobservable Inputs (Level 3) \| Recurring
Financial assets at fair value:
Debt Securities, including held for sale assets	0	0
State and local government \| Recurring
Financial assets at fair value:
Debt Securities, including held for sale assets	37	38
State and local government \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Financial assets at fair value:
Debt Securities, including held for sale assets	0	0
State and local government \| Significant Other Observable Inputs (Level 2) \| Recurring
Financial assets at fair value:
Debt Securities, including held for sale assets	37	38
State and local government \| Significant Unobservable Inputs (Level 3) \| Recurring
Financial assets at fair value:
Debt Securities, including held for sale assets	0	0
Foreign government \| Recurring
Financial assets at fair value:
Debt Securities, including held for sale assets	344	352
Foreign government \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Financial assets at fair value:
Debt Securities, including held for sale assets	0	0
Foreign government \| Significant Other Observable Inputs (Level 2) \| Recurring
Financial assets at fair value:
Debt Securities, including held for sale assets	344	352
Foreign government \| Significant Unobservable Inputs (Level 3) \| Recurring
Financial assets at fair value:
Debt Securities, including held for sale assets	0	0
Corporate \| Recurring
Financial assets at fair value:
Debt Securities, including held for sale assets	8,423	8,833
Corporate \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Financial assets at fair value:
Debt Securities, including held for sale assets	0	0
Corporate \| Significant Other Observable Inputs (Level 2) \| Recurring
Financial assets at fair value:
Debt Securities, including held for sale assets	8,049	8,432
Corporate \| Significant Unobservable Inputs (Level 3) \| Recurring
Financial assets at fair value:
Debt Securities, including held for sale assets	374	401
Mortgage and other asset-backed \| Recurring
Financial assets at fair value:
Debt Securities, including held for sale assets	338	365
Mortgage and other asset-backed \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Financial assets at fair value:
Debt Securities, including held for sale assets	0	0
Mortgage and other asset-backed \| Significant Other Observable Inputs (Level 2) \| Recurring
Financial assets at fair value:
Debt Securities, including held for sale assets	295	319
Mortgage and other asset-backed \| Significant Unobservable Inputs (Level 3) \| Recurring
Financial assets at fair value:
Debt Securities, including held for sale assets	43	46
Derivatives \| Recurring
Financial assets at fair value:
Derivative assets	168	132
Liabilities, Fair Value Disclosure [Abstract]
Derivative liabilities	1	4
Derivatives \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Financial assets at fair value:
Derivative assets	0	0
Liabilities, Fair Value Disclosure [Abstract]
Derivative liabilities	0	0
Derivatives \| Significant Other Observable Inputs (Level 2) \| Recurring
Financial assets at fair value:
Derivative assets	168	131
Liabilities, Fair Value Disclosure [Abstract]
Derivative liabilities	1	4
Derivatives \| Significant Unobservable Inputs (Level 3) \| Recurring
Financial assets at fair value:
Derivative assets	0	1
Liabilities, Fair Value Disclosure [Abstract]
Derivative liabilities	$ 0	$ 0

Fair Value Measurements - Quantitative Information About Unobservable Inputs (Details) - Recurring - Significant Unobservable Inputs (Level 3) $ in Millions	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Debt securities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value, including held for sale assets	$ 417	$ 447
Corporate \| Securities Priced by the Company
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value, including held for sale assets	$ 373	$ 401
Corporate \| Securities Priced by the Company \| Minimum \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment, including held for sale assets	0.0060	0.0070
Corporate \| Securities Priced by the Company \| Maximum \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment, including held for sale assets	0.1520	0.1235
Corporate \| Securities Priced by the Company \| Weighted Average \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment, including held for sale assets	0.0370	0.0310
Mortgage and other asset-backed securities \| Securities Priced by the Company
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value, including held for sale assets	$ 43	$ 46
Mortgage and other asset-backed securities \| Securities Priced by the Company \| Minimum \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment, including held for sale assets	0.0100	0.0095
Mortgage and other asset-backed securities \| Securities Priced by the Company \| Maximum \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment, including held for sale assets	0.0550	0.0640
Mortgage and other asset-backed securities \| Securities Priced by the Company \| Weighted Average \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment, including held for sale assets	0.0280	0.0310
Other debt securities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value	$ 1	$ 0

Fair Value Measurements - Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Transfers into / (out of) Level 3
Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period	$ (9)	$ 3
Debt securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance		447
Beginning balance, including held for sale assets	447
Losses included in Shareholders' net income	(69)	(2)
(Losses) gains included in Other comprehensive loss	(9)	8
Purchases, sales and settlements
Purchases	17	10
Sales	(2)	0
Settlements	(21)	(52)
Total purchases, sales and settlements	(6)	(42)
Transfers into / (out of) Level 3
Transfers into Level 3	72	95
Transfers out of Level 3	(18)	(59)
Total transfers into / (out of) Level 3	54	36
Ending balance, including held for sale assets	417	447
Total losses included in Shareholders' net income attributable to instruments held at the reporting date	$ (69)	$ (2)

Fair Value Measurements - Separate Accounts (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Guaranteed separate accounts	$ 576	$ 578
Non-guaranteed separate accounts	6,070	6,172
Subtotal	6,646	6,750
Non-guaranteed separate accounts priced at NAV as a practical expedient	632	680
Separate account assets	7,278	7,430
Separate Account Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Separate accounts assets classified in Level 3, period increase (decrease), including transfers in and out of Level 3
Pension Plans
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Non-guaranteed separate accounts	3,800	4,000
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Guaranteed separate accounts	231	226
Non-guaranteed separate accounts	267	158
Subtotal	498	384
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Guaranteed separate accounts	345	352
Non-guaranteed separate accounts	5,575	5,797
Subtotal	5,920	6,149
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Guaranteed separate accounts	0	0
Non-guaranteed separate accounts	228	217
Subtotal	228	217
Significant Unobservable Inputs (Level 3) \| Pension Plans
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Non-guaranteed separate accounts	$ 200	$ 200

Fair Value Measurements - Assets and Liabilities Measured at Fair Value under Certain Conditions (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Equity Securities without Readily Determinable Fair Value, Amount	$ 524	$ 3,311
Impairments requiring certain assets and liabilities to be measured at fair value
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount
Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount
VillageMD
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount	$ 2,700

Fair Value Measurements - Fair Value Disclosures for Financial Instruments Not Carried at Fair Value (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Fair Value \| Significant Other Observable Inputs (Level 2)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, including current maturities, excluding finance leases	$ 28,392	$ 28,033
Fair Value \| Significant Unobservable Inputs (Level 3)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Commercial mortgage loans	1,256
Commercial mortgage loans, including assets held for sale		1,430
Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Commercial mortgage loans	1,351
Long-term debt, including current maturities, excluding finance leases	$ 31,008	29,585
Commercial mortgage loans, including assets held for sale		$ 1,533

Variable Interest Entities (Details) $ in Millions	Dec. 31, 2024 USD ($) limitedPartnership entity	Dec. 31, 2023 entity
Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Number of VIEs \| entity	0	0
Variable Interest Entity, Not Primary Beneficiary \| Securities limited partnerships and real estate limited partnerships
Variable Interest Entity [Line Items]
Number of VIEs \| limitedPartnership	195
VIEs, Carrying value	$ 3,200
Maximum exposure to loss, variable interest entities	5,600
Variable Interest Entity, Not Primary Beneficiary \| Real estate limited partnerhsips
Variable Interest Entity [Line Items]
Guaranty liability	0
Maximum guarantee exposure	272
Variable Interest Entity, Not Primary Beneficiary \| Real estate joint ventures
Variable Interest Entity [Line Items]
Maximum exposure to loss, variable interest entities	900
Variable Interest Entity, Not Primary Beneficiary \| Asset-backed and corporate securities
Variable Interest Entity [Line Items]
Maximum exposure to loss, variable interest entities	400
Variable Interest Entity, Not Primary Beneficiary \| Other Variable Interest Entities
Variable Interest Entity [Line Items]
VIEs, Carrying value
Maximum exposure to loss, variable interest entities
Variable Interest Entity, Not Primary Beneficiary \| Securities limited partnerships and real estate limited partnerships \| Maximum
Variable Interest Entity [Line Items]
Ownership percentage, less than	10.00%
Variable Interest Entity, Not Primary Beneficiary \| Commitment to fund partnership \| Securities limited partnerships and real estate limited partnerships
Variable Interest Entity [Line Items]
Additional commitments	$ 2,400

Collectively Significant Operating Unconsolidated Subsidiaries (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Equity Method Investment, Summarized Financial Information [Abstract]
Loss related to unconsolidated entities reported on the equity method	$ 2,341	$ 2,341	$ 1,864
Income Statement [Abstract]
Revenues		247,121	195,265	$ 180,518
Net income		3,778	5,372	6,782
Balance Sheet [Abstract]
Total assets	155,881	155,881	152,761
Total liabilities	114,638	$ 114,638	106,410
Loss on sale of businesses, location, Consolidated Statements of Income		Net gain (loss) on sale of businesses
Portion Of Operating Joint Venture \| Disposed of by Sale
Balance Sheet [Abstract]
Gain (loss) on sale of business, pre-tax	496
Operating joint ventures
Equity Method Investment, Summarized Financial Information [Abstract]
Equity method investments, carrying value	656	$ 656	911
Loss related to unconsolidated entities reported on the equity method	979	979	510
Joint venture in China
Equity Method Investment, Summarized Financial Information [Abstract]
Equity method investments, carrying value	43	43	214
Operating joint ventures
Income Statement [Abstract]
Revenues		7,309	5,962	4,665
Net income		607	98	$ (12)
Balance Sheet [Abstract]
Total assets	34,395	34,395	26,681
Total liabilities	$ 33,892	$ 33,892	$ 25,534

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance	$ 46,244	$ 44,688	$ 46,976
Other comprehensive income (loss)	(477)	(206)	(590)
Balance	41,243	46,244	44,688
Other Comprehensive Income (Loss), Net of Tax, Alternative [Abstract]
Other comprehensive income (loss), including temporary equity, net of tax	(477)	(206)	(592)
Less: Net translation (loss) on foreign currencies attributable to noncontrolling interests	0	0	(2)
Translation of foreign currencies including portion attributable to noncontrolling interest
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Net amounts reclassified from AOCI to net income	11	0	387
Other Comprehensive Income (Loss), Net of Tax, Alternative [Abstract]
Net translation of foreign currencies, before reclassifications, after-tax	(60)	5	(310)
Other comprehensive income (loss), including temporary equity, net of tax	(49)	5	77
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) including temporary equity, before reclassifications, tax	2	5	(33)
Reclassification from AOCI, Current Period, Tax [Abstract]
Reclassification adjustment, tax	0	0	29
Translation of foreign currencies attributable to noncontrolling interest
Other Comprehensive Income (Loss), Net of Tax, Alternative [Abstract]
Less: Net translation (loss) on foreign currencies attributable to noncontrolling interests	0	0	(2)
AOCI Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance	(1,864)	(1,658)	(1,068)
Other comprehensive income (loss)	(477)	(206)	(590)
Balance	(2,341)	(1,864)	(1,658)
Other Comprehensive Income (Loss), Tax [Abstract]
Other Comprehensive Income (Loss), Tax	149	79	165
Securities and Derivatives
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance	171	(332)	1,266
Other comprehensive income (loss) before reclassifications, after-tax	601	474	(1,807)
Net amounts reclassified from AOCI to net income	60	29	209
Other comprehensive income (loss)	661	503	(1,598)
Balance	832	171	(332)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss), before reclassifications, tax	(207)	(146)	467
Reclassification from AOCI, Current Period, Tax [Abstract]
Reclassification adjustment, tax	(16)	(8)	(48)
Net long-duration insurance and contractholder liabilities measurement adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance	(971)	(256)	(765)
Other comprehensive income (loss)	(1,067)	(715)	509
Balance	(2,038)	(971)	(256)
Change in discount rate for certain long-duration liabilities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Other comprehensive income (loss) before reclassifications, after-tax	(1,044)	(691)	520
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss), before reclassifications, tax	357	222	(122)
Change in instrument-specific credit risk for market risk benefits
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Other comprehensive income (loss) before reclassifications, after-tax	(23)	(24)	(11)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss), before reclassifications, tax	6	5	3
Translation of foreign currencies
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance	(149)	(154)	(233)
Other comprehensive income (loss)	(49)	5	79
Balance	(198)	(149)	(154)
Postretirement benefits liability
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance	(915)	(916)	(1,336)
Other comprehensive income (loss) before reclassifications, after-tax	(44)	(34)	372
Net amounts reclassified from AOCI to net income	22	35	48
Other comprehensive income (loss)	(22)	1	420
Balance	(937)	(915)	(916)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss), before reclassifications, tax	14	12	(115)
Reclassification from AOCI, Current Period, Tax [Abstract]
Reclassification adjustment, tax	$ (7)	$ (11)	$ (16)

Pension - Narrative (Details) - USD ($)	12 Months Ended
Pension - Narrative (Details) - USD ($)	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Non-Qualified Plan
Defined Benefit Plan Disclosure [Line Items]
Plan assets	$ 0
Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Plan assets	3,854,000,000	$ 4,138,000,000	$ 4,186,000,000
Contributions to qualifed pension plans	4,000,000	$ 0
Plan assets invested in separate accounts of subsidiaries	3,800,000,000
Plan assets invested in funds offered by an unaffiliated insurance company	100,000,000
Pension Plans \| Qualified Plan
Defined Benefit Plan Disclosure [Line Items]
Contributions to qualifed pension plans
Expected contributions to qualified pension plans in next fiscal year

Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.

Pension - Projected Benefit Obligations and Assets (Details) - Pension Plans - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Change in benefit obligation
Benefit obligation, January 1	$ 3,934	$ 3,948
Service cost	1	1	$ 2
Interest cost	194	204	140
Actuarial (gains), net	(146)	93
Benefits paid from plan assets	(328)	(294)
Other	(12)	(18)
Benefit obligation, December 31	3,643	3,934	3,948
Change in plan assets
Fair value of plan assets, January 1	4,138	4,186
Actual return on plan assets	40	246
Benefits paid	(328)	(294)
Contributions	4	0
Fair value of plan assets, December 31	3,854	4,138	$ 4,186
Funded status	211	204
Amounts presented in Consolidated Balance Sheets
Other assets	$ 211	$ 204

Pension - Benefit Payments (Details) - Pension Plans $ in Millions	Dec. 31, 2024 USD ($)
Benefit payments including expected future services [Abstract]
2025	$ 315
2026	314
2027	311
2028	309
2029	306
2030 - 2034	$ 1,443

Pension - Amounts Included in Accumulated Other Comprehensive Income (Details) - Pension Plans - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]
Unrecognized net (losses)	$ (1,228)	$ (1,207)
Unrecognized prior service cost	(4)	(4)
Postretirement benefits liability adjustment	$ (1,232)	$ (1,211)

Pension - Net Pension Cost (Details) - Pension Plans - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]
Service cost	$ 1	$ 1	$ 2
Interest cost	194	204	140
Expected long-term return on plan assets	(247)	(204)	(272)
Amortization of:
Prior actuarial losses, net	39	52	89
Curtailment loss	1	0	0
Net (benefit) cost	$ (12)	$ 53	$ (41)

Pension - Assumptions Used for Pension (Details) - Pension Plans	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Discount rate:
Pension benefit obligation	5.57%	5.10%
Pension benefit cost	5.10%	5.43%
Expected long-term return on plan assets:
Pension benefit cost	6.50%	6.50%

Pension - Pension Plan Assets (Details) - Pension Plans - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Pension assets at fair value	$ 3,854	$ 4,138	$ 4,186
Debt securities
Defined Benefit Plan Disclosure [Line Items]
Pension assets at fair value	$ 2,986	3,191
Target allocation percentages	90.00%
Federal government and agency
Defined Benefit Plan Disclosure [Line Items]
Pension assets at fair value	$ 99	12
Corporate
Defined Benefit Plan Disclosure [Line Items]
Pension assets at fair value	2,673	2,780
Mortgage and other asset-backed
Defined Benefit Plan Disclosure [Line Items]
Pension assets at fair value	138	121
Fund investments
Defined Benefit Plan Disclosure [Line Items]
Pension assets at fair value	$ 76	278
Other investments
Defined Benefit Plan Disclosure [Line Items]
Target allocation percentages	10.00%
Equity securities
Defined Benefit Plan Disclosure [Line Items]
Pension assets at fair value	$ 27	33
Domestic
Defined Benefit Plan Disclosure [Line Items]
Pension assets at fair value	21	27
International, including funds and pooled separate accounts
Defined Benefit Plan Disclosure [Line Items]
Pension assets at fair value	6	6
Securities partnerships
Defined Benefit Plan Disclosure [Line Items]
Pension assets at fair value	402	419
Real estate funds, including pooled separate accounts
Defined Benefit Plan Disclosure [Line Items]
Pension assets at fair value	228	270
Commercial mortgage loans
Defined Benefit Plan Disclosure [Line Items]
Pension assets at fair value	27	46
Guaranteed deposit account contract
Defined Benefit Plan Disclosure [Line Items]
Pension assets at fair value	47	48
Cash equivalents and other current assets, net
Defined Benefit Plan Disclosure [Line Items]
Pension assets at fair value	$ 137	$ 131

Pension - Annual Expense for 401(k) Plans (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Retirement Benefits [Abstract]
401(k) plan expense	$ 301	$ 296	$ 274

Employee Incentive Plans - Shares of Common Stock Available for Award (Details) - shares shares in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Common shares available for award (in shares)	12.4	14.4	16.6

Employee Incentive Plans - Narrative (Details) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($) employee $ / shares shares	Dec. 31, 2023 $ / shares shares	Dec. 31, 2022 $ / shares shares	Dec. 31, 2021 shares
Employee Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining maturity of traded options	1 year
Compensation expense to be recognized	$ 69
Period over which compensation expense will be recognized	2 years
Restricted Stock Grants and Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense to be recognized	$ 203
Period over which compensation expense will be recognized	2 years
Number of employees holding share-based payment awards \| employee	8,900
Awards outstanding (in shares) \| shares	1,250	1,404	1,535	1,524
SPSs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense to be recognized	$ 64
Period over which compensation expense will be recognized	2 years
Weighted average fair value per share for expense purposes, including the Monte Carlo Factor \| $ / shares	$ 377.23	$ 329.11	$ 258.37
Number of employees holding share-based payment awards \| employee	600
Awards outstanding (in shares) \| shares	601	686	780	860
Performance period	3 years
Minimum \| Employee Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	1 year
Minimum \| Restricted Stock Grants and Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	1 year
Minimum \| SPSs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of original shares granted that may be awarded at end of performance period	0.00%
Maximum \| Employee Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Award expiration period	10 years
Maximum \| Restricted Stock Grants and Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Maximum \| SPSs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of original shares granted that may be awarded at end of performance period	200.00%

Employee Incentive Plans - Black-Scholes Option-Pricing Model Assumptions (Details) - Employee Stock Options - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	1.74%	1.58%	1.98%
Expected volatility	30.00%	30.00%	30.00%
Risk free interest rate	4.00%	3.60%	1.60%
Expected option life	4 years 9 months 18 days	4 years 8 months 12 days	4 years 6 months
Weighted average fair value of options (in dollars per share)	$ 92.36	$ 79.66	$ 50.61

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Employee Incentive Plans - Status of and Changes in Common Stock Options (Details) - Employee Stock Options - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Options
Outstanding - January 1 (in shares)	6,696	6,992	8,490
Granted (in shares)	781	915	1,375
Exercised (in shares)	(1,727)	(1,080)	(2,617)
Expired or canceled (in shares)	(95)	(131)	(256)
Options outstanding - December 31 (in shares)	5,655	6,696	6,992
Options exercisable at year-end (in shares)	3,941	4,616	4,410
Weighted Average Exercise Price
Outstanding - January 1 (in dollars per share)	$ 202.02	$ 186.54	$ 169.47
Granted (in dollars per share)	336.48	294.37	226.95
Exercised (in dollars per share)	178.82	174.66	149.97
Expired or canceled (in dollars per share)	278.78	246.95	211.22
Outstanding - December 31 (in dollars per share)	226.38	202.02	186.54
Options exercisable at year-end (in dollars per share)	$ 196.01	$ 179.28	$ 168.97

Employee Incentive Plans - Summary of Information for Stock Options Exercised (Details) - Employee Stock Options - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Intrinsic value of options exercised	$ 275	$ 126	$ 313
Cash received for options exercised	305	187	389
Tax benefit from options exercised	$ 34	$ 17	$ 47

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Employee Incentive Plans - Summary of Information for Stock Options Outstanding (Details) - Employee Stock Options - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Options Outstanding
Number (in shares)	5,655	6,696	6,992	8,490
Total intrinsic value	$ 341
Weighted average exercise price (in dollars per share)	$ 226.38	$ 202.02	$ 186.54	$ 169.47
Weighted average remaining contractual life	5 years 9 months 18 days
Options Exercisable
Number (in shares)	3,941	4,616	4,410
Total intrinsic value	$ 320
Weighted average exercise price (in dollars per share)	$ 196.01	$ 179.28	$ 168.97
Weighted average remaining contractual life	4 years 8 months 12 days

Employee Incentive Plans - Status of and Changes in Restricted Stock Awards and SPSs (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Restricted Stock Grants and Units
Grants/Units
Outstanding - January 1 (in shares)	1,404	1,535	1,524
Awarded (in shares)	624	700	876
Vested (in shares)	(713)	(759)	(714)
Forfeited (in shares)	(65)	(72)	(151)
Outstanding - December 31 (in shares)	1,250	1,404	1,535
Weighted Average Fair Value at Award Date
Outstanding - January 1 (in dollars per share)	$ 257.38	$ 219.25	$ 202.85
Awarded (in dollars per share)	319.39	294.60	229.60
Vested (in dollars per share)	245.35	214.70	197.83
Forfeited (in dollars per share)	283.62	256.24	215.02
Outstanding - December 31 (in dollars per share)	$ 302.42	$ 257.38	$ 219.25
SPSs
Grants/Units
Outstanding - January 1 (in shares)	686	780	860
Awarded (in shares)	195	219	294
Vested (in shares)	(242)	(250)	(261)
Forfeited (in shares)	(38)	(63)	(113)
Outstanding - December 31 (in shares)	601	686	780
Weighted Average Fair Value at Award Date
Outstanding - January 1 (in dollars per share)	$ 243.90	$ 212.68	$ 197.07
Awarded (in dollars per share)	336.81	293.85	230.69
Vested (in dollars per share)	214.93	191.78	183.60
Forfeited (in dollars per share)	289.35	237.50	207.75
Outstanding - December 31 (in dollars per share)	$ 282.83	$ 243.90	$ 212.68

Employee Incentive Plans - Fair Value of Vested Restricted Stock and SPSs (Details) - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Restricted Stock Grants and Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of vested shares	$ 238	$ 220	$ 167
SPSs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of The Cigna Group common stock distributed upon SPS vesting (in shares)	257	257	137
Fair value of vested shares	$ 86	$ 76	$ 31

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Employee Incentive Plans - Compensation Cost and Tax Effects of Share-based Compensation (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Total compensation cost for shared-based awards	$ 308	$ 286	$ 264
Tax benefits recognized	$ 94	$ 92	$ 80

Goodwill, Other Intangibles and Property and Equipment - Narrative (Details) - USD ($) $ in Billions	Dec. 31, 2024	Dec. 31, 2023
Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]
Indefinite-lived intangible assets	$ 8.5	$ 8.5
Minimum
Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]
Amortization period, other intangible assets	6 years
Maximum
Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]
Amortization period, other intangible assets	30 years
Buildings and Improvements \| Minimum
Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]
Estimated useful life, property, plant and equipment	10 years
Buildings and Improvements \| Maximum
Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]
Estimated useful life, property, plant and equipment	40 years
Purchased and internally developed software \| Minimum
Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]
Estimated useful life, property, plant and equipment	3 years
Purchased and internally developed software \| Maximum
Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]
Estimated useful life, property, plant and equipment	5 years
Furniture and Equipment (including Computer Equipment) \| Minimum
Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]
Estimated useful life, property, plant and equipment	3 years
Furniture and Equipment (including Computer Equipment) \| Maximum
Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]
Estimated useful life, property, plant and equipment	10 years
Leasehold Improvements
Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]
Estimated useful life, leasehold improvements	Useful Life, Shorter of Lease Term or Asset Utility [Member]

Goodwill, Other Intangibles, and Property and Equipment - Goodwill Activity (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Goodwill [Roll Forward]
Balance at January 1	$ 44,259	$ 45,811
Goodwill acquired	114
Goodwill transferred to assets of businesses held for sale(1)		(1,553)
Impact of foreign currency translation and other adjustments	(3)	1
Balance at December 31	44,370	44,259
Evernorth Health Services
Goodwill [Roll Forward]
Balance at January 1	35,130	35,130
Goodwill acquired	114
Goodwill transferred to assets of businesses held for sale(1)		0
Impact of foreign currency translation and other adjustments	190	0
Balance at December 31	35,434	35,130
Cigna Healthcare
Goodwill [Roll Forward]
Balance at January 1	9,129	10,681
Goodwill acquired	0
Goodwill transferred to assets of businesses held for sale(1)		(1,553)
Impact of foreign currency translation and other adjustments	(193)	1
Balance at December 31	$ 8,936	$ 9,129

Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482598/350-20-45-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Goodwill, Other Intangibles, and Property and Equipment - Other Intangible Assets (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Finite-lived intangible assets
Accumulated Amortization, including held for sale assets	$ 9,250	$ 7,755
Indefinite-lived intangible assets
Cost	8,500	8,500
Net Carrying Value	8,500	8,500
Other intangible assets (1)
Net Carrying Value	29,417	30,863
Cost, including held for sale assets	38,687	38,695
Net Carrying Value, including held for sale assets	29,437	30,940
Value of business acquired ("VOBA" reported in Other assets) (2)
Cost, including held for sale assets	211	211
Accumulated Amortization, including held for sale assets	142	142
Net Carrying Value, including held for sale assets	69	69
Total
Cost, including held for sale assets	38,898	38,906
Accumulated Amortization, including held for sale assets	9,392	7,897
Net Carrying Value, including held for sale assets	29,506	31,009
Held-for-Sale \| Medicare Advantage and related Cigna Healthcare businesses
Total
VOBA, held for sale	69	69
Other intangible assets, held for sale	20	77
Customer relationships
Finite-lived intangible assets
Cost, including held for sale assets	29,971	29,978
Accumulated Amortization, including held for sale assets	9,119	7,645
Net Carrying Value, including held for sale assets	20,852	22,333
Trade name - Express Scripts
Indefinite-lived intangible assets
Cost, including held for sale assets	8,400	8,400
Net Carrying Value, including held for sale assets	8,400	8,400
Other
Finite-lived intangible assets
Accumulated Amortization, including held for sale assets	131	110
Other intangible assets (1)
Cost, including held for sale assets	316	317
Net Carrying Value, including held for sale assets	$ 185	$ 207

Goodwill, Other Intangibles, and Property and Equipment - Property and Equipment (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Property and equipment, including held for sale assets
Cost	$ 13,410	$ 12,437
Accumulated Amortization	9,454	8,566
Net Carrying Value	3,956	3,871
Held-for-Sale \| Medicare Advantage and related Cigna Healthcare businesses
Property and equipment classified as Assets of businesses held for sale
Property and equipment, net carrying value classified as assets of business held for sale	302	176
Internal-use software
Property and equipment, including held for sale assets
Cost	11,295	10,155
Accumulated Amortization	8,167	7,161
Net Carrying Value	3,128	2,994
Other property and equipment
Property and equipment, including held for sale assets
Cost	2,115	2,282
Accumulated Amortization	1,287	1,405
Net Carrying Value	$ 828	$ 877

Goodwill, Other Intangibles, and Property and Equipment - Components of Depreciation and Amortization Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Depreciation And Amortization By Type [Line Items]
Depreciation and amortization	$ 2,775	$ 3,035	$ 2,937
Internal-use software
Depreciation And Amortization By Type [Line Items]
Depreciation and amortization	1,021	1,216	1,068
Other property and equipment
Depreciation And Amortization By Type [Line Items]
Depreciation and amortization	248	260	251
Value of business acquired (reported in Other assets)
Depreciation And Amortization By Type [Line Items]
Depreciation and amortization	0	7	12
Other intangibles
Depreciation And Amortization By Type [Line Items]
Depreciation and amortization	$ 1,506	$ 1,552	$ 1,606

Goodwill, Other Intangibles, and Property and Equipment - Estimated Annual Pre-Tax Amortization for Intangible Assets (Details) $ in Millions	Dec. 31, 2024 USD ($)
Goodwill Other Intangibles And Property And Equipment [Abstract]
2025	$ 2,339
2026	2,050
2027	2,015
2028	1,943
2029	$ 1,557

Shareholders Equity and Dividend Restrictions (Details) - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Equity [Abstract]
Net income	$ 3.9	$ 5.3	$ 5.7
Surplus	16.0	$ 14.9	$ 16.4
Minimum statutory surplus required by regulators	5.2
Investments on deposit with regulatory bodies	0.4
Maximum dividend distributions permitted in 2025 without regulatory approval	3.9
Maximum loans to the parent company permitted without regulatory approval	1.4
Restricted GAAP net assets of subsidiaries of The Cigna Group	11.3
Undistributed earnings from equity method subidiaries	$ 1.2

Income Taxes - Components of Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Current taxes
U.S. income taxes	$ 1,167	$ 1,459	$ 1,679
Foreign income taxes	248	161	219
State income taxes	171	180	189
Total current taxes	1,586	1,800	2,087
Deferred taxes (tax benefits)
U.S. income tax benefits	(142)	(533)	(275)
Foreign income taxes (tax benefits)	64	(1,046)	(28)
State income tax benefits	(17)	(80)	(169)
Total deferred tax benefits	(95)	(1,659)	(472)
Total income taxes	$ 1,491	$ 141	$ 1,615

Income Taxes - Nominal Tax Rate Reconciliation (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
$
Tax expense at nominal rate	$ 1,107	$ 1,158	$ 1,763
Change in valuation allowance	767	1,290	0
State income tax (benefit), net of federal income tax benefit	62	(39)	16
Investment tax credits	(111)	(48)	(14)
Effect of foreign earnings	(252)	(173)	(96)
Other	47	(7)	(17)
Total income taxes	$ 1,491	$ 141	$ 1,615
%
Tax expense at nominal rate	21.00%	21.00%	21.00%
Change in valuation allowance	14.60%	23.40%	0.00%
State income tax (benefit), net of federal income tax benefit	1.20%	(0.70%)	0.20%
Investment tax credits	(2.10%)	(0.80%)	(0.20%)
Effect of foreign earnings	(4.90%)	(3.10%)	(1.20%)
Other	0.90%	(0.10%)	(0.20%)
Total income taxes	28.30%	2.60%	19.20%
Disposed of by Sale \| International life, accident and supplemental benefits businesses
$
Impact of sale of businesses	$ 0	$ 0	$ (37)
%
Impact of sale of businesses	0.00%	0.00%	(0.40%)
Held-for-Sale \| Medicare Advantage and related Cigna Healthcare businesses
$
Impact of sale of businesses	$ (129)	$ (213)	$ 0
%
Impact of sale of businesses	(2.40%)	(3.90%)	0.00%
SWITZERLAND
$
Foreign tax attributes	$ 0	$ (1,674)	$ 0
%
Foreign tax attributes, percent	0.00%	(30.40%)	0.00%
Foreign Tax Jurisdiction, Other [Member]
$
Foreign tax attributes	$ 0	$ (153)	$ 0
%
Foreign tax attributes, percent	0.00%	(2.80%)	0.00%

Income Taxes - Foreign Operations (Details)	12 Months Ended
Income Taxes - Foreign Operations (Details)	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Pre-Tax Income \| Geographic Concentration Risk \| Foreign
Concentration Risk [Line Items]
Concentration percentage	62.00%	48.00%	46.00%

Income Taxes - Investment Tax Credits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Tax Credits and Adjustments	$ 1,057	$ 453	$ 129

Income Taxes - Deferred Income Taxes (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Deferred tax assets
Foreign tax attributes	$ 1,800	$ 1,800
Deferred loss - sale of business	773	584
Deferred tax assets, including held for sale assets
Foreign tax attributes	1,752	1,827
Deferred loss - sale of business	773	584
Investments	561	0
Other insurance and contractholder liabilities	300	353
Loss carryforwards	270	200
Other accrued liabilities	207	244
Employee and retiree benefit plans	177	217
Unrealized depreciation on investments and foreign currency translation	93	81
Policy acquisition expenses	0	39
Other	256	242
Deferred tax assets before valuation allowance	4,389	3,787
Valuation allowance for deferred tax assets	(2,332)	(1,498)
Deferred tax assets, net of valuation allowance	2,057	2,289
Deferred tax liabilities, including held for sale liabilities
Acquisition-related basis differences	7,822	8,105
Depreciation and amortization	243	371
Policy acquisition expenses	74	0
Total deferred tax liabilities	8,139	8,476
Deferred tax liabilities, net, including amounts reported in Liabilities of businesses held for sale	(6,082)	(6,187)
Deferred tax assets reported in Other Assets	954	1,055
Held-for-Sale \| Medicare Advantage and related Cigna Healthcare businesses
Deferred tax liabilities, including held for sale liabilities
Net deferred income tax liabilities classified as liabilities of businesses held for sale	$ 61	$ 69

Income Taxes - Valuation Allowances (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Valuation Allowance [Line Items]
Deferred tax assets, impairment of equity securities and other unrealized investment losses.	$ 880
Deferred tax assets, impairment of equity securities	561	$ 0
Foreign tax attributes	1,800	1,800
Deferred loss - sale of business	773	584
Equity securities
Valuation Allowance [Line Items]
Deferred tax assets, impairment of equity securities	636
Impairment of equity securities
Valuation Allowance [Line Items]
Deferred tax assets, valuation allowance	636
Impairment of equity securities \| Equity securities
Valuation Allowance [Line Items]
Deferred tax assets, valuation allowance	636
Foreign jurisdiction tax attributes
Valuation Allowance [Line Items]
Deferred tax assets, valuation allowance	772	772
Sale of Medicare Advantage and related businesses
Valuation Allowance [Line Items]
Deferred tax assets, valuation allowance	$ 715	$ 584

Income Taxes - Uncertain Tax Positions (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at January 1,	$ 1,399	$ 1,343	$ 1,230
Increase due to prior year tax positions			8
(Decrease) due to prior year tax positions	(7)	(26)
Increase due to current year positions	165	107	137
Reduction related to settlements with taxing authorities	(22)	(13)	(4)
Reduction related to lapse of applicable statute of limitations	(58)	(12)	(28)
Balance at December 31,	1,477	1,399	1,343
Liability for net interest expense on uncertain tax positions	$ 228	$ 220	$ 176

Contingencies and Other Matters (Details)			1 Months Ended	12 Months Ended
Contingencies and Other Matters (Details)	Mar. 31, 2022 USD ($)	Apr. 19, 2016 claim	Mar. 31, 2016 USD ($)	Dec. 31, 2024 USD ($)
Guaranty Fund Assessments
Commitments And Contingencies [Line Items]
Loss contingency accrual provision
Litigation Matters and Regulatory Matters
Commitments And Contingencies [Line Items]
Reserves for litigation matters, pre-tax
Express Scripts Litigation with Elevance \| Judicial Ruling \| Pricing Concessions
Commitments And Contingencies [Line Items]
Damages sought by Elevance	$ 14,800,000,000
Express Scripts Litigation with Elevance \| Pending Litigation \| Pricing Concessions Through Remaining Contract Term
Commitments And Contingencies [Line Items]
Damages sought by Elevance			$ 13,000,000,000
Express Scripts Litigation with Elevance \| Pending Litigation \| Pricing Concessions After Remaining Term of Agreement
Commitments And Contingencies [Line Items]
Damages sought by Elevance			1,800,000,000
Express Scripts Litigation with Elevance \| Pending Litigation \| Damages for Service Issues
Commitments And Contingencies [Line Items]
Damages sought by Elevance			$ 150,000,000	100,000,000
Express Scripts counterclaims against Elevance
Commitments And Contingencies [Line Items]
Number of counts dismissed \| claim		2
Number of counts \| claim		6
Indemnification obligations
Commitments And Contingencies [Line Items]
Liability for guarantees				0
Retiree and Life Insurance Benefits \| Financial Guarantees
Commitments And Contingencies [Line Items]
Maximum guarantee exposure				410,000,000
Assets maintained by employers (minimum)				410,000,000
Liability for guarantees				$ 0

Segment Information - Special Item Charges (Benefits) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Pre-tax
Integration and transaction-related costs, pre-tax (Selling, General and administrative expenses)	$ 275	$ 45	$ 135
Impairment of dividend receivable (Net investment income)	182	0	0
Deferred tax (benefits), net (Income taxes, less amount attributable to noncontrolling interests)	0	0	0
(Gain) loss on sale of business	(24)	1,499	(1,662)
Charge for organizational efficiency plan (Selling, general and administrative expenses)	0	252	22
(Benefits) charges associated with litigation matters (Selling, general and administrative expenses)	0	201	(28)
Total impact from special items	433	1,997	(1,533)
After-tax
Integration and transaction-related costs, after-tax (Selling, general and administrative expenses)	211	35	103
Impairment of dividend receivable, after-tax (Net investment income)	138	0	0
Deferred tax (benefits), net, after-tax (Income taxes, less amount attributable to noncontrolling interests)	84	(1,071)	0
(Gain) loss on sale of business, after-tax	(2)	1,429	(1,332)
Charge for organizational efficiency plan, after-tax (Selling, general and administrative expenses)	0	193	17
(Benefits) charges associated with litigation matters, after-tax (Selling, general and administrative expenses)	0	171	(20)
Total impact from special items	$ 431	$ 757	$ (1,232)

Segment Information - Summarized Segment Financial Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Revenues from customers	$ 246,148	$ 194,099	$ 179,363
Net investment income (loss)	973	1,166	1,155
TOTAL REVENUES	247,121	195,265	180,518
Net investment results from certain equity method investments	(204)	57	126
Special item related to impairment of dividend receivable	182	0	0
Adjusted revenues	247,099	195,322	180,644
Pharmacy and other service costs	182,509	133,801	124,834
Medical costs and other benefit expenses	38,648	36,287	32,184
Interest expense and other	(1,435)	(1,446)	(1,228)
Pre-tax adjusted income (loss) from operations	9,533	9,318	9,269
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	5,269	5,513	8,397
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) loss attributable to noncontrolling interests	(405)	(146)	(84)
Net realized investment (gains) losses	2,533	135	613
Amortization of acquired intangible assets	1,703	1,819	1,876
Special items
Integration and transaction-related costs	275	45	135
Impairment of dividend receivable	182	0	0
(Gain) loss on sale of business	(24)	1,499	(1,662)
Charge for organizational efficiency plan	0	252	22
(Benefits) charges associated with litigation matters	0	201	(28)
Pre-tax adjusted income (loss) from operations	9,533	9,318	9,269
Depreciation and amortization	2,775	3,035	2,937
Evernorth Health Services
Segment Reporting Information [Line Items]
Revenues from customers	198,177	147,588	135,786
Cigna Healthcare
Segment Reporting Information [Line Items]
Revenues from customers	47,528	46,219	41,738
Other Operations
Segment Reporting Information [Line Items]
Revenues from customers	440	291	1,839
Operating Segments \| Evernorth Health Services
Segment Reporting Information [Line Items]
Net investment income (loss)	21	241	86
TOTAL REVENUES	201,973	153,499	140,335
Net investment results from certain equity method investments	0	0	0
Special item related to impairment of dividend receivable	182
Adjusted revenues	202,155	153,499	140,335
Pharmacy and other service costs	190,968	143,571	131,284
Medical costs and other benefit expenses	0	0	0
Selling, general and administrative expenses	3,779	3,340	2,856
Interest expense and other	(2)	(2)	(2)
Less income attributable to noncontrolling interests	405	144	66
Pre-tax adjusted income (loss) from operations	7,001	6,442	6,127
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	3,929	4,768	4,421
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) loss attributable to noncontrolling interests	(405)	(144)	(66)
Net realized investment (gains) losses	2,129	0	0
Amortization of acquired intangible assets	1,662	1,774	1,772
Special items
Integration and transaction-related costs	0	0	0
Impairment of dividend receivable	182
(Gain) loss on sale of business	(496)	0	0
Charge for organizational efficiency plan		0	0
(Benefits) charges associated with litigation matters		44	0
Pre-tax adjusted income (loss) from operations	7,001	6,442	6,127
Depreciation and amortization	2,319	2,438	2,283
Operating Segments \| Cigna Healthcare
Segment Reporting Information [Line Items]
Net investment income (loss)	618	597	638
TOTAL REVENUES	53,118	51,148	44,911
Net investment results from certain equity method investments	(204)	57	126
Special item related to impairment of dividend receivable	0
Adjusted revenues	52,914	51,205	45,037
Pharmacy and other service costs	0	0	0
Medical costs and other benefit expenses	37,887	35,678	31,119
Selling, general and administrative expenses	10,805	11,055	9,827
Interest expense and other	7	8	12
Less income attributable to noncontrolling interests	0	2	4
Pre-tax adjusted income (loss) from operations	4,229	4,478	4,099
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	3,315	2,664	3,470
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) loss attributable to noncontrolling interests	0	(2)	(4)
Net realized investment (gains) losses	401	133	530
Amortization of acquired intangible assets	41	45	103
Special items
Integration and transaction-related costs	0	0	0
Impairment of dividend receivable	0
(Gain) loss on sale of business	472	1,481	0
Charge for organizational efficiency plan		0	0
(Benefits) charges associated with litigation matters		157	0
Pre-tax adjusted income (loss) from operations	4,229	4,478	4,099
Depreciation and amortization	417	569	638
Operating Segments \| Other Operations
Segment Reporting Information [Line Items]
Net investment income (loss)	309	305	424
TOTAL REVENUES	828	596	2,263
Net investment results from certain equity method investments	0	0	0
Special item related to impairment of dividend receivable	0
Adjusted revenues	828	596	2,263
Pre-tax adjusted income (loss) from operations	(9)	96	509
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	(12)	76	2,101
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) loss attributable to noncontrolling interests	0	0	(14)
Net realized investment (gains) losses	3	2	83
Amortization of acquired intangible assets	0	0	1
Special items
Integration and transaction-related costs	0	0	0
Impairment of dividend receivable	0
(Gain) loss on sale of business	0	18	(1,662)
Charge for organizational efficiency plan		0	0
(Benefits) charges associated with litigation matters		0	0
Pre-tax adjusted income (loss) from operations	(9)	96	509
Depreciation and amortization	9	3	6
Corporate and Eliminations
Segment Reporting Information [Line Items]
TOTAL REVENUES	(8,798)	(9,978)	(6,991)
Adjusted revenues	(8,798)	(9,978)	(6,991)
Special items
Depreciation and amortization	30	25	10
Corporate
Segment Reporting Information [Line Items]
Revenues from customers	3	1	0
Net investment income (loss)	25	23	7
Net investment results from certain equity method investments	0	0	0
Special item related to impairment of dividend receivable	0
Pre-tax adjusted income (loss) from operations	(1,688)	(1,698)	(1,466)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	(1,963)	(1,995)	(1,595)
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) loss attributable to noncontrolling interests	0	0	0
Net realized investment (gains) losses	0	0	0
Amortization of acquired intangible assets	0	0	0
Special items
Integration and transaction-related costs	275	45	135
Impairment of dividend receivable	0
(Gain) loss on sale of business	0	0	0
Charge for organizational efficiency plan		252	22
(Benefits) charges associated with litigation matters		0	(28)
Pre-tax adjusted income (loss) from operations	(1,688)	(1,698)	(1,466)
Intersegment Eliminations
Segment Reporting Information [Line Items]
Revenues from customers	(8,826)	(10,002)	(6,998)
Intersegment Eliminations \| Evernorth Health Services
Segment Reporting Information [Line Items]
Revenues from customers	(3,775)	(5,670)	(4,463)
Intersegment Eliminations \| Cigna Healthcare
Segment Reporting Information [Line Items]
Revenues from customers	(4,972)	(4,332)	(2,535)
Intersegment Eliminations \| Other Operations
Segment Reporting Information [Line Items]
Revenues from customers	$ (79)	$ 0	$ 0

Segment Information - Revenue from External Customers (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Revenue from External Customer [Line Items]
Premiums	$ 45,996	$ 44,237	$ 39,916
Total revenues from external customers	246,148	194,099	179,363
Pharmacy revenues
Revenue from External Customer [Line Items]
Revenue from contract with customer	185,362	137,243	128,566
Service
Revenue from External Customer [Line Items]
Revenue from contract with customer	14,790	12,619	10,881
Service, Fees And Other Revenues [Member]
Revenue from External Customer [Line Items]
Revenue from contract with customer	14,790	12,619	10,881
Evernorth Health Services
Revenue from External Customer [Line Items]
Total revenues from external customers	198,177	147,588	135,786
Cigna Healthcare
Revenue from External Customer [Line Items]
Total revenues from external customers	47,528	46,219	41,738
Other Operations
Revenue from External Customer [Line Items]
Total revenues from external customers	440	291	1,839
Operating Segments \| Other revenue
Revenue from External Customer [Line Items]
Revenue from contract with customer	584	210	168
Operating Segments \| Evernorth Health Services \| Pharmacy revenues
Revenue from External Customer [Line Items]
Revenue from contract with customer	189,361	142,293	132,982
Operating Segments \| Evernorth Health Services \| Network revenues
Revenue from External Customer [Line Items]
Revenue from contract with customer	105,340	67,514	64,946
Operating Segments \| Evernorth Health Services \| Home delivery and specialty revenues
Revenue from External Customer [Line Items]
Revenue from contract with customer	72,476	65,732	61,283
Operating Segments \| Evernorth Health Services \| Other revenues
Revenue from External Customer [Line Items]
Revenue from contract with customer	11,545	9,047	6,753
Operating Segments \| Evernorth Health Services \| Service, Fees And Other Revenues [Member]
Revenue from External Customer [Line Items]
Revenue from contract with customer	12,591	10,965	7,267
Operating Segments \| Cigna Healthcare
Revenue from External Customer [Line Items]
Premiums	45,512	43,882	38,094
Operating Segments \| Cigna Healthcare \| Service, Fees And Other Revenues [Member]
Revenue from External Customer [Line Items]
Revenue from contract with customer	6,988	6,669	6,179
Operating Segments \| Cigna Healthcare \| U.S. Healthcare
Revenue from External Customer [Line Items]
Premiums	41,888	40,587	35,188
Operating Segments \| Cigna Healthcare \| U.S. Healthcare \| Employer insured
Revenue from External Customer [Line Items]
Premiums	17,576	16,490	15,199
Operating Segments \| Cigna Healthcare \| U.S. Healthcare \| Medicare Advantage
Revenue from External Customer [Line Items]
Premiums	8,679	8,771	7,896
Operating Segments \| Cigna Healthcare \| U.S. Healthcare \| Stop loss
Revenue from External Customer [Line Items]
Premiums	6,744	6,143	5,461
Operating Segments \| Cigna Healthcare \| U.S. Healthcare \| Individual and Family Plans
Revenue from External Customer [Line Items]
Premiums	3,951	5,088	2,636
Operating Segments \| Cigna Healthcare \| U.S. Healthcare \| Other
Revenue from External Customer [Line Items]
Premiums	4,938	4,095	3,996
Operating Segments \| Cigna Healthcare \| International Health
Revenue from External Customer [Line Items]
Premiums	3,624	3,295	2,906
Operating Segments \| Other Operations \| Pharmacy revenues
Revenue from External Customer [Line Items]
Revenue from contract with customer	60	0	0
Operating Segments \| Other Operations \| Service, Fees And Other Revenues [Member]
Revenue from External Customer [Line Items]
Revenue from contract with customer	79	10	18
Operating Segments \| Other Operations \| Divested International businesses
Revenue from External Customer [Line Items]
Premiums	0	0	1,596
Operating Segments \| Other Operations \| Other Operations excluding Divested International businesses
Revenue from External Customer [Line Items]
Premiums	380	281	225
Corporate and Eliminations
Revenue from External Customer [Line Items]
Premiums	104	74	1
Corporate and Eliminations \| Pharmacy revenues
Revenue from External Customer [Line Items]
Revenue from contract with customer	(4,059)	(5,050)	(4,416)
Corporate and Eliminations \| Service, Fees And Other Revenues [Member]
Revenue from External Customer [Line Items]
Revenue from contract with customer	(4,868)	(5,025)	(2,583)
Corporate
Revenue from External Customer [Line Items]
Total revenues from external customers	3	1	0
Intersegment Eliminations
Revenue from External Customer [Line Items]
Total revenues from external customers	(8,826)	(10,002)	(6,998)
Intersegment Eliminations \| Evernorth Health Services
Revenue from External Customer [Line Items]
Total revenues from external customers	(3,775)	(5,670)	(4,463)
Intersegment Eliminations \| Cigna Healthcare
Revenue from External Customer [Line Items]
Total revenues from external customers	(4,972)	(4,332)	(2,535)
Intersegment Eliminations \| Other Operations
Revenue from External Customer [Line Items]
Total revenues from external customers	$ (79)	$ 0	$ 0

Segment Information - Major Customers (Details) - Revenue - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Single Pharmacy Benefit Client
Concentration Risk [Line Items]
Concentration percentage	16.00%
U.S. Federal Government Agencies
Concentration Risk [Line Items]
Concentration percentage	11.00%	15.00%	14.00%

Segment Information - U.S. and Foreign Revenues (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Loss Contingencies [Line Items]
Revenues from external customers	$ 246,148	$ 194,099	$ 179,363
United States
Loss Contingencies [Line Items]
Revenues from external customers	241,563	189,840	174,540
Foreign countries
Loss Contingencies [Line Items]
Revenues from external customers	$ 4,585	$ 4,259	4,823
Revenues, disposal group			$ 1,600
Revenues from external customers \| Geographic Concentration Risk \| Single foreign country
Loss Contingencies [Line Items]
Concentration percentage	2.00%	2.00%	2.00%

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Cash and cash equivalents

Schedule I - Condensed Financial Information of The Cigna Group - Statements of Income (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Revenues
Net investment income (loss)	$ 973	$ 1,166	$ 1,155
TOTAL REVENUES	247,121	195,265	180,518
Operating expenses
Selling, general and administrative expenses	14,844	14,822	13,174
TOTAL BENEFITS AND EXPENSES	237,704	186,729	172,068
Income from operations	9,417	8,536	8,450
Interest expense and other	(1,435)	(1,446)	(1,228)
Net investment losses	(2,737)	(78)	(487)
Income before income taxes	5,269	5,513	8,397
Income tax benefits	1,491	141	1,615
SHAREHOLDERS' NET INCOME	3,434	5,164	6,704
Other comprehensive income (loss), net of tax
Net long-duration insurance and contractholder liabilities measurement adjustments	(1,067)	(715)	509
SHAREHOLDERS' COMPREHENSIVE INCOME	2,957	4,958	6,114
The Cigna Group
Revenues
Net investment income (loss)	26	22	5
Intercompany interest income	469	516	478
TOTAL REVENUES	495	538	483
Operating expenses
Selling, general and administrative expenses	14	2	2
TOTAL BENEFITS AND EXPENSES	14	2	2
Income from operations	481	536	481
Interest expense and other	(1,388)	(1,332)	(1,215)
Intercompany interest expense	(2)	(118)	(147)
Income before income taxes	(909)	(914)	(881)
Income tax benefits	(189)	(192)	(183)
Loss of parent company	(720)	(722)	(698)
Equity in income of subsidiaries	4,154	5,886	7,402
SHAREHOLDERS' NET INCOME	3,434	5,164	6,704
Other comprehensive income (loss), net of tax
Net unrealized appreciation (depreciation) on securities and derivatives	661	503	(1,598)
Net long-duration insurance and contractholder liabilities measurement adjustments	(1,067)	(715)	509
Net translation (losses) gains of foreign currencies	(49)	5	79
Postretirement benefits liability adjustment	(22)	1	420
Shareholders' other comprehensive loss, net of tax	(477)	(206)	(590)
SHAREHOLDERS' COMPREHENSIVE INCOME	$ 2,957	$ 4,958	$ 6,114

Schedule I - Condensed Financial Information of The Cigna Group - Balance Sheets (Details) - USD ($)
$ in Millions

Dec. 31, 2024

Dec. 31, 2023

Dec. 31, 2022

Assets

$ 7,550

$ 7,822

Short-term investments

665

925

Other current assets

2,732

2,169

Total current assets

48,870

37,351

Other non-current assets

2,786

3,421

TOTAL ASSETS

155,881

152,761

Total current liabilities

Short-term debt

3,035

2,775

57,979

48,716

Long-term debt

28,937

28,155

Additional paid-in capital

3,215

3,441

TOTAL LIABILITIES

114,638

106,410

Shareholders' equity

Common stock

^[1]

4

31,288

30,669

Accumulated other comprehensive loss

(2,341)

(1,864)

Retained earnings

43,519

41,652

Less: Treasury stock, at cost

(31,437)

(24,238)

TOTAL SHAREHOLDERS' EQUITY

41,033

46,223

Total liabilities and equity

$ 155,881

$ 152,761

Common stock, shares issued (in shares)

402,512,000

399,894,000

397,819,000

Common stock, shares authorized (in shares)

600,000,000

The Cigna Group

Assets

Cash and cash equivalents

$ 164

$ 303

Other current assets

103

6

Total current assets

267

309

TOTAL ASSETS

73,771

81,564

Other current liabilities

Short-term debt

2,848

2,448

1,528

1,854

Total current liabilities

4,376

4,302

Long-term debt

28,134

27,151

TOTAL LIABILITIES

32,738

35,341

Shareholders' equity

Common stock

4

Additional paid-in capital

31,288

30,669

Accumulated other comprehensive loss

(2,341)

(1,864)

Retained earnings

43,519

41,652

Less: Treasury stock, at cost

(31,437)

(24,238)

TOTAL SHAREHOLDERS' EQUITY

41,033

46,223

Total liabilities and equity

$ 73,771

$ 81,564

Common stock, shares issued (in shares)

403,000,000

400,000,000

Common stock, shares authorized (in shares)

600,000,000

The Cigna Group | Nonrelated Party

Assets

Other non-current assets

$ 71

$ 77

The Cigna Group | Subsidiaries

33

14

Assets

Investments in subsidiaries

62,887

69,703

Other non-current assets

10,546

11,475

Cash Flows from Operating Activities

$ 195

$ 3,874

[1]	Par value per share, $0.01; shares issued, 403 million as of December 31, 2024 and 400 million as of December 31, 2023; authorized shares, 600 million.

Schedule I - Condensed Financial Information of The Cigna Group - Statements of Cash Flows (Details) - USD ($)
$ in Millions

12 Months Ended

Dec. 19, 2024

Sep. 19, 2024

Jun. 20, 2024

Mar. 21, 2024

Dec. 21, 2023

Sep. 21, 2023

Jun. 22, 2023

Mar. 23, 2023

Dec. 21, 2022

Sep. 22, 2022

Jun. 23, 2022

Mar. 24, 2022

Dec. 31, 2024

Dec. 31, 2023

Dec. 31, 2022

Shareholders' net income

$ 3,434

$ 5,164

$ 6,704

Adjustments to reconcile shareholders' net income to net cash provided by (used in) operating activities:

Other liabilities

1,138

3,481

1,734

NET CASH PROVIDED BY OPERATING ACTIVITIES

774

463

325

10,363

11,813

8,656

Cash Flows from Investing Activities

Net proceeds from short-term investments sold

(1,309)

(1,205)

(1,563)

NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES

(2,102)

(5,174)

3,098

Repayment of long-term debt

(3,000)

(2,967)

(500)

Net proceeds on issuance of long-term debt

4,462

1,491

0

Issuance of common stock

305

187

389

Common dividends paid

$ (384)

$ (390)

$ (392)

$ (401)

$ (358)

$ (362)

$ (368)

$ (334)

$ (341)

$ (352)

$ (357)

(1,567)

(1,450)

(1,384)

Repurchase of common stock

(7,034)

(2,284)

(7,607)

NET CASH USED IN FINANCING ACTIVITIES

(349)

(413)

(23)

(7,647)

(4,294)

(11,240)

Net increase in cash, cash equivalents and restricted cash

594

2,361

428

Cash, cash equivalents and restricted cash and cash equivalents January 1,

^[1]

7,870

5,976

Cash, cash equivalents and restricted cash, end of year (1)

^[1]

7,592

7,870

5,976

The Cigna Group

Cash Flows from Operating Activities

Shareholders' net income

3,434

5,164

6,704

Adjustments to reconcile shareholders' net income to net cash provided by (used in) operating activities:

Equity in income of subsidiaries

(4,154)

(5,886)

(7,402)

Dividends received from subsidiaries

2,916

1,381

2,056

Other liabilities

(306)

540

5

NET CASH PROVIDED BY OPERATING ACTIVITIES

243

640

298

2,133

1,839

1,661

Cash Flows from Investing Activities

Net proceeds from short-term investments sold

0

99

NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES

0

622

(802)

Net change in short-term debt

(357)

1,237

(2,027)

Repayment of long-term debt

(2,731)

(2,822)

(430)

Net proceeds on issuance of long-term debt

4,462

1,491

0

Issuance of common stock

305

187

389

Common dividends paid

(1,567)

(1,450)

(1,384)

Repurchase of common stock

(7,034)

(2,284)

(7,607)

Tax withholding on stock compensation and other

(117)

(110)

(73)

NET CASH USED IN FINANCING ACTIVITIES

(2,278)

(740)

Net increase in cash, cash equivalents and restricted cash

(145)

183

119

Cash, cash equivalents and restricted cash and cash equivalents January 1,

335

152

33

Cash, cash equivalents and restricted cash, end of year (1)

190

335

152

The Cigna Group | Subsidiaries

Cash Flows from Investing Activities

Net change in amounts due from affiliates

0

622

(901)

Net change in amounts due to affiliates

4,761

1,473

10,392

Net amounts due from affiliates settled through capital transactions

$ (7,565)

$ (5,221)

$ (5,037)

[1]	Restricted cash and cash equivalents were reported in other long-term investments.

Schedule I - Condensed Financial Information of The Cigna Group - Short-term and Credit Facilities Debt (Details) - USD ($)	1 Months Ended	12 Months Ended
	Apr. 30, 2024	Dec. 31, 2024	Jul. 31, 2024	Jun. 30, 2024
Line of Credit Facility [Line Items]
Commercial paper average interest rate		4.65%
Commercial Paper
Line of Credit Facility [Line Items]
Maximum borrowing capacity		$ 6,500,000,000	$ 6,500,000,000	$ 5,000,000,000.0
Revolving Credit Agreements, April 2024
Line of Credit Facility [Line Items]
Outstanding balances		$ 0
Aggregate amount of options to increase commitments	$ 1,500,000,000
Maximum total commitment	$ 8,000,000,000.0
Leverage ratio covenant	60.00%
Five-year Revolving Credit Agreement, Maturing April 2029
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 5,000,000,000.0
Credit agreement term	5 years
Credit agreement extension term	1 year
Five-year Revolving Credit Agreement, Maturing April 2029 \| Letter of Credit
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 500,000,000
364-day Revolving Credit Agreement, Maturing April 2025
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 1,500,000,000
Credit agreement term	364 days
Credit facility, conversion to term loan, term	1 year
The Cigna Group
Line of Credit Facility [Line Items]
Commercial paper average interest rate		4.65%
The Cigna Group \| Commercial Paper
Line of Credit Facility [Line Items]
Outstanding balances		$ 900,000,000
Maximum borrowing capacity		6,500,000,000
The Cigna Group \| Revolving Credit Agreements, April 2024
Line of Credit Facility [Line Items]
Outstanding balances		$ 0
Aggregate amount of options to increase commitments	$ 1,500,000,000
Maximum total commitment	$ 8,000,000,000.0
Leverage ratio covenant	60.00%
The Cigna Group \| Five-year Revolving Credit Agreement, Maturing April 2029
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 5,000,000,000.0
Credit agreement term	5 years
Credit agreement extension term	1 year
The Cigna Group \| Five-year Revolving Credit Agreement, Maturing April 2029 \| Letter of Credit
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 500,000,000
The Cigna Group \| 364-day Revolving Credit Agreement, Maturing April 2025
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 1,500,000,000
Credit agreement term	364 days
Credit facility, conversion to term loan, term	1 year

Schedule I - Condensed Financial Information of The Cigna Group - Long-term Debt (Details)	1 Months Ended	12 Months Ended
	Feb. 29, 2024 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Mar. 31, 2024 USD ($)
Debt Instrument [Line Items]
Aggregate principal amount of outstanding debt securities redeemed					$ 1,800,000,000
Repayment of long-term debt		$ 3,000,000,000	$ 2,967,000,000	$ 500,000,000
$1,000 million, 5.000% Notes due May 2029
Debt Instrument [Line Items]
Interest Rate		5.00%
Gross value		$ 1,000,000,000
$750 million, 5.125% Notes due May 2031
Debt Instrument [Line Items]
Interest Rate		5.125%
Gross value		$ 750,000,000
$1,250 million, 5.250% Notes due February 2034
Debt Instrument [Line Items]
Interest Rate		5.25%
Gross value		$ 1,250,000,000
$1,500 million, 5.600% Notes due February 2054
Debt Instrument [Line Items]
Interest Rate		5.60%
Gross value		$ 1,500,000,000
Senior Notes
Debt Instrument [Line Items]
Principal	$ 4,500,000,000
Senior Notes \| $1,000 million, 5.000% Notes due May 2029
Debt Instrument [Line Items]
Principal	1,000,000,000
Net proceeds	$ 995,000,000
Interest Rate	5.00%
Redemption price discount, spread on variable rate	0.0015
Senior Notes \| $750 million, 5.125% Notes due May 2031
Debt Instrument [Line Items]
Principal	$ 750,000,000
Net proceeds	$ 746,000,000
Interest Rate	5.125%
Redemption price discount, spread on variable rate	0.0015
Senior Notes \| $1,250 million, 5.250% Notes due February 2034
Debt Instrument [Line Items]
Principal	$ 1,250,000,000
Net proceeds	$ 1,244,000,000
Interest Rate	5.25%
Redemption price discount, spread on variable rate	0.0020
Senior Notes \| $1,500 million, 5.600% Notes due February 2054
Debt Instrument [Line Items]
Principal	$ 1,500,000,000
Net proceeds	$ 1,485,000,000
Interest Rate	5.60%
Redemption price discount, spread on variable rate	0.0020
The Cigna Group
Debt Instrument [Line Items]
Aggregate principal amount of outstanding debt securities redeemed					$ 1,700,000,000
Repayment of long-term debt		$ 2,731,000,000	$ 2,822,000,000	$ 430,000,000
The Cigna Group \| Senior Notes
Debt Instrument [Line Items]
Principal	$ 4,500,000,000
The Cigna Group \| Senior Notes \| $1,000 million, 5.000% Notes due May 2029
Debt Instrument [Line Items]
Principal	1,000,000,000
Net proceeds	$ 995,000,000
Interest Rate	5.00%
Redemption price discount, spread on variable rate	0.0015
The Cigna Group \| Senior Notes \| $750 million, 5.125% Notes due May 2031
Debt Instrument [Line Items]
Principal	$ 750,000,000
Net proceeds	$ 746,000,000
Interest Rate	5.125%
Redemption price discount, spread on variable rate	0.0015
The Cigna Group \| Senior Notes \| $1,250 million, 5.250% Notes due February 2034
Debt Instrument [Line Items]
Principal	$ 1,250,000,000
Net proceeds	$ 1,244,000,000
Interest Rate	5.25%
Redemption price discount, spread on variable rate	0.0020
The Cigna Group \| Senior Notes \| $1,500 million, 5.600% Notes due February 2054
Debt Instrument [Line Items]
Principal	$ 1,500,000,000
Net proceeds	$ 1,485,000,000
Interest Rate	5.60%
Redemption price discount, spread on variable rate	0.0020

Schedule I - Condensed Financial Information of The Cigna Group - Debt Maturities (Details) $ in Millions	Dec. 31, 2024 USD ($)
Debt Instrument [Line Items]
2025	$ 2,116
2026	2,534
2027	2,359
2028	3,800
2029	1,000
Maturities after 2029	19,522
The Cigna Group
Debt Instrument [Line Items]
2025	1,973
2026	2,301
2027	2,056
2028	3,800
2029	1,000
Maturities after 2029	$ 19,292

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482949/835-30-55-8

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(f))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69F
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482900/835-30-50-1

Schedule I - Condensed Financial Information of The Cigna Group - Intercompany Balances (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Condensed Financial Statements, Captions [Line Items]
Other current assets	$ 2,732	$ 2,169
The Cigna Group
Condensed Financial Statements, Captions [Line Items]
Other current assets	103	6
The Cigna Group \| Evernorth Health, Inc.
Condensed Financial Statements, Captions [Line Items]
Other current assets	$ 8,500	$ 8,500
Interest rate, intercompany receivables	5.50%

Schedule I - Condensed Financial Information of The Cigna Group - Guarantees (Details) $ in Billions	Dec. 31, 2024 USD ($)
The Cigna Group
Guarantor Obligations [Line Items]
Maximum guarantee exposure	$ 9.4

Schedule I - Condensed Financial Information of The Cigna Group - Share Repurchase (Details) - Accelerated Share Repurchase Agreement, February 2024 - USD ($) shares in Millions	8 Months Ended
	Sep. 30, 2024	Feb. 15, 2024
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Accelerated stock repurchase, amount authorized		$ 3,200,000,000
Shares repurchased	9.3
The Cigna Group
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Accelerated stock repurchase, amount authorized		$ 3,200,000,000
Shares repurchased	9.3

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2